AUSTRALIAN GUIDELINES FOR THE TREATMENT OF ADULTS WITH

Acute Stress Disorder and Posttraumatic Stress Disorder

Australian Centre for Posttraumatic Mental Health

Australian Government
National Health and Medical Research Council
The development of these guidelines has been generously supported by:

**Emergency Management Australia**

**Department of Veterans’ Affairs**

**Department of Defence**
AUSTRALIAN GUIDELINES FOR THE TREATMENT OF ADULTS WITH

Acute Stress Disorder and Posttraumatic Stress Disorder

ASD and PTSD Treatment Guidelines

Australian Centre for Posttraumatic Mental Health

February 2007

Approved by the National Health and Medical Research Council
February 2007

Endorsed by the Royal Australian and New Zealand College of Psychiatrists
and the Australian Psychological Society
GUIDELINES DEVELOPMENT GROUP

STEERING GROUP

Professor Mark Creamer
Director ACPMH, Department of Psychiatry,
University of Melbourne

Professor Beverley Raphael
Director Centre for Disasters and Terrorism,
University of Western Sydney

WORKING PARTY

Chair
Associate Professor David Forbes
Clinical Director ACPMH,
Department of Psychiatry,
University of Melbourne

Trauma Experts
Professor Richard Bryant
School of Psychology,
University of New South Wales

Professor Mark Creamer
Director ACPMH,
Department of Psychiatry,
University of Melbourne

Professor Grant Devilly
Brain Sciences Institute,
Swinburne University of Technology

Professor Alexander McFarlane
Department of Psychiatry,
University of Adelaide

Psychosocial Rehabilitation Expert
Dr Lynda Matthews
Behavioural and Community Health Sciences,
University of Sydney

Consultant Health Economist
Associate Professor Chris Doran
School of Population Health,
University of Queensland

Guideline Assessment Registrar
Dr Adele Weston
Director,
Health Technology Analysts

Project Manager
Ms Andrea Phelps
Clinical Specialist ACPMH,
Department of Psychiatry,
University of Melbourne
The Australian Centre for Posttraumatic Mental Health (ACPMH) and the working party gratefully acknowledge the contribution of the following:

**Multidisciplinary panel**
- **Professor Beverley Raphael**
  (Panel chair)
- **Dr Anne Arnott**
  (Psychologist)
- **Dr David Barton**
  (Royal Australian and New Zealand College of Psychiatrists)
- **Ms Bronwen Browning**
  (Australian Association of Occupational Therapists)
- **Associate Professor David Crompton**
  (Psychiatry trauma specialist)
- **Dr Rob Gordon**
  (Psychology trauma specialist)
- **Ms Brenda Happell**
  (Mental health nurse)
- **Ms Vivian Jarrett**
  (Consumer representative, Mental Health Council of Australia)
- **Ms Charlene Micallef**
  (Consumer representative)
- **Associate Professor Helen Milroy**
  (Psychiatry, Indigenous mental health specialist)
- **Mr Brian McKenzie**
  (Consumer representative)
- **Ms Julie Sharrock**
  (Australian and New Zealand College of Mental Health Nurses)
- **Professor Derrick Silove**
  (Psychiatry refugee trauma specialist)
- **Ms Elizabeth Sommerville**
  (Australian Association of Social Work)
- **Mr David Stokes**
  (Australian Psychological Society)
- **Dr Alex Tahmindjis**
  (Rural and Remote General Practitioners)
- **Dr Ian Wilson**
  (Royal Australian College of General Practitioners)
- **Ms Carolyn Worth**
  (Social work trauma specialist)

**Expert panel for Aboriginal and Torres Strait Islander peoples**
- **Associate Professor Helen Milroy**
  (Panel convenor)
- **Mr Tom Brideson**
  (Office for Aboriginal & Torres Strait Islander Health)
- **Dr Anne Harrison**
  (Psychiatrist, Winnunga Aboriginal Community Controlled Health Organisation)
- **Professor Ernest Hunter**
  (Department of Public Health, University of Queensland)
- **Joylene Koolmatrie**
  (Psychologist)
- **Professor Beverley Raphael**
  (Director, Centre for Disasters and Terrorism, University of Western Sydney)

**Expert panel for refugees and asylum seekers**
- **Professor Derrick Silove**
  (Panel convenor)
- **Mariano Coello**
  (Clinical Director, Service for the Treatment and Rehabilitation of Torture and Trauma Survivors)
- **Ida Kaplan**
  (Clinical Director, Victorian Foundation for Survivors of Torture)
- **Associate Professor Harry Minas**
  (Director, Victorian Transcultural Psychiatry Unit)

We also thank the Adelaide Health Technology Assessment Reviewers who conducted the systematic review (see Appendix D), the ACPMH Project Support Team (see Appendix E) and the National Collaborating Centre for Mental Health for granting permission to reproduce the National Institute for Clinical Excellence guideline recommendations for the recognition and management of posttraumatic stress disorder in children and young people.
CONTENTS

GUIDELINE DEVELOPMENT GROUP IV
ACKNOWLEDGMENTS V
LIST OF ABBREVIATIONS XII
EXECUTIVE SUMMARY XIV
SUMMARY OF GUIDELINE RECOMMENDATIONS XVI

1 INTRODUCTION 1

WHAT ARE CLINICAL PRACTICE GUIDELINES? 1
RATIONALE FOR DEVELOPING PRACTICE GUIDELINES ON THE TREATMENT OF ACUTE STRESS DISORDER AND POSTTRAUMATIC STRESS DISORDER 1
OBJECTIVE OF THESE GUIDELINES 1
SCOPE OF THE GUIDELINES 1
GUIDELINE RECOMMENDATIONS 2
APPROACH TO GUIDELINE DEVELOPMENT 2
The development of clinical practice guidelines 2
Overview of methodology 4
Limitations of the review 8
## 2 ASD AND PTSD

### BACKGROUND TO ASD AND PTSD

- Trauma, traumatic event and potentially traumatic event
- Potentially traumatic events
- Common responses to potentially traumatic events
- Resilience in the face of potentially traumatic events
- Traumatic stress syndromes

### ACUTE STRESS DISORDER (ASD)

### POSTTRAUMATIC STRESS DISORDER (PTSD)

- Re-experiencing symptoms
- Avoidance and numbing symptoms
- Arousal symptoms
- Associated features
- Comorbid conditions
- Prevalence and incidence of PTSD
- The course of PTSD
- Economic burden of PTSD
- Posttraumatic mental health disorders: key differences between ASD and PTSD

### SCREENING, ASSESSMENT AND DIAGNOSIS

- Comprehensive assessment of PTSD
- Diagnosis
- Differential diagnosis
- ‘Recovered memories’
- Symptom exaggeration and malingering
- Assessment instruments

### INTERVENTION PLANNING

- Factors influencing treatment outcome
- Treatment goals
- Cultural and linguistic diversity
- The impact of PTSD on family
- General professional issues
## 3 INTERVENTIONS

### PSYCHOLOGICAL INTERVENTIONS

- Trauma-focussed CBT
- Eye movement desensitization reprocessing (EMDR)
- Brief psychodynamic psychotherapy
- Stress management
- Supportive counselling/therapy
- Narrative exposure therapy (NET)
- Hypnosis/hypnotherapy
- Interapy
- Imagery rehearsal
- Group therapy
- Debriefing
- Psychological first aid

### PHARMACOLOGICAL INTERVENTIONS

### PHYSICAL THERAPIES

- Medical
- Exercise
- Alternative therapies

### PSYCHOSOCIAL REHABILITATION

## 4 EVIDENCE REVIEW AND TREATMENT RECOMMENDATIONS FOR ADULTS WITH PTSD

### INTERVENTIONS FOR ADULTS WITH PTSD

- Psychological interventions
- Single versus multiple psychological interventions
- Individual and group psychological interventions
- Self-delivered interventions
- Pharmacological interventions
- Combined pharmacological interventions
- Initial psychological or pharmacological intervention
- Combined psychological and pharmacological intervention
- Psychosocial rehabilitation
- Physical therapies and exercise
- Comorbidities
### 5 EVIDENCE REVIEW AND TREATMENT RECOMMENDATIONS:
#### EARLY INTERVENTION

<table>
<thead>
<tr>
<th>INTERVENTIONS FOR ADULTS EXPOSED TO POTENTIALLY TRAUMATIC EVENTS</th>
<th>103</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychological interventions</td>
<td>103</td>
</tr>
<tr>
<td>Pharmacological interventions</td>
<td>109</td>
</tr>
<tr>
<td>Combined psychological and pharmacological interventions</td>
<td>111</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INTERVENTIONS FOR ADULTS WITH ASD</th>
<th>115</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychological interventions</td>
<td>115</td>
</tr>
<tr>
<td>Pharmacological interventions</td>
<td>119</td>
</tr>
<tr>
<td>Combined interventions</td>
<td>121</td>
</tr>
</tbody>
</table>

### 6 ECONOMIC CONSIDERATIONS

<table>
<thead>
<tr>
<th>SUMMARY OF LITERATURE COLLECTED</th>
<th>127</th>
</tr>
</thead>
<tbody>
<tr>
<td>COMMENTARY ON ECONOMIC BURDEN</td>
<td>128</td>
</tr>
<tr>
<td>CURRENT FUNDING OF ASD/PTSD TREATMENT</td>
<td>129</td>
</tr>
<tr>
<td>POTENTIAL IMPLICATIONS</td>
<td>129</td>
</tr>
<tr>
<td>RECOMMENDATIONS</td>
<td>129</td>
</tr>
</tbody>
</table>

### 7 SPECIFIC POPULATIONS AND TRAUMA TYPES: ISSUES FOR CONSIDERATION IN THE APPLICATION OF THE GUIDELINES

<table>
<thead>
<tr>
<th>ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLES</th>
<th>134</th>
</tr>
</thead>
<tbody>
<tr>
<td>REFUGEES AND ASYLUM SEEKERS</td>
<td>137</td>
</tr>
<tr>
<td>MILITARY AND EMERGENCY SERVICE PERSONNEL</td>
<td>141</td>
</tr>
<tr>
<td>MOTOR VEHICLE ACCIDENT AND OTHER INJURY SURVIVORS</td>
<td>144</td>
</tr>
<tr>
<td>VICTIMS OF CRIME</td>
<td>145</td>
</tr>
<tr>
<td>SEXUAL ASSAULT</td>
<td>147</td>
</tr>
<tr>
<td>NATURAL DISASTERS</td>
<td>149</td>
</tr>
<tr>
<td>TERRORISM</td>
<td>151</td>
</tr>
</tbody>
</table>

**ADDENDUM TO THE SPECIAL POPULATIONS SECTION: NICE GUIDELINE RECOMMENDATIONS FOR THE RECOGNITION AND MANAGEMENT OF PTSD IN CHILDREN AND YOUNG PEOPLE**

<table>
<thead>
<tr>
<th>GLOSSARY OF TERMS</th>
<th>156</th>
</tr>
</thead>
<tbody>
<tr>
<td>REFERENCES</td>
<td>158</td>
</tr>
<tr>
<td>APPENDICES</td>
<td>Included in accompanying CD-ROM</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>Appendix A</td>
<td>Guideline working party members</td>
</tr>
<tr>
<td>Appendix B</td>
<td>Multidisciplinary panel members</td>
</tr>
<tr>
<td>Appendix C</td>
<td>Expert panel members</td>
</tr>
<tr>
<td>Appendix D</td>
<td>Adelaide health technology assessment reviewers</td>
</tr>
<tr>
<td>Appendix E</td>
<td>ACPMH project support team</td>
</tr>
<tr>
<td>Appendix F</td>
<td>Process report</td>
</tr>
<tr>
<td>Appendix G</td>
<td>Evidence tables</td>
</tr>
<tr>
<td>Appendix H</td>
<td>Excluded studies</td>
</tr>
<tr>
<td>Appendix I</td>
<td>Updated meta-analyses</td>
</tr>
<tr>
<td>Appendix J</td>
<td>NICE grading scheme</td>
</tr>
</tbody>
</table>
List of abbreviations

<table>
<thead>
<tr>
<th>A, B, C, D, GPP</th>
<th>Grades of evidence forming the basis for a guideline statement for NICE guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACPMH</td>
<td>Australian Centre for Posttraumatic Mental Health</td>
</tr>
<tr>
<td>AHTA</td>
<td>Adelaide Health Technology Assessment</td>
</tr>
<tr>
<td>ASD</td>
<td>Acute stress disorder</td>
</tr>
<tr>
<td>BAI</td>
<td>Beck anxiety inventory</td>
</tr>
<tr>
<td>BDI</td>
<td>Beck depression inventory</td>
</tr>
<tr>
<td>CAPS</td>
<td>Clinician-administered PTSD scale for DSM–IV</td>
</tr>
<tr>
<td>CBT</td>
<td>Cognitive behavioural therapy</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CIDI</td>
<td>Composite international diagnostic interview</td>
</tr>
<tr>
<td>CISD</td>
<td>Critical incident stress debriefing</td>
</tr>
<tr>
<td>CISM</td>
<td>Critical incident stress management</td>
</tr>
<tr>
<td>COAG</td>
<td>Council of Australian Governments</td>
</tr>
<tr>
<td>DES-II</td>
<td>Dissociative experiences scale-II</td>
</tr>
<tr>
<td>DESNOS</td>
<td>Disorders of extreme stress not otherwise specified</td>
</tr>
<tr>
<td>DSM-IV</td>
<td><em>Diagnostic and Statistical Manual of Mental Disorders</em>, fourth edition</td>
</tr>
<tr>
<td>DTS</td>
<td>Davidson trauma scale</td>
</tr>
<tr>
<td>DVA</td>
<td>Department of Veterans’ Affairs</td>
</tr>
<tr>
<td>EMDR</td>
<td>Eye movement desensitization and reprocessing</td>
</tr>
<tr>
<td>GAR</td>
<td>Guideline assessment registrar</td>
</tr>
<tr>
<td>GP</td>
<td>General practitioner</td>
</tr>
<tr>
<td>GPP</td>
<td>Good practice point</td>
</tr>
<tr>
<td>HAMA</td>
<td>Hamilton rating scale for anxiety</td>
</tr>
<tr>
<td>HAMD</td>
<td>Hamilton rating scale for depression</td>
</tr>
<tr>
<td>HMO</td>
<td>Health maintenance organisation</td>
</tr>
<tr>
<td>HTA</td>
<td>Health technology appraisal</td>
</tr>
<tr>
<td>IES</td>
<td>Impact of event scale</td>
</tr>
<tr>
<td>ITT</td>
<td>Intention-to-treat</td>
</tr>
<tr>
<td>k</td>
<td>Number of studies, the evidence from which has been used to compile an evidence statement</td>
</tr>
<tr>
<td>MADRS</td>
<td>Montgomery-Asberg depression rating scale</td>
</tr>
<tr>
<td>MDP</td>
<td>Multidisciplinary panel</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>MVA</td>
<td>Motor vehicle accident</td>
</tr>
<tr>
<td>n</td>
<td>Number of participants</td>
</tr>
<tr>
<td>NET</td>
<td>Narrative exposure therapy</td>
</tr>
<tr>
<td>NHMRC</td>
<td>National Health and Medical Research Council</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Clinical Excellence (UK)</td>
</tr>
<tr>
<td>NNH</td>
<td>Number needed to harm</td>
</tr>
<tr>
<td>NNT</td>
<td>Number needed to treat</td>
</tr>
<tr>
<td>PCL</td>
<td>PTSD checklist</td>
</tr>
<tr>
<td>PDS</td>
<td>Posttraumatic Diagnostic Scale</td>
</tr>
<tr>
<td>PE</td>
<td>Prolonged exposure</td>
</tr>
<tr>
<td>PICO</td>
<td>Specifies the studies to be included in the systematic review by: population, intervention, comparator, outcome</td>
</tr>
<tr>
<td>PSS</td>
<td>Posttraumatic stress scale</td>
</tr>
<tr>
<td>PTE</td>
<td>Potentially traumatic event</td>
</tr>
<tr>
<td>PTSD</td>
<td>Posttraumatic stress disorder</td>
</tr>
<tr>
<td>QOL</td>
<td>Quality of life</td>
</tr>
<tr>
<td>QOLI</td>
<td>Quality of life inventory</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>RR</td>
<td>Relative risk/risk ratio</td>
</tr>
<tr>
<td>rTMS</td>
<td>Repeated transcranial magnetic stimulation</td>
</tr>
<tr>
<td>SCL</td>
<td>Symptom checklist</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>SIT</td>
<td>Stress inoculation training</td>
</tr>
<tr>
<td>SMD</td>
<td>Standard mean difference</td>
</tr>
<tr>
<td>SSRI</td>
<td>Selective serotonin reuptake inhibitors</td>
</tr>
<tr>
<td>STAI</td>
<td>Spielberger state-trait anxiety inventory</td>
</tr>
<tr>
<td>SUD</td>
<td>Substance use disorder</td>
</tr>
<tr>
<td>TBI</td>
<td>Traumatic brain injury</td>
</tr>
<tr>
<td>VA/DoD</td>
<td>Veterans Affairs/Department of Defense (US)</td>
</tr>
<tr>
<td>YLD</td>
<td>Years lived with disability</td>
</tr>
</tbody>
</table>
Acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) are psychological reactions that develop in some people following the experience of traumatic events such as major disaster, war, sexual or physical assault, motor vehicle accidents, and torture. Exposure to a traumatic event is not an uncommon experience. Large community surveys in Australia and overseas reveal that 50–65 per cent of people report at least one traumatic event in their lives. Most people will have some kind of psychological reaction to trauma — feelings of fear, sadness, guilt and anger are common. However, the majority recover over time with only a small proportion developing ASD or PTSD. It is estimated that 1.3 per cent of Australians have experienced PTSD in the last year, and that between 5 and 10 per cent of people have had PTSD at some point in their lives.

ASD and PTSD are very similar psychological disorders, sharing the following core symptoms:

- **Re-experiencing** — intrusive distressing recollections of the traumatic event; flashbacks; nightmares; intense psychological distress or physical reactions such as sweating, heart palpitations or panic when faced with reminders of the event
- **Avoidance and emotional numbing** — avoidance of activities, places, thoughts, feelings or conversations related to the event; restricted emotions; loss of interest in normal activities; feeling detached from others
- **Hyperarousal** — difficulty sleeping, irritability, difficulty concentrating, hypervigilance, exaggerated startle response.

In addition, ASD includes dissociative symptoms such as detachment, reduced awareness of surroundings, derealisation, depersonalisation, and dissociative amnesia.

The main difference between ASD and PTSD is the time that has elapsed since the traumatic event. ASD is diagnosed between two days and one month after a traumatic incident, and PTSD is diagnosed after the first month.

The volume of research studies on the treatment of ASD and PTSD published over the past decade, and the emerging consensus from those studies, warrants the development of clinical practice guidelines. In recent years practice guidelines have been developed in both the United Kingdom by the National Institute for Clinical Excellence (NICE) (NICE, 2005), and the United States, by the American Psychiatric Association (APA, 2004) and Departments of Veterans Affairs and Defence (VA/DoD, 2004). While the Australian guidelines are tailored to the needs of our population and health care system, where appropriate they have drawn from the systematic reviews underpinning the NICE (2005) and VA/DoD (2004) guidelines.

The guidelines were developed in accord with National Health and Medical Research Council guideline development requirements, by a working party comprising key trauma experts from throughout Australia, in consultation with a multidisciplinary panel comprising representatives of the range of health professionals involved in the care of people with ASD and PTSD, and service users. The systematic review of the literature was undertaken by Adelaide Health Technology Assessment (AHTA), and economic considerations were addressed by an independent health economist.

Eighteen research questions underpinned the systematic review. Eight of these updated questions were previously addressed by the NICE (2005) guidelines, five updated questions were previously addressed by the VA/DoD (2004) guidelines and five were new questions, representing gaps identified in the previous reviews. The findings of the previous systematic reviews were combined with the findings of the current systematic review to determine the current state of the evidence. Recommendations for practice were then developed by the working party on the basis of the current evidence. For areas of practice not addressed by current research, recommendations were developed on the basis of expert consensus opinion. Where gaps were identified in the existing evidence-base, recommendations were made for future research.
In addition to the systematic review of the literature and treatment and research recommendations arising from the review, this guideline document contains background information on ASD and PTSD, screening and assessment, intervention planning, and issues to consider in the application of the guideline recommendations to a range of specific trauma-affected populations. The guidelines are intended as a framework of best practice around which treatment provided by qualified professionals should be structured. They are not intended to be used prescriptively, but applied with clinical judgment to each person’s unique circumstances and overall mental health care needs.

The guideline recommendations along with key background information are presented in two brief companion documents developed for health practitioners and the public respectively. These documents, available from the Australian Centre for Posttraumatic Mental Health website (http://www.acpmh.org.au), are:

*Australian Guidelines for the Treatment of Adults with Acute Stress Disorder and Posttraumatic Stress Disorder: Practitioner Guide.*

*Australian Guidelines for the Treatment of Adults with Acute Stress Disorder and Posttraumatic Stress Disorder: Information for People with ASD and PTSD, their Families and Carers.*
Summary of guideline recommendations

The research evidence and/or expert opinion underpinning these recommendations is presented in the full text of the document. The relevant sections of the document are cited for each recommendation. Similarly, the grading system for each recommendation is fully explained in the Overview of Methodology in Chapter 1. As a quick guide, recommendations are graded A through D according to the quality of the evidence upon which they are based, with A being the highest quality evidence. In the absence of research evidence, expert clinical consensus is indicated by the designation good practice point (GPP). Please note the use of abbreviated forms of posttraumatic stress disorder (PTSD) and acute stress disorder (ASD) in this summary.

SCREENING, ASSESSMENT AND TREATMENT PLANNING

Screening, assessment and diagnosis

2.1 For people presenting to primary care services with repeated non-specific physical health problems, it is recommended that the primary care practitioner consider asking whether the person has experienced a traumatic event and describe some examples of such events. gpp

2.2 Service planning should consider the application of screening of individuals at high-risk for PTSD after major disasters or incidents. gpp

2.3 Programs responsible for the management of refugees should consider the application of culturally appropriate screening for refugees and asylum seekers at high-risk for developing PTSD. gpp

2.4 Screening should be undertaken in the context of a service system that includes adequate provision of services for those who require care. gpp

Comprehensive assessment of PTSD

2.5 A thorough assessment is required, covering PTSD and related diagnoses, quality of life and psychosocial functioning, trauma history, general psychiatric status (noting extent of comorbidity), physical health, substance use, marital and family situation, and vocational and social status. gpp

2.6 Assessment should include assessment of strengths and resilience. gpp

2.7 Assessment and intervention must be considered in the context of the time that has elapsed since the traumatic event occurred. Assessment needs to recognise that whereas the majority of people will display distress in the initial weeks after trauma exposure, most of these reactions will remit within the following three months. gpp

2.8 Assessment and monitoring should be undertaken throughout treatment. When adequate progress in treatment is not being made, the practitioner should revisit the case formulation, reassess potential treatment obstacles and implement appropriate strategies. gpp

Differential diagnosis

2.9 Assessment should cover the broad range of potential posttraumatic mental health problems beyond PTSD. gpp

Assessment instruments

2.10 It is recommended that practitioners be guided in their assessment of PTSD, comorbidity and quality of life by the available validated self-report and structured clinical interview measures. gpp

2.11 It is recommended that practitioners also use self-report measures to support their assessments of treatment outcomes over time. gpp
Intervention planning

2.12 Mental health practitioners are advised to note the presence and severity of comorbidities in their assessments, with a view to considering their implications for treatment planning. (Please note also recommendations 4.40–4.44 regarding PTSD and comorbidity)

2.13 The development of a robust therapeutic alliance should be regarded as the necessary basis for undertaking specific psychological interventions and may require extra time for people who have experienced prolonged and/or repeated traumatic exposure.

2.14 Mental health practitioners should provide a clear rationale for treatment and promote realistic and hopeful outcome expectancy.

Treatment goals

2.15 The practitioner should assess immediate needs for practical and social support and provide education and referrals accordingly.

2.16 Appropriate goals of treatment should be tailored to the unique circumstances and overall mental health care needs of the individual and established in collaboration with the person.

2.17 From the outset, there should be a collaborative focus on recovery and rehabilitation between the person and practitioners and, where appropriate, family members.

Cultural and linguistic diversity

2.18 Recommended treatments for PTSD should be available to all Australians regardless of cultural and linguistic background.

The impact of PTSD on family

2.19 Wherever possible family members should be included in assessment processes, education and treatment planning, and their own needs for care considered alongside the needs of the person with PTSD.

General professional issues

2.20 Primary care practitioners, especially in rural and remote areas, who assume responsibility for the care of people with ASD and PTSD in the absence of specialist providers, should be supported with accessible education and training.

2.21 In their self-care, practitioners should pay particular attention to skill and competency development and maintenance including regular supervision, establishing and maintaining appropriate emotional boundaries with PTSD sufferers, and effective self-care, including maintaining a balanced and healthy lifestyle and responding early to signs of stress.

2.22 For those practitioners who work in an organisational context, broader policies and practices should support individual practitioners in these self-care measures.
INTERVENTIONS FOR ADULTS WITH PTSD

Psychological interventions for adults with PTSD

4.1 Adults with PTSD should be provided with trauma-focussed interventions (trauma-focussed cognitive behavioural therapy [CBT] or eye movement desensitization [EMDR] and reprocessing, in addition to in vivo exposure). a

4.2 As available evidence does not support the importance of eye movements per se in EMDR, it is recommended that practitioners who use EMDR be aware that treatment gains are more likely to be due to the engagement with the traumatic memory, cognitive processing and rehearsal of coping and mastery responses. g pp

4.3 Where symptoms have not responded to one form of first line trauma-focussed interventions (trauma-focussed CBT or EMDR in addition to in vivo exposure), health practitioners may consider the alternative form of trauma-focussed interventions. g pp

4.4 Non trauma-focussed interventions such as supportive counselling and relaxation should not be provided to adults with PTSD in preference to trauma-focussed interventions. b

4.5 Where symptoms have not responded to a range of trauma-focussed interventions, evidence-based non trauma-focussed interventions (such as stress management) and/or pharmacotherapy should be considered. c

4.6 Sessions that involve imaginal exposure require 90 minutes to ensure that therapy is adequate in those sessions. c

4.7 Following diagnosis, assessment and treatment planning, 8–12 sessions of trauma-focussed treatment is usually sufficient. d

4.8 For PTSD sufferers with several problems arising from multiple traumatic events, traumatic bereavement, or where PTSD is chronic and associated with significant disability and comorbidity, further sessions using specific treatments to address those problems may be required. g pp

4.9 Where adults have developed PTSD and associated features following exposure to prolonged and/or repeated traumatic events, more time to establish a trusting therapeutic alliance, more attention to teaching emotional regulation skills and a more gradual approach to exposure therapy may be required. g pp

Individual and group psychological interventions

4.10 Group CBT (trauma-focussed or non trauma-focussed) may be provided as adjunctive to, but should not be considered an alternative to, individual therapy. c

Self-delivered interventions

4.11 For adults with PTSD, self-delivered interventions should not be prescribed in place of evidence-based practitioner delivered interventions. b

4.12 Facilitated, although non face-to-face interventions, such as interapy may be considered where face-to-face practitioner delivered interventions are not available. d

4.13 Self-delivered interventions may be useful as adjunctive to practitioner-delivered interventions. g pp

Pharmacological interventions for adults with PTSD

4.14 Drug treatments for PTSD should not be used as a routine first line treatment for adults, either by general medical practitioners or by specialist mental health professionals, in preference to a trauma-focussed psychological therapy. a

(See also Combined psychological and pharmacological treatment Recommendation 4.30 and 4.31)

4.15 Where medication is considered for the treatment of PTSD in adults, selective serotonin reuptake inhibitors (SSRI) antidepressants should be the first choice for both general practitioners and mental health specialists. b

4.16 Other new generation antidepressants (notably mirtazapine) and the older tricyclic antidepressants should be considered as a second-line option. Phenelzine should be considered for use by mental health specialists for people with treatment resistant symptoms. b
4.17 Antidepressant medication should be considered for the treatment of PTSD in adults when:

- the sufferer is unwilling to engage in trauma-focussed psychological treatment gpp
- the sufferer is not sufficiently stable to commence trauma-focussed psychological treatment (as a result, for example, of being actively suicidal or homicidal, or of severe ongoing life stress such as domestic violence) gpp
- the sufferer has not gained significant benefit from trauma-focussed psychological treatment gpp
- the sufferer is experiencing a high level of dissociative symptoms that are likely to be significantly exacerbated by trauma-focussed therapy. gpp

4.18 Where a decision has been made to commence pharmacotherapy, the person’s mental state should be regularly monitored with a view to commencing adjunctive psychological treatment if/when appropriate. In the interim, supportive psychotherapy with a substantial psychoeducational component should be offered. gpp

4.19 Where significant sleep disturbance or excessive distress does not settle in response to reassurance, simple psychological first aid, or other non-drug intervention, cautious use of hypnotic medication may be appropriate in the short term. If the sleep disturbance is of more than one month duration and medication is likely to be of benefit in the management of the person’s PTSD, a suitable antidepressant should be considered. The risk of tolerance and dependence are relative contraindications to the use of hypnotics for more than one month except if their use is intermittent. gpp

4.20 Antidepressant medication (see Recommendation 4.15) should be considered as an adjunct to psychological treatment in adults where core PTSD symptoms are of sufficient severity to significantly interfere with the sufferer’s ability to benefit from psychological treatment. gpp

4.21 Where conditions comorbid with PTSD (e.g., depression, other anxiety conditions) are of sufficient severity to significantly interfere with the sufferer’s ability to benefit from psychological treatment, or where a more rapid relief of symptoms is likely to offer significant clinical benefit, drug treatments that have a demonstrable evidence base for the treatment of that condition should be considered. gpp

4.22 Where symptoms have not responded adequately to pharmacotherapy, consideration should be given to:

- increasing the dosage within approved limits gpp
- switching to an alternative antidepressant medication gpp
- adding risperidone or olanzapine as an adjunctive medication gpp
- considering the potential for psychological intervention. gpp

4.23 When an adult sufferer with PTSD has responded to drug treatment, it should be continued for at least 12 months before gradual withdrawal. b

4.24 Best practice prescribing procedures should be adopted when using drug treatments for PTSD in adults, including provision of information prior to commencement, monitoring and management of side effects, monitoring of suicide risk, and appropriate discontinuation and withdrawal practices. gpp

4.25 Adult PTSD sufferers receiving pharmacotherapy should be seen at least weekly if there is a significant risk of suicide; if there is no significant risk of suicide, fortnightly contact is recommended initially, dropping to less frequent after three months if the response is good. The role of the clinician in providing information and support is an important component of the management. gpp

Combined pharmacological interventions

4.28 Where symptoms have not responded to pharmacotherapy, consideration should be given to adding olanzapine as an adjunctive medication. c

Initial psychological or pharmacological intervention

4.29 Drug treatments for PTSD should not be used as a routine first line treatment for adults, either by general medical practitioners or by specialist mental health professionals, in preference to a trauma-focussed psychological therapy. b

Combined psychological and pharmacological interventions

4.30 In cases where the person has not gained benefit from first-line psychological treatments, health practitioners may wish to consider commencing adjunctive pharmacotherapy gpp

4.31 Where a decision has been made to commence treatment pharmacotherapy, the person’s mental state should be constantly monitored with a view to commencing adjunctive psychological treatment if/when appropriate. In the interim, supportive psychotherapy with a substantial psychoeducational component should be offered. gpp
Psychosocial rehabilitation

4.32 There should be a focus on vocational, family and social rehabilitation interventions from the beginning of treatment. gpp

4.33 Where symptoms of PTSD have been present for three months or longer, psychosocial rehabilitation should be considered as an intervention to prevent or reduce disability associated with the disorder. gpp

4.34 In cases where people with PTSD have not benefited from a number of courses of evidence-based treatment, psychosocial rehabilitation interventions may reduce disability, improve functioning and community tenure. gpp

4.35 Health care professionals should be aware of the potential benefits of psychosocial rehabilitation and promote practical advice on how to access appropriate information and services. gpp

4.36 Psychosocial rehabilitation interventions should be provided by competent and appropriately qualified practitioners who received regular supervision. gpp

4.37 Psychosocial rehabilitation may be used as an adjunctive therapy in combination with psychotherapy or pharmacotherapy. gpp

Physical therapies and exercise

4.39 As part of general mental health care, practitioners may wish to advise people with PTSD that regular aerobic exercise may be helpful in managing their symptoms and as part of self-care practices more generally. gpp

Sequencing treatment in the context of comorbidity

4.40 In the context of comorbid PTSD and depression, health practitioners may consider treating the PTSD first, as the depression will often improve with treatment of the PTSD. b

4.41 Where the severity of comorbid depression precludes effective engagement in therapy and/or is associated with high-risk suicidality, health practitioners are advised to manage the suicide risk and treat the depression prior to treating the PTSD. gpp

4.42 In the context of PTSD and substance use disorders, practitioners should consider treating both conditions simultaneously. c

4.43 In the context of PTSD and substance use disorders, the trauma-focused component of PTSD treatment should not commence until the PTSD sufferer has demonstrated a capacity to manage distress without recourse to substance use, and to attend sessions without being drug or alcohol affected. d

4.44 In the context of PTSD and substance use disorders where the decision is made to treat substance use disorders first, treatment should include information on PTSD and strategies to deal with PTSD symptoms as the person controls their substance abuse. gpp
**EARLY INTERVENTION**

**Treatment for all: psychological interventions**

5.1 For adults exposed to trauma, structured psychological interventions such as psychological debriefing should not be offered on a routine basis.  

5.2 For adults exposed to trauma, clinicians should implement psychological first aid in which survivors of potentially traumatic events are supported, immediate needs met, and monitored over time. Psychological first aid includes provision of information, comfort, emotional and instrumental support to those seeking help. Psychological first aid should be provided in a stepwise fashion tailored to the person’s needs.  

5.3 Adults exposed to trauma who wish to discuss the experience, and demonstrate a capacity to tolerate associated distress, should be supported in doing so. In doing this, the practitioner should keep in mind the potential adverse effects of excessive ventilation in those who are very distressed.  

5.4 For adults who develop an extreme level of distress or are at risk of harm to self or others, immediate psychiatric intervention should be provided.  

**Treatment for all: pharmacological interventions**

5.5 For adults exposed to trauma, drug treatments should not be used non-selectively as a preventive intervention.  

**Treatment for ASD: psychological interventions**

5.6 Adults displaying ASD or PTSD reactions at least two weeks after the traumatic event should be offered trauma-focussed cognitive behaviour therapy including exposure and/or cognitive therapy once a clinical assessment has been undertaken.  

5.7 For adults with ASD, treatment should be provided on an individual basis.  

5.8 For adults with ASD, trauma-focussed CBT should, under normal circumstances, be provided in 5–10 sessions.  

5.9 For adults with ASD, 90 minutes should be allowed for sessions that involve imaginal exposure.  

5.10 Trauma-focussed interventions should not commence within two weeks of trauma exposure.  

5.11 Combination psychological interventions for ASD should not be used routinely.  

**Treatment for ASD: pharmacological interventions**

5.13 Drug treatments should generally not be used to treat ASD or related conditions (i.e., within four weeks of symptoms onset) in adults unless the severity of the person’s distress can not be managed by psychological means alone, particularly when there is a pattern of extreme hyperarousal.  

5.14 In individuals who have a prior history of depression that has responded well to medication, the prescription of an antidepressant should be considered if a progressive pattern of clinically significant symptoms, such as persistent intrusions with increasing affective distress, begin to emerge.  

5.15 Where significant sleep disturbance does not settle in response to reassurance and simple psychological first aid, cautious use of hypnotic medication or other drug treatment may be appropriate for adults in the short term.  

**Combined interventions for adults with ASD**

5.17 Trauma-focussed CBT should be used for the treatment of ASD and acute PTSD.  

**Economic considerations**

6.1 Conduct a comprehensive assessment of the economic burden associated with PTSD.  

6.2 Implement economic evaluation studies alongside clinical evaluations of various treatment options.  

6.3 Review financing arrangements from the treatment of PTSD in Australia.
WHAT ARE CLINICAL PRACTICE GUIDELINES?

Clinical practice guidelines are systematically developed statements formulated to assist health practitioners, consumers and policy makers to make appropriate decisions about health care. Such statements of ‘best practice’ are based on a thorough evaluation of the evidence from published research studies on the outcomes of treatment or other health care procedures (NHMRC, 2000b: vii).

RATIONALE FOR DEVELOPING PRACTICE GUIDELINES ON THE TREATMENT OF ACUTE STRESS DISORDER AND POSTTRAUMATIC STRESS DISORDER

Over the last decade there have been an increasing number of published research studies on the outcomes of a range of treatments for acute stress disorder (ASD) and posttraumatic stress disorder (PTSD). As such, it is now possible to generate evidence-based clinical practice guidelines. In recent years both the United Kingdom National Institute for Clinical Excellence (NICE) (NICE 2005) and the United States American Psychiatric Association (APA) 2004, and departments of Veterans Affairs/Defence (VA/DoD) 2004, have published treatment guidelines for PTSD. In the development of these Australian clinical practice guidelines, we drew on the systematic reviews that underpinned the NICE (2005) and VA/DoD (2004) guidelines, including the adaptation of recommendations made in these previous guideline documents where appropriate. However, there is a need to develop guidelines tailored to Australian needs and its health care system.

OBJECTIVE OF THESE GUIDELINES

These guidelines aim to support high quality treatment for adults with ASD and PTSD by providing a framework of best practice around which to structure treatment. The guidelines have been designed to be used by: the range of general and mental health practitioners planning treatment across clinical settings; consumers making decisions about their treatment; and funding bodies making service purchasing decisions. These guidelines should not be regarded as an inflexible prescription for the content of treatment, and they should not limit treatment innovation and development that is based upon scientific evidence, expert consensus, practitioner judgment of the needs of the person and the person’s preferences.

SCOPE OF THE GUIDELINES

These guidelines provide information and recommendations about evidence-based methods of treating adults who, following exposure to traumatic events, have developed (or are at risk of developing) problems consistent with the criteria for ASD and PTSD. The guideline developers recognise that there are a number of interventions that are widely used in clinical practice that have not been adequately tested and it is important to acknowledge that the absence of evidence does not necessarily mean that these interventions are ineffective. The gap between evidence-based interventions and routine clinical practice should help define the research agenda into the future.
The guidelines have been formulated with the assumption that treatment will be provided by qualified professionals who are skilled in the relevant psychosocial and medical interventions, as assessed against the prevailing professional standards. The guidelines do not substitute for the knowledge and skill of competent individual practitioners. The recommendations are not intended to be used prescriptively, but as a guide to appropriate interventions in the context of each person’s unique circumstances and their overall mental health care needs. Practitioners should use their experience and expertise in applying these guidelines in routine clinical practice. In the application of these guidelines to the Australian health care setting, consideration needs to be given to the availability and accessibility of appropriate and relevant services in rural and remote settings, and of appropriate education and training to support practitioners in the delivery of the recommended evidence-based interventions.

In regard to the pharmacotherapeutic recommendations outlined in these guidelines doctors, when prescribing in Australia, should be mindful of regulations that may apply where the cost of the medicine is subsidised by the Government (Schedule of Pharmaceutical Benefits) or another third party.

While adults suffering PTSD in combination with broader posttraumatic mental health problems or other mental health problems may require additional treatment and care, the recommendations in these guidelines are still relevant and applicable. The guidelines are intended to include the care of older adults who do not have significant age-related comorbidity but do not include the care of children for whom there is an independent evidence-based care literature. The United Kingdom (NICE, 2005) recommendations for the care of children with PTSD are included as an addendum to the special populations section.

Most of the evidence reviewed in this guideline comes from clinical efficacy trials. In order to determine the efficacy of treatment, clinical efficacy trials need to have carefully controlled conditions. This often involves substantial deviation from usual care, for example, ‘eliminating treatment preferences, providing free care, using specialised providers and settings, maintaining high treatment compliance, and excluding patients with major comorbid conditions’. (Wells, 1999). In contrast, effectiveness trials evaluate the effects of treatment under standard practice conditions.

While the recommendations outlined in these guidelines are applicable and appropriate to the Australian health care context, there is a need for further evaluation of the recommended interventions under conditions approximating usual care.

**GUIDELINE RECOMMENDATIONS**

The guidelines have been developed using the National Health and Medical Research Council (NHMRC) pilot process, blending the current official NHMRC levels with the interim levels of evidence and system for grading recommendations. Recommendations included in the guideline are graded according to the strength of the evidence upon which they are based. The grading ranges from A for the strongest evidence through to D for the weakest evidence. The designation good practice point (GPP) is given to recommendations based on expert consensus opinion, in the absence of an evidence base. The approach to guideline development and the grading system are outlined in detail in the following section.

Recommendations regarding assessment and treatment practices are made throughout the guideline document. The recommendations are not intended to be used prescriptively but rather as guidelines to assist the practitioner. In each case, assessment and treatment decisions should be based on guideline recommendations combined with the clinical judgment of the practitioner and the person’s preferences.

**APPROACH TO GUIDELINE DEVELOPMENT**

**THE DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES**

The NHMRC have developed a series of ‘Guidelines for Guidelines’ handbooks to assist developers with the process of producing and disseminating clinical practice guidelines (NHMRC, 1999, 2000ab, 2001). These guideline handbooks have been followed in the production of the *Practice Guidelines for Acute Stress Disorder and Posttraumatic Stress Disorder*.

Evidence-based guidelines are practice-based action statements based on the results of systematic literature reviews. Systematic literature reviews use explicit, systematic methods to review the literature underpinning a specific clinical query. Since the technique limits bias and reduces the effect of chance in the review, it provides a more reliable and consistent evidence-base upon which to draw conclusions and to develop clinical practice guidelines.
These reviews are characterised by:

1. The development and statement of a specific research question or hypothesis.
2. A transparent methodical process defined a priori (i.e. a review protocol).
3. An exhaustive search for relevant primary (and secondary) research on the topic.
4. Application of inclusion criteria and critical appraisal of the research.
5. An attempt to answer the research question(s) and to resolve conflicts in the literature.
6. The identification of issues central to future research on the topic and the practical application of results.
7. The development of guidelines or recommendations that are based on this evidence (research), and are applicable to the target population or patient group (Clarke & Oxman, 2000; Cooper & Hedges, 1994; Mulrow et al., 1997; NHMRC, 1999, 2000ab, 2001).

The current guidelines were in the preliminary stages of development when ASD and PTSD treatment guidelines were published in the United Kingdom (NICE, 2005) and the United States (VA/DoD, 2004). The guideline development working party decided to build on those high quality systematic reviews and recent guidelines wherever possible, rather than replicating existing reviews. As such, where questions asked in the previous systematic reviews were similar to those planned in the current systematic review, the same questions were repeated with updated search periods (2002–2005 for questions from the VA/DoD systematic review and 2004–2005 for the NICE review). In this way the previous evidence could be combined with new evidence for the current guideline. The guideline development working party identified only a small number of additional questions, for which a new search (1996–2005) was conducted. The composition of the guidelines working party is in Appendix A.

Research questions for the current review were formulated on the combined basis of questions asked in previous reviews, the working party’s knowledge of the literature, expert consensus opinion on questions of relevance to the field, and consultation with a multidisciplinary panel comprising representatives of mental health professionals and consumers. The composition of the multidisciplinary panel is in Appendix B.

The research questions investigated are listed below. Questions used in previous reviews are marked accordingly.

1. For adults exposed to trauma, do early psychological interventions improve outcomes compared to no intervention? (NICE, 2005)
2. For adults exposed to trauma, does any early psychological intervention confer any advantage over other early psychological interventions? (NICE, 2005)
3. For adults with PTSD, do psychological interventions improve outcomes compared to no intervention? (NICE, 2005)
4. For adults with PTSD, does any psychological intervention confer any advantage over other psychological interventions? (NICE, 2005)
5. Is individual therapy more effective than group therapy for PTSD? (VA/DoD, 2004)
6. For adults with PTSD, is the combination of individual therapy and group therapy more effective than either alone? (New review)
7. Are established interventions for PTSD effective when self-delivered or self-delivered with practitioner support? (New review)
8. For adults exposed to trauma, do early pharmacological interventions improve outcomes compared to no intervention? (NICE, 2005)
9. For adults exposed to trauma, does any early pharmacological intervention confer any advantage over other early pharmacological interventions? (NICE, 2005)
10. For adults with PTSD, do pharmacological interventions improve outcomes compared with a placebo? (NICE, 2005)
11. For adults with PTSD, does any pharmacological intervention confer any advantage over other pharmacological interventions? (NICE, 2005)
12. For adults with PTSD, does psychosocial rehabilitation improve outcomes compared to no intervention? (New search)
13. For adults with PTSD, does psychosocial rehabilitation confer an advantage over any other psychological or pharmacological interventions? (New search)
14. For adults with ASD or PTSD, do physical interventions or exercise confer an advantage over psychological or pharmacological interventions? (New search)
15. For people exposed to trauma, is a single early intervention more effective than multiple early interventions? (VA/DoD, 2004)
16. For adults with PTSD, is a single intervention more effective than multiple interventions? (VA/DoD, 2004)

17. For adults with PTSD, is initial pharmacotherapy more effective than initial psychotherapy? (VA/DoD, 2004)

18. In the context of PTSD and comorbidity, is sequencing of intervention per diagnosis more effective than simultaneous interventions for both diagnoses? (VA/DoD, 2004)

**OVERVIEW OF METHODOLOGY**

As noted in the previous section, this systematic review was designed to update the systematic reviews performed by NICE (2005) and VA/DoD (2004). Both performed systematic reviews consistent with the NHMRC process. The method of reporting findings differed, however, with the method reported by NICE (evidence statements including number of studies [k], standardised mean difference [SMD] and confidence intervals [CI]) lending itself to easier integration of subsequent evidence. For this reason and due to the more recent literature review conducted by NICE, the current review was designed to update the NICE review wherever possible. Where the current review asked questions not addressed by NICE, the VA/DoD review was updated. Where the current review asked questions not addressed by either of the previous reviews, the systematic review was conducted from 1996 onwards. The personnel from Adelaide Health Technology Assessment (AHTA), who conducted the evidence review on behalf of the working party, are in Appendix D.

**Inclusion criteria**

Criteria for including studies in this systematic literature review are provided in the Process Report in Appendix F. In order to ensure that the selection of studies to answer specific research questions was not biased, these criteria were delineated prior to collating the literature. The type of population, intervention (treatment), comparator (against which the treatment’s effectiveness is measured), and outcomes of interest were made explicit — these are known as the PICO criteria and they relate directly to each research question that was addressed. Additional limits to the literature search were also made clear, such as restricting the search to studies of a certain research design(s) (e.g., those studies likely to provide unbiased or more reliable results), or to a certain search period or language.

Studies were excluded if:

- they did not meet the inclusion criteria
- data on outcomes was inadequate (e.g., data presented graphically, missing information, or data were of a type or format unable to be used)
- they were updates of previous studies by the same research group on the same research question for the same participants, with follow-up of less than 50 per cent
- the article could not be located.

To be included, studies needed:

- PTSD symptoms to be measured;
- the main target of the treatment to be ASD or PTSD or preventing the development of these disorders;
- (for questions pertaining to PTSD) at least 70 per cent of the participants to have PTSD, and the remaining participants to have symptoms of PTSD following a traumatic event;
- participants over 16 years old; and
- data on at least 50 per cent of the intent-to-treat sample assessed at the relevant time point.

In studies reporting updates of previous research, only additional follow-up information was included in the current review.
**Literature sources**

To be consistent with the two evidence-based guidelines documents that were being updated (NICE and VA/DoD), the following databases were searched: Medline, Embase, Cinahl, PsychINFO, the Dartmouth College Published International Literature on Traumatic Stress (PILOTS) catalogue and the Cochrane Library. To meet NHMRC requirements, clinical evidence and the internet (Google Scholar, and websites of specialty organisations) along with economic databases (ECONLIT, National Health Service Economic Evaluation database and Health Economic Evaluations Database (HEED)) were also searched, and the reference lists of all included studies were pearl for potentially relevant studies (see Appendix F).

Also, to be consistent with the previous evidence-based guideline documents, the searches were restricted to English language literature and to the highest level of evidence available to answer the research question, that is, if a question could not be answered by a systematic review/meta-analysis of randomised controlled trials (level I evidence), then the search was extended to randomised controlled trials only (level II evidence), then — if unsuccessful — to non-randomised controlled trials/cohort studies (level III evidence) if that was what was required by the inclusion criteria.

**Search strategies**

Since the search strategies used for the two previous reviews (NICE and VA/DoD) were quite different, this review utilises elements of both strategies.

A series of five separate literature searches were conducted to extract comparative studies relating to psychological interventions, pharmacological interventions, psychosocial rehabilitation, physical therapies and exercise and comorbidities. Relevant papers from the searches were identified for each research question. The search terms used are listed in Appendix F. These were developed on a PubMed platform. Similar search strategies were used for the different bibliographic databases, with the same text words being used along with the relevant alternatives to medical subject headings.

**Validity assessment**

Included studies were critically appraised — in terms of internal and external validity — and the statistical and clinical relevance and applicability of results were determined utilising the NHMRC dimensions of evidence (NHMRC, 2000ab) and the recently developed NHMRC interim levels and grades of evidence (see Appendix F). Designated levels of evidence for intervention research questions are presented in Table 1.1 below:

<table>
<thead>
<tr>
<th>Level</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A systematic review of level II studies</td>
</tr>
<tr>
<td>II</td>
<td>A randomised controlled trial</td>
</tr>
<tr>
<td>III-1</td>
<td>A pseudorandomised controlled trial (i.e., alternate allocation or some other method)</td>
</tr>
<tr>
<td>III-2</td>
<td>A comparative study with concurrent controls: non-randomised, experimental trial</td>
</tr>
<tr>
<td></td>
<td>Cohort study</td>
</tr>
<tr>
<td></td>
<td>Case-control study</td>
</tr>
<tr>
<td></td>
<td>Interrupted time series with a control group</td>
</tr>
<tr>
<td>III-3</td>
<td>A comparative study without concurrent controls:</td>
</tr>
<tr>
<td></td>
<td>Historical control study</td>
</tr>
<tr>
<td></td>
<td>Two or more single arm studies</td>
</tr>
<tr>
<td></td>
<td>Interrupted time series without a parallel control group</td>
</tr>
<tr>
<td>IV</td>
<td>Case series with either post-test or pre-test/post-test outcomes</td>
</tr>
</tbody>
</table>

The levels of evidence noted for the NICE evidence statements were as reported in the NICE guidelines. The NICE evidence rating system can be seen in Appendix J. VA/DoD summary statements did not report levels of evidence.

Critical appraisal of the included systematic reviews, randomised and non-randomised studies occurred using the NHMRC quality criteria (NHMRC, 2000ab) (see Appendix F). As noted above, the guidelines have been developed using the NHMRC pilot process, blending the current official NHMRC levels with the interim levels of evidence and system for grading recommendations. This approach has been followed as much as possible, bearing in mind that recommendations 1) often married evidence reported in the NICE and VA/DoD systematic reviews with that of the current review, and 2) spanned more than one research question.
The NHMRC dimensions of evidence (Appendix F) consider three main aspects that are critical to an assessment of evidence: strength of the evidence, size of the effect and relevance of the evidence. The first domain is derived directly from the literature identified as informing a particular intervention. The last two require expert clinical input as part of their determination. These three dimensions of evidence were applied to individual studies during the critical appraisal process.

### Table 1.2 Evidence dimensions

<table>
<thead>
<tr>
<th>Type of evidence</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strength of the evidence</td>
<td>Level: The study design used, as an indicator of the degree to which bias has been eliminated by design. Quality: The methods used by investigators to minimise bias within a study design. Statistical precision: The p-value or, alternatively, the precision of the estimate of the effect. It reflects the degree of certainty about the existence of a true effect.</td>
</tr>
<tr>
<td>Size of effect</td>
<td>The distance of the study estimate from the ‘null’ value and the inclusion of only clinically important effects in the confidence interval.</td>
</tr>
<tr>
<td>Relevance of evidence</td>
<td>The usefulness of the evidence in clinical practice, particularly the appropriateness of the outcome measures used.</td>
</tr>
</tbody>
</table>

*See Appendix F

### Data extraction and analysis

The process of study selection went through six phases and the number of literature citations retrieved and retained at each phase was documented (see Appendix F). Evidence tables were used as a guide to summarise the extraction of data from the individual studies (see Appendix G) (NHMRC, 2005b). Intention-to-treat analyses (ITT) should be used in preference to completer data as it limits the effect of selection bias on the results. Therefore intention-to-treat data was used in preference to completer data, when it was available. However, when such data was not available, completer data were presented and clearly labelled as such.

Meta-analyses for some of our specific research questions were conducted originally in the NICE (2005) guidelines document and were updated, where appropriate, by the results of the new randomised controlled trials identified for this report. Meta-analyses were conducted using a fixed effects model when studies were homogeneous or a random effects model in the presence of between-study heterogeneity (where that heterogeneity could not be explained). Effect measures that were extracted or calculated for individual or pooled results included relative risk (RR) for count data and SMD for continuous data. Heterogeneity in the meta-analysis was assessed using the Cochran Q statistic and publication bias was tested using the Begg funnel plot. Where a meta-analysis could not be conducted, a qualitative synthesis of the data was undertaken.

### Development of evidence statements

Effect sizes were interpreted using methodology developed by NICE (quoted below):

*For each outcome a clinical statement describing the evidence found was developed. To assess clinical importance where a statistically significant summary was obtained (after controlling for heterogeneity) the Group set thresholds for determining clinical importance, in addition to taking into account the trial population and nature of the outcome.*

**Two separate thresholds for determining clinical importance were set. For comparisons of one active treatment against waiting list or non-active interventions, a higher threshold was applied than for comparisons of active treatments against one another.**

**For comparisons of one active treatment against another treatment the following thresholds were applied:** for dichotomous outcomes an RR of 0.80 or less was considered clinically important and for continuous outcomes an effect size of approximately 0.5 (a ‘medium’ effect size; Cohen, 1988) or more* was considered clinically important.

**For comparisons of active treatment against waiting list the following thresholds were applied:** for dichotomous outcomes a RR of 0.65 or less was considered clinically important and for continuous outcomes an effect size of approximately 0.8 (Cohen) or more* was considered clinically important.
In cases where the point estimate of the effect was judged clinically important, a further consideration was made about the precision of the evidence by examining the range of estimates defined by the CI. For level I evidence, where the effect size was judged clinically important for the full range of plausible estimates, the result was described as evidence favouring intervention x over intervention y (i.e. statement 1, or S1). For non-level-I evidence or in situations where the point estimate was clinically important but the CI included clinically unimportant effects, the result was described as limited evidence favouring intervention x over intervention y (i.e., S2). Where a point estimate was judged as not clinically important and the CI did not include any clinically important effects, the result was described as unlikely to be clinically important (i.e., S3). Alternatively, if the range of estimates defined by the CI included clinically important benefits as well as no effect or harmful effects, the result was described as inconclusive (i.e., S4).

S1= There is evidence favouring x over y on…
S2= There is limited evidence favouring x over y on…
S3= There is evidence suggesting that there is unlikely to be a clinically important difference between x and y on…
S4= The evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between x and y on…”

Source: NICE (2005:45)

*An error in the NICE document indicating that a medium effect size of 0.5 or less was considered clinically important for comparison between treatments, and a large effect size of 0.8 or less was considered clinically important for comparison of one treatment with waitlist has been corrected in this reproduction.

NHMRC designations of level of evidence were used (Appendix F). The levels of evidence assigned to the evidence statements reflect the highest level of evidence of a single study amongst those that address the question. All statistical calculations and testing were undertaken using the biostatistical computer package Stata version 8.2 (StataCorp, 2004). Calculations of effect sizes (Hedges G) for individual studies were performed using The Effect Size Generator version 2.3 (Devilly, 2004) and meta-analyses were undertaken using Comprehensive Meta-analysis (Biostat, 2000).

Grading the evidence

The NHMRC pilot process of blending the current official NHMRC levels with the interim levels of evidence and system for grading recommendations was followed as much as possible, given that recommendations were based on combined evidence from previous and current reviews and sometimes spanned more than one research question.

Once each included study was assessed according to the three dimensions of evidence, a grade for the whole body of evidence supporting each recommendation can be determined (see Appendix F).

NHMRC grades of recommendation are provided to assist users of the clinical practice guidelines in making clinical judgments and to indicate the strength of the recommendation. Grade A and B recommendations are generally based on a body of evidence which can be trusted to guide clinical practice, whereas grade C and D recommendations must be applied carefully to individual clinical and organisational circumstances and should be followed with care (NHMRC, 2005b).

Table 1.3 NHMRC grades of recommendation

<table>
<thead>
<tr>
<th>Grade of recommendation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Body of evidence can be trusted to guide practice</td>
</tr>
<tr>
<td>B</td>
<td>Body of evidence can be trusted to guide practice in most situations</td>
</tr>
<tr>
<td>C</td>
<td>Body of evidence provides some support for recommendation(s) but care should be taken in its application</td>
</tr>
<tr>
<td>D</td>
<td>Body of evidence is weak and recommendation must be applied with caution</td>
</tr>
</tbody>
</table>

In addition, and following NICE (2005), the designation good practice point (GPP) is given to recommendations based on expert consensus opinion, in the absence of an evidence base.

The applicability (whether the body of evidence is applicable to the Australian health care context) and generalisability (the degree to which the body of evidence is generalisable to the target population for the guidelines) of the evidence, has also been included in the evidence statements. For example, where the evidence is deemed to be both applicable and generalisable, the evidence statement reads: ‘There is relevant and applicable evidence favouring x over y on …’
LIMITATIONS OF THE REVIEW

This systematic review of the treatments for ASD and PTSD is limited by the following factors. The review:

- does not assess levels of evidence lower than randomised controlled trials (level II intervention evidence) for many questions due to the inclusion criteria specified in the guideline documents that this review was updating

- does not provide a comprehensive review of potential safety issues (i.e., most studies were too small to detect many adverse events, particularly rare adverse events) — this is of specific relevance to the section on pharmacological treatments

- duplicates some of the NICE guidelines document as the search periods overlapped for some months in 2004

- was based on the NICE systematic review and the VA/DoD guidelines, which both have their own limitations. In updating these guidelines, some of these limitations must be acknowledged, despite the use of a near identical methodology
  - The NICE guidelines stated that intention-to-treat data would be used where available, however, in at least one instance completer data was used where intention-to-treat data was available (Kubany et al., 2004).
  - Effect sizes were calculated on the difference in posttreatment scores between the groups, the assumption being that randomisation negated any potential baseline differences between the groups. This assumption may be valid for large trials but is not necessarily correct for small trials.
  - Some of the studies included in the reviews presented statistical testing on a large range of outcomes, without correction for multiple comparisons in their analysis. This increases the likelihood that a statistically significant difference will be identified, just through chance.
ASD and PTSD

Trauma, traumatic event and potentially traumatic event

The word trauma is used inconsistently within the mental health field, referring at times to an event and at other times to psychological injury arising from an event. Literally, trauma means an injury or wound and so, in mental health terms, it refers to an injury or wound to the ‘psyche’: that is, damage to a person’s emotional or psychological health with its biopsychosocial underpinnings.

Potentially traumatic event (PTE) will be used in these guidelines to refer to events that meet the Diagnostic and Statistical Manual of Mental Disorders (fourth edition) (DSM-IV) (APA, 1994) stressor criterion for PTSD. This term reflects the importance of the subjective component of the experience. A particular event, regardless of how threatening it may seem, is not necessarily going to cause ‘psychic injury’ to all who experience it.

Traumatic event will be used in these guidelines to refer to an event that has actually resulted in psychic injury, and trauma will be used to refer to the psychic injury itself.

Potentially traumatic events

As defined by DSM-IV (APA, 1994), PTEs include any threat, actual or perceived, to the life or physical safety of the individual, their loved ones or those around them. PTEs include, but are not limited to, war, torture, sexual assault, physical assault, natural disasters, accidents and terrorism. Experiences may be single or repeated events. By their very nature, some events are more likely than others to be experienced as extremely traumatic, and cause ongoing difficulties and clinically diagnosable symptoms of ASD and/or PTSD. Intentional acts of interpersonal violence, such as torture and assault, and prolonged and/or repeated events such as childhood sexual abuse and concentration camps are more likely than natural events to result in a traumatic response. It is important to note the definition of PTE’s above includes ‘perceived’ threat. As such, it is the appraisal of the event as a threat to safety or physical integrity that is the critical factor in determining whether an event is considered a PTE.

Although beyond the conceptualisation of PTEs in DSM-IV it is important to recognise the potential for transgenerational effects of trauma, in which the impact of systematic torture, genocide or family violence is seen in mental health problems in the next generation.

Generally, events that do not include an element of serious physical threat are not considered PTEs even if they constitute significant threats to psychological integrity or well being. Thus, events such as divorce or separation, loss of a job, and verbal abuse/harassment would not be considered PTEs.

Common responses to potentially traumatic events

A degree of psychological distress is very common in the early aftermath of traumatic exposure and can therefore be considered a part of the normal response. In cases of severe traumatic events, most people may be symptomatic in the initial fortnight after the event. Traumatised people are likely to experience emotional upset, increased anxiety, and sleep and appetite disturbance. Some will have additional reactions such as fear, sadness, guilt or anger. In most cases, psychological symptoms of distress settle down in the days and weeks following the traumatic event, as people make use of their customary coping strategies and naturally occurring support networks to come to terms with the experience. However, in a minority of people the symptoms persist and develop into ASD and/or PTSD.
Resilience in the face of potentially traumatic events

While the primary focus of this guideline is the treatment of people who develop ASD and/or PTSD following traumatic experience, it needs to be emphasised that the majority of people exposed to trauma do not go on to develop these conditions (see, for example, Bonanno et al.'s 2006 investigation of the consequences of the 9/11 terrorist attacks in New York). Resilience, defined as 'the ability to adapt and cope successfully despite threatening or challenging situations' (Agaibi and Wilson, 2005:198), is the the usual outcome following traumatic exposure (Shalev et al., 2004).

Traumatic stress syndromes

When the individual's psychological distress following exposure to a traumatic event persists, and is severe enough to interfere with important areas of psychosocial functioning, it can no longer be considered a normal response to traumatic exposure. The possibility of a posttraumatic mental health syndrome or disorder, including ASD or PTSD should be considered. It should be noted that the range of other mental health syndromes including anxiety, affective, substance misuse or even psychotic disorders, may be present either alone or together with ASD or PTSD.
ACUTE STRESS DISORDER (ASD)

After an individual has been exposed to a traumatic event they may experience significant distress and/or impairment in social, occupational or other important areas of functioning. When this lasts longer than two days, a diagnosis of acute stress disorder (ASD) may be considered.

The DSM-IV (APA, 1994) requires six criteria to be met in order for the diagnosis of ASD to be made (see Table 2.1). Criterion A requires that the individual experiences or witnesses an event that involved the actual or threatened death or serious injury to self or others, and responded with fear, helplessness or horror. Criterion B refers to dissociative symptoms during or after the event (three or more of: a subjective sense of numbing, detachment or absence of emotional responsiveness, reduced awareness of one’s surroundings, derealisation, depersonalisation, and dissociative amnesia). Criterion C requires one or more re-experiencing symptoms (reliving the event through one or more of: recurrent images, thoughts, dreams, illusions, flashbacks, sense of reliving the experience or distress on exposure to reminders of the event). Criteria D, E and F involve marked avoidance of reminders, marked anxiety or increased arousal, and evidence of significant distress or impairment, respectively. These symptoms must last for a minimum of two days and a maximum of four weeks following the event, after which time a diagnosis of PTSD should be considered. Not surprisingly, a growing body of evidence indicates that individuals who experience ASD are at high-risk of developing PTSD (Difede et al., 2002; Harvey & Bryant., 1999b; Holeva et al., 2001). However, there is also a large body of evidence indicating that many of those who go on to develop PTSD did not meet criteria for ASD (e.g. Creamer et al., 2004). Thus, having an ASD diagnosis is predictive of PTSD, but not having an ASD diagnosis should not necessarily be interpreted as indicating a good prognosis.

Table 2.1 DSM-IV criteria for acute stress disorder

| A. | The person has been exposed to a traumatic event in which both of the following were present: |
|    | (1) The person experienced, witnessed, or was confronted with an event or events that involved actual or threatened death or serious injury, or a threat to the physical integrity of self or others. |
|    | (2) The person’s response involved intense fear, helplessness, or horror. |
| B. | Either while experiencing or after experiencing the distressing event, the individual has three (or more) of the following dissociative symptoms: |
|    | (1) a subjective sense of numbing, detachment or absence of emotional responsiveness |
|    | (2) a reduction in awareness of his or her surroundings (e.g., ‘being in a daze’) |
|    | (3) derealisation |
|    | (4) depersonalisation |
|    | (5) dissociative amnesia (i.e., inability to recall an important aspect of the trauma). |
| C. | The traumatic event is persistently re-experienced in at least one of the following ways: recurrent images, thoughts, dreams, illusions, flashback episodes, or a sense of reliving the experience; or distress on exposure to reminders of the traumatic event. |
| D. | Marked avoidance of stimuli that arouse recollections of the trauma (e.g., thoughts, feelings, conversations, activities, places or people). |
| E. | Marked symptoms of anxiety or increased arousal (e.g., difficulty sleeping, irritability, poor concentration, hypervigilance, exaggerated startle response, motor restlessness). |
| F. | The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning or impairs the individual’s ability to pursue some necessary tasks, such as obtaining necessary assistance or mobilising personal resources by telling family members about the traumatic experience. |
| G. | The disturbance lasts for a minimum of two days and a maximum of four weeks and occurs within four weeks of the traumatic event. |
| H. | The disturbance is not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition, is not accounted for by brief psychotic disorder, and is not merely an exacerbation of a pre-existing axis I or axis II disorder. |
POSTTRAUMATIC STRESS DISORDER (PTSD)

As seen in Table 2.2, DSM-IV requires six criteria to be met in order for the diagnosis of PTSD to be made. Criterion A defines the stressor, including features relating to the event itself (Criterion A1) and the response to the stressor (Criterion A2). The Criteria B, C, and D refer to re-experiencing, avoidance and numbing, and hyperarousal symptom clusters, respectively. One of five, three of seven and two of five criteria are required in each of those symptom clusters respectively, to qualify for the diagnosis. Criterion E stipulates that the symptoms of clusters B, C and D need to have been present for at least one month. Criterion F requires that the disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning. PTSD is specified as acute when the duration of the symptoms is less than three months, and chronic if the duration of the symptoms is three months or more. In instances where the onset of symptoms is at least six months following the event, the disorder is specified as delayed onset.

Re-experiencing symptoms

The re-experiencing symptoms are often regarded as the hallmark feature of traumatic stress. Re-experiencing symptoms include intrusive and unwanted thoughts and images of the event and distressing dreams or nightmares. Re-experiencing symptoms can also include ‘flashbacks’ where sufferers may lose awareness of their surroundings and become immersed in the memory of the event. These flashbacks may be so vivid that people feel as if they are experiencing the traumatic event again. People can become upset or distressed when reminded of what happened, and have intense physical reactions like sweating and rapid heart beat.

Avoidance and numbing symptoms

Avoidance and numbing symptoms are combined in DSM-IV but are generally understood to result from different underlying mechanisms. Avoidance is characterised by deliberate attempts to keep memories of the traumatic event out of mind. Such avoidance can result in a person going to extreme lengths to avoid people, places and activities that trigger distressing memories. While avoidance symptoms involve effortful behaviour, numbing symptoms are involuntary. Numbing symptoms are reflected through a loss of interest in activities that formerly brought enjoyment, detachment or estrangement from others, restricted emotional responses (e.g., being unable to experience joy or love), and a sense of foreshortened future. These numbing symptoms are thought to particularly characterise more chronic and severe forms of the disorder. As such, they are usually considered to be a poor prognostic indicator.

Arousal symptoms

PTSD is associated with a sustained increase in sympathetic nervous system activity, well beyond its adaptive function in response to the traumatic event. The individual experiences ongoing increased arousal, as though the ‘fear system’ has been recalibrated to a higher idling level. Increased arousal is evident in a range of symptoms such as poor concentration and memory, irritability and anger, difficulty in falling and staying asleep, being easily startled, and being constantly alert to signs of danger (hypervigilance).
Table 2.2 DSM-IV criteria for posttraumatic stress disorder

| A | The person has been exposed to a traumatic event in which both of the following were present: |
|   | (1) The person experienced, witnessed, or was confronted with an event or events that involved actual or threatened death or serious injury, or a threat to the physical integrity of self or others. |
|   | (2) The person’s response involved intense fear, helplessness, or horror. Note: In children, this may be expressed instead by disorganised or agitated behaviour |
| B | The traumatic event is persistently re-experienced in one (or more) of the following ways: |
|   | (1) Recurrent and intrusive distressing recollections of the event, including images, thoughts or perceptions. Note: In young children, repetitive play may occur in which themes or aspects of the trauma are expressed. |
|   | (2) Recurrent distressing dreams of the event. Note: In children, there may be frightening dreams without recognisable content. |
|   | (3) Acting or feeling as if the traumatic event were recurring (includes a sense of reliving the experience, illusions, hallucinations, and dissociative flashback episodes, including those that occur on awakening or when intoxicated). Note: In young children, trauma-specific re-enactment may occur. |
|   | (4) Intense psychological distress at exposure to internal or external cues that symbolise or resemble an aspect of the traumatic event. |
|   | (5) Physiological reactivity on exposure to internal or external cues that symbolise or resemble an aspect of the traumatic event. |
| C | Persistent avoidance of stimuli associated with the trauma and numbing of general responsiveness (not present before the trauma), as indicated by three (or more) of the following: |
|   | (1) Efforts to avoid thoughts, feelings or conversations associated with the trauma |
|   | (2) Efforts to avoid activities, places or people that arouse recollections of the trauma |
|   | (3) Inability to recall an important aspect of the trauma |
|   | (4) Markedly diminished interest or participation in significant activities |
|   | (5) Feeling of detachment or estrangement from others |
|   | (6) Restricted range of affect (e.g., unable to have loving feelings) |
|   | (7) Sense of a foreshortened future (e.g., does not expect to have a career, marriage, children, or a normal life span) |
| D | Persistent symptoms of increased arousal (not present before the trauma), as indicated by two (or more) of the following: |
|   | (1) Difficulty falling or staying asleep |
|   | (2) Irritability or outbursts of anger |
|   | (3) Difficulty concentrating |
|   | (4) Hypervigilance |
|   | (5) Exaggerated startle response |
| E | Duration of the disturbance (symptoms in Criteria B, C, and D) is more than 1 month. |
| F | The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning. |
Associated features

In addition to these core symptoms, PTSD is also commonly associated with a range of features including anger/aggression (Forbes et al., 2003), guilt (Kubany et al., 1995, 1996), dissociation (van der Hart et al., 2005) and physical health problems (Schnurr et al., 2005).

A subset of individuals with PTSD, more commonly those who have experienced events of an interpersonal, prolonged and repeated nature (e.g. childhood sexual abuse, imprisonment, torture), often referred to as Type II trauma (Terr, 1991), present with a constellation of characteristic features alongside the core PTSD symptoms. These features can include: impaired emotional control; self-destructive and impulsive behaviour; impaired relationships with others; hostility; social withdrawal; feeling constantly threatened; dissociation; somatic complaints; feelings of ineffectiveness, shame, despair or hopelessness; feeling permanently damaged; and a loss of prior beliefs and assumptions about their safety and the trustworthiness of others (van der Kolk et al., 2005). Issues of chronic self harm and/or suicidal ideation are more common in this group.

People exhibiting this constellation of features are often referred as having complex PTSD (Herman, 1992) or disorders of extreme stress not otherwise specified (DESNOS) (APA, 1994).

Comorbid conditions

In chronic cases of PTSD (beyond three months) the core symptoms rarely exist in isolation. More commonly they exist alongside a number of the associated features, described above, and other comorbid mental health disorders. Epidemiological data drawn from the Australian National Mental Health & Well Being study (Creamer et al., 2001) found that 85 per cent of men and 80 per cent of women with PTSD also met criteria for another axis 1 disorder. Most commonly this included depression (51% of men and 65% of women), generalised anxiety disorder (40% of men and 22% of women), social phobia (23% of men and 13% of women), panic disorder (15% of men and 17% of women), alcohol abuse/dependence (37% of men and 12% of women), and drug abuse/dependence (22% of men and 15% of women). These figures are largely consistent with those found in the American National Comorbidity Survey (Kessler et al., 1995). A small number of studies examine the prevalence of comorbid personality disorder, although these are primarily studies of United States male combat veterans with chronic PTSD. These studies (Bollinger et al., 2000; Southwick et al., 1993) suggest a high comorbidity of personality disorder with chronic PTSD in combat veterans.

In addition to complexities arising from comorbidity, health practitioners working with more chronic cases of PTSD often find themselves having to work with a myriad of psychosocial problems that have evolved secondary to the core disorder.

Prevalence and incidence of PTSD

Rates of PTSD should be considered in the context of rates of exposure to PTEs in the general community. Large community surveys (Kessler et al., 1995; Creamer et al., 2001) reveal that 50–65 per cent of people report at least one PTE in their lives, with many reporting two or more events. In Australia, the most commonly reported PTEs are witnessing death or injury to others (reported by about 35% of the population), accidents (27%), natural disasters (20%), and physical assaults (15%) (Creamer et al., 2001).

When examining PTSD rates, both prevalence and incidence figures are used. Prevalence refers to the proportion of a population that has had PTSD during a given period of time, and incidence refers to the rate at which new diagnoses of PTSD occur following exposure to a PTE.

Reports of lifetime prevalence of PTSD (percentage of the population who have had PTSD at some time in their lives), in community samples range between 5–10 per cent. This can be interpreted to mean that approximately 15–25 per cent of people exposed to PTEs have also had a PTSD diagnosis (Breslau, 2001). These lifetime prevalence rates may be somewhat misleading however, as around half those people who develop PTSD recover in the first 12 months regardless of treatment (Kessler et al., 1995). Reports of 12 month prevalence of PTSD (percentage of the population who have had PTSD in the past year) vary between 1.3 per cent in Australia (Creamer et al., 2001) and 3.9 per cent in the United States (Kessler et al., 1999).

An important risk factor for developing PTSD following a PTE is the nature of the traumatic exposure. Creamer et al (2001) found the highest 12 month prevalence of PTSD was associated with a prior history of rape and molestation, and that the lowest 12 month prevalence of PTSD was associated with natural disasters and witnessing someone being badly injured or killed. These findings closely resemble those of Kessler et al (1995) from the United States data. PTSD has traditionally been associated with military combat and amongst Australia’s Vietnam veterans, the six month and lifetime prevalence of PTSD has been found to be 11.6 per cent, and 20.9 per cent respectively (O’Toole et al., 1996). Comparable, or slightly lower, rates have been found among veterans of other conflicts both in Australia and overseas (Creamer & Forbes, 2003). The prevalence of PTSD following acts of terrorism has been estimated at between 28 and 35 per cent (Lee et al., 2002a).
Currently, prevalence rates of ASD in the general Australian community are not available. However, studies examining the incidence of ASD following particular PTEs have found rates of 16–21 per cent following road traffic accidents (Harvey & Bryant, 1999a; Holeva et al., 2001), and 19 per cent following burn injury (Difede et al., 2002).

The course of PTSD

Information about the course of PTSD has been derived from epidemiological studies (Kessler et al., 1995) that have asked respondents how many weeks, months or years, after onset of symptoms, they continued to have symptoms at least a few times per week. Kessler and colleagues (1995) used these retrospective reports to create ‘survival curves’ or models of the course of PTSD symptoms following exposure to a traumatic event. Their findings suggest that symptoms decreased most substantially in the first 12 months following the event and continued to decline over the following six years. Approximately 40 per cent of people had ongoing PTSD that did not remit even after many years.

Higher rates of unremitting PTSD have been found in other populations. A study of Australian Vietnam veterans found that half those who reported having a diagnosis of PTSD at some point in their lifetime still had the disorder decades later (O'Toole et al., 1996). Similar rates of chronic PTSD have been found in firefighters after a major bushfire, where 56 per cent of those who had the disorder following the fire still had it four years later (McFarlane & Papay, 1992). Data from several studies suggest that people who meet PTSD criteria at around six months post trauma are likely (in the absence of effective treatment) to show a chronic course with symptoms lasting for many decades (Kessler et al., 1995; Solomon, 1989).

PTSD is less likely to follow a chronic course with effective treatment. On the basis of several studies it is reasonable to assume that around one-third will make a good recovery following effective treatment, one-third will do moderately well and one-third are unlikely to benefit.

Economic burden of PTSD

Following a literature review of the population prevalence and societal cost of PTSD, Kessler (2000) concluded that, as a highly prevalent and impairing condition that is frequently associated with psychiatric comorbidity and broader societal costs, including work impairment and reduced life course opportunities (educational attainment, teenage childbearing, marital instability and earning capacity), PTSD is a high burden disorder. Similarly, Khouzam et al (2005) noted that PTSD is often a chronic disorder that impairs functioning in many, if not all, areas of life, with consequences extending beyond the individual to impact on family members and society as a whole.

One index of the societal costs of PTSD is the elevated rate of medical visits and other health service use amongst people with PTSD, compared to similar groups without PTSD. Populations studied include treatment seeking combat veterans (Calhoun et al., 2002), US Vietnam veterans (Schnurr et al., 2000), Australian Vietnam veterans (Marshall et al., 2000), female health organisation members (Walker et al., 2003), psychiatric outpatients (Switzer et al., 1999) and motor vehicle accident survivors (Chan et al., 2003). As yet there is no research that clearly identifies whether these increased health care costs are a direct result of the PTSD or are indirectly accounted for by the poor physical health commonly associated with PTSD (O'Donnell et al., 2005).

In terms of direct treatment costs, Issakidis et al (2004) found that PTSD treatment has higher per case per year costs than any of the other anxiety disorders ($1224 compared to $1188 for panic/agoraphobia, $1011 for social phobia and $795 for generalised anxiety disorder). According to this study, individuals with PTSD constitute one-third of people treated for an anxiety disorder, but their treatment including mental health, general health and pharmaceutical services, accounts for 40 per cent of the total cost of treatment for all anxiety disorders. In Australia in the 1997/8 financial year, this amounted to $158.2 million.

Unfortunately, there is evidence that current treatment practices for PTSD are not cost-effective. The Australian National Survey of Mental Health and Wellbeing (Issakidis et al 2004) has found that PTSD is undertreated in Australia, and when it is treated, optimal care is not always provided. Data from the survey suggest that only 40 per cent of the respondents with PTSD were in current contact with health services for their condition. Of those, 64 per cent had received some component of an evidence-based intervention — medication and/or cognitive behavioural therapy (CBT) — but the pattern of care was not optimal given the current evidence. Current treatment practices, when compared to an optimal treatment regime derived from the literature, reveal a greater emphasis on general practitioner (GP) prescribed medication and less emphasis on psychological interventions from psychologists and psychiatrists. The authors argued that this optimal care regime would be no more expensive, but would result in increased efficacy of care and improved population cost-effectiveness as measured by a decrease in years lived with disability (Issakidis et al., 2004).

In addition to direct health care costs, PTSD has additional indirect costs through work impairment. Kessler and Frank (1997) found that PTSD was associated with an average of 3.6 lost working days per month, a rate similar to that found with depression. Given the morbidity and cost of this disorder, prompt recognition and treatment for PTSD are important public health issues (Khouzam et al., 2005).
Posttraumatic mental health disorders: key differences between ASD and PTSD

There is significant overlap in the diagnostic criteria for the two posttraumatic mental health conditions, ASD and PTSD, described above. The key distinguishing feature between the two disorders is the duration of symptoms required for the diagnosis to be made. ASD is diagnosed between two days and one month following the traumatic event while PTSD requires that the symptoms be present for at least one month following the traumatic event. Acute PTSD is diagnosed if symptoms have persisted for between one and three months; chronic PTSD is diagnosed if symptoms have persisted for three months or more. In terms of symptom constellation, the diagnoses differ only in emphasis; ASD requires a number of dissociative symptoms not included in PTSD, while PTSD places greater emphasis on avoidance symptoms.

SCREENING, ASSESSMENT AND DIAGNOSIS

People with ASD and PTSD will not necessarily present to their doctor or mental health professional with expressed concern about a traumatic experience in the first instance. They may present with any of a range of problems including mood disorders, anger, relationship problems, poor sleep, sexual dysfunction, or physical health complaints such as headaches, gastrointestinal problems, rheumatic pains and skin disorders. Their traumatic experience may not even be mentioned. This problem arises, in part, to avoidance which prevents them speaking about it or seeking assistance. It also needs to be acknowledged that there remains a social stigma attached to mental health problems, and the fear of discrimination may be a barrier to some people reporting their symptoms. Furthermore, there is stigma attached to some forms of traumatic experience such as sexual assault which may discourage the individual from disclosing the experience. The practitioner needs to be sensitive to these issues when screening for PTSD and consider this when selecting cut-off scores in the self-reporting instruments. This problem emphasises the importance of empirically establishing the optimal cut-offs in different populations.

In seeking to understand the origins of presenting problems, the practitioner should routinely enquire about any experience of stressful or traumatic events, recently or in the past. If a traumatic experience is suspected, the practitioner may utilise a traumatic events checklist. If the person endorses any events on the checklist, then it is recommended a brief PTSD screening tool be administered.

There is a range of PTSD screening measures currently in use (see Brewin, 2005, for a recent review). These include the SPAN (Meltzer-Brody et al., 2004: 4 items); the BPTSD-6 (Fullerton et al., 2000), DRPST (Chou et al., 2003: 7 items) and a four question measure published in the United States VA/DoD PTSD treatment guideline document (United States VA/DoD, 2004). There is probably little to choose between the various measures. The following is an example of a screening measure (Breslau et al., 1999) that has been empirically validated.

1. Do you avoid being reminded of the experience by staying away from certain places, people or activities?
2. Have you lost interest in activities that were once important or enjoyable?
3. Have you begun to feel more distant or isolated from other people?
4. Do you find it hard to feel love or affection for other people?
5. Have you begun to feel that there is no point in planning for the future?
6. Have you had more trouble than usual falling or staying asleep?
7. Do you become jumpy or easily startled by ordinary noise or movements?

Research into this scale has established that, among trauma exposed individuals, 71 per cent of people who score positively on four or more items have a diagnosis of PTSD and 98 per cent of people who score less than four do not have a diagnosis of PTSD. On this basis, it can be said that if four or more questions are answered positively, a PTSD diagnosis is likely. This level of diagnostic accuracy is equal or superior to the more lengthy measures.

The section above is predicated on the notion of people presenting to the practitioner for care and the implementation of screening in this context. It is also important to acknowledge that there are populations who may be identified as higher risk on the basis of their exposure to a major disaster, occupational role such as emergency service and military populations, or other population-wide exposure, such as refugees for whom screening may be delivered on a more systematic basis. This has implications for service planning. Screening high-risk populations is a way of identifying those who are at risk, and targeting the resources available to those who are going to benefit from the provision of an evidence-based intervention. Of critical importance to obtaining evidence-based care is the existence of an adequate pool of trained and experienced practitioners within the community. Currently, there are a number of locations where individuals with posttraumatic stress disorder have significant difficulties accessing evidence-based care for these reasons.
RECOMMENDATIONS

2.1 For people presenting to primary care services with repeated non-specific physical health problems, it is recommended that the primary care practitioner consider asking whether the person has experienced a traumatic event, and describe examples of such events. gpp

2.2 Service planning should consider the application of screening of individuals at high-risk for PTSD after major disasters or incidents. gpp

2.3 Programs responsible for the management of refugees should consider the application of culturally appropriate screening for refugees and asylum seekers at high-risk for developing PTSD. gpp

2.4 Screening should be undertaken in the context of a service system that includes adequate provision of services for those who require care. gpp

Comprehensive assessment of PTSD

PTSD is often associated with diffuse and broad patterns of symptoms and impairments, and clinical presentations vary according to the unique characteristics and circumstances of the individual. As such, comprehensive assessment processes are necessary. Comprehensive assessment includes details of the person’s personal history including, but not limited to, trauma history. With regard to trauma history, pretrauma history (encourage disclosure of any prior traumatic experience through routine enquiry), the traumatic event itself, their pretrauma, current and past psychosocial functioning (past psychosocial functioning is particularly important where trauma has involved early sexual or physical abuse), the presence and course of PTSD symptoms, and any comorbid problems (including substance use) should all be considered. Particular attention should also be paid to physical health issues. This may include issues related to injury arising from the traumatic incident to health behaviour change following the incident, to concurrent or developing physical health problems and potential medications prescribed for any physical health issues. Broader quality of life indicators such as physical health, marital and family situation and occupational, legal and financial status should also be assessed. For instance, good social support is associated with recovery (Brewin et al., 2000; Ozer et al., 2003) and, therefore, the person’s support network should be examined. Attention should be directed towards key issues to consider in formulating treatment plans, including prior mental health problems, especially depression (Ozer et al., 2003), prior treatment experience and pretrauma coping strategies. The comprehensive assessment should include assessment of risk of self harm, suicide and harm to others. PTSD sufferers who are suicidal or homicidal need to be closely monitored. The assessment should also consider the person’s resilience and strengths.

It is important to note that comprehensive assessment should not be confined to the initial period of care but should be an ongoing process. Throughout treatment, the person’s wellbeing and progress should be monitored and reassessed in an ongoing way. This becomes particularly critical where treatment does not appear to be helping the person to recover. In these circumstances the practitioner should thoroughly reassess and address co-existing psychosocial problems and more thoroughly assess personality.

RECOMMENDATIONS:

2.5 A thorough assessment is required, covering PTSD and related diagnoses, quality of life and psychosocial functioning, trauma history, general psychiatric status (noting extent of comorbidity), physical health, substance use, marital and family situation and vocational and social status. gpp

2.6 Assessment should include assessment of strengths and resilience. gpp

2.7 Assessment and intervention must be considered in the context of the time that has elapsed since the traumatic event occurred. Assessment needs to recognise that whereas the majority of people will display distress in the initial weeks after trauma exposure, most of these reactions will remit within the following three months. gpp

2.8 Assessment and monitoring should be undertaken throughout treatment. When adequate progress in treatment is not being made, the practitioner should revisit the case formulation, reassess potential treatment obstacles and implement appropriate strategies. gpp

Diagnosis

In most clinical settings, an unstructured interview comprises the primary assessment strategy. However, because PTSD can be grounds for compensation, there may be a need for objective assessment that will stand up to more rigorous scrutiny. Regardless of the context, the practitioner must maintain a balance between providing empathic support to a distressed person while obtaining reliable and objective information. For a comprehensive overview of assessment issues in PTSD see Simon (1995) and Wilson & Keane (1997).
There is currently no agreed gold standard with which to make a comprehensive diagnostic assessment for PTSD. Rather, practitioners should adopt a multifaceted approach incorporating information from a variety of sources. In clinical settings, this may comprise unstructured psychiatric interviews (to collect the information detailed in the previous paragraph), structured clinical interviews, self-report inventories, and (where possible) the report of significant others in the person’s life. In research contexts, the addition of psychophysiological measures which assess sympathetic nervous system activity through measures such as heart rate, blood pressure and perspiration, may provide an extra degree of objectivity, which is rarely practical in clinical settings.

**Differential diagnosis**

It is important to remember that PTSD is not the only mental health consequence of exposure to traumatic events. Other common diagnoses for consideration as potential differential diagnoses include depression, other anxiety disorders such as panic disorder, generalised anxiety disorder and specific phobias, substance abuse/dependence and adjustment disorders. Consideration should also be given to the diagnosis of complicated grief (formerly known as traumatic grief), following bereavement, which has received increasing demand for inclusion as a separate diagnostic entity in the DSM (see Lichtenhal et al., 2004, for a review). Proposed criteria for complicated grief (Horowitz et al., 1997; Prigerson et al., 1999) contain some similarities to PTSD in regard to symptoms such as intrusive thoughts and memories of the deceased, and avoidance of reminders of the loss. Importantly however, complicated grief is also defined by grief-specific symptoms such as yearning and searching for the deceased, which differentiate it from PTSD.

Survivors of prolonged or repeated traumatic events (e.g. childhood sexual abuse, torture) are more likely to experience a number of the associated features of PTSD. There is substantial symptom overlap between this more complex PTSD presentation and borderline personality disorder, and so careful assessment is required to differentiate between these two diagnoses.

**RECOMMENDATIONS**

2.9 Assessment should cover the broad range of potential posttraumatic mental health problems beyond PTSD. gpp

**‘Recovered memories’**

A recovered memory is thought to be the recollection of a memory that has been unavailable to deliberate recall for some period of time. This is distinct from incomplete or fragmented memories that may be associated with PTSD. The issue of recovered memories has most commonly arisen in the area of childhood abuse. It is controversial, and has attracted debate in both the professional and public arenas. While it is possible that trauma memories can be both forgotten and then remembered, and that 'false memories' can be suggested and remembered as true, the former is arguably rare. Therapy that attempts to recover otherwise forgotten memories of childhood abuse as the basis for relieving emotional distress has been criticised for lacking a sound theoretical basis, failing to consider the fallibility of memory and using techniques such as suggestion that increase memory distortion and confabulation. In the absence of corroboration, it is not possible to unequivocally determine the validity of recovered memories.

Risk associated with the concept of recovered memory can be minimised when practitioners are trained to professional standards, conduct full assessments at the start of treatment, adopt a neutral stance towards a history of abuse avoiding preconceived beliefs about factors that may or may not be causing the presenting problems, and avoid use of techniques that increase suggestibility and memory distortion. In the absence of corroboration of new memories of childhood abuse, treatment should enable the person to arrive at their own conclusions with some understanding of memory processes, and to adapt to uncertainty when it persists.

**Symptom exaggeration and malingering**

PTSD is the only mental health condition with experience of a traumatic event as part of the diagnosis. Issues of financial compensation can therefore arise with PTSD, arguably more than for any other disorder. Studies investigating whether compensation seeking affects assessment processes have had mixed results and so any relationship between financial incentives and symptom reporting in PTSD is presently unclear. It is important however, to consider the possibility of symptom exaggeration and malingering in the assessment of PTSD.

The possibility of symptom exaggeration should be carefully considered in any of the following circumstances: the person reports all 17 PTSD symptoms; the person emphasises re-experiencing, (rather than avoidance and numbing) symptoms; or the person does not report sexual dysfunction or sleep disturbance. In order to assist in clarification of this issue, clinicians should not be satisfied with a simple ‘yes/no’ response to questions, but should request further elaboration of reported symptoms (e.g., ‘tell me about the last time you experienced that — what was it like?’). During the interview the practitioner should remain alert for PTSD symptoms that are directly observable (e.g., hypervigilance and flattened affect) and to any contradictions in the person’s reports (e.g., complete inability to work but retention of an active social life).
It needs to be emphasised that the issue of symptom exaggeration and malingering primarily arises in the context of litigation, compensation claims and contested cases rather than in the course of routine clinical practice. Even in these settings, the practitioner must retain and convey empathy for the person to avoid the risk of compounding suffering by being interviewed in an interrogatory fashion.

There are of course factors other than financial gain that can contribute to prolonged symptoms. Secondary gain in social, family or occupational settings may exert a powerful influence on the individual's sick role and ongoing disability, of which they are unaware.

Assessment instruments
Diagnostic instruments for PTSD include both structured clinical interviews and self-report measures.

STRUCTURED CLINICAL INTERVIEWS
Structured clinical interviews provide the optimal strategy for making a reliable clinical diagnosis and an indication of symptom severity. For a competent, well-trained practitioner, these measures combine a standardised and objective instrument with an element of clinical judgment. The questions directly address PTSD symptoms and an objective scale determines whether each is sufficiently severe to meet criteria.

The clinician administered PTSD scale (CAPS) (Blake et al., 1995; Weathers et al., 2001) is a psychometrically robust instrument designed to overcome many of the limitations of other structured PTSD interviews. Each symptom is assessed for intensity and frequency and, where possible, is behaviourally defined. While the CAPS is highly recommended in research settings, it is a little complex for use in routine clinical practice. Several other well validated structured PTSD interviews, which are briefer and simpler to administer, are appropriate in this context (see Weiss, 1997, for a review). Two that are strongly recommended include the PTSD symptom scale interview (PSS-I) (Foa et al., 1993) and the structured interview for PTSD (SIP) (Davidson et al., 1997).

SELF-REPORT MEASURES
There are a variety of general and population-specific self-report measures available to assess PTSD symptoms and a number of comprehensive reviews of measures are available (e.g. Norris & Riad, 1997; Solomon et al., 1996). The best scales are psychometrically robust and relatively non-intrusive. While these measures provide a valid assessment of the person's own perception of his/her symptoms without influence from the interviewer, their weakness lies in the potential for symptom exaggeration or minimisation. They are also limited in their diagnostic accuracy as they pick up general feelings of distress more reliably than specific symptoms. Accordingly, it is not appropriate to rely on self-report measures as the only (or even the primary) diagnostic tool. Rather, they provide a useful screening device prior to more intensive interview procedures, or to assess symptom change as a function of treatment through repeated administration (Forbes et al., 2001).

Several established scales have been in use for decades and continue to be popular among clinicians and researchers (e.g. the impact of events scale, Horowitz et al., 1979). However, the diagnostic criteria have evolved in recent years and it is recommended that newer scales that are consistent with the current diagnostic criteria be used where possible. One example is the PTSD checklist (PCL) (Weathers et al., 1993) which assesses the 17 DSM-IV PTSD symptoms, with each rated on a five-point scale from 'not at all' to 'extremely'. The scale takes only five minutes to complete and possesses excellent psychometric qualities (Blanchard et al., 1996; Forbes et al., 2001). A score of 50 is recommended as the diagnostic cutoff. Separate forms are available for military (M) and civilians (C) stressors. The self-report version of the PTSD symptom scale (PSS) (PSS-SR) (Falsetti et al., 1993) is similar to the PCL, while the Davidson trauma scale (DTS) (Zlotnick et al., 1996) allows for both frequency and intensity ratings. In the final analysis, there is probably little to choose between these scales; any would be a useful addition for clinicians and researchers alike. It is worth noting however, that the PCL is the only scale available in the public domain.

In addition to symptom measures, a broader quality of life instrument that measures progress in recovery and rehabilitation would be of value. One of the most commonly used quality of life measures is the short form of the World Health Organization Quality of Life (WHOQOL) Project, the WHOQOL Bref (WHOQOL Group 1998).

Although there has been increased interest in resilience, there is not yet sufficient data from which to identify an optimal or recommended measure at this point.

RECOMMENDATIONS

2.10 It is recommended that practitioners be guided in their assessment of PTSD, comorbidity and quality of life by the available validated self-report and structured clinical interview measures. gpp

2.11 It is recommended that practitioners also use self-report measures to support their assessments of treatment outcomes over time. gpp
INTERVENTION PLANNING

Factors influencing treatment outcome

There is a range of factors that have been found to potentially influence treatment outcome that should be considered when planning interventions. These factors include comorbid conditions, development of a working or therapeutic alliance, and treatment expectancy. In terms of influence of comorbidity on treatment response, the data are mixed and inconsistent. Several studies identify features such as depression (van Minnen et al., 2002), generalized anxiety disorder (Tarrier et al., 2000), borderline personality disorder (Feeny et al., 2002; Forbes et al., 2002), anger (Foa et al., 1995; Forbes et al., 2003, 2005), alcohol use disorder (Perconte & Griger, 1991; Steindl et al., 2003), social alienation (Ehlers et al., 1998; Forbes et al., 2002), and emotional dysregulation (Cloitre et al., 2002) as negatively influencing outcome. On the other hand, a number of studies have failed to find these outcomes, suggesting that the influence of comorbidity on outcome may be sample specific (van Minnen et al., 2002), or that more specific predictive components of these factors have not yet been identified.

The establishment of a good therapeutic alliance has been found to improve the outcome of PTSD treatment (Cloitre et al., 2002, 2004). This is consistent with findings for a range of other anxiety and mood disorders (Hatcher & Barends, 1996). Unfortunately, for people who have experienced a severe interpersonal trauma such as torture or childhood sexual abuse, the establishment of a trusting therapeutic relationship can often be particularly difficult. In most cases this difficulty will be overcome if the practitioner is able to convey genuine empathy and warmth towards the person.

There is also evidence that a person’s expectation of the outcome of their treatment is positively related to actual outcomes. This effect of treatment expectancy has been found with Vietnam veterans with PTSD (Collins & Hyer, 1986), and others with PTSD, generalized anxiety disorder (Borkovec & Costello, 1993; Devilly & Borkovec, 2000) and social phobia (Chambless et al., 1997).

Interestingly, the evidence suggests that demographic variables such as age, marital status, employment and level of education are unrelated to treatment outcome (Ehlers et al., 1998; Foa et al., 1991; Munley et al., 1994). While female gender may be predictive of PTSD development, findings suggest either that females respond better to treatment (Tarrier et al., 2000) or no significant gender differences in outcome (Jaycox et al., 1998; Marks et al., 1998). Other predictors such as education, IQ and marital status have also been found to be unrelated to outcome.

It is often speculated that outcomes are compromised in people seeking compensation for PTSD, however few studies have investigated this issue. DeViva and Bloem (2003) did not find differences in PTSD treatment outcomes between veterans seeking compensation and those who were not, although neither group showed significant posttreatment improvement. Fontana and Rosenheck (1998) also found that compensation seeking did not affect PTSD treatment outcomes for veterans undergoing outpatient treatment or short term inpatient programs. They did however find that compensation seeking was associated with worse treatment outcomes for veterans undergoing long term inpatient programs that automatically trigger increased benefits.

RECOMMENDATIONS (Please note also recommendations regarding PTSD and comorbidity in Chapter 4)

2.12 Mental health practitioners are advised to note the presence and severity of comorbidities in their assessments, with a view to considering their implications for treatment planning. gpp

2.13 The development of a robust therapeutic alliance should be regarded as the necessary basis for undertaking specific psychological interventions and may require extra time for people who have experienced prolonged and/or repeated traumatic exposure. gpp

2.14 Mental health practitioners should provide a clear rationale for treatment and promote realistic and hopeful outcome expectancy. gpp
Treatment goals

In general terms the goals of treatment of PTSD include reduction in PTSD symptoms and achieving optimal psychosocial functioning. While much of the evidence-based literature focuses on the goal of symptom reduction, the practitioner should not lose sight of the broader wellbeing and quality of life issues. In all cases, the goals of treatment should be established collaboratively with the person, guided by best practice recommendations and a comprehensive assessment of the individual, as outlined above. In terms of symptom focussed treatment, prominent anxiety, anger and guilt all have varying implications for treatment. For some, especially those who have been subjected to protracted child sexual abuse or torture, clinical interventions often need to focus initially on symptoms of dissociation, impulsivity, emotional lability, somatisation and interpersonal difficulties (Foa et al., 2000).

Optimal recovery from PTSD requires a focus on wellbeing and rehabilitation from the outset. Immediate needs for practical and social support should be assessed. The family and broader system of care should be engaged early and provided with information about PTSD, as well as being involved in the collaborative care and recovery plan as far as is possible. Attention should be paid to vocational rehabilitation needs from the outset, which may include supporting the individual's capacity to stay at work.

While the treatment of all adults with PTSD should have a rehabilitation focus, for those with chronic PTSD, improvements in psychosocial functioning may be the primary goal over and above reduction of PTSD symptoms.

RECOMMENDATIONS

2.15 The practitioner should assess immediate needs for practical and social support and provide education and referrals accordingly. \( \text{gpp} \)

2.16 Appropriate goals of treatment should be tailored to the unique circumstances and overall mental health care needs of the individual and established in collaboration with the person. \( \text{gpp} \)

2.17 From the outset, there should be a collaborative focus on recovery and rehabilitation between the person and practitioners and, where appropriate, family members. \( \text{gpp} \)

Cultural and linguistic diversity

Australian adults with PTSD come from diverse ethnic and cultural backgrounds, with English a second language for many. Services should be made as accessible as possible with information available in a number of different languages and distributed through general practitioners and health centres that provide primary care services to various ethnic and cultural groups. Further, interpreters should be available as required. Several issues for consideration when working with interpreters are included in Chapter 7 Refugees and asylum seekers. When working with an individual from a non-English speaking background, the practitioner should familiarise themselves with the person’s cultural background and liaise with population-specific health care providers, as necessary, to understand cultural expressions of distress, and support the appropriate applications of the interventions described in these guidelines.

RECOMMENDATIONS

2.18 Recommended treatments for PTSD should be available to all Australians regardless of cultural and linguistic background. \( \text{gpp} \)

The impact of PTSD on family

The impact of PTSD can extend beyond the individual directly affected, to those around them — family and close friends. As such, the practitioner should consider the support and treatment needs of those close to the person with PTSD as well as the person’s own needs. In involving family members, the person’s confidentiality must be respected and the family members’ clinical needs considered. In exceptional circumstances, where there are issues of risk of harm to self or others, family involvement may need to occur without the person’s consent.

Family members can be affected both directly and indirectly by the person’s PTSD symptoms, and may even develop emotional difficulties of their own as a result. The impact of PTSD on the individual can often lead to him or her becoming more difficult to get along with, for instance becoming more irritable or angry, withdrawing from family involvement, or drinking to excess. Additional problems such as being unable to cope at work may emerge, leading to financial pressures for the family. Family members may adjust their own lives in an attempt to support the family member with PTSD or to conceal difficulties from those outside the family.
Over time, family members may develop emotional problems of their own. In some cases, these may mirror the problems of the person with PTSD, for example, adopting similar views of the world as a dangerous place and resultant fear and avoidant behaviours. In other cases, emotional problems of family members may be in response to living with the person with PTSD, for example, developing feelings of helplessness and hopelessness if the PTSD sufferer’s condition remains untreated and unchanged over time, or turning to alcohol to avoid having to face the problems at home.

**RECOMMENDATIONS**

2.19 Wherever possible, family members should be included in assessment processes, education and treatment planning, and their own needs for care considered alongside the needs of the person with PTSD. 

**General professional issues**

This guideline document makes recommendations about treatment for people with ASD and PTSD on the assumption that treatment is being provided by appropriately qualified and professionally supported practitioners. In effect, this means that individual practitioners should not deliver interventions that are beyond their level of expertise given available training and support.

It needs to be recognised that various practitioners will contribute to the care of the individual with PTSD in different ways. In most cases the specialist symptom-focused interventions will be undertaken by psychiatrists, psychologists and other mental health practitioners specifically trained in recommended treatments, while occupational therapists, rehabilitation counsellors and social workers are more likely to address family, social and occupational recovery, and rehabilitation issues. Ideally, the general practitioner will have an existing relationship with the individual that allows them to provide holistic care and support to the person and family over time. Where a number of practitioners are involved in care, the general practitioner is well placed to assume overall management of care, making appropriate referrals and coordinating the contribution of other practitioners. The individual, their family and carers also play a critical role in support and recovery. Effective collaboration between relevant people is important for optimal care of the person with PTSD.

Unfortunately, this ideal circumstance is not always possible, most notably in rural and remote parts of Australia where a visiting nurse or general practitioner may be the sole health professional in the region. In these circumstances, the responsibility for care of people with ASD and PTSD may largely rest with these primary care practitioners. It needs to be recognised that these practitioners are unlikely to have the time or training to undertake the full range of recommended psychological and psychosocial rehabilitation interventions for ASD and PTSD. Their role is more likely to involve screening, assessment and general psychological interventions such as psychoeducation and arousal management as well as overall mental health care. Where the PTSD sufferer is using self help materials (e.g. web-based treatment) the primary care practitioner should ideally consult with a psychosocial rehabilitation specialist in planning interventions. In their care of people with ASD and PTSD, primary care practitioners should be supported with provision of education and training material that can be accessed remotely, for example via the internet.

All practitioners in the field of posttraumatic mental health need to be aware of the potential adverse impacts of the work on themselves. Health professionals can be at risk of stress or adverse psychological reactions if they do not receive sufficient training and support. Responsibility for self care should be shared between the individual practitioner and, where appropriate, their employer organisation. With evidence that isolation is a risk factor for developing stress related problems, the needs of practitioners working in isolated rural and remote communities again warrant special consideration. For these practitioners, routine training and support needs may need to be addressed remotely, for example via the internet and teleconferencing. General practitioner Balint Groups, which offer peer support to practitioners who are geographically isolated in their work, operate in some areas of Australia (Benson & Magraith, 2005).

**RECOMMENDATIONS**

2.20 Primary care practitioners, especially in rural and remote areas, who assume responsibility for the care of people with ASD and PTSD in the absence of specialist providers, should be supported with accessible education and training.

2.21 In their self care, practitioners should pay particular attention to skill and competency development, and maintenance including regular supervision, establishing and maintaining appropriate emotional boundaries with PTSD sufferers, and effective self care including maintaining a balanced and healthy lifestyle and responding early to signs of stress.

2.22 For those practitioners who work in an organisational context, broader policies and practices should support individual practitioners in these self-care measures.
Interventions

There is a range of psychological and pharmacological interventions currently used in the treatment of people with ASD and PTSD. Of course, in routine clinical practice these interventions do not occur in isolation but in the context of a trusting therapeutic relationship and in many cases, broader mental health care for a range of associated posttraumatic mental health issues.

The systematic evidence review underpinning the development of these guidelines investigated the range of current treatments used for people with PTSD, people with ASD and ‘treatment for all’ following exposure to a traumatic event. In this section, each of the treatments specified in the research questions will be described. Please note that the interventions described in this section are not necessarily recommended treatments for ASD and PTSD.

**TRAUMA-FOCUSED COGNITIVE BEHAVIOURAL THERAPY (CBT)**

Cognitive behavioural therapy is a short-term, structured psychological intervention that aims to address the emotional, cognitive and behavioural sequelae of exposure to traumatic events. CBT strategies are derived from learning and behavioural theories. They include preparatory work in the form of psychoeducation and arousal management along with exposure techniques and cognitive therapies.

Exposure therapy has long been established as an effective treatment for a range of anxiety disorders. The key objective of exposure therapy is to help the person confront the object of their anxieties. A fundamental principle underlying the process of exposure is that of habituation, the notion that if people can be kept in contact with the anxiety provoking stimulus for long enough, their anxiety will inevitably reduce. This may occur within an exposure session or across a series of sessions. In the case of PTSD, this means confronting the memory of their traumatic experiences in a controlled and safe environment (imaginal exposure), as well as confronting trauma-related avoided situations through in vivo exposure to external situations. Exposure therapy, beginning with Foa’s prolonged exposure (PE) for PTSD, has become the cornerstone of psychological treatment of PTSD.

Beck introduced cognitive therapy (CT) into the treatment literature in the 1970s, as a treatment for depression. Since then it has been successfully used in the treatment of a range of other emotional disorders including anxiety disorders and to some extent the psychoses and personality disorders (see Beck, 2005, for an overview). In the treatment of PTSD, cognitive therapy helps the individual to identify, challenge and modify any biased and distorted thoughts and memories of their traumatic experience, as well as any subsequent maladaptive or unhelpful beliefs about themselves and the world they may have developed.

Resick’s cognitive processing therapy (CPT) has been developed for sexual assault victims with PTSD. The therapy combines a small component of exposure to the traumatic memory with systematic cognitive work that addresses themes of safety, trust, power/control, esteem and intimacy.
EYE MOVEMENT DESENSITIZATION REPROCESSING (EMDR)

EMDR is based on the assumption that during a traumatic event, overwhelming emotions or dissociative processes may interfere with information processing, and lead to the experience being stored in an unprocessed way disconnected from existing memory networks. In EMDR, the person is asked to focus on trauma-related imagery, negative thoughts and body sensations while simultaneously moving their eyes back and forth, following the movement of the therapist’s fingers across their field of vision, for 20–30 seconds or more. This process may be repeated many times. It is proposed that this dual attention facilitates the processing of the traumatic memory into existing knowledge networks, although the precise mechanism involved is not known. It is important to note that eye movement desensitization and then EMDR over time has increasingly included more treatment components that would be considered core CBT interventions. These include cognitive interweaving (cognitive therapy), imaginal templating (rehearsal of mastery or coping responses to anticipated stressors) and standard in vivo exposure. Combined with its initial inclusion of imaginal focus on traumatic images, EMDR now includes most of the core elements of standard trauma-focussed CBT. In addition, the protocol has shifted from a single session treatment to a twelve session protocol with the above elements included, comparable in length to standard trauma-focussed CBT.

Given the above, there is a case for considering EMDR, as reflected in its current protocol, as a variant of trauma-focussed CBT with a novel component, rather than as a separate treatment. However, for consistency with other international guidelines, and given the view of the developer of the initial EMDR techniques that it is atheoretical, in these guidelines EMDR will be considered as a separate intervention.

BRIEF PSYCHODYNAMIC PSYCHOTHERAPY

Psychodynamic therapy is a method of treatment that encourages the individual to use the supportive relationship with a therapist and the transference that occurs within that relationship, to verbalise and reflect upon their experiences. This process allows unconsciously held memories, thoughts and emotions to be brought into conscious awareness, which in turn allows the cognitive, emotional and social aspects of experience to be integrated into a meaningful structure that helps the person to accept and adapt to their experiences. Brief models of psychodynamic psychotherapy have been developed for the treatment of PTSD following recent traumatic events. Brief psychodynamic therapy involves a specific trauma focus whereby the individual is encouraged to put their experience into words and examine the meaning that the event and surrounding circumstances holds for them, and thereby integrate the experience.

STRESS MANAGEMENT

Stress management interventions cover a broad range of cognitive, behavioural and physiological techniques aimed at reducing levels of arousal and modifying lifestyle factors that contribute to an individual’s level of stress or anxiety. The application of stress management to PTSD aims to reduce arousal symptoms and address the impact of anxiety and avoidance symptoms on the individual’s lifestyle. Core components of stress management used in PTSD include relaxation training, controlled breathing (to counter hyperventilation), adaptive coping statements for use when confronting feared or avoided situations, and thought-stopping distraction techniques.

SUPPORTIVE COUNSELLING/ THERAPY

Supportive counselling is characterised by the development of a therapeutic relationship that focuses on aspects of a person’s current life situation looking to address and solve current issues or problems. In PTSD, supportive counselling addresses problems arising from posttraumatic psychopathology as well as general circumstances. It aims to help the individual better understand and help themselves through the application of practical problem solving and coping strategies. The level of therapist direction and advice varies in supportive counselling.

NARRATIVE EXPOSURE THERAPY (NET)

NET is a standardised short-term intervention adapted from exposure therapy for survivors of torture and war exposed to numerous traumatic experiences. In NET, the person is asked to construct a complete narrative of their life, focussing in detail on the traumatic events and elaborating on the associated thoughts and emotions. It is proposed that NET works in two ways: promoting habituation to traumatic memories through exposure, and reconstructing the individual’s autobiographic memory.

HYPNOSIS/HYPNOTHERAPY

Hypnotherapy is the therapeutic application of hypnosis to various mental health problems. Hypnosis involves a form of dissociation, in that a state of heightened mental focus and suggestibility is induced, that allows the individual to better control their symptoms. Hypnosis is thought to be of particular value for people with ASD and PTSD because of the maladaptive dissociation involved in some of the symptoms. Hypnosis is used in PTSD in addressing traumatic memories as well as increasing control over hyperarousal symptoms.
INTERAPY

Interapy is an internet-mediated therapy. The therapist and PTSD sufferer communicate via a computer, which is designed to treat posttraumatic stress symptoms and pathological grief, but not a full PTSD diagnosis. Lange et al (2003b) suggest that this approach is particularly useful for people living in remote areas, for those who are physically disabled and have restricted mobility, or who are unwilling to seek face-to-face therapy due to anxiety or fear of stigmatisation. Treatment includes psychoeducation, exposure and cognitive reappraisal, all of which involve structured writing assignments that are submitted to the therapist for feedback.

IMAGERY REHEARSAL

Imagery rehearsal therapy involves the person planning a change to the imagery of the traumatic memory or dream in a way that increases their sense of mastery or control, and then rehearsing the changed imagery in their imagination.

GROUP THERAPY

Group therapies for PTSD include supportive, psychodynamic and cognitive behavioural approaches with common features being homogenous group membership; acknowledgment and validation of the traumatic experience; normalisation of traumatic responses; use of the presence of other individuals with similar experiences to overcome beliefs that the therapist cannot be helpful as they have not experienced the specific trauma; and a non-judgmental approach toward behaviour required for survival during the traumatic event (Foy et al, 2000).

DEBRIEFING

The terms psychological debriefing and critical incident stress debriefing (CISD) are often used interchangeably. The former describes a class of interventions delivered immediately following trauma (usually within three days) that aim to relieve stress in an attempt to mediate or avoid long-term psychopathology. Psychological debriefing operates on the principles of ventilation/catharsis, normalisation of distress, and psychoeducation regarding presumed symptoms. CISD, on the other hand, is a specific form of debriefing developed in the 1980s (Mitchell, 1983, et seq). It centres predominantly around group based interventions for secondary victims such as emergency service personnel, rather than primary victims. While generally group based it also advocates individual (or ‘one-on-one’) interventions as an acceptable and expected variant. It relies heavily on processes of reconstruction of the traumatic event, ventilation and normalisation, and includes a structured education component. More recently, CISD has been amalgamated within a framework of self help activities and structured organisational processes, called critical incident stress management (CISM) (Everly & Mitchell, 1995).

Other models of debriefing have been proposed that emerge from the crisis intervention literature. For example, Raphael's (1986) model of group debriefing is less structured and outlines a range of topics that may be useful for discussion. These include personally experienced disaster stressors such as death encounter, survivor conflict and loss dislocation; positive and negative feelings; victims and their problems and the special nature of disaster work and personal feelings.

PSYCHOLOGICAL FIRST AID

Psychological first aid seeks to reduce distress and provide basic needs following a traumatic event, such as comfort, information, support and immediate practical and emotional (NCTSN/NCTSD, 2006). There are eight core components of psychological first aid. These involve initiating contact and engaging with an affected person in a non-intrusive, compassionate and helpful manner; providing immediate and ongoing safety and both physical and emotional comfort; if necessary, stabilising survivors who are overwhelmed and distraught; gathering information to determine immediate needs and concerns and to tailor psychological first aid interventions; providing practical assistance in helping the survivor address immediate needs and concerns; connecting the survivor with social supports by helping to structure opportunities for brief or ongoing contacts with primary support persons and/or community helping services; providing information on coping, including education about stress reactions and coping (often in a written format) and linking the survivor with collaborative services and providing information about those that may be needed in the future. Thus psychological first aid is designed to enhance an individuals natural resilience and coping in the face of trauma.
PHARMACOLOGICAL INTERVENTIONS

Pharmacological treatments (medications) used in PTSD are intended to ameliorate symptoms and, as a result, improve function. A wide range of medications have been examined and used in clinical practice to treat PTSD. The different classes of psychotropic (affecting a person’s mental state) agents have been assessed in most detail.

Antidepressant medications can be categorised as either older or more recent, in terms of when they began to be used in clinical practice. The class of antidepressants is usually named according to their presumed mode of action or their chemical structure.

There are two classes of older antidepressant medicines: tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). There are numerous types of newer antidepressants, with most belonging to the class of selective serotonin reuptake inhibitors (SSRIs). The other classes are: serotonin-noradrenaline reuptake inhibitor (SNRI); selective noradrenaline reuptake inhibitor (NRI); noradrenaline-dopamine reuptake inhibitor (NDRI); reversible inhibitor of MAO-A (RIMA); noradrenergic and specific serotonergic antidepressant (NaSSA) – alpha 2 antagonist.

Other psychotropic medications that may be used to treat PTSD and related symptoms include hypnosedative agents that reduce anxiety and insomnia (benzodiazepines, other sleeping tablets), atypical antipsychotic medications, mood stabilisers and anticonvulsants. Medications that are not traditionally considered to be psychotropic have also been borrowed from other areas of medicine to target specific PTSD symptoms. The most commonly used of these are medications that alter adrenergic function. These include beta-blockers and alpha-adrenergic agents. Another example of non-psychotropic medication that has been used to treat PTSD symptoms is the older antihistamine medicines.

PHYSICAL THERAPIES

MEDICAL

ELECTROCONVULSIVE THERAPY

Electroconvulsive therapy (ECT) involves the induction of a modified seizure, under general anaesthetic, by passing electricity through the brain. This treatment is mainly used in the treatment of severe depression (Helsley et al, 1999).

REPEATED TRANSCRANIAL MAGNETIC STIMULATION

Repeated transcranial magnetic stimulation (rTMS) by an electromagnetic coil pulsing high intensity current, is a non-invasive technique for stimulating cortical neurons that may assist in reducing the symptoms of various conditions, including PTSD (Grisaru et al, 1998).

EXERCISE

Various forms of exercise, both aerobic and anaerobic, have general benefits for physical and mental health. Many programs of mental health treatment include structured exercise, and evidence exists that exercise is beneficial for depression and anxiety. Consequently, there may be both direct and indirect benefits from exercise in the treatment of PTSD.

ALTERNATIVE THERAPIES

The list of alternative therapies included in the literature search in relation to PTSD have been described as touch, energy and ‘power’ therapies and include: acupuncture, reiki, craniosacral therapy, Tapas acupressure technique, visual-kinesthetic dissociation, osteopathy, therapeutic touch, thought field therapy, emotion freedom techniques, and traumatic incident reduction.
PSYCHOSOCIAL REHABILITATION

Traditionally, psychosocial rehabilitation interventions are used to facilitate independent living, socialisation, and effective life management in people who have chronic mental health conditions including PTSD (Weinstein & Hughes, 2000). Psychosocial interventions help an individual compensate for the negative effects of disability by reducing some of the problems associated with PTSD, such as lack of self-care/independent living skills, homelessness, high-risk behaviours, interactions with family or friends who do not understand PTSD, social inactivity, unemployment, and other barriers to receiving various forms of treatment/rehabilitation (DVA/DoD, 2004). Components of psychosocial rehabilitation include social skills training and activities, job skills training, housing support, vocational rehabilitation, case management, and family support (Weinstein & Hughes, 2000).

Psychosocial rehabilitation often occurs alongside other treatments, but rather than aiming to reduce symptoms, these interventions are designed to promote community integration and improved functioning.

There is increasing recognition that rehabilitation interventions that promote optimal vocational, family and social functioning should routinely begin in the earliest phase of care rather than being reserved for chronic conditions. For an individual with PTSD, this would entail early psychoeducation of the individual and family members, maximising existing social supports or creating new ones, and providing vocational support to enable the individual to maintain their optimal work/study performance.
Evidence review and treatment recommendations for adults with PTSD

PSYCHOLOGICAL INTERVENTIONS

Research questions and PICO

Box 4.1 Single psychological interventions for adults with PTSD: research question(s) and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. For adults with PTSD do psychological interventions improve outcomes compared to no intervention?</td>
</tr>
<tr>
<td>4. For adults with PTSD, does any psychological intervention confer any advantage over other psychological interventions?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selection criteria</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Adults with PTSD</td>
</tr>
<tr>
<td>Intervention</td>
<td>Psychological intervention (e.g., trauma-focussed CBT, stress management therapy, EMDR, narrative exposure therapy, supportive counselling, interapy)</td>
</tr>
<tr>
<td>Comparator</td>
<td>3. No intervention</td>
</tr>
<tr>
<td></td>
<td>4. Other psychological intervention</td>
</tr>
<tr>
<td>Outcome</td>
<td>Primary outcome: resolution of symptoms of PTSD</td>
</tr>
<tr>
<td></td>
<td>Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, functional improvement, quality of life, treatment refusal, dropout over 12 months, posttraumatic growth</td>
</tr>
<tr>
<td>Study design</td>
<td>Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies.</td>
</tr>
<tr>
<td>Search period</td>
<td>2004–8/2005*</td>
</tr>
<tr>
<td>Language</td>
<td>English</td>
</tr>
</tbody>
</table>

These were psychological questions 1 and 2 in the NICE review, with a search period up to 2004.
Studies included in previous reviews: NICE (2005)

The NICE review team conducted systematic research for RCTs of each of the five therapy groupings outlined above (trauma-focussed CBT, EMDR, stress management, group CBT and other therapies) that compared these treatments against waiting list or usual care or against another psychological treatment. (Full details of the search strategy for this and other reviews of the guideline are given in Appendix 6 of the NICE guidelines. Information about each study along with an assessment of methodological quality is given in Appendix 14 of the NICE guidelines, which also contains a list of excluded studies with reasons for exclusions.) The following studies were identified by the NICE Guideline Development Group as meeting the inclusion criteria:

- 24 studies compared trauma-focussed CBT with waiting list or other psychological interventions (Blanchard et al., 2003; Brom et al., 1989; Bryant et al., 2003a; Cloitre et al., 2002; Cooper & Clum, 1989; Devilly & Spence, 1999; Echeburua et al., 1997; Ehlers et al., 2005; Fecteau & Nicki, 1999; Foa et al., 1999a; Foa et al., 1991; Gersons et al., 2000; Ironson et al., 2002; Keane et al., 1989; Kubany et al., 2003; Kubany et al., 2004; Lee et al., 2002b; Marks et al., 1998; Paunovic & Ost, 2001; Peniston & Kulkosky, 1991; Power et al., 2002; Resick et al., 2002; Taylor et al., 2003; Vaughan et al., 1994)

- 11 studies compared EMDR with waiting list or other psychological interventions (Carlson et al., 1998; Devilly & Spence, 1999; Ironson et al., 2002; Jensen, 1994; Lee et al., 2002b; Marcus et al., 1997; Power et al., 2002; Rothbaum, 1997; Scheck et al., 1998; Taylor et al., 2003; Vaughan et al., 1994).

- 7 studies compared stress management with waiting list or other psychological interventions (Carlson et al., 1998; Echeburua et al., 1997; Foa et al., 1999a; Foa et al., 1991; Marks et al., 1998; Taylor et al., 2003; Vaughan et al., 1994)

- 6 studies compared other therapies (supportive therapy, psychodynamic therapies, hypnotherapy) with waiting list or other psychological interventions (Blanchard et al., 2003; Brom et al., 1989; Bryant et al., 2003a; Foa et al., 1991; Scheck et al., 1998)

- 4 studies compared group CBT with waiting list or other psychological interventions (Classen et al., 2001; Krakow et al., 2001; Schnurr et al., 2003; Zlotnick et al., 1997).

Studies included in the current review of psychological treatments (2004–2005)

The review team conducted systematic research for RCTs published from 2004 to 2005, of the same five therapy groupings outlined above (trauma-focussed CBT, EMDR, stress management, group CBT and other therapies) that compared these treatments against waiting list or usual care or against another psychological treatment. The following studies were identified by the NHMRC Guideline Development Group as meeting the inclusion criteria:

- 4 additional studies that compared trauma-focussed CBT with waiting list were identified (Basoglu et al., 2005; Lindauer et al., 2005; McDonagh et al., 2005; Rothbaum et al., 2005).

- 1 additional study that compared trauma-focussed CBT with other psychological intervention was (Blanchard et al., 2004). This was a follow-up to Blanchard (2003) identified in the NICE review.

- 2 additional studies that compared EMDR with waiting list or other psychological interventions (Marcus et al., 2004; Rothbaum et al., 2005) were identified. NB: Marcus et al., (2004) was a follow-up to Marcus et al., (1997) identified in the NICE review.

- 1 additional study that compared stress management with waiting list or other psychological interventions was identified (McDonagh et al., 2005).

- No additional studies that compared other therapies with waiting list or other psychological interventions were identified.
Treatment comparisons (waitlist/usual care or alternate treatment)

TRAUMA-FOCUSED CBT VERSUS WAITLIST

Previous evidence: NICE Guidelines evidence statements

There is evidence favouring trauma-focussed CBT over waiting list on reducing the likelihood of having a PTSD diagnosis after treatment (k = 14; n = 716; RR = 0.47; 95% CI, 0.37 to 0.59). I

There is evidence favouring trauma-focussed CBT over waiting list on reducing the severity of PTSD symptoms (self-report measures) (k = 8; n = 388; SMD = -1.7; 95% CI, -2.21 to -1.18). I

There is evidence favouring trauma-focussed CBT over waiting list on reducing the severity of PTSD symptoms (clinician-rated measures) (k = 13; n = 609; SMD = -1.36; 95% CI, -1.88 to -0.84). I

There is limited evidence favouring trauma-focussed CBT over waiting list on reducing depression symptoms (k = 13; n = 585; SMD = -1.2; 95% CI, -1.65 to -0.75). I

There is limited evidence favouring trauma-focussed CBT over waiting list on reducing anxiety symptoms (self-report measures) (k = 10; n = 375; SMD = -0.94; 95% CI, -1.16 to -0.72). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and waitlist/usual care on reducing the likelihood of leaving treatment early for any reason (k = 14; n = 814; RR = 1.47; 95% CI, 1.07 to 2.02). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and waitlist/usual care on improving quality of life (k = 5; n = 233; SMD = -0.35; 95% CI, -1.27 to 0.56). I

Further evidence identified in the current review (2004–2005)

There were six randomised controlled trials that compared trauma-focussed CBT with waitlist. Two of these studies were included in the systematic review by NICE (Ehlers et al., 2005; Kubany et al., 2004) and the other four were identified only in the current review (Basoglu et al., 2005; Lindauer et al., 2005; McDonagh et al., 2005; Rothbaum et al., 2005). All six of the included studies compared a form of individual CBT against a waitlist or no-treatment condition. Two studies assessed the effectiveness of a single session of CBT (Basoglu et al., 2005; Lindauer et al., 2005) while the other four studies assessed a series of 4–14 individual treatment sessions at weekly or twice weekly intervals (Ehlers et al., 2005; Kubany et al., 2004; McDonagh et al., 2005; Rothbaum et al., 2005).

Posttraumatic Stress

All six trials in the current guidelines analysed PTSD severity or PTSD diagnosis posttreatment. These trials (varying in quality) were conducted in the United States, Turkey, the Netherlands, and the United Kingdom. The PTSD populations in these trials included women with partner abuse-related PTSD; earthquake victims; women with sexual abuse history; and people experiencing PTSD as a consequence of a single traumatic event in adulthood. Three of these six trials used intention-to-treat (ITT) analyses (Ehlers et al., 2005; Kubany et al., 2004; McDonagh et al., 2005), and of these only McDonagh et al., (2005) was found as new evidence. Kubany et al (2004) and Ehlers et al (2005) were previously included in the NICE guidelines, however NICE reported completer data from Kubany et al., (2004) while this review has included the ITT data.

The study by Basoglu et al., (2005) was described in the NICE guidelines as an example of the wide range of settings that CBTs are used.

Results obtained from a combination of completer data and ITT concerning posttraumatic stress symptoms are provided in Table 4.1. For all these trials, CBT was found to be consistently clinically and statistically significantly superior to a waitlist condition.
## Table 4.1: Posttraumatic stress symptoms

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
<th>CBT</th>
<th>Waitlist/no-treatment</th>
<th>Difference$^*$</th>
<th>Effect size [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>STUDY:</strong> Kubany (2004) United States previously included in NICE$^*$</td>
<td>Clinician-Administered PTSD Scale (CAPS; 0-136)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td>125 women with partner abuse-related PTSD</td>
<td>Level II (RCT)</td>
<td>74.4±19.9</td>
<td>33.3±32.8</td>
<td>78.0±20.5</td>
<td>74.1±21.9</td>
</tr>
<tr>
<td>Assignment: c</td>
<td></td>
<td>Selection bias: c</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding: c</td>
<td></td>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT: Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **STUDY:** Basoglu (2005) Turkey | Clinician-Administered PTSD Scale (CAPS; 0-136) | | | | | |
| Level II (RCT) | 59 earthquake victims with PTSD | Level II (RCT) | 67.8±16.5 | 44.4±25.0 | 60.5±14.1 | 54.7±21.4 | F(1,57)=14.0 p<0.001 SMD -0.44 [95% CI -0.97 to 0.08] |
| Assignment: a | | Selection bias: c | | | | | |
| Blinding: b | | Assessment: a | | | | | |
| ITT: No | | | | | | |

| **STUDY:** McDonagh (2005) United States | Clinician-Administered PTSD Scale (CAPS; 0-136) | | | | | |
| Level II (RCT) | Women with PTSD secondary to Child Sexual Abuse | Level II (RCT) | CBT group n = 29 | 69.9±16.8 | 67.1±18.4 | 65.5±18.6 | NS |
| Assignment: c | | Selection bias: c | | | | | |
| Blinding: b | | Assessment: a | | | | | |
| ITT: Yes | | | | | | |

| **STUDY:** Ehlers (2005) United Kingdom previously included in NICE | Clinician-Administered PTSD Scale (CAPS; 0-136) | | | | | |
| Level II (RCT) | 28 people with PTSD, linked to single event in adulthood | Level II (RCT) | frequency 42.0±8.5 | frequency 16.0±15.3 | frequency 31.6±8.4 | frequency 35.5±11.4 | frequency p<0.0005* intensity p<0.0005* |
| Assignment: c | | Selection bias: c | | | | | |
| Blinding: b | | Assessment: a | | | | | |
| ITT: Yes | | | | | | |

| **STUDY:** Lindaur (2005) The Netherlands Structured Interview for PTSD (SI-PTSD) | Structured Interview for PTSD (SI-PTSD) | | | | | |
| Level II (RCT) | 24 patients with PTSD (DSM-IV criteria) referred to outpatient clinic | Structured Interview for PTSD (SI-PTSD) | Deposition 25% | 12/12 (100%) | 2/2 (16.7%) | 12/12 (100%) | 9/12 (75%) |
| Assignment: a | | Structured Interview for PTSD (SI-PTSD) | waitlist group (n = 12) | Depression 0% | 12/12 (100%) | 2/2 (16.7%) | 12/12 (100%) | 9/12 (75%) |
| Blinding: b | | Structured Interview for PTSD (SI-PTSD) | Wrap-up group | 12/12 (100%) | 2/2 (16.7%) | 12/12 (100%) | 9/12 (75%) |
| Assessment: a | | Structured Interview for PTSD (SI-PTSD) | 12/12 (100%) | 2/2 (16.7%) | 12/12 (100%) | 9/12 (75%) |
| ITT: No | | Structured Interview for PTSD (SI-PTSD) | | | | | |

| **STUDY:** Rothbaum et al (2005) United States Structured Clinical Interview for DSM-IV (SCID) | Structured Clinical Interview for DSM-IV (SCID) | | | | | |
| Level II (RCT) | 60 adult rape victims$^*$ | Structured Clinical Interview for DSM-IV (SCID) | No significant differences between groups | 20/20 (100%) | 1/20 (5%) | 20/20 (100%) | 18/20 (90%) |
| Assignment: c | | Structured Clinical Interview for DSM-IV (SCID) | | | | | |
| Selection bias: c | | Structured Clinical Interview for DSM-IV (SCID) | | | | | |
| Blinding: b | | Structured Clinical Interview for DSM-IV (SCID) | | | | | |
| Assessment: a | | Structured Clinical Interview for DSM-IV (SCID) | | | | | |
| ITT: No | | Structured Clinical Interview for DSM-IV (SCID) | | | | | |

CAPS = clinician administered PTSD scale; $^*$ group differences posttreatment, univariate test; BEP = brief eclectic psychotherapy; SI-PTSD = structured interview for PTSD; NS = not stated; $^\dagger$ = results of author's analysis; RR = risk ratio; $^\ddagger$ = composite data from NICE reevaluated as intention-to-treat analysis; SMD = standardised mean difference; SCID = structured clinical interview for DSM-IV; $^\S$ women were randomised to treatment, but only completers were analysed, due to similar dropout rates and demographics between groups; $^\S$ unable to give exact results, as analyses provided combined EMDR and prolonged exposure treatment groups together in their comparison with the waitlist group; CBT = cognitive behavioural therapy; CI = confidence interval; ITT = intention-to-treat; NR = not reported; RCT = randomised controlled trial.
Depression

All six recent randomised controlled trials provided data on the impact of CBT on depressive symptoms in PTSD sufferers (Table 4.2). Where statistical testing was conducted, results indicate that CBT was associated with significantly reduced depression in populations that were predominantly female and aged in their late thirties to forties. The one study where CBT had no effect on depression symptoms appears to be confounded by a higher rate of depression in the active treatment group.

Findings from three of these studies (Ehlers et al., 2005; Kubany et al., 2004; McDonagh et al., 2005) were obtained from intention to treat analyses while the remaining studies used completer data (Basoglu et al., 2005; Lindauer et al., 2005; Rothbaum et al., 2005). These latter studies potentially present more biased results, although Rothbaum et al (2005) reported that intention-to-treat analyses were conducted and provided no significant differences to completer data.
<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Effectiveness</th>
<th>Effect size [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study</strong>: Kubany (2004) United States</td>
<td>125 women with partner abuse-related PTSD</td>
<td>Beck Depression Inventory (BDI)</td>
<td>Mann Whitney U=0.83 [p=0.001 (two-tailed)] SMD -0.28 [95% CI -0.63 to -0.0]</td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assignment: c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selection bias: c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding: c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT: Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>26.9±10.1</td>
<td>12.0±14.2</td>
<td>27.4±11.0</td>
<td>15.5±10.5</td>
</tr>
<tr>
<td><strong>Study</strong>: Rothbaum et al (2005) United States</td>
<td>60 adult rape victims</td>
<td>Beck Depression Inventory (BDI)</td>
<td>NR [SMD -2.08 [95% CI -2.78 to -1.38]]</td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assignment: c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selection bias: c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding: b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT: No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>16.7±8.2</td>
<td>4.7±5.0</td>
<td>24.1±10.5</td>
<td>22.2±10.6</td>
</tr>
<tr>
<td><strong>Study</strong>: Basoglu et al (2005) Turkey</td>
<td>59 earthquake victims with PTSD</td>
<td>Beck Depression Inventory (BDI)</td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assignment: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selection bias: c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding: b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT: No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>22.0±9.8</td>
<td>15.1±11.4</td>
<td>18.6±8.8</td>
<td>16.1±9.5</td>
</tr>
<tr>
<td><strong>Study</strong>: McDonagh et al (2005) United States</td>
<td>Women with PTSD secondary to Child Sexual Abuse</td>
<td>Beck Depression Inventory (BDI)</td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assignment: c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selection bias: c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding: b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT: Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT Completer</td>
<td>ITT Completer</td>
<td>ITT Completer</td>
<td>ITT Completer</td>
</tr>
<tr>
<td>18.9±9.6</td>
<td>12.9±12.5</td>
<td>20.9±7.8</td>
<td>19.0±11.3</td>
</tr>
<tr>
<td>15.7±7.0</td>
<td>7.5±7.9</td>
<td>21.2±8.1</td>
<td>20.1±12.1</td>
</tr>
<tr>
<td><strong>Study</strong>: Ehlers et al (2005) previously included in NICE</td>
<td>28 people with PTSD, linked to single event in adulthood</td>
<td>Beck Depression Inventory (BDI)</td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assignment: c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selection bias: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding: b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT: Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>23.7±9.0</td>
<td>10.6±8.6</td>
<td>23.2±8.0</td>
<td>19.3±7.2</td>
</tr>
<tr>
<td><strong>Study</strong>: Lindauer et al (2005)</td>
<td>24 patients with PTSD (DSM-IV criteria) referred to outpatient clinic</td>
<td>Hospital Anxiety and Depression Scale – Depression (HADS-D)</td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assignment: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selection bias: b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding: b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT: No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>11.8±4.3</td>
<td>8.0±6.7</td>
<td>9.0±3.5</td>
<td>9.1±5.7</td>
</tr>
</tbody>
</table>

Completer data from NICE reevaluated as intention-to-treat analysis. a)Women were randomised to treatment, but onlyCompleter data were analysed, due to similar dropout rates and demographics between groups. b)Univariate comparison between groups posttreatment; BEP = brief eclectic psychotherapy; NS = not stated; a)Author's reported value statistical analysis; SMD = standardised mean difference; CBT = cognitive behavioural therapy; CI = confidence interval; ITT = intent-to-treat; NR = not reported; RCT = randomised controlled trial.
Anxiety

Four of the trials assessed the effectiveness of CBT on anxiety-related symptoms and found various degrees of improvement compared to waitlist controls (Table 4.3).

Two of these studies used ITT analysis (Ehlers et al., 2005; McDonagh et al., 2005) one of which used both ITT and completer data. On the other hand, results obtained from Lindauer (2005) and Rothbaum et al (2005) were based on completer data.

Table 4.3 Anxiety

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CBT</td>
<td>Waitlist/no-treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY: McDonah (2005)</td>
<td></td>
<td>Spielberger State-Trait Anxiety Inventory</td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td></td>
<td>n = 29</td>
<td>CBT group</td>
</tr>
<tr>
<td>Assignment: c</td>
<td></td>
<td></td>
<td>Completer</td>
</tr>
<tr>
<td>Selection bias: c</td>
<td></td>
<td></td>
<td>Completer</td>
</tr>
<tr>
<td>Blinding: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT: Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY: Rothbaum et al (2005)</td>
<td></td>
<td>Spielberger State-Trait Anxiety Inventory- State</td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td></td>
<td>n = 23</td>
<td>Waitlist group</td>
</tr>
<tr>
<td>Assignment: c</td>
<td></td>
<td></td>
<td>Completer</td>
</tr>
<tr>
<td>Selection bias: c</td>
<td></td>
<td></td>
<td>Completer</td>
</tr>
<tr>
<td>Blinding: b</td>
<td></td>
<td></td>
<td>Completer</td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td>Completer</td>
</tr>
<tr>
<td>ITT: No</td>
<td></td>
<td></td>
<td>Completer</td>
</tr>
<tr>
<td>STUDY: (Ehlers et al., 2005)</td>
<td></td>
<td>Beck Anxiety Inventory (BAI)</td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td></td>
<td>n = 28</td>
<td>linked to single event in adulthood</td>
</tr>
<tr>
<td>Assignment: c</td>
<td></td>
<td></td>
<td>28 people with PTSD, referred to outpatient clinic</td>
</tr>
<tr>
<td>Selection bias: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding: b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT: Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY: (Lindauer et al., 2005)</td>
<td></td>
<td>Hospital Anxiety and Depression Scale – Anxiety (HADS-A)</td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td></td>
<td>n = 12</td>
<td>Depression = 25%</td>
</tr>
<tr>
<td>Assignment: a</td>
<td></td>
<td></td>
<td>BEP group (n = 12)</td>
</tr>
<tr>
<td>Selection bias: b</td>
<td></td>
<td></td>
<td>Depression = 0%</td>
</tr>
<tr>
<td>Blinding: b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT: No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*74 women were randomised to treatment, but only completer data were analysed due to similar dropout rates and demographics between groups; unable to give exact results, as analyses provided combined EMDR and prolonged exposure treatment groups together in their comparison with the waitlist group; Univariate comparison between groups posttreatment; BEP = brief eclectic psychotherapy; NR = not reported; Author’s reported value for statistical analysis; SMD = standardised mean difference; CBT = cognitive behavioural therapy; CI = confidence interval; ITT = intention-to-treat; RCT = randomised controlled trial.
Functional improvement

Statistically significant improvements in functioning were noted in people receiving CBT, compared to waitlist controls in the two trials reporting on this outcome (see Table 4.4).

These results were obtained from a study that used ITT analysis (Ehlers et al., 2005) and two using completer data (Basoglu et al., 2005; Rothbaum et al., 2005).

Table 4.4 Functioning

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre</td>
</tr>
<tr>
<td>STUDY: Basoglu (2005) Turkey</td>
<td>Work and Social Adjustment (WSA; 0-8)</td>
<td>59 earthquake victims with PTSD</td>
</tr>
<tr>
<td>STUDY: Ehlers (2005)</td>
<td>Disability, self-report, Sheehan scale</td>
<td>28 people with PTSD, linked to single event in adulthood</td>
</tr>
<tr>
<td>STUDY: Rothbaum et al (2005)</td>
<td>Good end-state functioning*</td>
<td>60 adult rape victims*</td>
</tr>
</tbody>
</table>

*Univariate comparison between groups posttreatment; §author's reported value for statistical analysis; SMD = standardised mean difference; 74 women were randomised to treatment, but only completer data were analysed, due to similar dropout rates and demographics between groups; *good end-state functioning was defined as ≥50% decrease on clinician-administered PTSD scale from pretreatment, a score of ≤10 on Beck depression inventory, and a score of ≤40 on Spielberger state-trait anxiety inventory; CBT = cognitive behavioural therapy; CI = confidence interval; ITT = intention-to-treat; NA = not applicable; NR = not reported; RCT = randomised controlled trial.

Quality of life

One average quality trial assessed the effect of CBT on quality of life, as measured by the quality of life inventory (QOLI) (McDonagh et al., 2005). CBT improved quality of life scores more than the waitlist condition, but the clinical importance of the benefit is unclear (Table 4.5). This study conducted ITT analyses as well as results from completer data (McDonagh et al., 2005).
Table 4.5 Quality of life

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CBT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre</td>
</tr>
<tr>
<td>STUDY: McDonagh (2005)</td>
<td></td>
<td>ITT</td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td>Women with PTSD secondary to Child Sexual Abuse</td>
<td>ITT 36.1±15.9</td>
</tr>
<tr>
<td>Assignment: c</td>
<td>n = 29</td>
<td>ITT</td>
</tr>
<tr>
<td>Selection bias: c</td>
<td>ITT</td>
<td>NR</td>
</tr>
<tr>
<td>Blinding: b</td>
<td>ITT</td>
<td>NR</td>
</tr>
<tr>
<td>Assessment: a</td>
<td>ITT</td>
<td>NR</td>
</tr>
<tr>
<td>ITT: Yes</td>
<td>ITT</td>
<td>NR</td>
</tr>
</tbody>
</table>

NR = not reported; $^2$author’s reported value for statistical analysis; SMD = standardised mean difference; CBT = cognitive behavioural therapy; CI = confidence interval; ITT = intent-to-treat; RCT = randomised controlled trial.

Current review evidence statements

There is limited relevant and applicable evidence favouring CBT over waitlist/usual care for PTSD symptom severity ($k = 3; n = 205; SMD = -1.32; 95% CI, -2.13 to -0.49$). I

There is relevant and applicable evidence suggesting that there is unlikely to be a clinically important difference between CBT versus waitlist/usual care for depression ($k = 3; n = 205; SMD = -0.44; 95% CI, -0.72 to -0.16$).

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and waitlist/usual care for anxiety ($k = 2; n = 80; SMD = -0.67; 95% CI, -1.13 to -0.22$).

There is limited relevant and applicable evidence favouring CBT over waitlist/usual care on improving functional improvement ($k = 1; n = 28; SMD = -1.43; 95% CI, -2.26 to -0.6$). II

There is relevant and applicable evidence suggesting that there is unlikely to be a clinically important difference between CBT and waitlist on improving quality of life ($k = 1; n = 52; SMD = -0.14; 95% CI, -0.69 to 0.40$). II

Updated evidence statements on the combined evidence from previous and current reviews

There is relevant and applicable evidence favouring trauma-focussed CBT over waitlist/usual care on reducing the severity of PTSD symptoms ($k = 14; n = 654; SMD = -1.21; 95% CI, -1.62 to -0.80$). I

There is limited relevant and applicable evidence favouring trauma-focussed CBT over waitlist/usual care on reducing depression symptoms ($k = 14, n = 637; SMD = -0.96; 95% CI, -1.32 to -0.59$). I

There is relevant and applicable limited evidence favouring trauma-focussed CBT over waitlist/usual care on reducing anxiety symptoms ($k = 11, n = 420; SMD = -0.89; 95% CI, -1.09 to -0.68$). I

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between trauma-focussed CBT and waitlist/usual care on improving quality of life ($k = 6, n = 278; SMD = -0.76; 95% CI, -1.25 to -0.20$). I

EMDR VERSUS WAITLIST

Previous evidence: NICE Guidelines evidence statements

There is limited evidence favouring EMDR over waiting list on reducing the likelihood of having a PTSD diagnosis after treatment ($k = 5; n = 169; RR = 0.51; 95% CI, 0.28 to 0.95$). I

There is limited evidence favouring EMDR over waiting list on reducing the severity of PTSD symptoms (self-report measures) ($k = 4; n = 116; SMD = -1.1; 95% CI, -2.42 to 0.23$). I

There is evidence favouring EMDR over waiting list on reducing the severity of PTSD symptoms (clinician-rated measures) ($k = 4; n = 122; SMD = -1.54; 95% CI, -1.96 to -1.12$). I

There is evidence favouring EMDR over waiting list on reducing depression symptoms ($k = 4; n = 120; SMD = -1.67; 95% CI, -2.1 to -1.25$). I

There is limited evidence favouring EMDR over waiting list on reducing anxiety symptoms ($k = 4; n = 116; SMD = -1.18; 95% CI, -1.58 to -0.78$). I
The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and waitlist/usual care on reducing the likelihood of leaving treatment early for any reason (k = 5; n = 168; RR = 1.28; 95% CI, 0.64 to 2.56).

There is limited evidence favouring EMDR over waitlist/usual care on improving quality of life (k = 1; n = 51; SMD = –1.36; 95% CI, –1.97 to –0.74).

Further evidence identified in the current review

One new poor-to-average quality trial (Rothbaum et al., 2005) was identified which compared the effectiveness of EMDR versus waitlist for female rape victims with PTSD. Completer data were confounded by the fact that the EMDR participants had higher baseline levels of PTSD symptoms, depression, dissociation and trait anxiety than waitlist controls. Despite the discrepancy in baseline differences, the EMDR group had consistently better outcomes at follow-up than the waitlist group (see Table 4.6).

Table 4.6 Effectiveness of EMDR versus waitlist for treating PTSD

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY: Rothbaum et al (2005)</td>
<td>PTSD diagnosis (SCID-IV)</td>
<td></td>
</tr>
<tr>
<td>Level II (RCT) Assignment: c Selection bias: c Blinding: b Assessment: a ITT: No</td>
<td>60 adult rape victims&lt;sup&gt;a&lt;/sup&gt; Patients in EMDR condition had significantly more PTSD symptoms, anxiety and depression than those in the waitlist condition</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20/20 (100%)</td>
<td>5/20 (25%) 6 months 20/20 (100%)</td>
</tr>
<tr>
<td>Dissociation (DES-II)</td>
<td>18.7±12.7 8.1±8.0 6 months 12.5±10.2 12.4±8.5</td>
<td>NR SMD -0.51 [95% CI -0.13 to 0.60]</td>
</tr>
<tr>
<td>Anxiety (State)</td>
<td>51.1±11.1 32.6±11.6 46.6±13.5 49.0±13.7</td>
<td>NR SMD -1.27 [95% CI -1.69 to -0.85]</td>
</tr>
<tr>
<td>Anxiety (Trait)</td>
<td>56.8±14.3 41.1±14.5 53.4±13.1 54.0±13.0</td>
<td>NR SMD -0.92 [95% CI -1.52 to -0.33]</td>
</tr>
<tr>
<td>Depression (BDI)</td>
<td>26.0±7.1 10.7±11.5 24.1±10.5 22.2±10.6</td>
<td>NR SMD -1.02 [95% CI -1.63 to -0.42]</td>
</tr>
<tr>
<td>Good end-state functioning&lt;sup&gt;c&lt;/sup&gt;</td>
<td>- 10/20 (50%) 10/20 (50%)</td>
<td>- 0%</td>
</tr>
</tbody>
</table>

<sup>a</sup> Women were randomised to treatment, but only completer data were analysed, due to similar dropout rates and demographics between groups; SCID = structured clinical interview of DSM-IV, non-patient version; <sup>b</sup> Unable to give exact results, as analyses provided combined EMDR and prolonged exposure treatment groups together in their comparison with the waitlist group; <sup>c</sup> Good end-state functioning was defined as ≥50% decrease on clinician-administered PTSD scale from pretreatment, a score of ≤10 on Beck depression inventory, and a score of ≤40 on Spielberger state-trait anxiety inventory; NR = not reported; NA = not applicable; <sup>d</sup> Author’s reported value for statistical analysis; SMD = standardised mean difference; BDI = Beck depression inventory; CI = confidence interval; DES-II = Dissociative experiences scale-II; EMDR = Eye movement desensitization and reprocessing; RCT = randomised controlled trial; RR = risk ratio; SCID-IV = structured clinical interview for DSM-IV.
Current review evidence statements

There is relevant and applicable evidence favouring EMDR over waitlist on reducing the likelihood of having a PTSD diagnosis (SCID) after treatment (k = 1; n = 40; RR = 0.28; 95% CI, 0.13 to 0.60). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and waitlist/usual care on reducing dissociation (DES-II) after treatment (k = 1; n = 40; SMD = –0.23; 95% CI, –0.95 to 0.49). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and waitlist/usual care on reducing dissociation at six months (k = 1; n = 39; SMD = –0.39; 95% CI, –0.96 to 0.18). II

There is limited relevant and applicable evidence favouring EMDR over waitlist/usual care on reducing anxiety (state) symptoms (k = 1; n = 40; SMD = –1.27; 95% CI, –1.89 to –0.65). II

There is limited relevant and applicable evidence favouring EMDR over waitlist/usual care on reducing anxiety (trait) symptoms (k = 1; n = 40; SMD = –0.92; 95% CI, –1.52 to –0.33). II

There is limited relevant and applicable evidence favouring EMDR over waitlist/usual care on reducing depression symptoms (k = 1, n = 40; SMD = –0.51; 95% CI, –1.09 to 0.06). II

There is limited relevant and applicable evidence favouring EMDR over waitlist/usual care on reducing depression symptoms (k = 6, n = 156; SMD = –1.53; 95% CI, –1.88 to –1.17). I

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and waitlist/usual care on having a PTSD diagnosis after treatment (k = 6, n = 209; RR = –0.74; 95% CI, 0.64 to 0.86). I

STRESS MANAGEMENT VERSUS WAITLIST

Previous evidence: NICE Guidelines evidence statements

There is limited evidence favouring stress management therapy over waitlist on reducing the likelihood of having a PTSD diagnosis after treatment (k = 4; n = 121; RR = 0.64; 95% CI, 0.47 to 0.87). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between stress management therapy and waitlist on reducing the severity of PTSD symptoms (self-report measures) (k = 1; n = 24; SMD = 0.33; 95% CI, –0.47 to 1.14). I

There is limited evidence favouring stress management therapy over waitlist on reducing the severity of PTSD symptoms (clinician-rated measures) (k = 3; n = 86; SMD = –1.14; 95% CI, –1.62 to –0.67). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between stress management therapy and waitlist on reducing depression symptoms (k = 4; n = 109; SMD = –0.73; 95% CI, –1.12 to –0.33). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between stress management therapy and waitlist on reducing anxiety symptoms (k = 3; n = 82; SMD = –0.77; 95% CI, –1.23 to –0.32). I

There is limited evidence favouring waitlist/usual care over stress management therapy on reducing the likelihood of leaving treatment early for any reason (k = 4; n = 121; RR = 2.19; 95% CI, 0.71 to 6.73). I

There is limited evidence favouring stress management therapy over waitlist/usual care on improving quality of life (k = 1; n = 34; SMD = –0.98; 95% CI, –1.7 to –0.26). I

Further evidence identified in the current review

One poor-to-average quality trial assessed the effectiveness of a present-centred therapy compared with a waitlist group in a population of women with PTSD secondary to childhood sexual trauma (McDonagh et al., 2005). The therapy included psychoeducation about PTSD and the effects of childhood sexual abuse, and focussed on current problem-solving skills and coping strategies without focussing on the trauma. For all outcome measures, excepting quality of life, posttreatment scores were reduced in the present-centred therapy group, compared to the waitlist controls. However, in general, the active treatment group had slightly lower baseline scores for these outcomes and so it is unclear whether the differences between the groups were in some part due to treatment differences as opposed to preexisting inequalities, as it is not stated whether statistical adjustment for baseline differences was conducted in this trial. This study reported on both intention to treat (ITT) and completer data (see Table 4.7) although only ITT is included in the evidence statements.
Table 4.7 Effectiveness of present-centred therapy versus waitlist for treating PTSD

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
<th>Effect size [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Present-centred therapy</td>
<td>Waitlist</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>STUDY: (McDonagh, 2005) United States</td>
<td>CAPS (ITT)</td>
<td>67.7±14.2 (n = 22)</td>
<td>47.2±22.4</td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td>Women with PTSD secondary to child sexual abuse</td>
<td>BDI (ITT)</td>
<td>17.0±7.7</td>
</tr>
<tr>
<td>Assignment: c</td>
<td>PCT group n = 22</td>
<td>STAI (ITT)</td>
<td>54.5±9.2</td>
</tr>
<tr>
<td>Selection bias: c</td>
<td>Waitlist group n = 23</td>
<td>QOLI (ITT)</td>
<td>35.2±15.3</td>
</tr>
<tr>
<td>Blinding: b</td>
<td></td>
<td>CAPS (Completer)</td>
<td>67.5±15.1 (n = 20)</td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td>BDI (Completer)</td>
<td>17.7±8.2</td>
</tr>
<tr>
<td>ITT: Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CBT = cognitive behavioural therapy; PCT = present-centred therapy; ITT = intent-to-treat; CAPS = clinician administered PTSD scale; BDI = Beck depression inventory; STAI = Spielberger state-trait anxiety inventory; QOLI = Quality of life inventory; ES = Effect size (Cohen’s d); NR = not reported; ^*author’s reported value for statistical analysis; SMD = standardised mean difference.

Current review evidence statements

There is limited applicable evidence favouring present-centred therapy over waitlist on reducing the severity of PTSD symptoms (CAPS) (k = 1; n = 45; SMD = –0.89; 95% CI, –1.51 to –0.28). II

The applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between present-centred therapy and waitlist on reducing depression symptoms (BDI) (k = 1; n = 45; SMD = –0.78; 95% CI, –1.39 to –0.18). II

The applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between present-centred therapy and waitlist on reducing anxiety symptoms (STAI) (k = 1; n = 45; SMD = –0.46; 95% CI, –1.06 to 0.13). II

There is applicable evidence suggesting that there is unlikely to be a clinically important difference between present-centred therapy and waitlist on improving quality of life (QOLI) (k = 1; n = 45; SMD = –0.13; 95% CI, –0.71 to 0.46). II

The generalisability of the evidence is limited as the study population included only women with PTSD secondary to child sexual abuse.

Updated evidence statements on the combined evidence from previous and current review

There is relevant and applicable limited evidence favouring stress management therapy over waitlist/usual care on reducing the severity of PTSD symptoms (k = 4, n = 111; SMD = –1.07; 95% CI, –1.45, –0.70). I

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between stress management therapy and waitlist/usual care on reducing depression symptoms (k = 5, n = 154; SMD = –0.76; 95% CI, –1.09 to –0.43). I

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between stress management therapy and waitlist/usual care on reducing anxiety symptoms (k = 4, n = 127; SMD = –0.67; 95% CI, –1.04 to –0.31). I

There is relevant and applicable evidence suggesting that there is unlikely to be a clinically important difference between stress management therapy and waitlist/usual care on improving quality of life (k = 2, n = 79; SMD = –0.42; 95% CI, –1.53 to –0.70). I
OTHER THERAPIES VERSUS WAITLIST

Previous evidence: NICE Guidelines evidence statements

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between other therapies and waiting list on reducing the likelihood of having a PTSD diagnosis after treatment (k = 2; n = 85; RR = 0.79; 95% CI, 0.53 to 1.18).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between other therapies and waiting list on reducing the severity of PTSD symptoms (self-report measures) (k = 2; n = 132; SMD = –0.61; 95% CI, –0.98 to –0.24).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between other therapies and waiting list on reducing the severity of PTSD symptoms (clinician-rated measures) (k = 2; n = 72; SMD = –0.43; 95% CI, –0.9 to 0.04).

There is evidence suggesting there is unlikely to be a clinically important difference between other therapies and waiting list on reducing depression symptoms (k = 2; n = 72; SMD = –0.25; 95% CI, –0.71 to 0.22).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between other therapies and waiting list on reducing anxiety symptoms (k = 3; n = 153; SMD = –0.48; 95% CI, –0.9 to 0.04).

There is limited evidence favouring waitlist/usual care over other therapies on reducing the likelihood of leaving treatment early for any reason (k = 3; n = 166; RR = 3.82; 95% CI, 1.19 to 12.29).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between group CBT and waitlist/usual care on improving quality of life (k = 1; n = 51; SMD = –0.33; 95% CI, –0.88 to 0.23).

Further evidence identified in the current review

No new studies were identified comparing other therapies to waitlist.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

GROUP CBT VERSUS WAITLIST

Previous evidence: NICE Guidelines evidence statements

The full range of outcome measures was not provided in the three studies of group CBT.

There is limited evidence favouring group CBT over waiting list on reducing the likelihood of having a PTSD diagnosis after treatment (k = 1; n = 48; RR = 0.56; 95% CI, 0.31 to 1.01).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between group CBT and waitlist/usual care on reducing the severity of PTSD symptoms (self-report measures) (k = 2; n = 71; SMD = –0.71; 95% CI, –1.2 to –0.22).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between group CBT and waitlist/usual care on reducing the severity of PTSD symptoms (clinician) (k = 1; n = 97; SMD = –0.72; 95% CI, –1.14 to –0.31).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between group CBT and waitlist/usual care on reducing the likelihood of leaving treatment early for any reason (k = 3; n = 271; RR = 1; 95% CI, 0.64 to 1.56).

Further evidence identified in the current review

No new studies were identified comparing group CBT to waitlist.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.
INTERAPY VERSUS WAITLIST

Previous evidence: NICE Guidelines evidence statements

There is evidence favouring interapy over waitlist on reducing severity of PTSD symptoms as measured by self-report IES at endpoint (k = 1; n = 101; SMD = -1.32; 95% CI, -1.77 to -0.86). I

There is evidence favouring interapy over waitlist on reducing depression symptoms as measured by self-report SCL-90 at endpoint (k = 1; n = 101; SMD = -1.06; 95% CI, -1.51 to -0.62). I

There is limited evidence favouring interapy over waitlist on reducing anxiety symptoms as measured by self-report SCL-90 at endpoint (k = 1; n = 101; SMD = -0.81; 95% CI, -1.24 to -0.37). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between interapy and waitlist on reducing the likelihood of leaving the study prior to endpoint for any reason (k = 1; n = 184; RR = 0.9; 95% CI, 0.65 to 1.25). I

Further evidence identified in the current review

No new studies were identified comparing interapy to waitlist.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

Comparing intervention against intervention

Although many of the included studies compared active treatments against waiting list, there were fewer studies available for direct comparisons of each of the active treatments against one another. Each treatment is considered in the same order as in the preceding section (trauma-focussed CBT, EMDR, stress management and other therapies). The comparisons are therefore set out in the following order:

• trauma-focussed CBT versus EMDR
• trauma-focussed CBT versus stress management
• trauma-focussed CBT versus other therapies
• trauma-focussed CBT (exposure) versus trauma-focussed CBT (cognitive therapy)
• EMDR versus stress management therapies
• EMDR versus other therapies
• stress management therapies versus other therapies
• group CBT (trauma-focussed) versus group CBT (non trauma-focussed)
• narrative exposure therapy versus supportive therapy
• narrative exposure therapy versus psychoeducation
• psychoeducation versus supportive therapy.

Where available, three outcome measures are reported for each comparison: a self-report measure of the severity of PTSD symptoms (or where this is not reported, the clinician-rated measure), likelihood of having a PTSD diagnosis, and leaving treatment early.
TRAUMA-FOCUSED CBT VERSUS EMDR

Previous evidence: NICE Guidelines evidence statements

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and trauma-focussed CBT on reducing the likelihood of having a PTSD diagnosis after treatment (k = 6; n = 220; RR = 1.03; 95% CI, 0.64 to 1.66). 1

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and trauma-focussed CBT on reducing the severity of PTSD symptoms (self-report) (k = 6; n = 166; SMD = 0.31; 95% CI, -0.62 to 0). 1

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and trauma-focussed CBT on reducing the likelihood of leaving treatment early for any reason (k = 7; n = 240; RR = 0.83; 95% CI, 0.54 to 1.27). 1

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and trauma-focussed CBT on reducing the severity of PTSD symptoms (clinician-rated) at follow-up (3 months) (k = 3; n = 176; SMD = 0.19; 95% CI, -0.97 to 0.58). 1

There is evidence suggesting there is unlikely to be a clinically important difference between EMDR and trauma-focussed CBT on reducing the severity of self-report PTSD symptoms at follow-up (3 months) (k = 5; n = 111; SMD = 0.01; 95% CI, -0.39 to 0.37). 1

There is limited evidence favouring EMDR over trauma-focussed CBT on reducing self-report depression symptoms (k = 6; n = 166; SMD = -0.5; 95% CI, -1.04 to 0.04). 1

There is evidence suggesting there is unlikely to be a clinically important difference between EMDR and trauma-focussed CBT on reducing self-report depression symptoms at follow-up (2-5 months) (k = 5; n = 111; SMD = 0.09; 95% CI, -0.47 to 0.29). 1

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and trauma-focussed CBT on reducing self-report anxiety symptoms (k = 3; n = 96; SMD = 0.3; 95% CI, -0.71 to 0.11). 1

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and trauma-focussed CBT on reducing self-report anxiety symptoms at follow-up (2-5 months) (k = 2; n = 48; SMD = 0.24; 95% CI, -0.33 to 0.81). 1

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and trauma-focussed CBT on improving quality of life (k = 2; n = 71; SMD = 0.12; 95% CI, -1.2 to 0.95). 1

Further evidence identified in the current review

One trial was identified that compared EMDR to prolonged exposure (Rothbaum et al., 2005). Results from completer data indicate that for most outcomes EMDR was not beneficial compared to prolonged exposure. Avoidance scores were significantly lower in the EMDR group than the prolonged exposure group posttreatment, but this difference was no longer statistically significant at six months. Prolonged exposure was more effective than EMDR at achieving good end-state functioning and depression at six months. Baseline scores were consistently lower in the prolonged exposure group than the EMDR group, so differences between groups may be due to sample characteristics rather than treatment effects. The results are flawed by the use of completer data only, and EMDR had a higher dropout rate than prolonged exposure, so any conclusions made on the comparative effectiveness of the treatments should be made with caution.
### Table 4.8 Effectiveness of EMDR versus prolonged exposure for treating PTSD

<table>
<thead>
<tr>
<th>STUDY: Rothbaum et al (2005)</th>
<th>PTSD diagnosis SCID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level II (RCT)</td>
<td>20/20 (100%)</td>
</tr>
<tr>
<td>Assignment: c</td>
<td>20/20 (100%)</td>
</tr>
<tr>
<td>Selection bias: c</td>
<td>6 months (26.3%)</td>
</tr>
<tr>
<td>Blinding: b</td>
<td>X² = 1 = 2.58</td>
</tr>
<tr>
<td>Assessment: a</td>
<td>6 months</td>
</tr>
<tr>
<td>ITT: Yes</td>
<td>RR 5.0</td>
</tr>
<tr>
<td></td>
<td>[95% CI 0.64-39.0]</td>
</tr>
<tr>
<td>p=0.08</td>
<td>p=0.08</td>
</tr>
</tbody>
</table>

**Total score improvement**

<table>
<thead>
<tr>
<th>n/a</th>
<th>n/a</th>
<th>n/a</th>
<th>n/a</th>
</tr>
</thead>
<tbody>
<tr>
<td>F(1,57) = 0.3</td>
<td>p=0.608</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ES = 0.005</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Symptom cluster change**

<table>
<thead>
<tr>
<th>n/a</th>
<th>n/a</th>
<th>n/a</th>
<th>n/a</th>
</tr>
</thead>
<tbody>
<tr>
<td>F(1,57) = 0.3</td>
<td>p=0.608</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ES = 0.005</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Dissociation (DES-II)**

<table>
<thead>
<tr>
<th>18.7±12.7</th>
<th>8.1±8.0</th>
<th>10.1±5.5</th>
<th>4.8±4.7</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months</td>
<td>8.9±3.1</td>
<td>6 months</td>
<td>3.4±2.6</td>
</tr>
<tr>
<td>F(1,56) = 4.1</td>
<td>p=0.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F(2,33) = 2.2</td>
<td>Not significant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMD = 0.50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[95% CI 1.07 to 0.08]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMD = 0.79</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[95% CI 1.38 to 0.21]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Anxiety (State)**

<table>
<thead>
<tr>
<th>51.1±11.1</th>
<th>32.6±11.6</th>
<th>43.3±12.6</th>
<th>30.0±10.4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not significant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMD = 0.23</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[95% CI 0.30 to 0.34]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Anxiety (Trait)**

<table>
<thead>
<tr>
<th>56.8±11.0</th>
<th>41.1±14.5</th>
<th>48.7±8.6</th>
<th>35.6±9.9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not significant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMD = 0.44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[95% CI 1.00 to 0.14]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Depression (BDI)**

<table>
<thead>
<tr>
<th>30.0±7.1</th>
<th>10.7±11.5</th>
<th>16.7±8.2</th>
<th>4.7±5.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months</td>
<td>10.5±10.9</td>
<td>6 months</td>
<td>4.4±5.1</td>
</tr>
<tr>
<td>F(1,57) = 1.2</td>
<td>Not significant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F(2,34) = 6.0</td>
<td>Not significant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMD = 0.67</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[95% CI 1.25 to 0.08]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Good end-state functioning**

<table>
<thead>
<tr>
<th>-</th>
<th>10/20 (50%)</th>
<th>-</th>
<th>14/20 (70%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months</td>
<td>16/20 (80%)</td>
<td>6 months</td>
<td>12/20 (60%)</td>
</tr>
<tr>
<td>Not significant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p=0.017</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RR 0.71</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[95% CI 0.42 to 1.21]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Dropout rates**

<table>
<thead>
<tr>
<th>20%</th>
<th>13%</th>
<th>NS</th>
</tr>
</thead>
</table>

EMDR = eye movement desensitisation and reprocessing; a74 women were randomised to treatment, but only completer data was analysed, due to similar dropout rates and demographics between groups; bFishers exact test; ctotal score improvement = PTSD frequency and intensity total symptom scores measured by CAPS, PSS and IES; dSymptoms cluster = PTSD intrusion, avoidance, hyperarousal symptoms as measured by CAPS, PSS, and IES; egood end-state functioning was defined as ≥50% decrease on CAPS from pretreatment, a score of ≤10 on BDI, and a score of ≤40 on STAI-S; ES = effect size; n/a = not available; NS = not stated; NC = not calculated due to not count data reported; aauthor’s reported value for statistical analysis; SMD = standardised mean difference; RR = risk ratio; BDI = Beck depression inventory; CI = confidence interval; ITT = intention-to-treat; RCT = randomised controlled trial; SCID = structured clinical interview for DSM-IV.
Current review evidence statements

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and prolonged exposure on reducing the severity of symptoms (SCID) \( (k = 1; n = 40; RR = 5.0; 95\% CI, 0.64 to 39.0) \). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and prolonged exposure on reducing dissociation posttreatment (DES-II) \( (k = 1; n = 40; SMD = -0.50; 95\% CI, -1.07 to 0.08) \). II

There is relevant and applicable evidence favouring prolonged exposure over EMDR on reducing dissociation (DES-II) at six months \( (k = 1; n = 37; SMD = -0.7; 95\% CI, -1.38 to -0.21) \). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and prolonged exposure on reducing anxiety symptoms (state) \( (k = 1; n = 40; SMD = -0.23; 95\% CI, -0.80 to 0.34) \). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and prolonged exposure on reducing anxiety symptoms (trait) \( (k = 1; n = 40; SMD = -0.44; 95\% CI, -1.00 to 0.14) \). II

There is limited relevant and applicable evidence favouring prolonged exposure over EMDR on reducing depression symptoms posttreatment (BDI) \( (k = 1; n = 40; SMD = -0.67; 95\% CI, -1.25 to -0.08) \). II

There is limited relevant and applicable evidence favouring prolonged exposure on reducing depression symptoms (BDI) at six months \( (k = 1; n = 37; SMD = -0.71; 95\% CI, -1.29 to -0.12) \). II

There is limited relevant and applicable evidence favouring prolonged exposure over EMDR on good end-state functioning \( (k = 1; n = 40; RR = 0.71; 95\% CI, 0.42 to 1.21) \). II

Updated evidence statements on the combined evidence from previous and current reviews

There is relevant and applicable evidence suggesting that there is unlikely to be a clinically important difference between EMDR and trauma-focussed CBT on reducing depression symptoms \( (k = 7, n = 206; SMD = -0.34; 95\% CI, -0.94 to 0.25) \). I

There is relevant and applicable evidence suggesting that there is unlikely to be a clinically important difference between EMDR and trauma-focussed CBT on reducing depression symptoms at 2–6 months \( (k = 6, n = 151; SMD = 0.02; 95\% CI, -0.50 to 0.35) \). I

There is relevant and applicable evidence suggesting that there is unlikely to be a clinically important difference between EMDR and trauma-focussed CBT on reducing anxiety symptoms \( (k = 4, n = 136; SMD = -0.15; 95\% CI, -0.49 to 0.19) \). I

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and trauma-focussed CBT on reducing the likelihood of leaving treatment early for any reason \( (k = 8, n = 280; RR = 0.87, 95\% CI, 0.57 to 1.32) \). I

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and trauma-focussed CBT on reducing the likelihood of having a PTSD diagnosis after treatment \( (k = 7, n = 260; RR = 1.11, 95\% CI, 0.68 to 2.08) \). I

TRAUMA FOCUSED CBT VERSUS STRESS MANAGEMENT

Previous evidence: NICE Guidelines evidence statements

There is limited evidence favouring trauma-focussed CBT over stress management therapy on reducing the likelihood of having a PTSD diagnosis after treatment \( (k = 6; n = 284; RR = 0.78, 95\% CI, 0.61 to 0.99) \). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and stress management therapy on reducing the severity of PTSD symptoms (self-report measures) \( (k = 3; n = 127; SMD = -0.37; 95\% CI, -0.74 to 0.01) \). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and stress management therapy on reducing the likelihood of leaving treatment early for any reason \( (k = 6; n = 284; RR = 1.17, 95\% CI, 0.69 to 2.0) \). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and stress management therapy on reducing the severity of clinician-rated PTSD symptoms \( (k = 6; n = 239; SMD = -0.27; 95\% CI, -0.71 to 0.16) \). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and stress management therapy on reducing the severity of clinician-rated PTSD symptoms at follow-up (2–5 months) \( (k = 5; n = 127; SMD = -0.48; 95\% CI, -0.84 to -0.12) \). I
The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and stress management therapy on reducing the severity of self-report PTSD symptoms at follow-up (2–5 months) \((k = 2; n = 54; \text{SMD} = -0.44; 95\% \text{ CI}, -0.99 \text{ to } 0.10)\).\(^1\)

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and stress management therapy on reducing depression symptoms \((k = 5; n = 161; \text{SMD} = -0.25; 95\% \text{ CI}, -0.57 \text{ to } 0.08)\).\(^1\)

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and stress management therapy on reducing depression symptoms (self-report) at follow-up (2–5 months) \((k = 5; n = 147; \text{SMD} = -0.28; 95\% \text{ CI}, -0.62 \text{ to } 0.06)\).\(^1\)

There is evidence suggesting there is unlikely to be a clinically important difference between trauma-focussed CBT and stress management therapy on reducing anxiety symptoms \((k = 4; n = 127; \text{SMD} = -0.12; 95\% \text{ CI}, -0.49 \text{ to } 0.26)\).\(^1\)

There is limited evidence favouring trauma-focussed CBT over stress management therapy on improving quality of life \((k = 1; n = 20; \text{SMD} = -0.67; 95\% \text{ CI}, -1.58 \text{ to } 0.23)\).\(^1\)

There is evidence favouring trauma-focussed CBT over stress management therapy on improving quality of life at follow-up (3 months) \((k = 1; n = 20; \text{SMD} = -3.07; 95\% \text{ CI}, -4.45 \text{ to } -1.69)\).\(^1\)

Further evidence identified in the current review

One randomised controlled trial compared trauma-focussed CBT with interventions that may be defined as stress management (McDonagh et al., 2005). McDonagh et al., (2005) used ‘present-centred therapy’ in comparison with CBT in a population of women with PTSD secondary to childhood sexual abuse. McDonagh et al., (2005) used both intention to treat and completer data.

Table 4.9 Effectiveness of cognitive behavioural therapy versus present-centred therapy for PTSD

<table>
<thead>
<tr>
<th>STUDY: (McDonagh, 2005) United States</th>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level II (RCT)</td>
<td>Assignment: c</td>
<td>Women with PTSD secondary to child sexual abuse</td>
<td>CAPS (ITT)</td>
</tr>
<tr>
<td>Selection bias: c</td>
<td>CBT group</td>
<td>69.9±16.8 53.1±28.8 67.7±14.2 47.2±22.4</td>
<td>NS SMD -0.22 [95% CI -0.78 to 0.35]</td>
</tr>
<tr>
<td>Blinding: b</td>
<td>PCT group</td>
<td>18.9±9.6 12.9±12.5 17.0±7.7 10.8±9.5</td>
<td>NS SMD -0.18 [95% CI -0.74 to 0.37]</td>
</tr>
<tr>
<td>Assessment: a</td>
<td>CBT group</td>
<td>STAI (ITT)</td>
<td></td>
</tr>
<tr>
<td>ITT: Yes</td>
<td>53.5±10.4</td>
<td>46.2±13.9 54.5±9.2 46.4±12.2</td>
<td>NS SMD -0.02 [95% CI -0.57 to 0.54]</td>
</tr>
<tr>
<td></td>
<td>PCT group</td>
<td>QOLI (ITT)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>36.1±15.9</td>
<td>39.5±17.0 35.2±15.3 39.0±12.6</td>
<td>NS SMD -0.03 [95% CI -0.59 to 0.52]</td>
</tr>
<tr>
<td></td>
<td>CBT (Completer)</td>
<td>CAPS (Completer)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>67.1±184</td>
<td>38.5±27.7 67.5±15.1 44.9±22.1</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>PCT (Completer)</td>
<td>BDI (Completer)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15.7±7.0</td>
<td>7.5±7.9 17.7±8.2 10.4±10.2</td>
<td>NR</td>
</tr>
</tbody>
</table>

CBT = cognitive behavioural therapy; PCT = present-centred therapy; ITT = intent-to-treat; CAPS = clinician-administered PTSD scale; BDI = Beck depression inventory; STAI = Spielberger state-trait anxiety inventory; QOLI = quality of life inventory; *PTSD diagnosis determined by CAPS; NR = not stated; †author’s reported value for statistical analysis; SMD = standardised mean difference; NS = not significant.
Current review evidence statements

The applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and present-centred therapy on reducing the severity of PTSD symptoms (k = 1; n = 51; SMD = –0.22; 95% CI, −0.78 to 0.35). II

The applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and present-centred therapy on reducing depression symptoms (k = 1; n = 51; SMD = −0.18; 95% CI, −0.74 to 0.37). II

The applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and present-centred therapy on reducing anxiety symptoms (k = 1; n = 51; SMD = −0.02; 95% CI, −0.57 to 0.54). II

The applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and present-centred therapy on improving quality of life (k = 1; n = 51; SMD = −0.03; 95% CI, −0.59 to 0.52). II

The generalisability of the evidence is limited as the study population included only women with PTSD secondary to child sexual abuse.

Updated evidence statements on the combined evidence from previous and current reviews

There is relevant and applicable evidence suggesting that there is unlikely to be a clinically important difference between trauma-focused CBT and stress management therapy on reducing the severity of PTSD symptoms (k = 7, n = 290; SMD = −0.20; 95% CI, −0.60 to 0.20). I

There is relevant and applicable evidence suggesting that there is unlikely to be a clinically important difference between trauma-focused CBT and stress management therapy on reducing depression symptoms (k = 6, n = 212; SMD = −0.14; 95% CI, −0.42 to 0.14). I

There is relevant and applicable evidence suggesting that there is unlikely to be a clinically important difference between trauma-focused CBT and stress management therapy on reducing anxiety symptoms (k = 5, n = 178; SMD = −0.09; 95% CI, −0.40 to 0.22). I

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between trauma-focused CBT and stress management therapy on improving quality of life (k = 2, n = 71; SMD = −0.22; 95% CI, −0.69 to 0.26). I

TRAUMA FOCUSED CBT VERSUS OTHER THERAPIES

Previous evidence: NICE Guidelines evidence statements

There is limited evidence favouring trauma-focused CBT over other therapies on reducing the likelihood of having a PTSD diagnosis after treatment (k = 5; n = 286; RR = 0.71; 95% CI, 0.56 to 0.89). I

There is limited evidence favouring trauma-focused CBT over other therapies on reducing the severity of PTSD symptoms (self-report measures) (k = 3; n = 176; SMD = −1.18; 95% CI, −2.32 to −0.03). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focused CBT and other therapies on reducing the likelihood of leaving treatment early for any reason (k = 5; n = 290; RR = 1.14; 95% CI 0.68 to 1.90). I

There is limited evidence favouring trauma-focused CBT over other therapies on reducing the severity of clinician-rated PTSD symptoms (k = 3; n = 120; SMD = −0.81; 95% CI, −1.19 to −0.42). I

There is limited evidence favouring trauma-focused CBT over other therapies on reducing the severity of clinician-rated PTSD symptoms at follow-up (3 months) (k = 2; n = 70; SMD = −0.65; 95% CI, −1.13 to −0.16). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focused CBT and other therapies on reducing the severity of self-report PTSD symptoms at follow-up (2–5 months) (k = 2; n = 131; SMD = −0.28; 95% CI, −1.04 to 0.48). I

There is limited evidence favouring trauma-focused CBT over other therapies on reducing depression symptoms (k = 3; n = 120; SMD = −0.65; 95% CI, −1.03 to −0.28). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focused CBT and other therapies on reducing anxiety symptoms (k = 4; n = 197; SMD = −0.47; 95% CI, −1.11 to 0.17). I

There is limited evidence favouring trauma-focused CBT over other therapies on reducing depression symptoms (2–5 months) (k = 2; n = 72; SMD = −0.53; 95% CI, −0.10 to −0.05). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focused CBT and other therapies on reducing anxiety symptoms at follow-up (2-5 months) (k = 3; n = 149; SMD = −0.27; 95% CI, −0.6 to 0.07). I
There is evidence favouring trauma-focussed CBT over other therapies on reducing the severity of clinician-rated PTSD symptoms at follow-up (6–9 months) \( (k = 1; n = 45; \text{SMD} = -1.85; 95\% \ CI, -2.59 \text{ to } -1.11) \). 

There is evidence favouring trauma-focussed CBT over other therapies on reducing the severity of self-report PTSD symptoms at follow-up (6–9 months) \( (k = 1; n = 45; \text{SMD} = -1.72; 95\% \ CI, -2.45 \text{ to } -1.0) \). 

There is limited evidence favouring trauma-focussed CBT over other therapies on reducing depression symptoms at follow-up (6–9 months) \( (k = 1; n = 45; \text{SMD} = -1.08; 95\% \ CI, -1.74 \text{ to } -0.42) \). 

There is evidence favouring trauma-focussed CBT over other therapies on reducing anxiety symptoms at follow-up (6–9 months) \( (k = 1; n = 45; \text{SMD} = -1.18; 95\% \ CI, -1.85 \text{ to } -0.51) \).

Further evidence identified in the current review

One poor quality trial was included (Blanchard et al., 2004) that was an update of a randomised controlled trial that was included in the NICE systematic review, comparing CBT to supportive psychotherapy in motor vehicle accident survivors with PTSD (Blanchard et al., 2003). Follow-up was 91 per cent after one year and 75 per cent after two years. These experimenters only used data from people that had completed the study.

Supportive therapy included psychoeducation regarding PTSD in an effort to reassure participants that their reactions were normal. A history of coping strategies was kept, but no cognitive restructuring occurred, and no relaxation techniques were suggested (Blanchard et al., 2004).

Comparisons between the pretreatment and posttreatment time for the clinician-administered PTSD scale have not been made, as they were included in the previous paper (showing superiority of CBT over supportive psychotherapy; these comparisons were included in the previous NICE guidelines).

The comparative benefits of CBT were also found on the PTSD checklist, the impact of events scale, the Beck depression inventory, and the Spielberger state-trait inventory.
### Table 4.10 Effectiveness of cognitive behavioural therapy versus supportive psychotherapy for PTSD

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
<th>CBT (n = 28)</th>
<th>Supportive psychotherapy (n = 24)</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pre</td>
<td>Post</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pre</td>
<td>Post</td>
<td></td>
</tr>
<tr>
<td>STUDY: Blanchard (2004) Update on Blanchard (2003) United States</td>
<td>52/57 motor vehicle accident survivors 24 months 39 participants</td>
<td>CAPS</td>
<td>64.4±24.0</td>
<td>23.2±26.1</td>
<td>66.3±26.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3 months</td>
<td>21.9±24.9</td>
<td>3 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>12 months</td>
<td>21.3±28.4</td>
<td>12 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>24 months</td>
<td>20.1±25.0</td>
<td>24 months</td>
</tr>
</tbody>
</table>

PTSD checklist

|                  |            |               | 52.1±12.3   | 31.8±14.0 | 56.3±14.4 | 44.2±13.9 | NS | SMD 0.88 [95% CI: -1.45 to -0.31] |
|                  |            |               | 3 months    | 33.1±13.1 | 3 months | 41.6±14.9 | 3 months | SMD 0.61 [95% CI: -1.17 to -0.06] |
|                  |            |               | 12 months   | 35.0±14.5 | 12 months | 39.2±14.9 | 12 months | SMD 0.28 [95% CI: -0.83 to 0.27] |
|                  |            |               | 24 months   | 30.6±14.3 | 24 months | 40.1±13.5 | 24 months | SMD 0.67 [95% CI: -1.23 to -0.11] |

Impact of Events Scale

|                  |            |               | 38.1±13.7   | 13.1±15.3 | 40.5±20.4 | 27.1±18.9 | NS | SMD 0.81 [95% CI: -1.38 to -0.24] |
|                  |            |               | 3 months    | 33.1±13.5 | 3 months | 24.3±19.6 | 3 months | SMD 0.70 [95% CI: -1.26 to -0.13] |
|                  |            |               | 12 months   | 14.2±17.5 | 12 months | 19.2±19.5 | 12 months | SMD 0.28 [95% CI: -0.83 to 0.27] |
|                  |            |               | 24 months   | 9.9±12.1  | 24 months | 22.1±19.0 | 24 months | SMD 0.78 [95% CI: -1.33 to -0.20] |

Beck Depression Inventory

|                  |            |               | 22.8±11.4   | 11.8±12.6 | 27.0±11.8 | 20.4±12.3 | NS | SMD 0.68 [95% CI: -1.24 to -0.12] |
|                  |            |               | 3 months    | 12.6±12.8 | 3 months | 18.8±13.4 | 3 months | SMD 0.47 [95% CI: -1.02 to 0.09] |
|                  |            |               | 12 months   | 13.8±14.2 | 12 months | 18.8±11.9 | 12 months | SMD 0.37 [95% CI: -0.92 to 0.18] |
|                  |            |               | 24 months   | 11.8±14.2 | 24 months | 17.4±15.0 | 24 months | SMD 0.38 [95% CI: -0.93 to 0.17] |

STAI-state

|                  |            |               | 53.9±13.7   | 39.5±13.1 | 57.8±11.9 | 51.3±12.4 | F(1,50)=9.90<sup>a</sup> p=0.004 ES=0.151 SMD 0.91 [95% CI: -1.48 to -0.34] |
|                  |            |               | 3 months    | 42.9±14.8 | 3 months | 50.9±14.6 | 3 months | SMD 0.54 [95% CI: -1.09 to 0.02] |
|                  |            |               | 12 months   | 38.0±12.3 | 12 months | 50.0±12.7 | 12 months | SMD 0.95 [95% CI: -1.52 to 0.37] |
|                  |            |               | 24 months   | 37.1±14.8 | 24 months | 45.9±16.7 | 24 months | SMD 0.55 [95% CI: -1.11 to 0.003] |

STAI-trait

|                  |            |               | 53.8±13.7   | 41.4±15.3 | 56.4±10.1 | 52.3±11.6 | F(1,50)=3.98<sup>a</sup> p=0.050 ES=0.074 SMD 0.78 [95% CI: -1.35 to -0.22] |
|                  |            |               | 3 months    | 41.6±14.7 | 3 months | 49.1±10.9 | 3 months | SMD 0.56 [95% CI: -1.12 to -0.008] |
|                  |            |               | 12 months   | 42.2±15.8 | 12 months | 49.4±12.9 | 12 months | SMD 0.49 [95% CI: -1.04 to 0.07] |
|                  |            |               | 24 months   | 38.5±15.8 | 24 months | 46.8±17.0 | 24 months | SMD 0.50 [95% CI: -1.05 to 0.05] |

CBT = cognitive behaviour therapy; CAPS = clinician administered PTSD scale; STAI = Spielberger state-trait inventory; <sup>a</sup> Univariate ANOVAs performed to assess main effect of treatment condition at 3 and 12 months follow-up; ES = effect size; Author’s reported value for statistical analysis; SMD = standardised mean difference; CI = confidence interval; ITT = intent-to-treat; NS = not stated; RCT = randomised controlled trial.
Current review evidence statements

There is limited relevant and applicable evidence favouring CBT over supportive psychotherapy on reducing severity of PTSD symptoms (CAPS) at 12 months (k = 1; n = 52; SMD = –0.50; 95% CI, –1.05 to 0.05). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and supportive psychotherapy on reducing the severity of PTSD symptoms (CAPS) at 24 months (k = 1; n = 39; SMD = –0.38; 95% CI, –0.93 to 0.17). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and supportive psychotherapy on reducing severity of PTSD symptoms (PTSD checklist) at 12 months (k = 1; n = 52; SMD = –0.28; 95% CI, –0.83 to 0.27). II

There is limited relevant and applicable evidence favouring CBT over supportive psychotherapy on reducing severity of PTSD symptoms (PTSD checklist) at 24 months (k = 1; n = 39; SMD = –0.67; 95% CI, –1.23 to –0.11). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and supportive psychotherapy on improving impact of events scale score at 12 months (k = 1; n = 52; SMD = –0.28; 95% CI, –0.83 to 0.27). II

There is limited relevant and applicable evidence favouring CBT over supportive psychotherapy on improving an impact of events scale score at 24 months (k = 1; n = 39; SMD = –0.78; 95% CI, –1.33 to –0.20). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and supportive psychotherapy on reducing depression symptoms at 12 months (k = 1; n = 52; SMD = –0.37; 95% CI, –0.92 to 0.18). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and supportive psychotherapy on reducing depression symptoms at 24 months (k = 1; n = 39; SMD = –0.38; 95% CI, –0.93 to 0.17). II

There is limited relevant and applicable evidence favouring CBT over supportive psychotherapy on reducing anxiety symptoms (STAI-state) at 12 months (k = 1; n = 52; SMD = –0.95; 95% CI, –1.52 to –0.37). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and supportive psychotherapy on reducing anxiety symptoms (STAI-state) at 24 months (k = 1; n = 39; SMD = –0.55; 95% CI, –0.81 to 0.26). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and supportive psychotherapy on reducing anxiety symptoms (STAI-trait) at 12 months (k = 1; n = 52; SMD = –0.49; 95% CI, –0.81 to 0.26). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between CBT and supportive psychotherapy on reducing anxiety symptoms (STAI-trait) at 24 months (k = 1; n = 39; SMD = –0.50; 95% CI, –0.99 to 0.02). II

Updated evidence statements on the combined evidence from previous and current reviews

As stated above, the new evidence available for the current review only included follow-up data (12 and 24 months) on a previously reported study. Therefore there is no new combined evidence statement.

TRAUMA-FOCUSED CBT (EXPOSURE) VERSUS TRAUMA-FOCUSED CBT (COGNITIVE THERAPY)

Previous evidence: NICE Guidelines evidence statements

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focused CBT (exposure) and trauma-focused CBT (cognitive therapy) on reducing the severity of posttreatment PTSD symptoms using clinician measure CAPS (k = 1; n = 62; SMD = –0.09; 95% CI, –0.59 to 0.41). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focused CBT (exposure) and trauma-focused CBT (cognitive therapy) on reducing the severity of PTSD symptoms at 6 month follow-up using clinician measure CAPS (k = 1; n = 56; SMD = 0.08; 95% CI, –0.45 to 0.6). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focused CBT (exposure) and trauma-focused CBT (cognitive therapy) on reducing the severity of PTSD symptoms at 12 month follow-up using clinician measure CAPS (k = 1; n = 54; SMD = –0.28; 95% CI, –0.81 to 0.26). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focused CBT (exposure) and trauma-focused CBT (cognitive therapy) on reducing the severity of posttreatment PTSD symptoms using self-report IES avoidance subscale (k = 1; n = 62; SMD = –0.48; 95% CI, –0.99 to 0.02). I
The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT (exposure) and trauma-focussed CBT (cognitive therapy) on reducing the severity of PTSD symptoms at 6 month follow-up using self-report IES avoidance subscale (k = 1; n = 56; SMD = -0.06; 95% CI, -0.58 to 0.47).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT (exposure) and trauma-focussed CBT (cognitive therapy) on reducing the severity of PTSD symptoms at 12 month follow-up using self-report IES avoidance subscale (k = 1; n = 54; SMD = -0.24; 95% CI, -0.77 to 0.30).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT (exposure) and trauma-focussed CBT (cognitive therapy) on reducing the severity of PTSD symptoms at 6 month follow-up using self-report IES intrusions subscale (k = 1; n = 56; SMD = -0.19; 95% CI, -0.71 to 0.34).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT (exposure) and trauma-focussed CBT (cognitive therapy) on reducing the severity of PTSD symptoms at 12 month follow-up using self-report IES intrusions subscale (k = 1; n = 54; SMD = -0.32; 95% CI, -0.86 to 0.22).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT (exposure) and trauma-focussed CBT (cognitive therapy) on reducing the severity of posttreatment depression symptoms using self-report BDI (k = 1; n = 62; SMD = -0.13; 95% CI, -0.62 to 0.37).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT (exposure) and trauma-focussed CBT (cognitive therapy) on reducing the severity of depression symptoms at 6 month follow-up using self-report BDI (k = 1; n = 56; SMD = -0.04; 95% CI, -0.56 to 0.49).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT (exposure) and trauma-focussed CBT (cognitive therapy) on reducing the severity of depression symptoms at 12 month follow-up using self-report BDI (k = 1; n = 54; SMD = -0.05; 95% CI, -0.58 to 0.49).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT (exposure) and trauma-focussed CBT (cognitive therapy) on reducing the severity of posttreatment anxiety symptoms using self-report BAI (k = 1; n = 62; SMD = -0.02; 95% CI, -0.52 to 0.48).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT (exposure) and trauma-focussed CBT (cognitive therapy) on reducing the severity of anxiety symptoms at 6 month follow-up using self-report BAI (k = 1; n = 56; SMD = 0.19; 95% CI, -0.34 to 0.71).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT (exposure) and trauma-focussed CBT (cognitive therapy) on reducing the severity of anxiety symptoms at 12 month follow-up using self-report BAI (k = 1; n = 54; SMD = -0.07; 95% CI, -0.6 to 0.47).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT (exposure) and trauma-focussed CBT (cognitive therapy) on reducing the likelihood of having a posttreatment PTSD diagnosis (k = 1; n = 72; RR = 0.83; 95% CI, 0.55 to 1.24).

There is limited evidence favouring trauma-focussed CBT (cognitive therapy) over trauma-focussed CBT (exposure) on reducing the likelihood of leaving the study prior to end of treatment for any reason (k = 1; n = 72; RR = 1.59; 95% CI, 0.49 to 5.15).

Further evidence identified in the current review

No new studies were identified comparing trauma-focussed CBT (exposure) to trauma-focussed CBT (cognitive therapy).

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.
EMDR VERSUS STRESS MANAGEMENT

Previous evidence: NICE Guidelines evidence statements

There is limited evidence favouring EMDR over stress management on reducing the likelihood of having a PTSD diagnosis after treatment \((k = 3; n = 84; RR = 0.69; 95\% CI, 0.46 to 1.04).\) I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and stress management therapy on reducing the severity of PTSD symptoms (self-report measures) \((k = 3; n = 75; SMD = -0.4; 95\% CI, -0.86 to 0.06).\) I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and stress management therapy on reducing the likelihood of leaving treatment early for any reason \((k = 3; n = 84; RR = 1.03; 95\% CI, 0.37 to 2.88).\) I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and stress management therapy on reducing the severity of clinician-rated PTSD symptoms \((k = 2; n = 53; SMD = -0.35; 95\% CI, -0.9 to 0.19).\) I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and stress management therapy on reducing the severity of clinician-rated PTSD symptoms at follow-up (2–5 months) \((k = 3; n = 71; SMD = -0.59; 95\% CI, -1.08 to -0.09).\) I

There is limited evidence favouring EMDR over stress management therapy on reducing the severity of self-report PTSD symptoms at follow-up (2–5 months) \((k = 3; n = 75; SMD = -0.51; 95\% CI, -0.98 to -0.05).\) I

There is limited evidence favouring EMDR over stress management therapy on reducing depression symptoms \((k = 3; n = 75; SMD = -0.67; 95\% CI, -1.14 to -0.20).\) I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between EMDR and stress management therapy on reducing depression symptoms at follow-up (2–5 months) \((k = 3; n = 75; SMD = -0.23; 95\% CI, -0.70 to 0.23).\) I

There is limited evidence favouring EMDR over stress management therapy on reducing anxiety symptoms \((k = 2; n = 45; SMD = -0.75; 95\% CI, -1.36 to -0.13).\) I

Further evidence identified in the current review

No new studies were identified comparing EMDR to stress management therapies.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

EMDR VERSUS OTHER THERAPIES

Previous evidence: NICE Guidelines evidence statements

There is limited evidence favouring EMDR over other therapies on reducing the likelihood of having a PTSD diagnosis after treatment \((k = 1; n = 67; RR = 0.4; 95\% CI, 0.19 to 0.84).\) I

There is limited evidence favouring EMDR over other therapies on reducing the severity of PTSD symptoms (self-report measures) \((k = 2; n = 124; SMD = -0.84; 95\% CI, -1.21 to -0.47).\) I

There is limited evidence favouring other therapies over EMDR on reducing the likelihood of leaving treatment early for any reason \((k = 2; n = 127; RR = 1.48; 95\% CI, 0.26 to 8.54).\) I

There is limited evidence favouring EMDR over other therapies on reducing depression symptoms \((k = 2; n = 127; SMD = -0.67; 95\% CI, -1.03 to -0.32).\) I

There is limited evidence favouring EMDR over other therapies on reducing anxiety symptoms \((k = 2; n = 126; SMD = -0.72; 95\% CI, -1.08 to -0.36).\) I
Further evidence identified in the current review

One study by Marcus et al. (2004) provided follow-up information on a trial that compared the effectiveness of EMDR versus standard care for treating a group of people with PTSD in a health maintenance organisation (HMO) setting. Standard care was dependent on practitioner’s preference, and was a combination of individual psychotherapy, with the possible addition of medication or group therapy. The results of the initial study indicated that EMDR was superior to standard care at reducing PTSD symptoms on all outcome measures. The follow-up paper found that these differences were still maintained at three and six months posttreatment. The systematic review by NICE defined the standard care provided in the original study by Marcus et al. (1997) as ‘Other therapies’. Results of this average quality trial suggest that EMDR had statistically significant and clinically important benefits on several outcome measures for PTSD sufferers who completed treatment, compared to standard care.

Table 4.11 Effectiveness of EMDR versus standard care for treating PTSD

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>STUDY:</strong> Marcus (2004) update of Marcus (1997) United States</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td>53 women</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assignment: b</td>
<td>14 men</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selection bias: c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impact of Events Scale (IES)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post Follow-up</td>
<td>17.9±16.5</td>
<td>3 months 12.3±33.0</td>
<td>35.0±20.2</td>
<td>3 months 33.0±20.8</td>
<td>6 months 27.6±21.1</td>
</tr>
<tr>
<td>Follow-up</td>
<td>11.5±14.6</td>
<td>6 months 16.0±17.8</td>
<td>t(42)=-3.87</td>
<td>p=0.001</td>
<td>p(42)=-2.73</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>t(42)=-2.73</td>
<td>p=0.010</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td> </td>
<td></td>
<td>3 months SMD -0.74 [95% CI -1.23 to -0.24]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td> </td>
<td></td>
<td>6 months SMD -0.88 [95% CI -1.38 to -0.38]</td>
</tr>
<tr>
<td>Modified PTSD Scale (MPPTSD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>24.5±21.3</td>
<td>3 months 17.3±21.1</td>
<td>44.3±30.0</td>
<td>3 months 42.2±27.2</td>
</tr>
<tr>
<td></td>
<td>6 months 16.0±17.8</td>
<td>6 months 16.0±17.8</td>
<td>t(42)=-3.40</td>
<td>p=0.002</td>
<td>t(34)=3.12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td> </td>
<td></td>
<td>3 months SMD -1.01 [95% CI -1.52 to -0.50]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td> </td>
<td></td>
<td>6 months SMD -0.98 [95% CI -1.49 to -0.47]</td>
</tr>
<tr>
<td>Beck Depression Inventory (BDI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8.4±8.3</td>
<td>3 months 8.1±10.4</td>
<td>15.3±12.9</td>
<td>3 months 14.4±11.4</td>
</tr>
<tr>
<td></td>
<td>6 months 6.9±8.8</td>
<td>6 months 6.9±8.8</td>
<td>t(42)=-1.90</td>
<td>p=0.022</td>
<td>t(34)=-2.66</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td> </td>
<td></td>
<td>3 months SMD -0.57 [95% CI -1.06 to -0.08]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td> </td>
<td></td>
<td>6 months SMD -1.43 [95% CI -1.97 to -0.89]</td>
</tr>
<tr>
<td>Spielberger State-Trait Anxiety (STAI)-Trait</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>38.1±11.2</td>
<td>3 months 34.7±13.7</td>
<td>47.8±13.4</td>
<td>3 months 44.1±12.3</td>
</tr>
<tr>
<td></td>
<td>6 months 33.6±11.6</td>
<td>6 months 33.6±11.6</td>
<td>t(42)=2.35</td>
<td>p=0.023</td>
<td>t(34)=2.85</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td> </td>
<td></td>
<td>3 months SMD -0.71 [95% CI -1.21 to -0.22]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td> </td>
<td></td>
<td>6 months SMD -0.93 [95% CI -1.43 to -0.42]</td>
</tr>
<tr>
<td>Spielberger State-Trait Anxiety (STAI)-State</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>38.1±11.2</td>
<td>3 months 34.8±14.3</td>
<td>45.6±14.8</td>
<td>3 months 41.1±14.6</td>
</tr>
<tr>
<td></td>
<td>6 months 31.7±12.1</td>
<td>6 months 31.7±12.1</td>
<td>Not significant</td>
<td>t(34)=-2.50</td>
<td>p=0.017</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td> </td>
<td></td>
<td>SMD -0.43 [95% CI -0.92 to 0.05]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td> </td>
<td></td>
<td>6 months SMD -0.8 [95% CI -1.31 to 0.31]</td>
</tr>
</tbody>
</table>

*Author’s reported value for statistical analysis; SMD = standardised mean difference; CI = confidence interval; EMDR = Eye movement desensitization and reprocessing; RCT = randomised controlled trial.*
The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and standard care on improving an impact of events scale score at three months (k = 1; n = 44; SMD = -0.74; 95% CI, -1.23 to -0.24). II

There is limited relevant and applicable evidence favouring EMDR over standard care on improving an impact of events scale score at six months (k = 1; n = 36; SMD = -0.88; 95% CI, -1.38 to -0.38). II

There is limited relevant and applicable evidence favouring EMDR over standard care on improving a modified PTSD scale score at three months (k = 1; n = 44; SMD = -1.01; 95% CI, -1.52 to -0.50). II

There is limited relevant and applicable evidence favouring EMDR over standard care on improving a modified PTSD scale score at six months (k = 1; n = 36; SMD = -0.98; 95% CI, -1.49 to -0.47). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and standard care on reducing depression symptoms (BDI) at three months (k = 1; n = 44; SMD = -0.57; 95% CI, -1.06 to -0.08). II

There is relevant and applicable evidence favouring EMDR over standard care on reducing depression symptoms at six months (k = 1; n = 36; SMD = -1.43; 95% CI, -1.97 to -0.89). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and standard care on reducing anxiety (trait) symptoms at three months (k = 1; n = 44; SMD = -0.71; 95% CI, -1.21 to -0.22). II

There is limited relevant and applicable evidence favouring EMDR over standard care on reducing anxiety (trait) symptoms at six months (k = 1; n = 36; SMD = -0.93; 95% CI, -1.43 to -0.42). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and standard care on reducing anxiety (state) symptoms at three months (k = 1; n = 44; SMD = -0.43; 95% CI, -0.92 to 0.05). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between EMDR and standard care on reducing anxiety (state) symptoms at six months (k = 1; n = 36; SMD = -0.8; 95% CI, -1.31 to -0.31). II

Updated evidence statements on the combined evidence from previous and current reviews

As stated above the new evidence available for the NHMRC review only included follow-up data on a previously reported study. Therefore there is no new combined evidence statement.
Further evidence identified in the current review

No new studies were identified comparing stress management to other therapies.

**Current review evidence statements**

As no new studies were identified, there are no current review evidence statements.

**Updated evidence statements on the combined evidence from previous and current reviews**

As there are no current review evidence statements, there are no updated evidence statements.

**GROUP CBT (TRAUMA-FOCUSED) VERSUS GROUP CBT (NON TRAUMA-FOCUSED)**

**Previous evidence: NICE Guidelines evidence statements**

There is evidence suggesting there is unlikely to be a clinically important difference between group CBT (trauma-focussed) and group CBT (non trauma-focussed) on reducing the likelihood of having a PTSD diagnosis after treatment ($k = 1; n = 360; \text{RR} = 0.98; 95\% \ CI, 0.83 to 1.16$).  

There is evidence suggesting there is unlikely to be a clinically important difference between group CBT (trauma-focussed) and group CBT (non trauma-focussed) on reducing the severity of PTSD symptoms ($k = 1; n = 325; \text{SMD} = 0.12; 95\% \ CI, –0.34 to 0.1$).  

There is limited evidence suggesting a difference favouring group CBT (non trauma-focussed) over group CBT (trauma-focussed) on reducing the likelihood of leaving treatment early for any reason ($k = 1; n = 360; \text{RR} = 1.38; 95\% \ CI, 1.0 to 1.9$).

**Further evidence identified in the current review**

No new studies were identified comparing group CBT (trauma-focussed) to group CBT (non trauma-focussed).

**Current review evidence statements**

As no new studies were identified, there are no current review evidence statements.

**Updated evidence statements on the combined evidence from previous and current reviews**

As there are no current review evidence statements, there are no updated evidence statements.

**NARRATIVE EXPOSURE THERAPY VERSUS SUPPORTIVE THERAPY**

**Previous evidence: NICE Guidelines evidence statements**

There is limited evidence favouring narrative exposure therapy over supportive counselling on reducing the severity of PTSD symptoms at 12 month follow-up as measured by clinician interview CIDI ($k = 1; n = 27; \text{SMD} = –1.22; 95\% \ CI, –2.05 to –0.38$).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between narrative exposure therapy and supportive counselling on reducing the severity of PTSD symptoms posttreatment as measured by assisted self-report PDS ($k = 1; n = 28; \text{SMD} = –0.06; 95\% \ CI, –0.8 to 0.68$).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between narrative exposure therapy and supportive counselling on reducing the severity of PTSD symptoms at 4 month follow-up as measured by assisted self-report PDS ($k = 1; n = 28; \text{SMD} = 0.18; 95\% \ CI, –0.56 to 0.93$).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between narrative exposure therapy and supportive counselling on increasing posttreatment quality of life as measured by the Medical Outcomes Study Self-Report Form-12 ($k = 1; n = 28; \text{SMD} = –0.15; 95\% \ CI, –0.89 to 0.6$).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between narrative exposure therapy and supportive counselling on increasing posttreatment quality of life at 4 month follow-up as measured by the Medical Outcomes Study Self-Report Form-12 ($k = 1; n = 28; \text{SMD} = –0.37; 95\% \ CI, –1.12 to 0.38$).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between narrative exposure therapy and supportive counselling on increasing quality of life at 12 month follow-up as measured by the Medical Outcomes Study Self-Report Form-12 ($k = 1; n = 27; \text{SMD} = –0.46; 95\% \ CI, –1.23 to 0.3$).
There is limited evidence favouring narrative exposure therapy over supportive counselling on reducing the likelihood of having a PTSD diagnosis at 12 month follow-up ($k = 1; n = 31; RR = 0.48; 95% CI, 0.26 to 0.88$).

There is limited evidence favouring supportive counselling over narrative exposure therapy on reducing the likelihood of leaving the study early due to any reason ($k = 1; n = 31; RR = 2.47; 95% CI, 0.29 to 21.21$).

Further evidence identified in the current review

No new studies were identified comparing narrative exposure therapy to supportive therapy.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

**NARRATIVE EXPOSURE THERAPY VERSUS PSYCHOEDUCATION**

**Previous evidence: NICE Guidelines evidence statements**

There is evidence favouring narrative exposure therapy over brief psychoeducation on reducing the severity of PTSD symptoms at 12 month follow-up as measured by clinician interview CIDI ($k = 1; n = 25; SMD = -1.46; 95% CI, -2.37 to -0.56$).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between narrative exposure therapy and brief psychoeducation on reducing the severity of PTSD symptoms posttreatment as measured by assisted self-report PDS ($k = 1; n = 27; SMD = -0.19; 95% CI, -0.95 to 0.57$).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between narrative exposure therapy and brief psychoeducation on reducing the severity of PTSD symptoms at 4 month follow-up as measured by assisted self-report PDS ($k = 1; n = 27; SMD = -0.43; 95% CI, -1.19 to 0.34$).

There is limited evidence favouring narrative exposure therapy over brief psychoeducation on reducing the severity of PTSD symptoms at 12 month follow-up as measured by assisted self-report PDS ($k = 1; n = 25; SMD = -1.27; 95% CI, -2.15 to -0.39$).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between narrative exposure therapy and brief psychoeducation on increasing posttreatment quality of life as measured by the Medical Outcomes Study-Report Form-12 ($k = 1; n = 27; SMD = -0.15; 95% CI, -0.91 to 0.61$).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between narrative exposure therapy and brief psychoeducation on increasing quality of life at 4 month follow-up as measured by the Medical Outcomes Study Self-Report Form-12 ($k = 1; n = 27; SMD = -0.08; 95% CI, -0.83 to 0.68$).

There is limited evidence favouring narrative exposure therapy over brief psychoeducation on increasing quality of life at 12 month follow-up as measured by the Medical Outcomes Study Self-Report Form-12 ($k = 1; n = 25; SMD = -0.48; 95% CI, -1.28 to 0.32$).

There is limited evidence favouring narrative exposure therapy over brief psychoeducation on reducing the likelihood of having a PTSD diagnosis at 12 month follow-up ($k = 1; n = 29; RR = 0.55; 95% CI, 0.29 to 1.06$).

There is limited evidence favouring brief psychoeducation over narrative exposure therapy on reducing the likelihood of leaving the study early due to any reason ($k = 1; n = 29; RR = 2.12; 95% CI, 0.25 to 17.98$).

Further evidence identified in the current review

No new studies were identified comparing narrative exposure therapy to psychoeducation.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.
PSYCHOEDUCATION VERSUS SUPPORTIVE THERAPY

Previous evidence: NICE Guidelines evidence statements

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between supportive counselling and brief psychoeducation on reducing the severity of PTSD symptoms at 12 month follow-up as measured by clinician interview CIDI (k = 1; n = 24; SMD = –0.24; 95% CI, –1.04 to 0.57). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between supportive counselling and brief psychoeducation on reducing the severity of PTSD symptoms posttreatment as measured by assisted self-report PDS (k = 1; n = 25; SMD = –0.13; 95% CI, –0.92 to 0.65). I

There is limited evidence favouring supportive counselling over brief psychoeducation on reducing the severity of PTSD symptoms at 4 month follow-up as measured by assisted self-report PDS (k = 1; n = 25; SMD = –0.55; 95% CI, –1.35 to 0.25). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between supportive counselling and brief psychoeducation on increasing posttreatment quality of life as measured by the Medical Outcomes Study Self-Report Form-12 (k = 1; n = 25; SMD = 0.0; 95% CI, –0.78 to 0.78). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between supportive counselling and brief psychoeducation on increasing quality of life at 4 month follow-up as measured by the Medical Outcomes Study Self-Report Form-12 (k = 1; n = 25; SMD = 0.28; 95% CI, –0.87 to 0.74). I

The evidence is inconclusive and so it is not possible to determine if there is a psychoeducation on reducing the likelihood of having a PTSD diagnosis at 12 month follow-up (k = 1; n = 26; RR = 1.14; 95% CI, 0.77 to 1.69). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between supportive counselling and brief psychoeducation on reducing the likelihood of leaving the study early due to any reason (k = 1; n = 26; RR = 0.86; 95% CI, 0.06 to 12.28). I

Further evidence identified in the current review

No new studies were identified comparing psychoeducation to supportive therapy.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

Summary of evidence

PSYCHOLOGICAL INTERVENTIONS

Overall summary

There are now over 30 well controlled studies examining the effectiveness of psychological treatment for PTSD. While a small number of these studies have been published since the NICE guidelines, those later studies have not altered the findings that trauma-focussed cognitive behavioural therapy (CBT) and eye movement desensitization and reprocessing (EMDR) are the treatments of choice for PTSD. These treatments were found to be effective in the treatment not only of PTSD symptoms but also comorbid anxiety and depression, as well as achieving improvements in broader quality of life. Trauma-focussed CBT and EMDR share the two key elements of exposure to the traumatic memory and cognitive processing of the meaning or interpretations of the trauma (termed cognitive restructuring in CBT and cognitive interweaving in EMDR). There is some evidence to suggest that these components are the key ingredients in the effectiveness of these interventions.
Studies examining the effectiveness of non trauma-focussed interventions of anxiety management (AM) and stress inoculation training (SIT) suggest that these interventions were superior to no treatment in achieving gains in PTSD symptoms, as well as comorbid anxiety and depression. However, AM and SIT were not as effective as trauma-focussed CBT or EMDR in reducing the likelihood of having the diagnosis at posttreatment, or in achieving longer term reductions in PTSD symptoms and comorbidity. Importantly, although not as effective as trauma-focussed CBT or EMDR when used in isolation, elements of AM and SIT, such as controlled breathing and other coping and symptom management techniques, are often included as part of trauma-focussed intervention protocols.

Similarly, psychoeducation, when delivered as a ‘stand alone’ treatment, was found to be inferior to trauma-focussed exposure-based interventions. However, elements of psychoeducation, such as providing an explanatory model for the sufferer of their symptoms and a rationale for treatment, are regularly included as components of trauma-focussed CBT interventions. Therefore, while psychoeducation, AM and SIT were not as effective as trauma-focussed CBT or EMDR as stand alone interventions, elements of these interventions may well have a role as part of a broader trauma-focussed treatment.

While models of brief trauma-focussed psychodynamic therapy have been developed, they have not as yet been sufficiently tested in controlled studies to derive practice recommendations. It may be, given the potential inclusion in such models of engagement with the traumatic memory, and addressing the interpretations and meaning of the trauma, (the key components of effective treatments noted above), that such models are efficacious. However, until controlled studies of the intervention are conducted, this remains largely speculative.

Supportive counselling and hypnotherapy have not been found to be effective as ‘stand alone’ interventions when compared to trauma-focussed CBT or EMDR.

To varying degrees, the studies cited in this section also include adults with PTSD as a result of prolonged and/or repeated trauma. One study (Cloitre et al., 2002) specifically provided support for the effectiveness of graded trauma-focussed CBT for adult survivors of childhood sexual assault. Thus, there is evidence to support the use of trauma-focussed psychological interventions in adults with PTSD following prolonged and/or repeated trauma. Issues of chronic self harm and suicidal ideation are more likely in this group and, therefore, may warrant special attention or consideration. The adult presenting with these issues may have a comorbid personality disorder that requires management. In such cases, more time and attention to stabilisation and engagement may be required in preparation for trauma-focussed therapy, as outlined in Cloitre et al (2002). In the absence of adequate distress tolerance or emotion regulation skills, the distress associated with trauma focus work may exceed the individual’s coping capacity and become counter productive. In some cases, however, the individual with PTSD may have ongoing suicidality until the traumatic experience is addressed, in which case delay in trauma focus therapy should be avoided.

Although the evidence indicates that trauma-focussed CBT and EMDR combined with in vivo exposure are important and potent interventions for the treatment of adults with PTSD, their clinical application needs to be carefully considered in each case. The practitioner should note that the clinical efficacy studies upon which the cited evidence is based have generally excluded people with severe comorbid borderline personality disorder, psychotic illness, severe depression and suicide risk or ongoing threat. As such, caution should be exercised, and the use of exposure seriously questioned, when the traumatised person presents with any of these exclusion criteria. The section on comorbidities in this chapter reviews the evidence and provides recommendations for the treatment of adults with PTSD in the context of comorbidity.

**Trauma-focussed CBT and EMDR: a comparison of longer term outcomes**

In the development of practice recommendations, the issue of maintenance of treatment gains in the longer term is very important. Given the evidence supporting both trauma-focussed CBT and EMDR, it is important to examine closely comparative longer term outcomes for these two interventions. Four studies were cited by NICE which compared outcomes for trauma-focussed CBT and EMDR at three months follow-up. NICE evidence statements indicated that there was unlikely to be a clinically important difference between them. Interestingly, while this is the case when data across the studies is meta-analysed, a closer look at the individual studies reveals divergence on outcomes at follow-up. Two studies (Devilly & Spence, 1999; Taylor et al., 2003) demonstrate superiority of exposure, with EMDR showing some return to baseline at follow-up. The other two studies (Ironson et al., 2002; Lee et al., 2002b) demonstrate superiority of EMDR over exposure in certain outcome variables at follow-up. Subsequent evidence statements drawn from the current review, based on Rothbaum et al (2005), identified superior outcomes in depression, dissociation and end state functioning at six months, in the exposure condition, compared to EMDR.

In attempting to understand this divergence at follow-up for the purposes of developing practice recommendations, two issues are worth noting. Firstly, one of the two studies favouring EMDR in terms of longer term outcomes (Ironson et al., 2002) added in vivo exposure to the EMDR condition. Importantly, the trauma-focussed CBT studies also all included in vivo exposure. Secondly, as stated in the descriptions of treatments in Chapter 3, a number of core CBT interventions have been added to EMDR and reflected in its progressive protocols, including cognitive interweaving (cognitive therapy), future templating (modelling and imaginal rehearsal of coping and mastery responses to anticipated future stressors) and most recently references to, although no explicit procedures for, in vivo exposure (Shapiro, 1999). Therefore, the use of more recent elaborated EMDR protocols that incorporate these elements, including in vivo exposure (considered either as part of, or in addition to, EMDR), may be important for achieving longer term outcomes and explaining some of the divergence in existing studies.
Although the precise mechanisms involved in EMDR are not known, there is increasing evidence from dismantling studies that the eye movements themselves are unlikely to be an active ingredient in EMDR’s effectiveness (Foley & Spates, 1995; Renfrey & Spates, 1994; Sanderson & Carpenter, 1992). These studies have demonstrated comparable outcomes when eye movements have been replaced with alternate novel techniques such as fixing attention to a single point of light on a screen or a stationary raised hand. Given the above, there is a case for considering EMDR, based on the most recent protocols, as a variant of trauma-focussed CBT with the inclusion of a novel component, rather than as a separate treatment. However, this would be contrary to the position argued by the developers of EMDR who do not classify it as a CBT intervention. For this reason, and for consistency with other international guidelines, these guidelines will continue to treat EMDR as a separate intervention, but the inclusion and potential contribution of CBT components is noted.

Length and number of sessions

While length and number of sessions for both CBT and EMDR have not been empirically tested as independent variables in their own right, the recommendations in these guidelines draw on the length and number of sessions reported in the controlled studies and on expert consensus. They are also consistent with recommendations in the NICE guidelines. In relation to EMDR and trauma-focussed CBT, at this point there is no consistent evidence suggesting that fewer treatment sessions are required for one treatment over the other. As such, there is no basis for recommending one treatment over the other on cost-effectiveness grounds.

RECOMMENDATIONS

4.1 Adults with PTSD should be provided with trauma-focussed interventions (trauma-focussed CBT or eye movement desensitization and reprocessing in addition to in vivo exposure). a

4.2 As available evidence does not support the importance of eye movements per se in EMDR, it is recommended that practitioners who use EMDR be aware that treatment gains are more likely to be due to the engagement with the traumatic memory, cognitive processing and rehearsal of coping and mastery responses. gpp

4.3 Where symptoms have not responded to one form of first line trauma-focussed interventions (trauma-focussed CBT or EMDR in addition to in vivo exposure), health practitioners may consider the alternative form of trauma-focussed interventions. gpp

4.4 Non trauma-focussed interventions such as supportive counselling and relaxation should not be provided to adults with PTSD in preference to trauma-focussed interventions. b

4.5 Where symptoms have not responded to a range of trauma-focussed interventions, evidence-based non trauma-focussed interventions (such as stress management) and/or pharmacotherapy should be considered. c

4.6 Sessions that involve imaginal exposure require 90 minutes to ensure that therapy is adequate in those sessions. c

4.7 Following diagnosis, assessment and treatment planning, eight to 12 sessions of trauma-focussed treatment is usually sufficient. d

4.8 For PTSD sufferers with several problems arising from multiple traumatic events, traumatic bereavement or where PTSD is chronic and associated with significant disability and comorbidity, further sessions using specific treatments to address those problems may be required. gpp

4.9 Where adults have developed PTSD and associated features following exposure to prolonged and/or repeated traumatic events, more time to establish a trusting therapeutic alliance, more attention to teaching emotional regulation skills and a more gradual approach to exposure therapy may be required. gpp
SINGLE VERSUS MULTIPLE PSYCHOLOGICAL INTERVENTIONS

Research questions and PICO

Box 4.2 Multiple psychological interventions compared to single interventions for adults with PTSD: research question and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
<th>16. For adults with PTSD, is a single intervention more effective than multiple interventions?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Selection criteria</strong></td>
<td><strong>Inclusion criteria</strong></td>
</tr>
<tr>
<td>Population</td>
<td>Adults with PTSD</td>
</tr>
<tr>
<td>Intervention</td>
<td>Single psychological or pharmacological intervention or psychosocial rehabilitation strategy</td>
</tr>
<tr>
<td>Comparator (1)</td>
<td>Combined psychological interventions, combined pharmacological interventions, combined psychosocial interventions or combined psychological, pharmacological or psychosocial interventions</td>
</tr>
<tr>
<td>Outcome</td>
<td>Primary outcome: resolution of symptoms of PTSD</td>
</tr>
<tr>
<td></td>
<td>Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, social and occupational function, quality of life, treatment refusal, dropout over 12 months, side effects, posttraumatic growth</td>
</tr>
<tr>
<td>Comparator (2)</td>
<td>Combined psychological intervention and psychosocial rehabilitation (e.g., teaching self-care and independent living skills techniques, providing supported housing, marital/family skills training, social skills training, anger management, vocational rehabilitation and case management) or combined pharmacological intervention and psychosocial rehabilitation</td>
</tr>
<tr>
<td>Outcome</td>
<td>Primary outcome: resolution of symptoms of PTSD, social and occupational function, quality of life</td>
</tr>
<tr>
<td></td>
<td>Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, treatment refusal, dropout over 12 months, side effects, posttraumatic growth</td>
</tr>
<tr>
<td>Study design</td>
<td>Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies.</td>
</tr>
<tr>
<td>Search period</td>
<td>2002–8/2005*</td>
</tr>
<tr>
<td>Language</td>
<td>English</td>
</tr>
</tbody>
</table>

*This was question number 10 in the VA/DoD review, with a search period up to 2002.

Studies included in previous reviews: VA/DoD (2004)

Four studies that compared combined psychological interventions with single psychological interventions were identified in the VA/DoD review (Cooper & Clum, 1989; Foa et al., 1999a; Glynn et al., 1999; Marks et al., 1998).

Studies included in the current review of combined psychological treatments (2002–2005)

One randomised controlled trial was identified for the current review that assessed the effectiveness of the combination of two psychological treatments for PTSD against one of these alone (Bryant et al., 2003a). Bryant et al., (2003a) assessed the value of adding cognitive restructuring to eight weeks of exposure.

Treatment comparisons

STRESS INNOCULATION THERAPY (SIT) COMBINED WITH PROLONGED EXPOSURE (PE) VERSUS SIT OR PE ALONE

Previous evidence: VA/DoD summary statement

(Note: The VA/DoD review did not provide evidence statements in the form of the NICE review)

One high quality randomised trial (Foa et al., 1999) showed poorer outcomes with a combination of stress inoculation therapy (SIT) than with exposure therapy alone. Number needed to treat for harm (NHTH) ranged from 4 to 5 for the various outcomes measured. No significant differences were found between the combination and SIT used alone.

Further evidence identified in the current review

No new studies were identified comparing SIT and PE with either intervention alone.
Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

**EXPOSURE THERAPY COMBINED WITH COGNITIVE RESTRUCTURING (CR) VERSUS EXPOSURE THERAPY OR CR ALONE**

Previous evidence: VA/DoD summary statement

A [second] randomised trial of good quality (Marks et al., 1998) showed poorer outcomes with a combination of exposure and cognitive restructuring when compared with cognitive restructuring alone. NNTH ranged from 5 to 8 for the various outcomes measured.

Further evidence identified in the current review

Bryant et al., (2003a) found limited benefit with the addition of CR to exposure therapy.

Table 4.12 Effectiveness of exposure therapy versus exposure therapy plus cognitive restructuring

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
<th>Effect size [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY: Bryant et al (2003a) Australia</td>
<td>Exposure (n = 20)</td>
<td>Cognitive restructuring + exposure (n = 20)</td>
<td>Difference</td>
</tr>
<tr>
<td>Level II (quasi-randomised controlled trial)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assignment: c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selection bias: c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding: b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 civilian trauma victims after nonsexual assault or motor vehicle accident</td>
<td>32.5±8.7 6 months</td>
<td>32.7±7.5 6 months</td>
<td>Not significant</td>
</tr>
<tr>
<td></td>
<td>20.7±12.0</td>
<td>15.7±14.8</td>
<td></td>
</tr>
<tr>
<td>OUTCOME: CAPS-intensity</td>
<td>32.5±8.7</td>
<td>32.7±7.5</td>
<td></td>
</tr>
<tr>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.7±12.0</td>
<td>15.7±14.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not significant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p&lt;0.05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMD -0.36 [-0.99-0.26]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36.8±9.8</td>
<td>20.6±12.7 6 months</td>
<td>36.0±8.7</td>
<td>17.2±15.6 6 months</td>
</tr>
<tr>
<td></td>
<td>23.3±12.9</td>
<td>15.7±15.2</td>
<td></td>
</tr>
<tr>
<td>OUTCOME: CAPS-frequency</td>
<td>36.8±9.8</td>
<td>36.0±8.7</td>
<td></td>
</tr>
<tr>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.6±12.7</td>
<td>15.7±15.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not significant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMD -0.53 [-1.16-0.10]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23.9±7.1</td>
<td>17.7±7.3 6 months</td>
<td>26.6±7.0</td>
<td>15.1±12.9 6 months</td>
</tr>
<tr>
<td></td>
<td>17.6±9.9</td>
<td>16.0±12.2</td>
<td></td>
</tr>
<tr>
<td>OUTCOME: IES-intrusion</td>
<td>23.9±7.1</td>
<td>26.6±7.0</td>
<td></td>
</tr>
<tr>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.7±7.3</td>
<td>15.1±12.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not significant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMD -0.14 [-0.76-0.48]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26.4±6.7</td>
<td>19.5±13.5 6 months</td>
<td>26.4±6.7</td>
<td>16.2±13.5 6 months</td>
</tr>
<tr>
<td></td>
<td>20.8±12.7</td>
<td>15.0±12.3</td>
<td></td>
</tr>
<tr>
<td>OUTCOME: IES-avoidance</td>
<td>26.4±6.7</td>
<td>26.4±6.7</td>
<td></td>
</tr>
<tr>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.5±13.5</td>
<td>16.2±13.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not significant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMD -0.24 [-0.86-0.38]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>56.8±11.2</td>
<td>43.1±13.5 6 months</td>
<td>54.6±8.2</td>
<td>41.5±14.8 6 months</td>
</tr>
<tr>
<td></td>
<td>42.9±14.9</td>
<td>43.3±11.9</td>
<td></td>
</tr>
<tr>
<td>OUTCOME: STAI-state</td>
<td>56.8±11.2</td>
<td>54.6±8.2</td>
<td></td>
</tr>
<tr>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>43.1±13.5</td>
<td>41.5±14.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not significant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMD 0.04 [-0.58-0.66]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21.7±11.2</td>
<td>17.5±12.8 6 months</td>
<td>23.2±10.1</td>
<td>13.9±14.3 6 months</td>
</tr>
<tr>
<td></td>
<td>16.2±12.2</td>
<td>15.0±14.0</td>
<td></td>
</tr>
<tr>
<td>OUTCOME: Beck Depression Inventory</td>
<td>21.7±11.2</td>
<td>23.2±10.1</td>
<td></td>
</tr>
<tr>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.5±12.8</td>
<td>13.9±14.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not significant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMD -0.09 [-0.71-0.53]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CAPS = clinician administered PTSD scale; IES = impact of events scale; STAI = state-trait anxiety inventory; *post hoc Tukey’s comparison; †author’s reported value; SMD = standardised mean difference; CI = confidence interval.
Current review evidence statements

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between cognitive restructuring in addition to exposure therapy and exposure therapy alone for improvement in clinician administered PTSD intensity score at 6 months (k = 1; n = 40; SMD = –0.36; 95% CI, –0.99 to 0.26). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between cognitive restructuring in addition to exposure therapy and exposure therapy alone for improvement in clinician administered PTSD frequency score at 6 months (k = 1; n = 40; SMD = –0.53; 95% CI, –1.16 to 0.10). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between cognitive restructuring in addition to exposure therapy and exposure therapy alone for improvement in impact of events scale (intrusion) score at 6 months (k = 1; n = 40; SMD = –0.14; 95% CI, –0.76 to 0.48). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between cognitive restructuring in addition to exposure therapy and exposure therapy alone for improvement in impact of events scale (avoidance) score at 6 months (k = 1; n = 40; SMD = –0.24; 95% CI, –0.86 to 0.38). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between cognitive restructuring in addition to exposure therapy and exposure therapy alone for improvement in State anxiety index score at 6 months (k = 1; n = 40; SMD = 0.04; 95% CI, –0.58 to 0.66). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between cognitive restructuring in addition to exposure therapy and exposure therapy alone for improvement in Beck depression inventory score at 6 months (k = 1; n = 40; SMD = –0.09; 95% CI, –0.71 to 0.53). II

Updated evidence statements on the combined evidence from previous and current reviews

The VA/DoD summary statements are not in a form that can be combined with evidence statements from the current review. Consideration of both bodies of evidence will be reflected in the summary and recommendations.

DIRECT THERAPEUTIC EXPOSURE COMBINED WITH BEHAVIOURAL FAMILY THERAPY VERSUS DIRECT EXPOSURE ALONE

Previous evidence: VA/DoD summary statement

A low quality RCT (Glynn et al., 1999) revealed that the addition of behavioural family therapy to the treatment of PTSD with direct therapeutic exposure did not improve outcomes.

Further evidence identified in the current review

No new studies were identified comparing direct therapeutic exposure and behavioural family therapy with direct therapeutic exposure alone.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.
IMAGINAL FLOODING COMBINED WITH STANDARD TREATMENT VERSUS STANDARD TREATMENT ALONE

Previous evidence: VA/DoD summary statement

A low quality trial (Cooper & Clum, 1989) found improved outcomes when imaginal flooding was added to standard individual and group psychotherapy. The irregular methods and small sample size make these results questionable.

Further evidence identified in the current review

No new studies were identified comparing SIT and PE with either intervention alone.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

Summary of the evidence

There are now three moderate to high quality trials examining the issue of single versus combined psychological treatment. Two of these studies (Bryant et al., 2005; Marks et al., 1998) examine the combination of cognitive restructuring and exposure compared to cognitive restructuring or exposure alone. The findings of these studies suggest that while exposure and cognitive restructuring are effective interventions, there was no evidence of improved outcomes when they were delivered in combination.

A number of issues need to be considered in relation to these findings. First, it is important to acknowledge that the two treatments are not completely independent — exposure treatments include by their nature some level of cognitive reprocessing and cognitive restructuring treatments include some level of engagement with, and exposure to the traumatic memory. While the evidence suggests that both treatments are effective in facilitating trauma recovery, studies investigating the benefits of combining treatment have been flawed by reducing the amount of each treatment when provided in combination with another. This, and other methodological issues (e.g. experimental power limitations) raised by combination studies mean that at this point recommendations cannot be made about combining these treatments.

In relation to SIT, while this treatment has been identified as an effective treatment for PTSD, although second line to trauma-focused interventions, it does not appear to demonstrate any advantage in combination with exposure in comparison to exposure alone (Foa et al., 1999a). However, the limitations described in relation to the combination studies examining cognitive restructuring and exposure also apply here. As such, recommendations cannot be made about combining these treatments.

The range of trauma populations included in the above studies and the interventions provided are generalisable to the PTSD populations in Australia and the Australian health care context.
## INDIVIDUAL AND GROUP PSYCHOLOGICAL INTERVENTIONS

### Research questions and PICO

#### Box 4.3 Individual compared to group therapy for adults with PTSD: research question and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research question</td>
<td>5. Is individual therapy more effective than group therapy for PTSD?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selection criteria</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Adults with PTSD</td>
</tr>
<tr>
<td>Intervention</td>
<td>Individual therapy (e.g., psychodynamic psychotherapy, individual cognitive behavioural therapies, EMDR, narrative exposure therapy, image rehearsal therapy, supportive counselling, hypnosis)</td>
</tr>
<tr>
<td>Comparator</td>
<td>Group therapy (e.g., supportive therapy, psychoeducation, psychodynamic therapy, group CBT such as anxiety management, stress inoculation, assertiveness training, prolonged exposure, cognitive restructuring)</td>
</tr>
</tbody>
</table>
| Outcome            | Primary outcome: resolution of symptoms of PTSD  
Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, functional improvement, quality of life, treatment refusal, dropout over 12 months, posttraumatic growth |
| Study design       | Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies |
| Search period      | 2002–8/2005* |
| Language           | English |

*This was question number 8 in the VA/DoD review with a search period up to 2002.

#### Box 4.4 Combination individual and group therapy: research question and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research question</td>
<td>6. For adults with PTSD, is the combination of individual therapy and group therapy more effective than either alone?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selection criteria</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Adults with PTSD</td>
</tr>
<tr>
<td>Intervention</td>
<td>Individual therapy and group therapy (See Box 8 for examples)</td>
</tr>
<tr>
<td>Comparator</td>
<td>Individual therapy or group therapy (See Box 8 for examples)</td>
</tr>
</tbody>
</table>
| Outcome            | Primary outcome: resolution of symptoms of PTSD  
Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, functional improvement, quality of life, treatment refusal / dropout over 12 months, posttraumatic growth |
| Study design       | Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies |
| Search period      | 1966–8/2005* |
| Language           | English |

*A new search (1996–2005) was conducted on this question as it was not addressed in either the NICE or VA/DoD reviews.

### Studies included in previous reviews: VA/DoD (2004)

Neither of these questions was addressed by the NICE review.

VA/DoD question 8 compared individual and group therapy for PTSD but no studies addressing this question were identified in the review.

The VA/DoD review did not address the question of combination individual and group therapy compared to either individual or group therapy alone.
Studies included in the current review
No studies were identified in the current review (2002–2005) that compared individual and group therapy for PTSD.

No studies were identified in the current review (1996–2005) that compared combined individual and group therapy with either individual or group therapy alone.

Treatment comparisons
Not applicable as no studies were identified.

Summary of evidence
While there were no studies examining the effectiveness of group versus individual therapy there is a small amount of evidence summarised in the NICE guidelines suggesting that group CBT is effective compared to waitlist and that trauma-focussed group CBT and non trauma-focussed group CBT were equally effective. The range of trauma populations included in the above studies and the interventions provided are generalisable to the PTSD populations in Australia and the Australian health care context.

The recommendations in these guidelines reflect the weight of evidence supporting the effectiveness of trauma-focussed CBT when delivered in individual therapy. However, given that there is some evidence supporting group CBT, its potential adjunctive value has been noted in the recommendations, with an appropriately lower level of evidence.

RECOMMENDATIONS
4.10 Group CBT (trauma-focussed or non trauma-focussed) may be provided as adjunctive to, but should not be considered an alternative to, individual therapy.
SELF-DELIVERED INTERVENTIONS

Research questions and PICO

Box 4.5 Self-delivered interventions: research question and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Research question</strong></td>
<td>7. Are established interventions for PTSD effective when self-delivered without face-to-face practitioner support?</td>
</tr>
<tr>
<td><strong>Population</strong></td>
<td>Adults with PTSD</td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
<td>Self-delivered psychological intervention without face-to-face practitioner support (e.g., web-based interapy or telephone support)</td>
</tr>
</tbody>
</table>
| **Comparator** | (1) Practitioner delivered psychological intervention  
(2) No-treatment (e.g., assessment only) |
| **Outcome** | Primary outcome: resolution of symptoms of PTSD  
Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, functional improvement, quality of life, treatment refusal, dropout over 12 months, posttraumatic growth |
| **Study design** | Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies |
| **Search period** | 1966–8/2005* |
| **Language** | English |

*A new search (1996–2005) was conducted on this question as it was not addressed in either the NICE or VA/DoD reviews.

Studies included in previous reviews

This question was not asked in either the NICE or VA/DoD reviews. However, the NICE question on psychological treatments (question 1) identified one study that compared interapy to waitlist (Lange et al., 2003a). Given its relevance to this question the NICE evidence statements have been included below.

Studies included in the current review (1996–2005)

There were no studies that met the inclusion criteria comparing self-delivered PTSD treatments with face-to-face therapy. However, one study of relevance to this question that investigated self help CBT as an early intervention for adults exposed to trauma (Ehlers et al., 2003) failed to find a difference with waitlist. This study was not included in the review of this question as it was delivered as an early intervention (therefore covered under question 2) and included a 40 minute session with a therapist at the beginning of treatment to explain the self help book and its content (face-to-face contact).

Treatment comparisons

INTERAPY VERSUS WAITLIST

Previous evidence: NICE Guidelines evidence statements

There is evidence favouring interapy over waitlist on reducing severity of PTSD symptoms as measured by self-report IES at endpoint (k = 1; n = 101; SMD = −1.32; 95% CI, −1.77 to −0.86). I

There is evidence favouring interapy over waitlist on reducing depression symptoms as measured by self-report SCL-90 at endpoint (k = 1; n = 101; SMD = −1.06; 95% CI, −1.51 to −0.62). I

There is limited evidence favouring interapy over waitlist on reducing anxiety symptoms as measured by self-report SCL-90 at endpoint (k = 1; n = 101; SMD = −0.81; 95% CI, −1.24 to −0.37). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between interapy and waitlist on reducing the likelihood of leaving the study prior to endpoint for any reason (k = 1; n = 184; RR = 0.9; 95% CI, 0.65 to 1.25). I
Further evidence identified in the current review

No further studies that compared interapy with waitlist were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

Summary of the evidence

Given the substantial body of evidence supporting practitioner delivered trauma-focussed CBT interventions, a single study examining and supporting interapy interventions, and a single study failing to support the effectiveness of a CBT self help booklet as an early intervention, these guidelines recommend seeking practitioner facilitated treatment where this is available. Self-delivered options such as interapy may be of some benefit where face-to-face practitioner support is not available. However, there is clearly a need for further research into self-care interventions and practitioner delivered interventions combined with components of self-care. This need is evident across the range from early intervention through to cases of chronic PTSD. In the latter case, the application of existing chronic disease self-management models to PTSD may be investigated. While not an alternative to practitioner delivered interventions, in routine care practitioners are advised to discuss self-care strategies with PTSD sufferers to support recovery and the practitioner delivered interventions.

The studies examining these treatment options are applicable and generalisable to the Australian health care context.

The following recommendations are not intended to be used prescriptively but rather as guidelines to assist the practitioner. In each case treatment decisions should be based on recommended treatment combined with the clinical judgement of the practitioner and the person’s preferences.

RECOMMENDATIONS

4.11 For adults with PTSD, self-delivered interventions should not be prescribed in place of evidence-based practitioner delivered interventions. b

4.12 Facilitated, although non face-to-face interventions such as interapy may be considered where face-to-face practitioner delivered interventions are not available d

4.13 Self-delivered interventions may be useful as adjunctive to practitioner delivered interventions. gpp
PHARMACOLOGICAL INTERVENTIONS

Research questions and PICO

Box 4.6 Pharmacological interventions for adults with PTSD: research questions and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>10. For adults with PTSD, do pharmacological interventions improve outcomes compared with placebo?</td>
<td>Adults with PTSD</td>
</tr>
<tr>
<td>11. For adults with PTSD, does any pharmacological intervention confer any advantage over other pharmacological interventions?</td>
<td>Pharmacological intervention (e.g., SSRIs, other second-generation antidepressants, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, mood stabilizers, anti-convulsants, and some non-benzodiazepine hypnotics and anti-anxiety medications)</td>
</tr>
</tbody>
</table>

| Comparator | 10. Placebo |
| 11. Other pharmacological intervention |

| Outcome | Primary outcome: resolution of symptoms of PTSD |
| Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, functional improvement, quality of life, treatment refusal, dropout over 12 months, side effects, posttraumatic growth |

| Study design | Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies. |

| Search Period | 2004-8/2005* |
| Language | English |

SSRIs = selective serotonin reuptake inhibitors. *These were pharmacological questions 1 and 2 in the NICE review, with a search period up to 2004.

Studies included in previous reviews: NICE (2005)
The following studies were identified by the NICE Guideline Development Group as meeting the inclusion criteria:

- 23 studies comparing drug treatments against placebo (Brady et al., 2000; Bryson et al., unpublished-a/b; Butterfield et al., 2001; Connor et al., 1999; Davidson et al., 1990; Davidson et al., unpublished; Davidson et al., 2001a/b; Davidson et al., 2003; Davidson, 2004; Eli Lilly, unpublished data; Hertzberg et al., 2000; Katz et al., 1994; Kosten et al., 1991; Marshall et al., 2001; Martenyi et al., 2002a/b; Pfizer 588, unpublished data; Pfizer 589, unpublished data; Stein et al., 2002; Tucker et al., 2001; Zohar et al., 2002).

- one study compared one pharmacological treatment against another pharmacological treatment (Hamner et al., 2003)

Study characteristics
In contrast to the reports of psychological interventions, the studies included did not typically provide data on remission of PTSD diagnosis, but instead reported response rate in terms of a percentage decrease in symptoms from baseline score. Response rate data were not used within the meta-analysis because of the inconsistency in reporting (thresholds for reported response rates typically vary from 30% to 50%). This decision was taken because it is known that relatively small differences in mean scores (which are not clinically significant) between two comparison groups can produce statistically significant differences when presented as response rates (Kirsch et al., 2002). Remission rates have the advantage of being clinically determined in advance (diagnosis v. no diagnosis). Recent research in depression suggests that remission is a more reliable indicator of a stable return to normal mood states than response rates (Keller, 2003). The most consistent evidence reported for tolerability was the number of participants leaving the treatment early and this is reported within the review.

Extracted from NICE (2005:69)

Studies included in the current review (2004–2005)
The review team conducted a systematic search for RCTs published from 2004 to 2005 that compared pharmacological treatments against waiting list or usual care or against another pharmacological treatment. The following studies were identified as meeting the inclusion criteria:

- five studies comparing drug treatments against placebo (Brady et al., 2005; Davidson et al., 2005a; Davis et al., 2004; Reich et al., 2004; Tucker et al., 2004)

- two studies comparing one drug treatment against another (Chung et al., 2004; McRae et al., 2004)
PAROXETINE VERSUS PLACEBO

Acute phase
The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between paroxetine and placebo on reducing the severity of PTSD symptoms (CAPS - clinician) (k = 3; n = 1070; SMD = -0.42; 95% CI, -0.55 to -0.3). I

There is evidence suggesting there is unlikely to be a clinically important difference between paroxetine and placebo on reducing the severity of PTSD symptoms (DTS - self-report) (k = 3; n = 1065; SMD = -0.37; 95% CI, -0.49 to -0.24). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between paroxetine and placebo on reducing depression symptoms (Montgomery-Asberg depression rating scale -clinician) (k = 3; n = 1069; SMD = -0.34; 95% CI, -0.61 to -0.07). I

There is evidence suggesting there is unlikely to be a clinically important difference between paroxetine and placebo on improving quality of life (k = 3; n = 1039; SMD = -0.27; 95% CI, -0.4 to -0.14). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between paroxetine and placebo on reducing the likelihood of leaving treatment early (k = 3; n = 1196; RR = 0.95; 95% CI, 0.79 to 1.15). I

Continuation/relapse prevention
The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between paroxetine and placebo on reducing the severity of PTSD symptoms (CAPS - clinician) (k = 1; n = 129; SMD = 0.19; 95% CI, -0.15 to 0.54). I

There is evidence suggesting there is unlikely to be a clinically important difference between paroxetine and placebo on reducing the severity of PTSD symptoms (DTS - self-report) (k = 1; n = 127; SMD = 0.06; 95% CI, -0.28 to 0.41). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between paroxetine and placebo on reducing the likelihood of leaving treatment early (k = 1; n = 176; RR = 0.84; 95% CI, 0.51 to 1.38). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between paroxetine and placebo on reducing the likelihood of having a PTSD diagnosis after treatment (k = 1; n = 176; RR = 0.81; 95% CI, 0.55 to 1.19). I

Dosage comparison: Paroxetine 20 mg versus paroxetine 40 mg
Acute phase
There is evidence suggesting there is unlikely to be a clinically important difference between paroxetine 20 mg and paroxetine 40 mg on reducing the severity of PTSD symptoms as measured by clinician measure CAPS (k = 1; n = 365; SMD = -0.06; 95% CI, -0.27 to 0.14). I

There is evidence suggesting there is unlikely to be a clinically important difference between paroxetine 20 mg and paroxetine 40 mg on reducing the severity of PTSD symptoms as measured by self-report DTS (k = 1; n = 365; SMD = -0.08; 95% CI, -0.29 to 0.12). I

There is evidence suggesting there is unlikely to be a clinically important difference between paroxetine 20 mg and paroxetine 40 mg on reducing depression symptoms as measured by Montgomery-Asberg depression rating scale (k = 1; n = 365; SMD = -0.08; 95% CI, -0.29 to 0.12). I

There is evidence suggesting there is unlikely to be a clinically important difference between paroxetine 20 mg and paroxetine 40 mg on increasing quality of life (k = 1; n = 365; SMD = -0.08; 95% CI, -0.28 to 0.13). I

There is evidence suggesting there is unlikely to be a clinically important difference between paroxetine 20 mg and paroxetine 40 mg on reducing the likelihood of leaving treatment early for any reason (k = 1; n = 375; RR = 0.89; 95% CI, 0.68 to 1.15). I

Further evidence identified in the current review
No new studies that compared paroxetine with placebo were identified.
Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

SERTRALINE VERSUS PLACEBO

Previous evidence: NICE Guidelines evidence statements

Six studies of sertraline were identified by the NICE review as meeting the inclusion criteria (Brady et al., 2000; Davidson et al., unpublished; Davidson et al., 2001a,b; Davidson, 2004; Zohar et al., 2002), one of which (Davidson et al., 2001a) was a continuation/relapse prevention study covering the same population as (Davidson et al., 2001b). Four trials were of mixed trauma populations and one was of military veterans. Full data for two large unpublished trials (Pfizer 588, unpublished data; Pfizer 589, unpublished data) held by the manufacturers were unavailable (n = 166 for a trial with combat veterans, n = 188 for a mixed trauma population trial) despite repeated requests to the manufacturer. In order to incorporate these substantial trials within the meta-analysis, estimates for missing standard deviation data are included (standard deviations were estimated as the highest standard deviation for each outcome measure as derived from the other published drug trials).

Acute phase

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between sertraline and placebo on reducing the severity of PTSD symptoms as measured by clinician-rated CAPS (k = 6; n = 1123; SMD = –0.26; 95% CI, –0.51 to 0.00). I

There is evidence suggesting there is unlikely to be a clinically important difference between sertraline and placebo on reducing the severity of PTSD symptoms as measured by the self-report Davidson trauma scale (k = 5; n = 1091; SMD = –0.18; 95% CI, –0.41 to 0.06). I

There is evidence suggesting there is unlikely to be a clinically important difference between sertraline and placebo on reducing the severity of PTSD symptoms as measured by the self-report impact of event scale (k = 4; n = 739; SMD = –0.06; 95% CI, –0.39 to 0.26). I

There is evidence suggesting there is unlikely to be a clinically important difference between sertraline and placebo on reducing severity of depression symptoms as measured by pooled Hamilton and Montgomery-Asberg depression scale ratings (k = 3; n = 417; SMD = –0.27; 95% CI, –0.46 to –0.07). I

There is evidence suggesting there is unlikely to be a clinically important difference between sertraline and placebo on reducing severity of depression symptoms as measured by clinician-rated Hamilton anxiety scale (k = 1; n = 202; SMD = –0.17; 95% CI, –0.45 to 0.10). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between sertraline and placebo on improving quality of life (k = 2; n = 385; SMD = –0.26; 95% CI, –0.59 to 0.07). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between sertraline and placebo on reducing the likelihood of leaving treatment early for any reason (k = 6; n = 1148; RR = 1.10; 95% CI, 0.90 to 1.33). I

Continuation/relapse prevention

There is evidence suggesting there is unlikely to be a clinically important difference between sertraline and placebo on reducing the likelihood of having a posttreatment PTSD diagnosis as measured by clinician-rated CAPS (k = 2; n = 747; RR = 0.91; 95% CI, 0.85 to 0.98). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between sertraline and placebo on reducing the severity of PTSD symptoms using clinician-rated CAPS-2 (relapse prevention phase) (k = 1; n = 42; SMD = –0.14; 95% CI, –0.75 to 0.47). I

There is limited evidence favouring sertraline over placebo on reducing the likelihood of leaving treatment early (relapse prevention phase) (k = 1; n = 96; RR = 0.75; 95% CI, 0.52 to 1.08). I

Further evidence identified in the current review

Two trials assessed the effectiveness of sertraline versus a placebo on reducing PTSD symptoms and depression (Brady et al., 2005; Tucker et al., 2004). Both trials included people with PTSD secondary to a wide range of traumas.
PTSD symptoms:

Brady et al., (2005), in their good quality trial, found no statistically significant difference between sertraline and placebo in reducing clinician administered PTSD scale (CAPS) scores ($F(2,68) = 2.68, p = 0.08$) for intention-to-treat analyses. On the sub-scales of the CAPS, there was a trend towards significance for lowering amount of intrusion ($F(2,68) = 2.49, p = 0.09$) and hyperarousal symptoms ($F(2,68) = 2.85, p = 0.07$). Tucker et al., (2004) did not assess whether the difference in CAPS change scores was statistically significant.

Depression:

Two trials assessed the effects of sertraline or placebo on depression within PTSD sufferers (Brady et al., 2005; Tucker et al., 2004). Those unwilling to stop their medication prior to either trial were excluded. It was not stated whether any participants were receiving concurrent psychological treatment.

Brady et al., (2005) found that there was no significant difference between sertraline and placebo at reducing depression. Tucker et al., (2004) reported that change in depression was similar for both sertraline and placebo groups even though baseline levels of depression were lower in the former group. A statistical comparison was not performed. Furthermore, Tucker et al., (2004) used the data of program completers rather than conducting intention-to-treat analyses.

Table 4.13 Effectiveness of sertraline versus placebo for reducing PTSD symptoms

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
<th>Difference $^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY: Brady (2005) United States</td>
<td>Clinician Administered PTSD Scale (CAPS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td>PSST patients secondary to civilian trauma</td>
<td>Sertraline (n = 49)</td>
<td>60.1 $\pm$18.1</td>
</tr>
<tr>
<td>STUDY: (Tucker, 2004) United States</td>
<td>Clinician Administered PTSD Scale (CAPS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td>50 outpatients with PTSD (DSM-IV, CAPS)</td>
<td>Sertraline (n = 18/23)</td>
<td>83.1 $\pm$19.3</td>
</tr>
</tbody>
</table>

NR = not reported; ITT = intention-to-treat; NA = not applicable; $^a$author’s reported value; SMD = standardised mean difference; CI = confidence interval; RCT = randomised controlled trial.

Table 4.14 Effectiveness of sertraline versus placebo for reducing depression in PTSD patients

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
<th>Difference $^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY: (Brady, 2005) United States</td>
<td>Hamilton Depression Scale (HAMD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td>PTSD patients secondary to civilian trauma</td>
<td>Sertraline (n = 49)</td>
<td>17.3$\pm$7.0</td>
</tr>
<tr>
<td>STUDY: (Tucker, 2004) United States</td>
<td>Beck Depression Inventory (BDI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td>50 outpatients with PTSD (DSM-IV, CAPS)</td>
<td>Sertraline (n = 18/23)</td>
<td>26.1$\pm$12.1</td>
</tr>
<tr>
<td></td>
<td>Placebo (n = 7/10)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NR = not reported; ITT = intention-to-treat; NA = not applicable; $^a$author’s reported value; SMD = standardised mean difference; CI = confidence interval; RCT = randomised controlled trial.
Current review evidence statements

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between sertraline and placebo on reducing the severity of PTSD symptoms (clinician-rated CAPS) (k = 1; n = 94; SMD = –0.37; 95% CI, –1.11 to 0.38). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between sertraline and placebo on reducing the severity of depression symptoms (BDI) (k = 1; n = 33; SMD = –0.58; 95% CI, –1.34 to 0.17). II

Updated evidence statements on the combined evidence from previous and current reviews

There is relevant and applicable evidence suggesting that there is unlikely to be a clinically important difference between sertraline and placebo for reducing the severity of PTSD symptoms (k = 7; n = 1148; SMD = –0.23; 95% CI, –0.48 to 0.03). I

There is relevant and applicable evidence suggesting that there is unlikely to be a clinically important difference between sertraline and placebo for reducing the severity of depression symptoms (k = 4; n = 442; SMD = –0.24; 95% CI, –0.61 to 0.13). I

**FLUOXETINE VERSUS PLACEBO**

Previous evidence: NICE Guidelines evidence statements

Five studies of fluoxetine met the inclusion criteria (Connor et al., 1999; Eli Lilly, unpublished data; Hertzberg et al., 2000; Martenyi et al., 2002a/b), one of which was a continuation/relapse prevention study. The studies were of mixed trauma populations with the exception of one small study (Hertzberg et al., 2000) of male military veterans.

**Acute phase**

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between fluoxetine and placebo on reducing the severity of PTSD symptoms (CAPS - clinician) (k = 1; n = 301; SMD = –0.28; 95% CI, –0.54 to –0.02). I

There is evidence suggesting there is unlikely to be a clinically important difference between fluoxetine and placebo on reducing the severity of PTSD symptoms (TO P-8 - clinician) (k = 1; n = 411; SMD = –0.02; 95% CI, –0.21 to 0.26). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between fluoxetine and placebo on reducing the severity of PTSD symptoms (DTS - self-report) (k = 1; n = 301; SMD = –0.41; 95% CI, –0.98 to 0.15). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between fluoxetine and placebo on reducing depression symptoms (Montgomery-Asberg depression rating scale -clinician) (k = 1; n = 301; SMD = –0.45; 95% CI, –0.71 to –0.18). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between fluoxetine and placebo on reducing depression symptoms (Hamilton - clinician) (k = 1; n = 301; SMD = –0.42; 95% CI, –0.68 to –0.16). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between fluoxetine and placebo on improving quality of life (k = 2; n = 61; SMD = –0.62; 95% CI, –1.13 to –0.1). I

There is limited evidence favouring fluoxetine over placebo on reducing the likelihood of leaving treatment early (k = 2; n = 66; RR = 0.6; 95% CI, 0.28 to 1.30). I

**Continuation/relapse prevention**

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between fluoxetine and placebo on reducing the severity of PTSD symptoms (CAPS - clinician) (k = 1; n = 98; SMD = –0.28; 95% CI, –0.68 to 0.12). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between fluoxetine and placebo on reducing the severity of PTSD symptoms (DTS - self-report) (k = 1; n = 98; SMD = –0.19; 95% CI, –0.59 to 0.21). I

There is limited evidence favouring fluoxetine over placebo on reducing the likelihood of leaving treatment early (k = 1; n = 131; RR = 0.51; 95% CI, 0.28 to 0.96). I
Further evidence identified in the current review

One trial compared the effects of fluoxetine versus placebo (Davidson et al., 2005b). Prior to treatment, participants were required to go through a washout period of any psychotropic medication they were also receiving.

Twelve month dropout rates were high for both the fluoxetine and placebo arms of the trial, although twice as high in the placebo arm. Although the rate of nightmares and insomnia were similar in treatment and placebo groups, people receiving placebo reported more additional symptoms of appetite increase and weight gain. No data were provided on the relative effectiveness of fluoxetine for the primary outcome of reducing PTSD symptoms.

Table 4.15 Dropouts and side effects from fluoxetine treatment versus placebo

<table>
<thead>
<tr>
<th>STUDY: Davidson (2005) United States</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level II (RCT) 62 patients with PTSD, between 18-70</td>
</tr>
<tr>
<td>Assignment: b Fluoxetine (n = 27) Placebo (n = 30)</td>
</tr>
<tr>
<td>Selection bias: c Side effects nightmares (n = 5) insomnia (n = 5)</td>
</tr>
<tr>
<td>Blinding a Assessment: a All cause dropouts 9/27 (33%) 18/30 (66%)</td>
</tr>
<tr>
<td>ITT: Yes Effec size [95% CI]</td>
</tr>
<tr>
<td>Outcome Fluoxetine Placebo Difference</td>
</tr>
<tr>
<td>All cause dropouts 9/27 (33%) 18/30 (66%) NR RR = 0.56 [0.30-1.02] p = 0.04</td>
</tr>
<tr>
<td>Side effects nightmares (n = 5) insomnia (n = 5)</td>
</tr>
<tr>
<td>Increased appetite (n = 7) weight gain (n = 6)</td>
</tr>
<tr>
<td>NR NC</td>
</tr>
<tr>
<td>NR = not reported; ITT = intention-to-treat; SMD = standardised mean difference; NA = not applicable; RR = relative risk; NC = not calculated because an event rate cannot be estimated; ‘author’s reported value; CI = confidence interval; RCT = randomised controlled trial.</td>
</tr>
</tbody>
</table>

Current review evidence statements

There is limited relevant and applicable evidence favouring fluoxetine over placebo for treatment dropout rate (k = 1; n = 57; RR = 0.56; 95% CI, 0.30 to 1.02). II

Updated evidence statements on the combined evidence from previous and current reviews

There is limited relevant and applicable evidence favouring fluoxetine over placebo for the likelihood of leaving treatment early (k = 3; n = 123; RR = 0.56; 95% CI, 0.35 to 0.91). I

TRICYCLIC ANTIDEPRESSANTS VERSUS PLACEBO

Previous evidence: NICE Guidelines evidence statements

Although they are not licensed for PTSD, tricyclic antidepressants have been in use for much longer than the SSRI drugs. The trials of tricyclic antidepressants are of older design and this needs to be borne in mind as these results are considered.

Amitriptyline versus placebo

Acute phase

One trial (in combat veterans) of amitriptyline met the study criteria (Davidson et al., 1990).

There is limited evidence favouring amitriptyline over placebo on reducing the severity of PTSD symptoms (using the total measure of the self-report IES) (k = 1; n = 33; SMD = –0.90; 95% CI, –1.62 to –0.18). I

There is limited evidence favouring amitriptyline over placebo on reducing depression symptoms as measured by the clinician-rated Hamilton scale (k = 1; n = 33; SMD = –1.16; 95% CI, –1.90 to –0.41). I

There is limited evidence favouring amitriptyline over placebo on reducing anxiety symptoms as measured by the clinician-rated Hamilton scale (k = 1; n = 33; SMD = –0.99; 95% CI, –1.72 to –0.26). I

There is limited evidence favouring placebo over amitriptyline on reducing the likelihood of leaving the study early for any reason (k = 1; n = 46; RR = 1.34; 95% CI, 0.52 to 3.49). I

Imipramine versus placebo

Acute phase

One trial in combat veterans of imipramine met the inclusion criteria (Kosten et al., 1991).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between imipramine and placebo on reducing the severity of PTSD symptoms (as measured by self-report IES) (k = 1; n = 41; SMD = –0.24 ; 95% CI, –0.86 to 0.38). I
The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between imipramine and placebo on reducing depression symptoms as measured by the clinician-rated Hamilton scale (k = 1; n = 41; SMD = –0.22; 95% CI, –0.84 to 0.40). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between imipramine and placebo on reducing anxiety symptoms as measured by the Covi anxiety scale (k = 1; n = 41; SMD = –0.46; 95% CI, –1.08 to 0.17). I

There is limited evidence favouring imipramine over placebo on reducing the likelihood of leaving the study early for any reason (k = 1; n = 41; RR = 0.78; 95% CI, 0.47 to 1.30). I

Further evidence identified in the current review

No new studies that compared tricyclic antidepressants with placebo were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

MONOAMINE OXIDISE INHIBITORS VERSUS PLACEBO

Previous evidence: NICE Guidelines evidence statements

The use of traditional monoamine oxidase inhibitors (MAOIs) such as phenelzine has been limited by the need to impose dietary restrictions. However, there has been research into this group of drugs in PTSD with trials of phenelzine and brofaromine. Brofaromine is not available in Australia and so will not be discussed further.

Phenelzine versus placebo

Acute phase
One trial in combat veterans phelalzine versus placebo met the inclusion criteria (Kosten et al., 1991).

There is limited evidence favouring phenelzine over placebo on reducing the severity of PTSD symptoms (as measured by self-report IES) (k = 1; n = 37; SMD = –1.06; 95% CI, –1.75 to –0.36). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between phenelzine and placebo on reducing depression symptoms as measured by the clinician-rated Hamilton scale (k = 1; n = 37; SMD = –0.4; 95% CI, –1.06 to 0.25). I

There is limited evidence favouring phenelzine over placebo on reducing anxiety symptoms as measured by the Covi anxiety scale (k = 1; n = 37; SMD = –0.67; 95% CI, –1.34 to –0.01). I

There is evidence favouring phenelzine over placebo on reducing the likelihood of leaving the study early due to any reason (k = 1; n = 37; RR = 0.32; 95% CI, 0.12 to 0.8). I

Further evidence identified in the current review

No new studies that compared monoamine oxidase inhibitors with placebo were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

MIRTIZAPINE VERSUS PLACEBO

Previous evidence: NICE Guidelines evidence statements

One study of mirtazapine (Davidson et al., 2003) for a mixed trauma population met the inclusion criteria.

Acute phase

There is evidence favouring mirtazipine over placebo on reducing the severity of PTSD symptoms (structured interview for PTSD - clinician) (k = 1; n = 21; SMD = –1.89; 95% CI, –3.0 to –0.78). I

There is limited evidence favouring mirtazipine over placebo on reducing the severity of PTSD symptoms (DTS - self-report) (k = 1; n = 26; SMD = –0.76; 95% CI, –1.60 to 0.08). I

There is limited evidence favouring mirtazipine over placebo on reducing depression symptoms (HADS-D - self-report) (k = 1; n = 25; SMD = –0.92; 95% CI, –1.81 to –0.04). I
There is limited evidence favouring mirtazapine over placebo on reducing anxiety symptoms (HADS-A - self-report) \((k = 1; n = 25; \text{SMD} = -0.88; 95\% \text{ CI}, -1.77 \text{ to } 0.0)\). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between mirtazapine and placebo on reducing the likelihood of leaving treatment early \((k = 1; n = 29; \text{RR} = 0.9; 95\% \text{ CI}, 0.29 \text{ to } 2.82)\). I

Further evidence identified in the current review

No new studies that compared mirtazapine with placebo were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

VENLAFAXINE VERSUS PLACEBO

Previous evidence: NICE Guidelines evidence statements

The United Kingdom Committee on Safety of Medicines has recently recommended that treatment with venlafaxine should only be initiated by mental health specialists because of concerns about cardiotoxicity and toxicity in overdose (CSM, 2004).

There is one unpublished study of venlafaxine that met the inclusion criteria (Davidson et al., unpublished); the trauma population was unspecified.

Acute phase

There is evidence suggesting there is unlikely to be a clinically important difference between venlafaxine and placebo on reducing the severity of PTSD symptoms (CAPS - clinician) \((k = 1; n = 358; \text{SMD} = -0.14; 95\% \text{ CI}, -0.35 \text{ to } 0.06)\). I

There is evidence suggesting there is unlikely to be a clinically important difference between venlafaxine and placebo on reducing the severity of PTSD symptoms (DTS - self-report) \((k = 1; n = 358; \text{SMD} = -0.19; 95\% \text{ CI}, -0.4 \text{ to } 0.01)\). I

There is evidence suggesting there is unlikely to be a clinically important difference between venlafaxine and placebo on improving quality of life (Quality of Life Enjoyment and Satisfaction Questionnaire - self-report) \((k = 1; n = 352; \text{SMD} = 0.2; 95\% \text{ CI}, -0.01 \text{ to } 0.40)\). I

There is evidence suggesting there is unlikely to be a clinically important difference between venlafaxine and placebo on improving quality of life (Global Assessment of Functioning - clinician) \((k = 1; n = 358; \text{SMD} = 0.18; 95\% \text{ CI}, -0.03 \text{ to } 0.39)\). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between venlafaxine and placebo on reducing the likelihood of leaving treatment early \((k = 1; n = 358; \text{RR} = 0.83; 95\% \text{ CI}, 0.62 \text{ to } 1.12)\). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between venlafaxine and placebo on reducing the likelihood of having a posttreatment PTSD diagnosis (using clinician measure CAPS) \((k = 1; n = 358; \text{SMD} = 0.87; 95\% \text{ CI}, 0.77 \text{ to } 0.98)\). I

Further evidence identified in the current review

No new studies that compared venlafaxine with placebo were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.
CITALOPRAM VERSUS PLACEBO

Previous evidence: NICE Guidelines evidence statements

No studies comparing citalopram with placebo were identified in the NICE review.

Further evidence identified in the current review

One trial assessed the effectiveness of citalopram and placebo on reducing the symptoms of PTSD and depression using completer data (Tucker et al., 2004). Patients were not on any psychotropic medications apart from occasional diphenhydramine for sleep within two weeks from baseline (Tucker et al., 2004).

The results of this average quality trial indicated that both citalopram and placebo caused statistically significant reductions in symptoms. However, a comparison between the two groups was not provided.

Table 4.16 Effectiveness of Citalopram and placebo on PTSD

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
<th>Effect size [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assignment: b</td>
<td>50 outpatients with PTSD (DSM-IV, CAPS)</td>
<td>Citalopram (n = 19)</td>
<td>Placebo (n = 7)</td>
</tr>
<tr>
<td>Selection bias: d</td>
<td>49.8±20.4</td>
<td>38.7±22.1</td>
<td>95.0±8.4</td>
</tr>
<tr>
<td>Blinding: a</td>
<td>88.5±10.4</td>
<td>38.7±22.1</td>
<td>p=0.0001</td>
</tr>
<tr>
<td>Assessment: a</td>
<td>Beck Depression Inventory (BDI)</td>
<td>Placebo (n = 10)</td>
<td></td>
</tr>
<tr>
<td>ITT: No</td>
<td>26.8±10.6</td>
<td>13.9±10.4</td>
<td>p=0.0001</td>
</tr>
</tbody>
</table>

Y = Author’s reported value; SMD = standardised mean difference; CI = confidence interval; ITT = intention-to-treat; NA = not available; NR = not reported; RCT = randomised controlled trial.

Current review evidence statements

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between citalopram and placebo for PTSD symptom severity (k = 1; n = 35; SMD = -0.40; 95% CI, -1.27 to 0.47). II

The evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between citalopram and placebo for Beck depression inventory (k = 1; n = 35; SMD = -0.51; 95% CI, -1.39 to 0.37). II

Updated evidence statements on the combined evidence from previous and current reviews

As there were no previous review evidence statements, there are no updated evidence statements.

NEFAZODONE VERSUS PLACEBO

One average-to-good quality trial assessed the effect of nefazodone on PTSD symptoms, compared to placebo (Davis et al., 2004). However, nefazodone has been withdrawn from circulation in Australia and therefore will not be discussed further.
OLANZAPINE VERSUS PLACEBO

Previous evidence: NICE Guidelines evidence statements

One trial met the inclusion criteria. This study (Butterfield et al., 2001) was of olanzapine alone versus placebo for a mixed-trauma population (predominantly female rape victims).

Acute phase

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between olanzapine and placebo on reducing the severity of PTSD symptoms (structured interview for PTSD and CAPS - clinician) (k = 1; n = 11; SMD = 0.16; 95% CI, –1.07 to 1.39).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between olanzapine and placebo on reducing the severity of PTSD symptoms (DTS - self-report) (k = 1; n = 11; SMD = 0.04; 95% CI, –1.19 to 1.26).

There is limited evidence favouring placebo over olanzapine on reducing the likelihood of leaving treatment early (k = 1; n = 15; RR = 1.5; 95% CI, 0.2 to 11.0).

Further evidence identified in the current review

No new studies that compared olanzapine with placebo were identified.

RISPERIDONE VERSUS PLACEBO

Previous evidence: NICE Guidelines evidence statements

No studies were identified in the NICE review that examined risperidone alone versus placebo. One study however examined risperidone as an adjunctive treatment with usual pharmacological treatment (Hamner et al., 2003). This is described in the combined pharmacological section below.

Further evidence identified in the current review

One average quality trial assessed the effectiveness of risperidone as a treatment for participants with PTSD secondary to child sexual abuse (Reich et al., 2004). Nine participants were taking other psychiatric medications during the study. Five participants randomised to risperidone were also receiving an SSRI (n = 1), tricyclic antidepressant (n = 1), and benzodiazepines (n = 1). Four participants randomised to placebo were on an SSRI (n = 2), a tricyclic antidepressant (n = 1), a benzodiazepine (n = 1) and trazodone (n = 1). These medications were kept stable throughout the study (Reich et al., 2004).

Risperidone was found to be statistically significantly better at reducing PTSD symptoms than placebo after eight weeks of treatment in people who completed the trial largely due to a reduction on the intrusion symptoms subscale of the clinician-administered PTSD scale.

Table 4.17 Effectiveness of risperidone versus placebo

<table>
<thead>
<tr>
<th>Study: Reich (2004) United States</th>
<th>Effectiveness</th>
<th>Effect size [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Name:</td>
<td>Risperidone (n = 12)</td>
<td>Placebo (n = 9)</td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td>Pre</td>
<td>Change</td>
</tr>
<tr>
<td>Assignment:</td>
<td>65.5±13.2</td>
<td>-29.6±31.5</td>
</tr>
<tr>
<td>Selection bias:</td>
<td>p = 0.015</td>
<td></td>
</tr>
<tr>
<td>Blinding:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT: Yes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CAPS-2 = clinician administered PTSD scale- 1-week version; ITT = intention-to-treat; NC = not calculated because only change scores reported; *=Author’s reported value; RCT = randomised controlled trial.
Current review evidence statements

This study did not provide enough raw data to calculate effect sizes, in that it reported mean change scores rather than mean scores. In order to write an evidence statement, standard deviations are needed, and these were not able to be deduced from the information provided.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no previous or current review evidence statements, there are no updated evidence statements.

**Intervention compared to intervention
VENLAFAXINE VERSUS SERTRALINE

Previous evidence: NICE Guidelines evidence statements

There is evidence suggesting there is unlikely to be a clinically important difference between venlafaxine and sertraline on reducing the severity of PTSD symptoms (CAPS - clinician) (k = 1; n = 352; SMD = –0.01; 95% CI, –0.22 to 0.20). I

There is evidence suggesting there is unlikely to be a clinically important difference between venlafaxine and sertraline on reducing the severity of PTSD symptoms (DTS - self-report) (k = 1; n = 352; SMD = –0.1; 95% CI, –0.31 to 0.11). I

There is evidence suggesting there is unlikely to be a clinically important difference between venlafaxine and sertraline on improving quality of life (Q-LES-Q -self-report) (k = 1; n = 352; SMD = –0.02; 95% CI, –0.23 to 0.19). I

There is evidence suggesting there is unlikely to be a clinically important difference between venlafaxine and sertraline on improving quality of life (GAF-Clinician) (k = 1; n = 352; SMD = –0.01; 95% CI, –0.22 to 0.20). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between venlafaxine and sertraline on reducing the likelihood of leaving treatment early (k = 1; n = 352; RR = 0.84; 95% CI, 0.62 to 1.14). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between venlafaxine and sertraline on reducing the likelihood of having a posttreatment PTSD diagnosis (k = 1; n = 352; RR = 0.92; 95% CI, 0.81 to 1.05). I

Further evidence identified in the current review

No new studies comparing venlafaxine with sertraline were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

**MIRTAZAPINE VERSUS SERTRALINE

Previous evidence: NICE Guidelines evidence statements

No studies that compared mirtazapine with sertraline were identified in the NICE review.

Further evidence identified in the current review

One poor-to-average quality trial by Chung et al., (2004) compared the effectiveness of mirtazapine with sertraline in a group of Korean veterans. Prior to the study, participants were required to have a seven day washout period of any medications except for zopiclone for insomnia. It was not stated whether participants were also receiving psychotherapy for PTSD or not. Participant dropouts were fairly evenly distributed between the two groups. There were no statistically significant differences in PTSD symptom severity for participants receiving mirtazapine compared to sertraline who completed treatment. Even though no statistical analyses were performed it appears that dry mouth, constipation and somnolence were more commonly reported by participants receiving mirtazapine than those taking sertraline. Conversely, indigestion and heart palpitations were more prevalent in the sertraline group.
Table 4.18 Effectiveness of mirtazapine versus sertraline

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
<th>Effect size [95% CI]</th>
<th>Mirtazapine (n = 51)</th>
<th>Sertraline (n = 49)</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY: Chung (2004) Korea</td>
<td>CAPS-2 total score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td>113 inpatients and outpatients of Veterans hospital with PTSD and comorbid major depression or dysthymia</td>
<td></td>
<td></td>
<td>103.2±24.4</td>
<td>-44.8±19.7</td>
<td>88.8±23.9</td>
</tr>
<tr>
<td>Assignment: c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selection bias: c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding: c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Mirtazapine Major depression=21.6% Dysthymia=72.6% | Sertraline Major depression=14.3% Dysthymia=81.6% | Side effects | |
| | | dry mouth (19.6%) constipation (19.6%) somnolence (15.7%) weight gain (2.0%) | indigestion (14.3%) palpitation (6.1%) agitation (2.0%) epigastric soreness (2.0%) sexual dysfunction (2.0%) |
| | | | | | | | | NR |
| | | | | | | | | NC |

| Dropouts | 7/51 (13.7%) | 6/49 (12.2%) | NR |
| | | | RR 0.98 |
| | | | [0.85 to 1.14] |
| | | | p = 0.83 |

NR = not reported; NC=not calculated because an event rate cannot be estimated or only change scores reported; Y = Author's reported value; RR = risk ratio; CAPS-2 = clinician-administered PTSD scale -2; CI = confidence interval; HAMD = Hamilton rating scale for depression.

Current review evidence statements

There is relevant and applicable evidence suggesting that there is unlikely to be a clinically important difference between mirtazapine and sertraline for treatment dropout rate (k = 1; n =100; RR = 0.98; 95% CI, 0.30 to 1.02). II

Updated evidence statements on the combined evidence from previous and current reviews

As there were no previous review evidence statements, there are no updated evidence statements.

NEFAZADONE VERSUS SERTRALINE

Previous evidence: NICE Guidelines evidence statements

No studies that compared nefazodone with sertraline were identified in the NICE review.

Further evidence identified in the current review

McRae et al., (2004) compared the effectiveness of nefazodone with sertraline in an outpatient setting. However, as stated earlier, nefazodone has been withdrawn from circulation in Australia and therefore will not be discussed further.

Updated evidence statements on the combined evidence from previous and current reviews

As there were no previous review evidence statements, there are no updated evidence statements.
Summary of evidence

Since the current guidelines build upon the NICE guidelines, it is appropriate to commence with a review of their approach and recommendations in the area of pharmacotherapy for PTSD. Two cautionary notes are required at the outset.

The NICE guidelines note the difficulty of comparing drug treatment trials with psychological treatment trials. While the latter compare an active treatment with an inert intervention or wait list control condition, pharmacological trials compare the active drug to placebo. Large placebo effects often render the effect size for the drug intervention small or insignificant, despite relatively large pre- to posttreatment changes (in both groups). Currently, there is no adequate trial comparing drug and psychological treatments for PTSD. Indirect methods of comparison are hard to interpret because of the differences in the degree of improvement in the non-active/placebo arms of psychotherapy and pharmacology trials.

A second issue to note from the NICE guidelines is that they chose to include unpublished data in their review of pharmacological treatments, but not in their review of psychological treatments. Inclusion of unpublished pharmacological data reduced the overall effect sizes obtained, particularly for sertraline. While the logic of including unpublished data in this case is clear (notably where the reason for not publishing appeared to have been a failure to demonstrate an effect), it could be argued that pharmacological interventions were treated unduly harshly.

Although not specific to the NICE review, it is worth noting that recruitment of participants into pharmacological trials is harder than psychotherapy trials as there tends to be a preferential desire for psychological treatments amongst participants. As a consequence, the comparability of the people in pharmacology trials and psychotherapy trials needs to take account of the potential for pretreatment differences in the participants. Random allocation is critical to removing this potential source of difference.

The NICE guidelines concluded that pharmacotherapy should not be used as a first line treatment for PTSD in preference to a trauma-focussed psychological therapy. In clinical practice, the person’s choice should also influence the choice of first line psychological versus pharmacological treatment. Further, they found evidence only for paroxetine, mirtazapine, amitriptyline, and phenelzine, using the predetermined effect size of 0.5. (It needs to be recognised that potentially useful gains in a symptom subset, such as irritability, can exist despite small effect sizes on the main endpoint measures).

Since completing our systematic review, the Cochrane Collaboration published their review of the evidence regarding pharmacological treatments in PTSD (Stein et al., 2006) available at http://tinyurl.com/8tvda). They found 35 short-term RCTs of PTSD (4597 participants) to review, three of which contained a maintenance component; five of those were unpublished. The authors concluded that, while no clear evidence exists to show that any particular class of medication is more effective or better tolerated than any other, the greatest number of trials showing efficacy to date, as well as the largest, have been with the SSRIs. On the basis of the data, the review recommends the SSRIs as first line agents in the pharmacotherapy of PTSD, and supports their value in long-term treatment.

We found no further studies since the NICE review with regard to pharmacological prevention and early intervention following traumatic exposure. Thus, in line with the NICE recommendations, we do not recommend drug treatments for use either as a preventive intervention non-selectively with traumatised populations or as an early intervention for ASD or related conditions. However, we do recognise the benefits of pharmacological interventions in terms of managing current acute (and chronic) symptoms in certain cases.

With regard to pharmacological treatments for PTSD, we found a small number of studies since the NICE review. Four studies examining SSRI antidepressants (one on citalopram, two on sertraline, one on fluoxetine) failed to provide evidence that these drugs were superior to placebo either in the treatment of PTSD symptoms or in the treatment of depression in the context of PTSD. Importantly, however, relatively large pre- to posttreatment effects were noted in both groups (active and placebo). One trial of nefazadone showed more promising results, particularly in terms of hyperarousal, but is of limited relevance to these guidelines since it has been withdrawn in Australia due to adverse side effects (liver damage). We found two new studies comparing different drug treatments for PTSD. In both cases, no differences were noted between sertraline and mirtazapine or between sertraline and nefazadone.

In interpreting the recommendations in this section, it is important to consider several caveats. First, it is important to note that all agents have the potential for negative effects. As such, adults with PTSD may be reluctant to accept pharmacological treatment or alternatively, side effects may lead to discontinuation. Side effects associated with the SSRI’s include headaches, nausea, loss of libido and agitation. The novel antipsychotics, particularly olanzapine, is associated with substantial weight gain and a risk of type II diabetes. Hence, the initiation and sustained involvement in treatment should not be considered as automatic.

Secondly, the inadequacy of data about the role of medication in conjunction with psychotherapy is a major deficiency. In clinical practice many people receive both CBT and medication, and participants in many psychotherapy trials have been stabilised on medication by the time of their participation. Thirdly, a variety of other agents, including the mood stabilisers, novel antipsychotics, and antihypertensives, have been trialed in open labeled studies, often with promising results. Finally, many people require a combination of medications; there is a paucity of clinical trial data to provide guidance about the effectiveness of different combinations of medication.
Importantly, in interpreting the above cited study findings, the range of trauma populations included in the studies and the pharmacotherapies provided are generalisable to the PTSD populations in Australia and the Australian health care context.

In summary, no new evidence has emerged in the last two years to warrant a substantial modification to the NICE recommendations. Notwithstanding the caveats above, we concur with their interpretation of the available evidence that larger clinical effects are likely to be obtained from trauma-focussed psychological treatment than from pharmacological treatment in most sufferers of PTSD. We do not, however, believe that the available evidence warrants a selective recommendation of one SSRI over another in the treatment of PTSD. Rather, we have chosen to recommend the SSRIs generally as the first choice for medication, leaving the final decision regarding the specific drug to the clinician. We note the evidence summarised in the NICE findings regarding mirtazapine, amitriptyline, and phenelzine. With regard to the former, we are not convinced that the current research evidence is sufficient to recommend mirtazapine above other new generation antidepressants as a second line pharmacological treatment. While we recommend that clinicians note the research support for amitriptyline and phenelzine, we recognise that these medications have been used only rarely in routine clinical practice for some time, and that they are more difficult to use. Thus, it makes little sense to recommend them as a first choice. The potential interaction of medications prescribed for any physical health issues, with those recommended for PTSD and comorbid psychological issues, needs to be considered in treatment decisions.

**CLINICAL RECOMMENDATIONS**

4.14 Drug treatments for PTSD should not be used as a routine first line treatment for adults, either by general medical practitioners or by specialist mental health professionals, in preference to a trauma-focussed psychological therapy. (See also Combined psychological and pharmacological treatment Recommendations 4.28 and 4.29)

4.15 Where medication is considered for the treatment of PTSD in adults, SSRI antidepressants should be the first choice for both general practitioners and mental health specialists.

4.16 Other new generation antidepressants (notably mirtazapine) and the older tricyclic antidepressants should be considered as a second line option. Phenelzine should be considered for use by mental health specialists for people with treatment resistant symptoms.

4.17 Antidepressant medication should be considered for the treatment of PTSD in adults when:
   a) the sufferer is unwilling to engage in trauma-focussed psychological treatment
   b) the sufferer is not sufficiently stable to commence trauma-focussed psychological treatment (as a result, for example, of being actively suicidal or homicidal, or of severe ongoing life stress such as domestic violence)
   c) the sufferer has not gained significant benefit from trauma-focussed psychological treatment
   d) the sufferer is experiencing a high level of dissociative symptoms that are likely to be significantly exacerbated by trauma-focussed therapy.

4.18 Where a decision has been made to commence pharmacotherapy, the person’s mental state should be regularly monitored with a view to commencing adjunctive psychological treatment if/when appropriate. In the interim, supportive psychotherapy with a substantial psychoeducational component should be offered.

4.19 Where significant sleep disturbance or excessive distress does not settle in response to reassurance, simple psychological first aid, or other non-drug intervention, cautious use of hypnotic medication may be appropriate in the short term. If the sleep disturbance is of more than one month duration and medication is likely to be of benefit in the management of the person’s PTSD, a suitable antidepressant should be considered. The risk of tolerance and dependence are relative contraindications to the use of hypnotics for more than one month except if their use is intermittent.

4.20 Antidepressant medication (see Recommendation 4.15 above) should be considered as an adjunct to psychological treatment in adults where core PTSD symptoms are of sufficient severity to significantly interfere with the sufferers ability to benefit from psychological treatment.

4.21 Where conditions comorbid with the PTSD (e.g., depression, other anxiety conditions) are of sufficient severity to significantly interfere with the sufferers ability to benefit from psychological treatment, or where a more rapid relief of symptoms is likely to offer significant clinical benefit, drug treatments that have a demonstrable evidence-base for the treatment of that condition should be considered.
4.22 Where symptoms have not responded adequately to pharmacotherapy, consideration should be given to:
   a) increasing the dosage within approved limits gpp
   b) switching to an alternative antidepressant medication gpp
   c) adding risperidone or olanzapine as an adjunctive medication gpp
   d) reconsidering the potential for psychological intervention. gpp

4.23 When an adult sufferer with PTSD has responded to drug treatment, it should be continued for at least 12 months before gradual withdrawal. b

4.24 Best practice prescribing procedures should be adopted when using drug treatments for PTSD in adults, including provision of information prior to commencement, monitoring and management of side effects, monitoring of suicide risk, and appropriate discontinuation and withdrawal practices. gpp

4.25 Adult PTSD sufferers receiving pharmacotherapy should be seen at least weekly if there is a significant risk of suicide; if there is no significant risk of suicide, fortnightly contact is recommended initially, dropping to less frequent after three months if the response is good. The role of the practitioner in providing information and support is an important component of the management. gpp

RESEARCH RECOMMENDATIONS

4.26 We concur with the NICE recommendations that a large, well controlled randomised trial comparing pharmacological with trauma-focussed psychological treatment across different trauma populations should be conducted.

4.27 We also recommend further exploration of the potential benefits of combination (pharmacological and trauma-focussed psychological) treatments in trials that adequately address both sides of the equation (i.e., drug versus drug + psychological is not sufficient; the design must include a trauma-focussed psychological treatment alone as it represents the current first line treatment).
**COMBINED PHARMACOLOGICAL INTERVENTIONS**

**Research questions and PICO**

**Box 4.7 Multiple pharmacological interventions compared to single pharmacological interventions for adults with PTSD: research question and study selection criteria**

<table>
<thead>
<tr>
<th>Research question</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>16. For adults with PTSD, is a single intervention more effective than multiple interventions?</td>
<td>Population: Adults with PTSD; Intervention: Single psychological or pharmacological intervention or psychosocial rehabilitation strategy; Comparator (1): Combined psychological interventions, combined pharmacological interventions, combined psychosocial interventions or combined psychological, pharmacological or psychosocial interventions; Outcome: Primary outcome: resolution of symptoms of PTSD; Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, social and occupational function, quality of life, treatment refusal, dropout over 12 months, side effects, posttraumatic growth; Comparator (2): Combined psychological intervention and psychosocial rehabilitation (e.g., teaching self-care and independent living skills techniques, providing supported housing, marital/family skills training, social skills training, anger management, vocational rehabilitation and case management) or combined pharmacological intervention and psychosocial rehabilitation; Outcome: Primary outcome: resolution of symptoms of PTSD, social and occupational function, quality of life; Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, treatment refusal, dropout over 12 months, side effects, posttraumatic growth; Study design: Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selection criteria</th>
<th>Language</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design</td>
<td>English</td>
</tr>
<tr>
<td>Search period</td>
<td>2002–8/2005*</td>
</tr>
</tbody>
</table>

*This question was based on question 10 in the VA/DoD review. However the PICO used in the VA/DoD review excluded pharmacological studies.

**Studies included in previous reviews**

This question was not asked in either of the previous reviews. However, two studies of relevance to this question were identified in the NICE review in response to their pharmacological question 2. Both studies investigated adjunctive pharmacological treatments (Hamner et al., 2003; Stein et al., 2002).

**Studies included in the current review (2002–2005)**

No studies were identified in the current review (2002–2005) that compared single and combined pharmacological interventions.

**Treatment comparisons**

**ADJUNCTIVE OLanzAPINE WITH NORMAL SSRI VERSUS ADJUNCTIVE PLACEBO WITH NORMAL SSRI**

Previous evidence: NICE Guidelines evidence statements

There was one study (Stein et al., 2002) of adjunctive olanzapine (taken in conjunction with SSRIs) for male combat veterans. This study examined the efficacy of olanzapine for people already receiving but not responsive to SSRI treatment within the first 12 weeks of SSRI treatment. During the trial, of the total of 19 participants, five were taking fluoxetine, seven were taking paroxetine and seven were taking sertraline.

**Acute phase**

There is limited evidence favouring adjunctive olanzapine (to SSRI) over placebo on reducing the severity of PTSD symptoms (structured interview for PTSD and CAPS - clinician) \( (k = 1; n = 19; SMD = -0.92; 95\% \, CI, -1.88 \, to \, 0.04, I) \)

There is limited evidence favouring adjunctive olanzapine (to SSRI) over placebo on reducing depression (Center for Epidemiologic Studies depression scale - self-report) \( (k = 1; n = 19; SMD = -1.20; 95\% \, CI, -2.20 \, to \, -0.21, I) \)

Further evidence identified in the current review

No further studies investigating olanzapine as an adjunctive treatment were identified in the current review.
ADJUNCTIVE RISPERIDONE WITH NORMAL PHARMACOTHERAPY VERSUS ADJUNCTIVE PLACEBO WITH NORMAL PHARMACOTHERAPY

Previous evidence: NICE Guidelines evidence statements

One study of adjunctive risperidone (Hamner et al., 2003) is relevant to this question. In this study, participants (all combat veterans) continued taking their previously prescribed antipsychotic, antidepressant, benzodiazepine or sleep medications. Given the variability in the other (non-risperidone) medications being taken by participants, some caution is required in interpreting the effect sizes from the review of this study.

Acute phase

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between adjunctive risperidone (misc. medn.) and placebo on reducing the severity of PTSD symptoms (CAPS and structured interview for PTSD - clinician) \((k = 1; n = 37; SMD = 0.1; 95\% \ CI, –0.55 to 0.74)\).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between adjunctive risperidone (misc. medn.) and placebo on reducing the severity of PTSD symptoms (positive and negative symptom scale - clinician) \((k = 1; n = 37; SMD = –0.24; 95\% \ CI, –0.89 to 0.40)\).

There is limited evidence favouring adjunctive risperidone (misc. medn.) over placebo on reducing the likelihood of leaving treatment early \((k = 1; n = 40; RR = 0.5; 95\% \ CI, 0.05 to 5.08)\).

Further evidence identified in the current review

No further studies investigating risperidone as an adjunctive treatment were identified in the current review.

Summary of the evidence

There is very little evidence examining combined pharmacological interventions with limited evidence favouring olanzapine as adjunctive to SSRI treatment in cases of initial non-response.

RECOMMENDATIONS

4.28 Where symptoms have not responded to pharmacotherapy, consideration should be given to adding olanzapine as an adjunctive medication.
INITIAL PSYCHOLOGICAL OR PHARMACOLOGICAL INTERVENTION

Research questions and PICO

Box 4.8 Initial pharmacotherapy compared to initial psychotherapy: research question and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
<th>Inclusion criteria</th>
</tr>
</thead>
</table>

*This question was addressed by VA/DoD (question 11) with a search period up to 2002.

Studies included in the previous reviews

The VA/DoD review identified one meta-analysis of controlled and uncontrolled trials of most available treatments for PTSD that indirectly addressed the question (Van Etten & Taylor, 1998).

Although the question was not asked in the NICE review, one study of relevance was identified in response to their combined psychology and pharmacology question (Frommberger et al., 2004).

Studies included in the current review (2000–2005)

The only study meeting criteria for inclusion in the current review was that previously reported in the NICE review (Frommberger et al., 2004). Another randomised controlled trial was found on the United States National Institutes of Health Clinical Trials register that compared fluoxetine with EMDR for treating PTSD, but the results of this trial were not found in the literature.

Treatment comparisons

PSYCHOTHERAPY VERSUS PHARMACOTHERAPY

Previous evidence: VA/DoD summary statements

a) Overall, there was a slightly increased improvement in self-reported symptoms with psychotherapy than with pharmacotherapy.

b) The most effective of the psychotherapies (behaviour therapy and EMDR) and pharmacotherapies (SSRIs) were equally effective.

c) Psychotherapy (14%) had lower dropout rate than pharmacotherapy (32%).

Further evidence identified in the current review

No further studies comparing initial psychotherapy with initial pharmacotherapy were identified in the current review.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.
Paroxetine versus trauma-focussed CBT

Previous evidence: NICE Guidelines evidence statements

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between paroxetine and trauma-focussed CBT on reducing clinician measured PTSD severity (using CAPS) posttreatment \((k = 1; n = 16; SMD = 0.09; 95\% CI, –0.89 to 1.07)\). I

There is limited evidence favouring trauma-focussed CBT over paroxetine on reducing self-rated PTSD severity (PSS) posttreatment \((k = 1; n = 16; SMD = 1.06; 95\% CI, –0.01 to 2.13)\). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between paroxetine and trauma-focussed CBT on reducing posttreatment depression symptoms using clinician measure MADRS \((k = 1; n = 16; SMD = –0.37; 95\% CI, –1.36 to 0.62)\). I

There is limited evidence favouring trauma-focussed CBT over paroxetine on reducing self-rated depression symptoms posttreatment using BDI \((k = 1; n = 16; SMD = 0.55; 95\% CI, –0.46 to 1.55)\). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between paroxetine and trauma-focussed CBT on reducing posttreatment anxiety symptoms using clinician measure HAMA \((k = 1; n = 16; SMD = –0.26; 95\% CI, –1.25 to 0.72)\). I

There is limited evidence favouring trauma-focussed CBT over paroxetine on reducing the likelihood of leaving the study early due to any reason prior to treatment endpoint \((k = 1; n = 21; RR = 1.36; 95\% CI, 0.28 to 6.56)\). I

There is limited evidence favouring paroxetine over trauma-focussed CBT on reducing the likelihood of leaving the study early due to any reason prior to 6 month follow-up \((k = 1; n = 21; RR = 0.57; 95\% CI, 0.28 to 1.16)\). I

Further evidence identified in the current review

No further studies comparing paroxetine with trauma-focussed CBT were identified in the current review.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

Summary of the evidence

In view of the limited evidence favouring trauma-focussed CBT over pharmacotherapy for the initial treatment of PTSD, these guidelines support the NICE guidelines recommendations that trauma-focussed CBT be the first line treatment for PTSD over pharmacotherapy.

RECOMMENDATIONS

4.29 Drug treatments for PTSD should not be used as a routine first line treatment for adults, either by general medical practitioners or by specialist mental health professionals, in preference to a trauma-focussed psychological therapy.
COMBINED PSYCHOLOGICAL AND PHARMACOLOGICAL INTERVENTION

Research questions and PICO

Box 4.9 Combined pharmacological and psychological interventions compared to either pharmacological or psychological intervention alone: research question and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>16. For adults with PTSD, is a single intervention more effective than multiple interventions?</td>
<td>Adults with PTSD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selection criteria</th>
<th>Population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adults with PTSD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Single psychological or pharmacological intervention or psychosocial rehabilitation strategy</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Comparator (1)</th>
<th>Combined psychological interventions, combined pharmacological interventions, combined psychosocial interventions or combined psychological, pharmacological or psychosocial interventions</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Primary outcome: resolution of symptoms of PTSD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, social and occupational function, quality of life, treatment refusal, dropout over 12 months/ side effects, posttraumatic growth</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comparator (2)</th>
<th>Combined psychological intervention and psychosocial rehabilitation (e.g., teaching self-care and independent living skills techniques, providing supported housing, marital/family skills training, social skills training, anger management, vocational rehabilitation and case management) or combined pharmacological intervention and psychosocial rehabilitation</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Primary outcome: resolution of symptoms of PTSD, social and occupational function, quality of life</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, treatment refusal, dropout over 12 months, side effects, posttraumatic growth</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study design</th>
<th>Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Search period</th>
<th>2002–8/2005*</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Language</th>
<th>English</th>
</tr>
</thead>
</table>

*This question was based on question 10 in the VA/DoD review. However the PICO used in the VA/DoD review excluded combined psychological and pharmacological studies.

Studies included in previous reviews

This question was not asked in either of the previous reviews. However, one study of relevance to this question was identified in the NICE review in response to their pharmacological question 2. This was a trial of combined imipramine and psychodynamic therapy versus placebo, and phenalzine and psychodynamic therapy versus placebo (Kosten et al., 1992).

Studies included in the current review (2002-2005)

Two average-to-good quality randomised controlled trials that assessed the effectiveness of a combination of psychotherapy and pharmacotherapy compared to single pharmacotherapy alone for treating people with PTSD were identified in the current review (Otto et al., 2003; Rothbaum, 2006).

Treatment comparisons

**IMIPRAMINE AND PSYCHODYNAMIC THERAPY VERSUS PLACEBO**

Previous evidence: NICE Guidelines evidence statements

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between imipramine and other psychological therapy and placebo on reducing the severity of PTSD symptoms (IES - self-report)$k = 1; n = 39; SMD = -0.16; 95% CI, −0.8 to 0.48$.

Further evidence identified in the current review

No further studies comparing imipramine and psychodynamic therapy versus placebo were identified in the current review.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.
Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

**PHENALZINE AND PSYCHODYNAMIC THERAPY VERSUS PLACEBO**

Previous evidence: NICE Guidelines evidence statements

There is limited evidence favouring phenelzine and other psychological therapy over placebo on reducing the severity of PTSD symptoms (IES - self-report) \(k = 1; n = 34; SMD = -1.01; 95\% CI, -1.73 to -0.29\).  

Further evidence identified in the current review

No further studies comparing phenelzine and psychodynamic therapy versus placebo were identified in the current review.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

**SERTRALINE COMBINED WITH PROLONGED EXPOSURE (PE) VERSUS SERTRALINE ALONE**

Previous evidence

Not applicable as the question was not asked in previous reviews.

Further evidence identified in the current review

Rothbaum et al., (2006) compared the effects of 10 weeks of sertraline medication followed by either sertraline alone or a combination of sertraline and prolonged exposure therapy. No statistically significant benefit from the addition of prolonged exposure was observed. However, there was a trend toward lower scores on the structured interview for PTSD in the prolonged exposure treatment group.

<table>
<thead>
<tr>
<th>Table 4.19 Effectiveness of sertraline versus sertraline plus prolonged exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Level and quality</strong></td>
</tr>
<tr>
<td>STUDY: Rothbaum et al. (2006)</td>
</tr>
<tr>
<td>Level II (RCT)</td>
</tr>
<tr>
<td>Assignment: b</td>
</tr>
<tr>
<td>Selection bias: b</td>
</tr>
<tr>
<td>Blinding: b</td>
</tr>
<tr>
<td>Assessment: a</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

SCID = structured interview for PTSD; SIP = structured interview for PTSD; BDI = Beck depression inventory; STAI= State-trait anxiety inventory; 
*author's reported value; SMD = standardised mean difference; CI = confidence interval; RCT = randomised controlled trial.
Current review evidence statements

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between sertraline alone and sertraline in addition to prolonged exposure therapy for improvement in structured interview for PTSD score \( (k = 1; n = 65; SMD = -0.38; 95\% \ CI, -0.87 \text{ to } 0.11) \). II

The relevant and applicable evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between sertraline alone and sertraline in addition to prolonged exposure therapy for improvement in Beck depression inventory \( (k = 1; n = 65; SMD = -0.20; 95\% \ CI, -0.68 \text{ to } 0.29) \). II

The relevant and applicable evidence suggests that there is unlikely to be a clinically important difference between sertraline alone and sertraline in addition to prolonged exposure therapy for improvement in state-trait anxiety inventory score \( (k = 1; n = 65; SMD = -0.01; 95\% \ CI, -0.49 \text{ to } 0.48) \). II

Updated evidence statements on the combined evidence from previous and current reviews

As there were no previous review evidence statements, there are no updated evidence statements.

SERTRALINE COMBINED WITH CBT VERSUS SERTRALINE ALONE

Previous evidence

Not applicable as the question was not asked in previous reviews.

Further evidence identified in the current review

Otto et al., (2003) found that the combined treatment with sertraline and CBT produced a greater reduction in symptoms than sertraline alone, in a group of women who had not previously responded to pharmacological treatment. In a sample of people who had previously failed to respond to a combination of clonazepam and another SSRI, treatment with sertraline alone resulted in an increase in scores for two of the subscales on the clinician administered PTSD scale (CAPS). The addition of CBT reduced scores on all the subscales of the CAPS.

Table 4.20 Effectiveness of sertraline versus sertraline plus cognitive behavioural therapy

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY: Otto et al (2003) United States</td>
<td>CAPS re-experiencing</td>
<td>15.2±6.2</td>
</tr>
<tr>
<td>Level II (RCT)</td>
<td>Assignment: c</td>
<td>10 Cambodian refugees who met DSM-IV criteria for PTSD. Women who failed to respond to clonazepam in combination with SSR1 other than sertraline Mean age=47.2 years</td>
</tr>
<tr>
<td>Selection bias: a</td>
<td>Blinding: c</td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAPS avoidance</td>
<td>21.4±14.7</td>
<td>0.6±9.9</td>
</tr>
<tr>
<td>CAPS hyperarousal</td>
<td>20.6±9.8</td>
<td>-0.6±5.6</td>
</tr>
<tr>
<td>HSCL-90 anxiety</td>
<td>31.4±6.2</td>
<td>5.2±5.3</td>
</tr>
<tr>
<td>HSCL-90 depression</td>
<td>38.2±9.2</td>
<td>8.6±6.0</td>
</tr>
<tr>
<td>HSCL-90 somatisation</td>
<td>26.2±6.1</td>
<td>8.6±6.0</td>
</tr>
<tr>
<td>ASI</td>
<td>47.8±5.8</td>
<td>1.2±4.8</td>
</tr>
</tbody>
</table>

CBT = cognitive behavioural therapy; "Change from baseline; CAPS = clinician-administered PTSD scale; HSCL-90 = Hopkins symptom checklist; ASI = anxiety sensitivity index; NC = unable to calculated due to change scores being reported; \(^a\)author’s reported value; CBT = cognitive behavioural therapy; CI = confidence interval; RCT = randomised controlled trial; SSRIs = selective serotonin reuptake inhibitors.
Current review evidence statements

No evidence statements could be derived from the Otto et al., (2003) study as it did not provide enough raw data to calculate effect sizes.

Updated evidence statements on the combined evidence from previous and current reviews

As there were no previous or current review evidence statements there are no updated evidence statements.

Summary of evidence

There is only a small body of literature examining the effectiveness of combinations of interventions compared with interventions alone. While the evidence is still inconclusive, there appears to be a trend toward improved outcomes with the combination of psychological and pharmacological interventions (Otto et al., 2003; Rothbaum et al., 2006), although little evidence that combined pharmacological or combined psychological interventions alone improve outcomes. As the Otto population was specific to Cambodian refugees, the generalisability of the study to PTSD populations in Australia is limited.

RECOMMENDATIONS

4.30 In cases where the person has not gained benefit from first line psychological treatments, health practitioners may wish to consider commencing adjunctive pharmacotherapy.

4.31 Where a decision has been made to commence treatment pharmacotherapy, the person’s mental state should be constantly monitored with a view to commencing adjunctive psychological treatment if/when appropriate. In the interim, supportive psychotherapy with a substantial psychoeducational component should be offered.

These recommendations should be read in conjunction with recommendations for psychological interventions and pharmacological interventions.
PSYCHOSOCIAL REHABILITATION

Research questions and PICO

Box 4.10 Psychosocial rehabilitation for PTSD: research questions and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>12. For adults with PTSD, does psychosocial rehabilitation improve outcomes compared to no intervention?</td>
<td>Adults with PTSD</td>
</tr>
<tr>
<td>13. For adults with PTSD, does psychosocial rehabilitation confer an advantage over any other psychological or pharmacological interventions?</td>
<td>Psychosocial rehabilitation (e.g., teaching self-care and independent living skills techniques, providing supported housing, marital/family skills training, social skills training, vocational rehabilitation and case management)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comparator</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>12. No intervention</td>
<td>Any other psychological or pharmacological intervention (e.g., trauma-focussed CBT, stress management therapy, EMDR, narrative exposure therapy, supportive counselling, therapy, SSRIs, other second-generation antidepressants, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, mood stabilisers, anti-convulsants, and some non-benzodiazepine hypnotics and anti-anxiety medications)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary outcome: functional improvement, quality of life</td>
<td>Functional improvement, quality of life</td>
</tr>
<tr>
<td>Secondary outcomes: resolution of symptoms of PTSD, depression, anxiety and substance misuse, treatment refusal, dropout over 12 months, side effects, posttraumatic growth</td>
<td>Functional improvement, quality of life</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study design</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies.</td>
<td>Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Search period</th>
<th>Inclusion criteria</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Language</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>English</td>
<td>English</td>
</tr>
</tbody>
</table>

*A new search (1996–2005) was conducted on this question as it was not addressed in either the NICE or VA/DoD reviews; SSRIs = selective serotonin reuptake inhibitors

Box 4.11 Single pharmacological, psychological or psychosocial intervention compared to combined pharmacological or psychological intervention with psychosocial intervention: research question and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>16. For adults with PTSD, is a single intervention more effective than multiple interventions?</td>
<td>Adults with PTSD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comparator (1)</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combined psychological interventions, combined pharmacological interventions, combined psychosocial interventions or combined psychological, pharmacological or psychosocial interventions</td>
<td>Combined psychological interventions, combined pharmacological interventions, combined psychosocial interventions or combined psychological, pharmacological or psychosocial interventions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comparator (2)</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combined psychological intervention and psychosocial rehabilitation (e.g., teaching self-care and independent living skills techniques, providing supported housing, marital/family skills training, social skills training, anger management, vocational rehabilitation and case management) or combined pharmacological intervention and psychosocial rehabilitation</td>
<td>Combined psychological intervention and psychosocial rehabilitation (e.g., teaching self-care and independent living skills techniques, providing supported housing, marital/family skills training, social skills training, anger management, vocational rehabilitation and case management) or combined pharmacological intervention and psychosocial rehabilitation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary outcome: resolution of symptoms of PTSD, social and occupational function, quality of life</td>
<td>Combined psychological intervention and psychosocial rehabilitation (e.g., teaching self-care and independent living skills techniques, providing supported housing, marital/family skills training, social skills training, anger management, vocational rehabilitation and case management) or combined pharmacological intervention and psychosocial rehabilitation</td>
</tr>
<tr>
<td>Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, treatment refusal, dropout over 12 months, side effects, posttraumatic growth</td>
<td>Combined psychological intervention and psychosocial rehabilitation (e.g., teaching self-care and independent living skills techniques, providing supported housing, marital/family skills training, social skills training, anger management, vocational rehabilitation and case management) or combined pharmacological intervention and psychosocial rehabilitation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study design</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies.</td>
<td>Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Search period</th>
<th>Inclusion criteria</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Language</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>English</td>
<td>English</td>
</tr>
</tbody>
</table>

*This question was based on question 10 in the VA/DoD review. However the PICO used in the VA/DoD review excluded combined psychological, pharmacological and psychosocial studies.

Studies included in previous reviews

This question was not asked in either the NICE (2005) or the VA/DoD (2004) review.
Studies included in the current review
No studies comparing psychosocial rehabilitation to waitlist or to psychological or pharmacological treatment were identified. Similarly, no studies of combined psychosocial interventions or the effectiveness of adjunctive psychosocial interventions were identified.

Treatment comparisons
As no studies were identified there were no-treatment comparisons.

Summary of existing literature
In the absence of any evidence-based outcome research examining psychosocial rehabilitation in PTSD being identified in this review, these recommendations are derived from a summary of the existing literature and expert consensus opinion.

Psychosocial rehabilitation may improve functional ability and facilitate recovery in people with PTSD by minimising associated problems such as homelessness, social inactivity, high-risk behaviours and unemployment. Targeted clinical and disability management interventions can assist people with PTSD improve their role functioning, increase ability, develop skills and resources specific to their individual needs and capacities with the aim of averting, preventing further, or reducing disability associated with the disorder (HIMH, 2002).

While high-level evidence on the efficacy of psychosocial interventions in PTSD-specific populations is not available, interventions based on this approach have strong empirical support in populations experiencing a range of persisting mental health conditions (Mueser et al., 2003). Intensive case management, psychoeducation, and social skills training, for example, have been associated with a number of positive outcomes including reduced time spent in hospital, symptom reduction, improved social functioning, and reduced stress in families (Dilk & Bond, 1996; Heinssen et al., 2000; Mueser et al., 1998; Phillips et al., 2001). Controlled studies have confirmed the effectiveness of supported employment, a vocational rehabilitation approach that involves the rapid placement of people into competitive employment; in helping people retain and maintain employment and significantly reduce symptom severity (Bell et al., 1996; Bond et al., 2001; Cook et al., 2005). Other studies show that people who work are less disabled by their condition, have an improved self esteem, and increased quality of life (Arns & Linney, 1993; Mueser et al., 1997). Provision of housing supports, together with case management and clinical services, has been reported as contributing significantly to increasing the social integration of people with persisting symptoms of PTSD (Rosenheck & Siebyl, 1998).

While psychosocial rehabilitation includes collaborative psychological and/or pharmacological treatments, interventions also address a number of potential barriers to treatment: homelessness, unemployment, and high-risk lifestyle behaviours, making it a useful approach to disability management for people who are reluctant to engage in, or are resistant to treatment (HIMH, 2002). Despite the absence of high-level evidence of efficacy in PTSD-specific populations, the strong empirical evidence supporting the use of psychosocial interventions in a range of other psychiatric disorders suggests that health care professionals should be aware of the potential benefits of these interventions for people who are experiencing persisting symptoms of PTSD.

CLINICAL RECOMMENDATIONS
4.32 There should be a focus on vocational, family and social rehabilitation interventions from the beginning of treatment. gpp
4.33 Where symptoms of PTSD have been present for three months or longer, psychosocial rehabilitation should be considered as an intervention to prevent or reduce disability associated with the disorder. gpp
4.34 In cases where people with PTSD have not benefited from a number of courses of evidence-based treatment, psychosocial rehabilitation interventions may reduce disability, improve functioning and community tenure. gpp
4.35 Health care professionals should be aware of the potential benefits of psychosocial rehabilitation and promote practical advice on how to access appropriate information and services. gpp
4.36 Psychosocial rehabilitation interventions should be provided by competent and appropriately qualified practitioners who received regular supervision. gpp
4.37 Psychosocial rehabilitation may be used as an adjunctive therapy in combination with psychotherapy or pharmacotherapy. gpp

RESEARCH RECOMMENDATIONS
4.38 The impact of a focus on wellness, recovery and rehabilitation on the psychosocial functioning and posttraumatic growth of adults with PTSD should be investigated.
PHYSICAL THERAPIES AND EXERCISE

Research questions and PICO

Box 4.12 Physical therapies and exercise for adults with ASD and PTSD: research question and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>14. For adults with ASD or PTSD, do physical interventions or exercise confer an advantage over psychological or pharmacological intervention?</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selection criteria</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Adults with ASD or PTSD</td>
</tr>
<tr>
<td>Intervention</td>
<td>(1) Physical therapy (e.g., electroconvulsive therapy, transcranial magnetic stimulation, massage, acupuncture, acupressure, healing touch, craniosacral therapy) (2) Exercise therapy (e.g., yoga, T’ai Chi, movement-to-music, rhythm activities, competitive sports, walking, jogging, swimming)</td>
</tr>
<tr>
<td>Comparator</td>
<td>Any psychological or pharmacological intervention (e.g., trauma-focussed CBT, stress management therapy, EMDR, narrative exposure therapy, supportive counselling, interapy, SSRIs, other second-generation antidepressants, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, mood stabilisers, anti-convulsants, and some non-benzodiazepine hypnotics and anti-anxiety medications)</td>
</tr>
<tr>
<td>Outcome</td>
<td>Primary outcome: resolution of symptoms of ASD or PTSD Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, functional improvement, quality of life, treatment refusal, dropout over 12 months, side effects, posttraumatic growth</td>
</tr>
<tr>
<td>Study design</td>
<td>Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies.</td>
</tr>
<tr>
<td>Search period</td>
<td>1966–8/2005*</td>
</tr>
<tr>
<td>Language</td>
<td>English</td>
</tr>
</tbody>
</table>

CBT = cognitive behavioural therapy; EMDR = eye movement desensitization and reprocessing; SSRIs = selective serotonin reuptake inhibitors

* A new search (1996–2005) was conducted on this question as it was not addressed in either the NICE or VA/DoD reviews.

Studies included in previous reviews

This question was not asked in either the NICE (2005) or the VA/DoD (2004) review. However, one study of repeated transcranial magnetic stimulation (rTMS) against placebo (sham treatment) was identified in the NICE review (Cohen et al., 2004).

Studies included in the current review

No studies were identified in this review that compared physical interventions or exercise with conventional forms of treatment such as psychological or pharmacological interventions.

Treatment comparisons

REPEATED TRANSCRANIAL MAGNETIC STIMULATION (RTMS) VERSUS PLACEBO

Previous evidence: NICE Guidelines evidence statements

High-frequency rTMS versus control

There is limited evidence favouring high-frequency repetitive transcranial magnetic stimulation (rTMS) over control on reducing the severity of PTSD symptoms as measured by clinician-rated CAPS at 14 day follow-up (k = 1; n = 16; SMD = −0.72; 95% CI, −1.77 to 0.33). I

There is limited evidence favouring high-frequency repetitive transcranial magnetic stimulation (rTMS) over control on reducing the severity of posttreatment PTSD symptoms as measured by self-report PTSD checklist (k = 1; n = 16; SMD = −1.5; 95% CI, −2.67 to −0.32). I

There is limited evidence favouring high-frequency repetitive transcranial magnetic stimulation (rTMS) over control on reducing the severity of PTSD symptoms at 14 day follow-up as measured by self-report PTSD checklist (k = 1; n = 16; SMD = −0.68; 95% CI, −1.73 to 0.36). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between high-frequency repetitive transcranial magnetic stimulation (rTMS) and control on reducing posttreatment depression symptoms as measured by the clinician-rated Hamilton scale (k = 1; n = 16; SMD = −0.3; 95% CI, −1.32 to 0.72). I
The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between high-frequency repetitive transcranial magnetic stimulation (rTMS) and control on reducing depression symptoms at 14 day follow-up as measured by the clinician-rated Hamilton scale (k = 1; n = 16; SMD = -0.13; 95% CI, -1.14 to 0.89). I

There is limited evidence favouring high-frequency repetitive transcranial magnetic stimulation (rTMS) over control on reducing posttreatment anxiety symptoms as measured by the clinician-rated Hamilton anxiety rating scale (k = 1; n = 16; SMD = -1.38; 95% CI, -2.53 to -0.23). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between high-frequency repetitive transcranial magnetic stimulation (rTMS) and control on reducing anxiety symptoms at 14 day follow-up as measured by the clinician-rated Hamilton Anxiety Rating Scale (k = 1; n = 16; SMD = 0; 95% CI, -1.01 to 1.01). I

There is limited evidence favouring high-frequency repetitive transcranial magnetic stimulation (rTMS) over control on reducing the likelihood of leaving the study early due to any reason prior to 14 day follow-up (k = 1; n = 19; RR = 0.36; 95% CI, 0.04 to 3.35). I

Low-frequency rTMS versus control

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between low-frequency repetitive transcranial magnetic stimulation (rTMS) and control on reducing the severity of PTSD symptoms as measured by clinician-rated CAPS at 14 day follow-up (k = 1; n = 14; SMD = 0.12; 95% CI, -0.94 to 1.18). I

There is limited evidence favouring control over low-frequency repetitive transcranial magnetic stimulation (rTMS) on reducing the severity of posttreatment PTSD symptoms as measured by self-report PTSD checklist (k = 1; n = 14; SMD = 0.67; 95% CI, -0.43 to 1.77). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between low-frequency repetitive transcranial magnetic stimulation (rTMS) and control on reducing posttreatment depression symptoms as measured by the clinician-rated Hamilton scale (k = 1; n = 14; SMD = 0.09; 95% CI, -1.15 to 0.97). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between low-frequency repetitive transcranial magnetic stimulation (rTMS) and control on reducing depression symptoms at 14 day follow-up as measured by the clinician-rated Hamilton scale (k = 1; n = 14; SMD = 0.36; 95% CI, -0.71 to 1.43). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between low-frequency repetitive transcranial magnetic stimulation (rTMS) and control on reducing posttreatment anxiety symptoms as measured by the clinician-rated Hamilton anxiety rating scale (k = 1; n = 14; SMD = 0.15; 95% CI, -0.91 to 1.21). I

There is limited evidence favouring control over low-frequency repetitive transcranial magnetic stimulation (rTMS) on reducing anxiety symptoms at 14 day follow-up as measured by the clinician-rated Hamilton anxiety rating scale (k = 1; n = 14; SMD = 0.57; 95% CI, -0.52 to 1.66). I

There is limited evidence favouring low-frequency repetitive transcranial magnetic stimulation (rTMS) over control on reducing the likelihood of leaving the study early due to any reason prior to 14 day follow-up (k = 1; n = 18; RR = 0.8; 95% CI, 0.14 to 4.49). I

Further evidence identified in the current review

No further studies of rTMS were identified in the current review.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.
Summary of evidence

Only one study of physical therapies was identified. This study examined the effectiveness of high and low-frequency rTMS. There was limited evidence suggesting that high-frequency rTMS was more effective over 14 days on a range of outcome measures, than control. The evidence for low-frequency rTMS was inconclusive. Since only one study was identified providing only limited evidence, and rTMS is not currently available outside of research environments, no recommendations have been made regarding rTMS.

No studies that examined the effectiveness of exercise as an adjunct to other PTSD treatment were identified in the current review. However, the positive effect of exercise on mental health conditions more generally (notably depression) has been established and a recent study published after the evidence review (Manger & Motta, 2005) suggests that exercise may have a similarly positive impact on people with PTSD. As such, notwithstanding the limited evidence, practitioners may consider promoting exercise as a self-care and stress management activity, in conjunction with practitioner delivered interventions.

RECOMMENDATIONS

4.39 As part of general mental health care, practitioners may wish to advise people with PTSD that regular aerobic exercise may be helpful in managing their symptoms and as part of self-care practices more generally. gpp
COMORBIDITIES

Research questions and PICO

Box 4.13 PTSD and comorbidity: research questions and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
<th>Selection criteria</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Research question</strong></td>
<td>Adults with PTSD and comorbidity (e.g., grief, depression, personality disorder, pain and substance misuse)</td>
<td>Sequenced psychological or pharmacological intervention per diagnosis (ie treatment for PTSD then comorbidity or vice versa)</td>
</tr>
<tr>
<td><strong>Population</strong></td>
<td>Simultaneous psychological and/or pharmacological interventions for both diagnoses</td>
<td>Primary outcome: resolution of symptoms of PTSD</td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
<td>Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies.</td>
<td>Secondary outcomes: resolution of symptoms of depression, anxiety and substance misuse, social and occupational function, quality of life, treatment refusal, dropout over 12 months, posttraumatic growth</td>
</tr>
<tr>
<td><strong>Comparator</strong></td>
<td>2002–8/2005*</td>
<td>English</td>
</tr>
<tr>
<td><strong>Outcome</strong></td>
<td>*This question was answered by VA/DoD question 17 with a search period up to 2002.</td>
<td></td>
</tr>
<tr>
<td><strong>Study design</strong></td>
<td>One prospective cohort study that investigated different forms of treatment for people with PTSD and substance use disorder (SUD) was identified in the current review</td>
<td></td>
</tr>
</tbody>
</table>

Studies included in previous reviews: VA/DoD

The VA/DoD review identified one randomised control trial (Triffleman, 2000) and eight descriptive/observational studies (Bohus et al., 1999; Donovan et al., 2001; Gershuny et al., 2002; Hertzberg et al., 2001; Kosten et al., 2000; Najavits et al., 1998; Ouimette et al., 2001; Sonawalla et al., 1999). The review summary is as follows.

Studies included in the current review

One prospective cohort study that investigated different forms of treatment for people with PTSD and substance use disorder (SUD) was identified in the current review

Treatment comparison

COMORBID PTSD AND SUBSTANCE ABUSE

Previous evidence: VA/DoD summary statement

Earlier reports of treatment for patients with comorbid PTSD and substance abuse (SA) have proposed that treatment for SA should take place first and that trauma-focussed therapy should occur only after the patient has developed a commitment to abstinence.

- One study (Donovan et al., 2001) suggests that an integrative treatment approach to chronic combat-related PTSD and comorbid SA can be effective. This integrated program focuses first on substance abuse and later on trauma processing.

- Another study (Triffleman, 2000) found no differences in effectiveness between a specialised substance dependence PTSD therapy (SDPT) program and 12-step facilitation therapy. The SDPT program focusses initially on developing substance abstinence, followed by PTSD symptom-focussed treatment, with continuing attention to substance abuse. In 12-step facilitation therapy, no specific PTSD focus is present.

- An additional study (Ouimette et al., 2001) suggests that 12-step programs with no specific PTSD treatment focus may be useful for patients with comorbid PTSD. In this study, greater participation predicted decreased symptom distress among those PTSD patients whose identity was more consistent with 12-step philosophy.

- Drug treatment may be helpful in some instances: naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder and PTSD (Bohus et al., 1999); bupropion sustained-release for smoking cessation in patients with chronic PTSD (Hertzberg et al., 2001); and fluvoxamine in the treatment of major depression with comorbid anxiety disorders (Sonawalla et al., 1999). Each of these studies undertook concurrent treatment of symptoms across both conditions and thus no recommendation for timing can be made.
Further evidence identified in the current review

One prospective cohort study assessed the relationship between different forms of treatment for people with comorbid SUD and PTSD, with the main outcome being the five year remission rate for the substance use disorder (Ouimette et al., 2001). This study was part of a larger trial evaluating SUD treatments, where outpatients received treatment for PTSD and/or SUD. One hundred and eighteen participants completed the five year follow-up. Logistic regression was performed, and receiving PTSD and SUD treatments within the first year of intake was significantly associated with five year remission ($X^2[2, n = 100] = 7.12, p = 0.03$). When SUD therapy was controlled for, PTSD treatment was found to be beneficial, with people who received PTSD therapy being 3.7 times more likely to be in remission than those who did not receive PTSD therapy in the first year (95% CI, 1.34 to 10.26; $X^2[1, n = 100] = 6.33, p = 0.01$). Treatment for the substance use disorder alone, within the first year, did not correlate with five year SUD remission.

These results provide limited evidence (level II-2) to suggest that in the case of comorbid substance use disorder and PTSD, PTSD therapy should not be delayed, as treatment within the first three months of receiving a PTSD diagnosis can be beneficial in assisting the remission of substance use disorder five years later. The authors hypothesised that providing PTSD treatment may provide people with more adaptive coping methods, which help their ability to abstain from drugs or alcohol (Ouimette, 2001).

Current review evidence statements

There is limited relevant and applicable evidence favouring substance use disorder treatment plus PTSD treatment over substance use disorder treatment or PTSD treatment on remission of substance use disorder at 12 months ($k = 1; n = 100; RR = 3.7; 95% CI, 1.3 to 10.3$). III-2

Updated evidence statements on the combined evidence from previous and current reviews

The VA/DoD summary statements are not in a form that can be combined with evidence statements from the current review. Consideration of both bodies of evidence will be reflected in the summary and recommendations.

Summary of the evidence

The limited research in the area of sequencing treatment in the context of comorbidity has primarily focused on PTSD and comorbid SA. Overall, there is some evidence, albeit limited, favouring combined SA and PTSD treatment. Dismantling studies are required to provide stronger evidence regarding elements of the interventions that may be applied sequentially or simultaneously. In the absence of such evidence, these guidelines provide additional recommendations for practitioners based on expert consensus opinion. This may involve commencing the education and symptom management components of PTSD treatment with the trauma-focussed component delayed until some level of control over substance use is achieved.

Depression is another condition often comorbid with PTSD. The early and ongoing assessment of suicide risk is of primary importance in these circumstances. There are as yet no studies examining the sequencing of the treatment of comorbid depression and PTSD. There are, however, studies outlining the effectiveness of PTSD treatment on comorbid depression and prediction studies (outlined in the introduction) identifying comorbid depression severity as a negative influence on PTSD outcome. This information has been considered in the recommendations below on the sequencing of treatment in the context of PTSD and major depression.

If these comorbid conditions are also associated with personality disorder, specific therapy tailored to that condition may be required prior to any trauma-focussed therapy.

The range of trauma populations included in the above studies and the interventions provided are generalisable to the PTSD populations in Australia and the Australian health care context.

RECOMMENDATIONS

4.40 In the context of comorbid PTSD and depression, health practitioners may consider treating the PTSD first as the depression will often improve with treatment of the PTSD. b

4.41 Where the severity of comorbid depression precludes effective engagement in therapy and/or is associated with high-risk suicidality, health practitioners are advised to manage the suicide risk and treat the depression prior to treating the PTSD. gpp

4.42 In the context of PTSD and substance use disorders, practitioners should consider treating both conditions simultaneously. c

4.43 In the context of PTSD and substance use disorders, the trauma-focussed component of PTSD treatment should not commence until the PTSD sufferer has demonstrated a capacity to manage distress without recourse to substance use and to attend sessions without being drug or alcohol affected. d

4.44 In the context of PTSD and substance use disorders, where the decision is made to treat substance use disorders first, treatment should include information on PTSD and strategies to deal with PTSD symptoms as the person controls their substance abuse. gpp
Evidence review and treatment recommendations: early intervention

There are two early interventions sections. The first addresses interventions for all adults exposed to traumatic events, regardless of the presence or absence of symptoms of psychological disorder. So called treatment for all interventions are intended to prevent the development of psychiatric sequelae following exposure to potentially traumatic events. The second early intervention section addresses interventions for the subgroup of adults exposed to traumatic events that have developed symptoms of ASD or early PTSD.

**PSYCHOLOGICAL INTERVENTIONS**

**Research questions and PICO**

**Box 5.1 Early psychological interventions for adults exposed to trauma: research questions and study selection criteria**

**Research questions**

1. For adults exposed to trauma, do early psychological interventions improve outcomes compared to no intervention?
2. For adults exposed to trauma, does any early psychological intervention confer any advantage over other early psychological interventions?

**Selection criteria**

<table>
<thead>
<tr>
<th>Selection criteria</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population</strong></td>
<td>Adults exposed to trauma, including the subgroup with ASD</td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
<td>Early psychological intervention (e.g., debriefing, trauma-focused counselling, education, performed within one month of trauma)</td>
</tr>
</tbody>
</table>
| **Comparator**     | 1. No intervention (e.g., assessment only)  
                      2. Other early psychological intervention |
| **Outcome**        | Primary outcomes: symptoms of ASD and PTSD  
                      Secondary outcomes: symptoms of depression, anxiety and substance misuse, social and occupational function, quality of life, treatment refusal, dropout over 12 months, posttraumatic growth |
| **Study design**   | Systematic reviews of randomised controlled trials, randomised controlled trials |
| **Search period**  | 2004–8/2005* |
| **Language**       | English |

*These questions were addressed by NICE (2005) research questions 3 and 4 with a search period up to 2004.
Studies included in the previous review: NICE (2005)

The NICE review team conducted a new systematic search for randomised controlled trials (RCTs) that assessed the efficacy of early psychological treatments following exposure to potentially traumatic events.

Ten studies that investigated treatments delivered to all traumatic incident survivors, normally within the first month after the incident, were identified (Bisson et al., 1997; Brom et al., 1993; Campfield & Hills, 2001; Conlon et al., 1999; Dolan et al., unpublished; Hobbs et al., 1996; Lee et al., 1996; Mayou et al., 2000; Rose et al., 1999; Zatzick et al., 2001). Four different types of early intervention were identified: education, collaborative care, trauma-focused counselling and debriefing. The 10 studies were as follows:

- one study tested an educational intervention against control (Rose et al., 1999)
- one study compared a collaborative care program with usual care (Zatzick et al., 2001)
- one study compared trauma-focused counseling with monitoring control (Brom et al., 1993)
- seven studies compared individual psychological debriefing to control (Bisson et al., 1997; Conlon et al., 1999; Dolan et al., unpublished; Hobbs et al., 1996; Lee et al., 1996; Mayou et al., 2000; Rose et al., 1999)
- one study compared delayed debriefing with immediate debriefing (Campfield & Hills, 2001).

Studies included in the current review (2004–2005)

One further study that compared the effectiveness of an early psychological intervention (single session counselling) with no intervention, was identified in the current review (Gamble et al., 2005).

Treatment comparisons

EDUCATION VERSUS CONTROL

Previous evidence: NICE Guidelines evidence statements

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between education and control on reducing the likelihood of having a PTSD diagnosis at 6 months’ follow-up (k = 1; n = 103; RR = 0.69; 95% CI, 0.37 to 1.30). I

There is evidence suggesting there is unlikely to be a clinically important difference between education and control on reducing the severity of PTSD symptoms (self-reported) at 6 months’ follow-up (k = 1; n = 91; SMD = −0.18; 95% CI, −0.59 to 0.24). I

Further evidence identified in the current review

No further studies comparing education with control were identified in the current review.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.
COLLABORATIVE CARE VERSUS CONTROL

Previous evidence: NICE Guidelines evidence statements

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between collaborative care and control on reducing the severity of PTSD symptoms (self-report measures) at 1 month’s follow-up (k = 1; n = 29; SMD = –0.5; 95% CI, –1.24 to 0.24). 1

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between collaborative care and control in severity of PTSD symptoms (self-report measures) at 4 months’ follow-up (k = 1; n = 26; SMD = 0.4; 95% CI, –0.38 to 1.18). 1

Further evidence identified in the current review

No further studies comparing collaborative care with control were identified in the current review.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

TRAUMA-FOCUSED COUNSELLING VERSUS CONTROL

Previous evidence: NICE Guidelines evidence statements

There is evidence suggesting there is unlikely to be a clinically important difference between trauma-focused counselling and control on reducing the severity of PTSD symptoms (self-report measures) at 6 months’ follow-up (k = 1; n = 151; SMD = 0.17; 95% CI, –0.15 to 0.49). 1

Further evidence identified in the current review

No further studies comparing trauma-focused counselling with control were identified in the current review.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

DEBRIEFING VERSUS CONTROL

Previous evidence: NICE Guidelines evidence statements

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between debriefing and control on reducing the likelihood of having a PTSD diagnosis at 3–6 months’ follow-up (k = 2; n = 238; RR = 1.2; 95% CI, 0.84 to 1.71). 1

There is limited evidence suggesting a difference favouring control over debriefing on reducing the likelihood of having a PTSD diagnosis at 13 months’ follow-up (k = 1; n = 133; RR = 1.87; 95% CI, 1.12 to 3.12). 1

There is evidence suggesting there is unlikely to be a clinically important difference between debriefing and control on reducing the severity of PTSD symptoms (self-report measures) at 1–4 months’ follow-up (k = 5; n = 356; SMD = 0.11; 95% CI, –0.1 to 0.32). 1

There is evidence suggesting there is unlikely to be a clinically important difference between debriefing and control on reducing depression symptoms at 1–4 months’ follow-up (k = 3; n = 225; SMD = 0; 95% CI, –0.27 to 0.26). 1

Further evidence identified in the current review

No further studies comparing debriefing with control were identified in the current review.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.
SINGLE SESSION COUNSELLING VERSUS CONTROL

Previous evidence: NICE Guidelines evidence statements

No studies comparing single session counselling with control were identified in the NICE review.

Further evidence identified in the current review

Only one further study (Gamble et al., 2005 — level II intervention evidence) met the inclusion criteria for the research question comparing the effectiveness of an early psychological intervention with no intervention. This study concerned a population of women in Australia at risk of developing psychological trauma symptoms after experiencing a traumatic childbirth. A single session of counselling was provided within 72 hours of the birth and contained elements of critical incident stress debriefing, as well as covering issues pertinent to childbirth (Gamble et al., 2005). For the purposes of a meta-analysis, the treatment may be defined as debriefing. Results from this study are presented in Table 5.1. Overall, there was little difference between the control group and the counselling intervention group at 4–6 weeks postpartum. However, at three months postpartum, there were fewer women in the counselling group with a diagnosis of PTSD (not statistically significant), and the counselling group had significantly less posttraumatic symptoms than the control group ($t[101] = 2.144$, $p = 0.035$). At three months postpartum, the intervention group also had less depression on both the Edinburgh postnatal depression scale (75% reduction in risk relative to the control group) and the depression anxiety and stress scale-21 (56% relative risk reduction), but no significant difference in levels of anxiety. Between four and five women would need to receive a single session of counselling to have one woman with a clinically important improvement in depression at three months postpartum.

The methodology reported in this study indicates that an intervention was provided over the course of the 4–6 week follow-up. As such, only the 4–6 week posttreatment data have been used to calculate evidence statements regarding early intervention.

Table 5.1 New evidence for early psychological interventions for adults exposed to trauma (treatment for all)

<table>
<thead>
<tr>
<th>Quality appraisal</th>
<th>Population</th>
<th>Effectiveness</th>
<th>Single session Counselling</th>
<th>Control group</th>
<th>Relative risk (95% CI)</th>
<th>Difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY: Gamble (2005)</td>
<td>103 women who met the DSM-IV-TR definition of traumatic event after childbirth</td>
<td>PTSD at 4–6 weeks</td>
<td>17/50</td>
<td>16/53</td>
<td>1.15 (0.66, 2.02)</td>
<td>$X^2=1.0236$ p=0.392 RR 1.15 [95% CI 0.66 to 2.02]</td>
</tr>
<tr>
<td>Allocation: a</td>
<td></td>
<td>PTSD at 3 months</td>
<td>3/50</td>
<td>9/53</td>
<td>0.35 (0.10, 1.23)</td>
<td>$X^2=3.014$ p=0.075 RR 0.35 [95% CI 0.10 to 1.23]</td>
</tr>
<tr>
<td>Selection bias: b</td>
<td></td>
<td>EPDS score &gt;12 at 4–6 weeks</td>
<td>16/50</td>
<td>18/53</td>
<td>0.96 (0.56, 1.67)</td>
<td>not significant RR 0.96 [95% CI 0.56 to 1.67]</td>
</tr>
<tr>
<td>Blinding: b</td>
<td></td>
<td>EPDS score &gt;12 at 3 months</td>
<td>4/50</td>
<td>17/53</td>
<td>0.25 (0.09, 0.69)</td>
<td>$X^2=9.188$ p=0.002 RR 0.25 [95% CI 0.09 to 0.69]</td>
</tr>
<tr>
<td>Outcome assessment: a</td>
<td></td>
<td>DASS-depression (&gt;13) at 3 months</td>
<td>3/50</td>
<td>14/53</td>
<td>0.23 (0.07, 0.76)</td>
<td>$X^2=7.549$ p=0.005 RR 0.23 [95% CI 0.07 to 0.76]</td>
</tr>
<tr>
<td>ITT: Yes</td>
<td></td>
<td>DASS-anxiety (&gt;9) at 3 months</td>
<td>1/50</td>
<td>6/53</td>
<td>0.18 (0.02, 1.45)</td>
<td>not significant RR 0.18 [95% CI 0.02 to 1.45]</td>
</tr>
<tr>
<td>RCT=randomised controlled trial; DSM-IV-TR=Diagnostic and Statistical Manual of Mental Disorders-fourth edition-text revision; PTSD=post traumatic stress disorder; EPDS=Edinburgh postnatal depression scale; DASS=depression anxiety and stress scale-21; n/a=not available; *see Appendix F for checklist for appraising the quality of intervention studies; ¥=author’s reported value; RR = risk ratio.</td>
<td></td>
<td>DASS-stress (&gt;19) at 3 months</td>
<td>7/50</td>
<td>17/53</td>
<td>0.44 (0.20, 0.96)</td>
<td>$X^2=4.478$ p=0.029 RR 0.44 [95% CI 0.20 to 0.96]</td>
</tr>
</tbody>
</table>
Current review evidence statements

There is relevant evidence suggesting that there is unlikely to be a clinically important difference between single-session counselling and control on reducing the likelihood of having a PTSD diagnosis at 4–6 weeks following traumatic childbirth \((k = 1; n = 103; RR = 1.15; 95\% CI, 0.66 to 2.02)\). II

The relevant evidence is inconclusive and so it is not possible to determine whether there is a clinically important difference between single-session counselling and control in reducing the likelihood of having a PTSD diagnosis at three months following traumatic childbirth \((k = 1; n = 103; RR = 0.35; 95\% CI, 0.10 to 1.23)\). II

There is limited relevant evidence favouring single-session counselling over control on reducing the likelihood of having an Edinburgh postnatal depression scale score greater than 12 at 4–6 weeks following traumatic childbirth \((k = 1; n = 103; RR = 0.96; 95\% CI, 0.56 to 1.67)\). II

There is limited relevant evidence favouring single-session counselling over control on reducing the likelihood of having a depression anxiety and stress scale-21 score greater than 13 at three months following traumatic childbirth \((k = 1; n = 103; RR = 0.25; 95\% CI, 0.09 to 0.69)\). II

There is limited relevant evidence favouring single-session counselling over control on reducing the likelihood of having a depression anxiety and stress scale-21 score greater than 9 at three months following traumatic childbirth \((k = 1; n = 103; RR = 0.18; 95\% CI, 0.02 to 1.45)\). II

The generalisability of the evidence is limited as the study population was specific to women with PTSD following traumatic childbirth.

Updated evidence statements on the combined evidence from previous and current reviews

As there was no previous evidence statements there are no updated evidence statements.
Summary of the evidence

One additional study has been published since the NICE guidelines (Gamble et al., 2005). This study reports improved postnatal depression scores at follow-up when debriefing is delivered following traumatic childbirth. However, there was an additional intervention at 4–6 weeks that may have contributed to this outcome. The essential recommendations reported by NICE are therefore not altered by this additional study.

The evidence statements generated both by NICE and this review, derived from the 11 adequately controlled studies, suggest there is unlikely to be a clinically important difference between debriefing and control in the development of PTSD symptoms or developing a PTSD diagnosis. These recommendations, therefore, are consistent with those outlined by NICE suggesting that structured debriefing interventions, including ventilation of emotions or narration of events, should not be delivered on a routine basis. Instead, practitioners are advised to adopt a stance of ‘watchful waiting’ combined with the provision of general psychological first aid where required. Psychological first aid includes provision of information, comfort, emotional and instrumental support. Additional assistance should be progressively provided according to individual need. The ventilation of emotions and narration of events on a routine basis is not supported by the evidence. However, individuals who wish to discuss the experience, and who demonstrate a capacity to tolerate associated distress, should be supported in doing so. Where adults exposed to trauma develop an extreme level of distress or are at risk of harm to self or others, immediate crisis intervention and possible psychiatric intervention should be provided.

Recommendations

RECOMMENDATIONS

5.1 For adults exposed to trauma, structured psychological interventions such as psychological debriefing should not be offered on a routine basis.

5.2 For adults exposed to trauma, clinicians should implement psychological first aid in which survivors of potentially traumatic events are supported, immediate needs met, and monitored over time. Psychological first aid includes provision of information, comfort, emotional and instrumental support to those seeking help. Psychological first aid should be provided in a stepwise fashion tailored to the person’s needs.

5.3 Adults exposed to trauma who wish to discuss the experience, and demonstrate a capacity to tolerate associated distress, should be supported in doing so. In doing this the practitioner should keep in mind the potential adverse effects of excessive ventilation in those who are very distressed.

5.4 For adults who develop an extreme level of distress or are at risk of harm to self or others, immediate psychiatric intervention should be provided.
PHARMACOLOGICAL INTERVENTIONS

Research questions and PICO

Box 5.2 Pharmacological interventions for adults exposed to trauma: research questions and study selection criteria

<table>
<thead>
<tr>
<th>Research questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>8. For adults exposed to trauma, do early pharmacological interventions improve outcomes compared to no intervention?</td>
</tr>
<tr>
<td>9. For adults exposed to trauma, does any early pharmacological intervention confer any advantage over other early pharmacological interventions?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selection criteria</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Adults exposed to trauma, including the subgroup with ASD</td>
</tr>
<tr>
<td>Intervention</td>
<td>Early pharmacological intervention, (e.g., imipramine, propranolol, benzodiazepines, other sympatholytics, other antidepressants, anticonvulsants, antipsychotics, chloral hydrate, given within one month of trauma)</td>
</tr>
<tr>
<td>Comparator</td>
<td>8. No intervention (e.g., assessment only)</td>
</tr>
<tr>
<td></td>
<td>9. Other early pharmacological intervention</td>
</tr>
<tr>
<td>Outcome</td>
<td>Primary outcomes: symptoms of ASD or PTSD</td>
</tr>
<tr>
<td></td>
<td>Secondary outcomes: symptoms of depression, anxiety and substance misuse, social and occupational function, quality of life, treatment refusal, dropout over 12 months, side effects, posttraumatic growth</td>
</tr>
<tr>
<td>Study design</td>
<td>8. Systematic reviews of randomised controlled trials, randomised controlled trials</td>
</tr>
<tr>
<td></td>
<td>9. Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies</td>
</tr>
<tr>
<td>Search period</td>
<td>8. 2004–8/2005</td>
</tr>
<tr>
<td>Language</td>
<td>English</td>
</tr>
</tbody>
</table>

*This question was answered by NICE pharmacology questions 3 and 4 with a search period up to 2004. NICE systematic review has identical questions, but no randomised control trials were found, so lower levels of evidence will be searched (NICE 2005)*

Studies included in the previous review: NICE (2005)

Two studies of early intervention drug treatments that met the inclusion criteria were identified in the NICE review (Pitman et al., 2002; Schelling et al., 2001). Both studies compared intervention against no intervention. No studies were identified that compared one type of pharmacological intervention against another.

Studies included in the current review (2004–2005)

No further studies were identified in the current review.
**Treatment comparisons**

**PROPRANOLOL VERSUS PLACEBO**

**Previous evidence: NICE Guidelines evidence statements**

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between propranolol and placebo on reducing the likelihood of having a PTSD diagnosis at 1 month (k = 1; n = 41; RR = 1.14; 95% CI, 0.55 to 2.35). I

There is limited evidence suggesting a difference favouring placebo over propranolol on reducing the likelihood of having a PTSD diagnosis at 3 months follow-up (k = 1; n = 41; RR = 1.28; 95% CI, 0.69 to 2.38). I

**Further evidence identified in the current review**

No further studies comparing propranolol with placebo were identified.

**Current review evidence statements**

As no new studies were identified, there are no current review evidence statements.

**Updated evidence statements on the combined evidence from previous and current reviews**

As there are no current review evidence statements, there are no updated evidence statements.

**HYDROCORTISONE VERSUS PLACEBO**

**Previous evidence: NICE Guidelines evidence statements**

There is limited evidence suggesting a difference favouring hydrocortisone over placebo on reducing the likelihood of having a PTSD diagnosis at approximately 31 months after treatment (k = 1; n = 20; RR = 0.17; 95% CI, 0.03 to 1.17). I

**Further evidence identified in the current review**

No further studies comparing hydrocortisone with placebo were identified.

**Current review evidence statements**

As no new studies were identified, there are no current review evidence statements.

**Updated evidence statements on the combined evidence from previous and current reviews**

As there are no current review evidence statements, there are no updated evidence statements.

**Summary of the evidence**

The NICE review found only two controlled trials examining pharmacological treatment for all interventions, one of which (Pitman et al., 2002) found in favour of the placebo condition. We found no further studies since the NICE review with regard to pharmacological prevention and early intervention following traumatic exposure. Thus, in line with the NICE recommendations, we do not recommend drug treatments for use as a preventive intervention non-selectively with traumatised populations.

**RECOMMENDATION**

5.5 For adults exposed to trauma, drug treatments should not be used non-selectively as a preventive intervention. c
COMBINED PSYCHOLOGICAL AND PHARMACOLOGICAL INTERVENTIONS

Research questions and PICO

Box 5.3 Combined early interventions for adults exposed to trauma: research question and study selection criteria

<table>
<thead>
<tr>
<th>Research question</th>
</tr>
</thead>
<tbody>
<tr>
<td>15. For adults exposed to trauma, is a single early intervention more effective than multiple early interventions?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selection criteria</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Adults exposed to trauma, including the subgroup with ASD</td>
</tr>
<tr>
<td>Intervention</td>
<td>Early combined psychological or combined pharmacological interventions</td>
</tr>
<tr>
<td>Comparator</td>
<td>Early combined psychological or combined pharmacological interventions</td>
</tr>
<tr>
<td>Outcome</td>
<td>Primary outcomes: symptoms of ASD or PTSD</td>
</tr>
<tr>
<td></td>
<td>Secondary outcomes: symptoms of depression, anxiety and substance misuse, social and occupational function, quality of life, treatment refusal/dropout over 12 months, side-effects, posttraumatic growth</td>
</tr>
<tr>
<td>Study design</td>
<td>Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies</td>
</tr>
<tr>
<td>Search period</td>
<td>1996–8/2005*</td>
</tr>
<tr>
<td>Language</td>
<td>English</td>
</tr>
</tbody>
</table>

*A new search (1996–2005) was conducted on this question as it was not addressed in either the NICE or VA/DoD reviews.

Studies included in previous reviews

There were no studies identified in previous reviews (NICE, 2005; VA/DoD, 2004) as the question was not addressed.

Studies included in the current review (1996–2005)

As stated in the search strategy, in the absence of levels I or II evidence, lower levels of evidence were sought. Two level III studies were identified that examined combination psychological treatment for all interventions (Eid et al., 2001; Richards, 2001).

Treatment comparisons

CRITICAL INCIDENT STRESS DEBRIEFING VERSUS CRITICAL INCIDENT STRESS MANAGEMENT

Previous evidence: NICE Guidelines evidence statements

No studies comparing critical incident stress debriefing with critical incident stress management were identified in the NICE review.

Further evidence identified in the current review

One poor quality, historically controlled study (Richards et al 2001) assessed the benefits of critical incident stress debriefing (CISD) versus critical incident stress management (CISM) in a group of financial institution employees following armed robberies (see Table 5.2). CISD included group discussions on thoughts, emotions and stress reactions, and participants received education about potential symptoms. The group who received CISM received pretrauma training, CISD and an individual counselling session one month after the incident, with therapy structured around a cognitive behavioural model of intervention (such as prolonged exposure). Historical control studies are susceptible to history effects, and this study had high loss to follow-up, therefore any conclusions should be tentative. Despite the group receiving CISM reporting consistently less mean symptoms on the impact of event scale or posttraumatic stress scale, no clinically significant differences were found between treatment groups.
Table 5.2 Effectiveness of critical incident stress debriefing versus critical incident stress management for preventing development of PTSD symptoms

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CISD</td>
</tr>
<tr>
<td>STUDY: Richards (2001) United Kingdom</td>
<td>Impact of events scale (IES)</td>
<td></td>
</tr>
<tr>
<td>Level III-3 (historically controlled trial)</td>
<td>Employees of a financial institution who were victims of armed robberies</td>
<td></td>
</tr>
<tr>
<td>Assignment: d</td>
<td>CISD</td>
<td>n = 225</td>
</tr>
<tr>
<td>Selection bias: d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding: c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: n</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Day 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 month</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follow-upa</td>
</tr>
</tbody>
</table>

CISD=critical incident stress debriefing; CIDM=critical incident stress management; ITT=intent-to-treat; iollow-up computed by taking mean score from 3, 6, or 12 month points; SMD=standard mean deviation.

Current review evidence statements

There is evidence suggesting that there is unlikely to be a clinically significant difference between critical incident stress debriefing and critical incident stress management on reducing intrusion and avoidance symptoms (IES) at three days (k = 1; n = 524; SMD = 0.12; 95% CI, –0.06 to 0.29). III-3

There is evidence suggesting that there is unlikely to be a clinically significant difference between critical incident stress debriefing and critical incident stress management on reducing intrusion and avoidance symptoms (IES) at one month (k = 1; n = 363; SMD = 0.20; 95% CI, –0.02 to 0.42). III-3

There is evidence suggesting that there is unlikely to be a clinically significant difference between critical incident stress debriefing and critical incident stress management on reducing intrusion and avoidance symptoms (IES) at 3–12 months (k = 1; n = 258; SMD = 0.43; 95% CI, –0.02 to 0.42). III-3

There is evidence suggesting that there is unlikely to be a clinically significant difference between critical incident stress debriefing and critical incident stress management on reducing severity of PTSD symptoms (PSS) at three days (k = 1; n = 524; SMD = 0.15; 95% CI, –0.03 to 0.32). III-3

There is evidence suggesting that there is unlikely to be a clinically significant difference between critical incident stress debriefing and critical incident stress management on reducing severity of PTSD symptoms (PSS) at one month (k = 1; n = 363; SMD = 0.15; 95% CI, –0.07 to 0.37). III-3

There is evidence suggesting that there is unlikely to be a clinically significant difference between critical incident stress debriefing and critical incident stress management on reducing severity of PTSD symptoms (PSS) at 3–12 months (k = 1; n = 258; SMD = 0.30; 95% CI, 0.05 to 0.55). III-3

Updated evidence statements on the combined evidence from previous and current reviews

As there are no previous review evidence statements, there are no updated evidence statements.
OPERATIONAL DEBRIEFING VERSUS OPERATIONAL DEBRIEFING AND GROUP PSYCHOLOGICAL DEBRIEFING

Previous evidence: NICE Guidelines evidence statements

No studies comparing operational debriefing with operational debriefing and group psychological debriefing were identified in the NICE review.

Further evidence identified in the current review

One poor quality Norwegian study compared the effects of different interventions on a group of firefighters and military personnel who attended the same serious traffic incident (see Table 5.3).

Both groups received stress management education and operational debriefing, while only the military personnel received additional semi-structured, group-critical incident debriefing (which they called psychological debriefing to distinguish from operational debriefing). Overall, the military personnel who received both operational and group psychological debriefing had less symptoms of posttraumatic symptoms than the firefighters, who received only operational debriefing, although this difference was only significant on the posttraumatic symptom scale–10. The differences in participant characteristics lead the study results to be prone to bias, so should be treated with caution.

Table 5.3 Effectiveness of operational debriefing vs operational debriefing and group debriefing for preventing development of PTSD symptoms

<table>
<thead>
<tr>
<th>Level and quality</th>
<th>Population</th>
<th>Debriefing</th>
<th>Debriefing + group debriefing</th>
<th>Difference$^1$</th>
<th>Effect size</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY: Eid (2001) Norway</td>
<td></td>
<td>Impact of events scale (IES)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Level III-2 (non-randomised controlled trial)</td>
<td>Participants had assisted at the site of a serious traffic incident in a road tunnel</td>
<td>17.0±10.7</td>
<td>11.4±6.4</td>
<td>ES=0.10</td>
<td>NS SMD 0.60 [95% CI -0.33 to 1.55]</td>
<td></td>
</tr>
<tr>
<td>Assignment: d</td>
<td>Debriefing n = 9</td>
<td>Civilian volunteer firefighters</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selection bias: a</td>
<td>Debriefing + group debriefing n = 9</td>
<td>Conscripted military personnel</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding: c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assessment: a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| | Posttraumatic symptom scale – 10 (PTSS-10) | 20.4±7.1 | 13.2±5.6 | ES=0.31 p<0.001 | NS SMD 1.22 [95% CI 0.21 to 2.22] |

$^1$Author’s reported value for statistical analyses; ES=effect size; SMD = standardised mean difference; NS=not significant

Current review evidence statements

There is evidence suggesting that there is unlikely to be a clinically significant difference between operational debriefing and combined operational debriefing and psychological debriefing on reducing intrusion and avoidance symptoms (IES) (k = 1; n = 18; SMD = 0.10; 95% CI, -0.33 to 1.55). III-2

There is evidence favouring combined operational debriefing and psychological debriefing over operational debriefing alone on reducing severity of PTSD symptoms (PTSS-10) (k = 1; n = 18; SMD = 1.22; 95% CI, 0.21 to 2.22). III-2

Updated evidence statements on the combined evidence from previous and current reviews

As there are no previous review evidence statements, there are no updated evidence statements.
Summary of the evidence

There was insufficient quality evidence from which to derive practice recommendations. As stated in the search strategy, in the absence of levels I or II evidence, lower levels of evidence was sought. Two level III studies were identified that examined combination psychological treatment for all interventions. The Richards et al. (2001) study suggested no benefit of combining CISD with a single individual counseling session at one month. Eid et al. (2001) compared a military sample that received stress management, operational debriefing and psychological debriefing, to fire fighters who attended the same accident and just received stress management and operational debriefing, without the group psychological debriefing. While this study suggested some benefit from the addition of psychological debriefing, the comparison of combination treatments in the context of two different populations must be interpreted with great caution. As such, there is considered to be insufficient evidence, at this stage, from which to derive practice recommendations for combined psychological treatment for all interventions for adults exposed to potentially traumatic events, with any reasonable confidence. There was also insufficient evidence to make recommendations regarding combined psychological and pharmacological treatment for all adults exposed to potentially traumatic events.

RECOMMENDATIONS

No recommendations have been made.
INTERVENTIONS FOR ADULTS WITH ASD

PSYCHOLOGICAL INTERVENTIONS

Research questions and PICO

Box 5.4 Early psychological interventions for adults with PTSD: research questions and study selection criteria

<table>
<thead>
<tr>
<th>Research questions</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. For adults exposed to trauma, do early psychological interventions improve outcomes compared to no intervention?</td>
<td>Population: Adults exposed to trauma, including the subgroup with ASD</td>
</tr>
<tr>
<td>2. For adults exposed to trauma, does any early psychological intervention confer any advantage over other early psychological interventions?</td>
<td>Intervention: Early psychological intervention (e.g., debriefing, trauma-focused counselling, education, performed within one month of trauma)</td>
</tr>
<tr>
<td>Comparator: 1. No intervention (e.g., assessment only) 2. Other early psychological intervention</td>
<td>Comparator: 1. No intervention (e.g., assessment only) 2. Other early psychological intervention</td>
</tr>
<tr>
<td>Outcome: Primary outcomes: symptoms of ASD and PTSD  Secondary outcomes: symptoms of depression, anxiety and substance misuse, social and occupational function, quality of life, treatment refusal, dropout over 12 months, post-traumatic growth</td>
<td>Outcome: Primary outcomes: symptoms of ASD and PTSD  Secondary outcomes: symptoms of depression, anxiety and substance misuse, social and occupational function, quality of life, treatment refusal, dropout over 12 months, post-traumatic growth</td>
</tr>
<tr>
<td>Study design: Systematic reviews of randomised controlled trials, randomised controlled trials</td>
<td>Study design: Systematic reviews of randomised controlled trials, randomised controlled trials</td>
</tr>
</tbody>
</table>

* These questions were answered by NICE questions 3 and 4 with a search period up to 2004.

Studies included in previous review: NICE (2005)

The NICE review team conducted a new systematic search for randomised controlled trials that investigated treatments delivered to people with ASD and acute PTSD, initiated within three months of the incident.

Nine studies were identified as falling within the category of early interventions for acute PTSD and acute stress disorder (Bisson et al., 2004; Bryant et al., 1998; Bryant et al., unpublished; Bryant et al., 2005; Bryant et al., 2003b; Bryant et al., 1999; Echeburua et al., 1996; Ehlers et al., 2003; Ost et al., unpublished). In Ehlers (2003) the self-monitoring period was taken to be part of the active intervention and as occurring within three months of the trauma. The studies were of five different types of intervention: trauma-focused CBT, trauma-focused CBT supplemented with hypnosis or anxiety management, relaxation techniques and a self-help booklet.

Studies included in the current review (2004–2005)

No further studies were identified in the current review.
Treatment comparisons

TRAUMA-FOCUSSED CBT VERSUS CONTROL

Previous evidence: NICE Guidelines evidence statements

There is limited evidence suggesting a difference favouring trauma-focussed CBT over waiting list (random effects) on reducing the likelihood of having a PTSD diagnosis posttreatment (k = 3; n = 252; RR = 0.4; 95% CI, 0.16 to 1.02). I

There is limited evidence suggesting a difference favouring trauma-focussed CBT over waiting list (random effects) on reducing the likelihood of having a PTSD diagnosis at 9–13 months’ follow-up (k = 2; n = 209; RR = 0.41; 95% CI, 0.11 to 1.45). I

There is limited evidence suggesting a difference favouring trauma-focussed CBT over waiting list (random effects) on reducing the severity of PTSD symptoms (self-report measures) (k = 3; n = 224; SMD = −0.98; 95% CI, −1.81 to −0.14). I

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and waiting list (random effects) on reducing the severity of PTSD symptoms (self-report measures) at 9–13 months’ follow-up (k = 2; n = 171; SMD = −0.68; 95% CI, −1.23 to −0.12). I

Further evidence identified in the current review

No further studies comparing trauma-focussed CBT with control were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

TRAUMA-FOCUSSED CBT VERSUS RELAXATION

Previous evidence: NICE Guidelines evidence statements

There is limited evidence suggesting a difference favouring trauma-focussed CBT over progressive muscular relaxation training on reducing the likelihood of having a PTSD diagnosis posttreatment (k = 1; n = 20; RR = 0.4; 95% CI, 0.1 to 1.6). I

There is limited evidence suggesting a difference favouring trauma-focussed CBT over progressive muscular relaxation training on reducing the likelihood of having a PTSD diagnosis at 12 months’ follow-up (k = 1; n = 20; RR = 0.2; 95% CI, 0.01 to 3.7). I

Further evidence identified in the current review

No further studies comparing trauma-focussed CBT with relaxation were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.
TRAUMA-FOCUSED CBT VERSUS SUPPORTIVE PSYCHOTHERAPY

Previous evidence: NICE Guidelines evidence statements

There is evidence suggesting a difference favouring trauma-focussed CBT over supportive psychotherapy on reducing the likelihood of having a PTSD diagnosis at 6 months’ follow-up (k = 3; n = 105; RR = 0.31; 95% CI, 0.32 to 0.8).  

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and supportive psychotherapy on reducing the likelihood of having a PTSD diagnosis at 4 years’ follow-up (k = 1; n = 80; RR = 0.9; 95% CI, 0.61 to 1.33).

There is evidence suggesting a difference favouring trauma-focussed CBT over supportive psychotherapy on reducing the severity of PTSD symptoms (self-report measures) (k = 3; n = 94; SMD = –1.11; 95% CI, –1.55 to –0.67).

Further evidence identified in the current review

No further studies comparing trauma-focussed CBT with supportive psychotherapy were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

SELF-HELP EDUCATION VERSUS CONTROL

Previous evidence: NICE Guidelines evidence statements

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between self-help booklet and waiting list on reducing the likelihood of having a PTSD diagnosis posttreatment (k = 1; n = 57; RR = 1.09; 95% CI, 0.81 to 1.46).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between self-help booklet and waiting list on reducing the likelihood of having a PTSD diagnosis at nine months’ follow-up (k = 1; n = 52; RR = 1.1; 95% CI, 0.71 to 1.71).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between self-help booklet and waiting list on reducing the severity of PTSD symptoms (self-report measures) (k = 1; n = 52; SMD = –0.27, 95% CI, –0.81 to 0.28).

There is evidence suggesting there is unlikely to be a clinically important difference between self-help booklet and waiting list on reducing the severity of PTSD symptoms (clinician-rated measures) at nine months’ follow-up (k = 1; n = 52; SMD = 0.07; 95% CI, –0.47 to 0.62).

Further evidence identified in the current review

No further studies that compared self help education with control were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.
Summary of evidence
There is now an increasing body of evidence for the effectiveness of trauma-focussed CBT over control, relaxation and supportive psychotherapy conditions for ASD and acute PTSD. A CBT self help booklet does not appear to be superior to a control condition (Ehlers et al., 2003). These guidelines are therefore consistent with those of NICE in recommending that practitioners consider trauma-focussed CBT treatment for problems consistent with ASD and acute PTSD. While length and number of sessions have not been empirically tested as independent variables in their own right, the recommendations below draw on the length and number of sessions reported in the cited controlled studies, expert consensus and with reference to recommendations in the NICE guidelines. Note that recommended treatment is the same for ASD and acute PTSD.

The range of trauma populations included in the above studies and the interventions provided are generalisable to the PTSD populations in Australia and the Australian health care context.

**CLINICAL RECOMMENDATION**

<table>
<thead>
<tr>
<th>Clause</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.6</td>
<td>Adults displaying ASD or PTSD reactions at least two weeks after the traumatic event should be offered trauma-focussed CBT including exposure and/or cognitive therapy once a clinical assessment has been undertaken. &lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>5.7</td>
<td>For adults with ASD, treatment should be provided on an individual basis. &lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>5.8</td>
<td>For adults with ASD, trauma-focussed CBT should, under normal circumstances, be provided in 5–10 sessions. &lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>5.9</td>
<td>For adults with ASD, 90 minutes should be allowed for sessions that involve imaginal exposure. &lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>5.10</td>
<td>Trauma-focussed interventions should not commence within two weeks of trauma exposure. &lt;sup&gt;gpp&lt;/sup&gt;</td>
</tr>
<tr>
<td>5.11</td>
<td>Combination psychological interventions for ASD should not be used routinely. &lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

**RESEARCH RECOMMENDATION**

<table>
<thead>
<tr>
<th>Clause</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.12</td>
<td>The conduct of effectiveness trials is recommended to evaluate trauma-focussed CBT and cognitive therapy for ASD in naturalistic clinical settings.</td>
</tr>
</tbody>
</table>
PHARMACOLOGICAL INTERVENTIONS

Research questions and PICO

Box 5.5 Pharmacological interventions for adults with acute stress disorder: research questions and study selection criteria

<table>
<thead>
<tr>
<th>Research questions</th>
<th>Selection criteria</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research questions</td>
<td>Population</td>
<td>Adults exposed to trauma, including the subgroup with ASD</td>
</tr>
<tr>
<td></td>
<td>Intervention</td>
<td>Early pharmacological intervention, (e.g., imipramine, propranolol, benzodiazepines, other sympatholytics, other antidepressants, anticonvulsants, antipsychotics, chloral hydrate, given within one month of trauma)</td>
</tr>
</tbody>
</table>
|                    | Comparator | 8. No intervention (e.g., assessment only)  
9. Other early pharmacological intervention |
|                    | Outcome | Primary outcomes: symptoms of ASD or PTSD  
Secondary outcomes: symptoms of depression, anxiety and substance misuse, social and occupational function, quality of life, treatment refusal, dropout over 12 months, side-effects, posttraumatic growth |
|                    | Study design | 8. Systematic reviews of randomised controlled trials, randomised controlled trials  
9. Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies. |
|                    | Search period | 8. 2004–8/2005  
|                    | Language | English |

*This question was answered by NICE pharmacology questions 3 and 4 with a review period up to 2004. bNICE systematic review has identical question, but no randomised control trials were found, so lower levels of evidence will be searched (NICE 2005).

Studies included in previous reviews: NICE (2005)

No studies meeting the selection criteria were identified in the NICE review.

Studies included in the current review (2004–2005)

No studies meeting the selection criteria were identified in the current review.

Treatment comparisons

As no studies were identified there are no treatment comparisons to report.

Summary of evidence

We found no further studies since the NICE review with regard to pharmacological early intervention following traumatic exposure. Thus, in line with the NICE recommendations, we do not recommend drug treatments for use as an early intervention for ASD or related conditions. However, we do recognise the benefits of pharmacological interventions in terms of managing current acute (and chronic) symptoms in certain cases.
**CLINICAL RECOMMENDATIONS**

5.13 Drug treatments should generally not be used to treat ASD or related conditions (i.e., within four weeks of symptoms onset) in adults unless the severity of the person’s distress can not be managed by psychological means alone, particularly when there is a pattern of extreme hyperarousal. gpp

5.14 In individuals who have a prior history of depression that have responded well to medication, the prescription of an antidepressant should be considered if a progressive pattern of clinically significant symptoms, such as persistent intrusions with increasing affective distress, begin to emerge. gpp

5.15 Where significant sleep disturbance does not settle in response to reassurance and simple psychological first aid, cautious use of hypnotic medication or other drug treatment may be appropriate for adults in the short term. gpp

**RESEARCH RECOMMENDATION**

5.16 The effect of pharmacological treatment of ASD on subsequent PTSD status or severity following cessation of medication, should be investigated.
COMBINED INTERVENTIONS

Research questions and PICO

Box 5.6 Combining interventions for adults with ASD: research question and study selection criteria

<table>
<thead>
<tr>
<th>Research questions</th>
<th>Inclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>15. For adults exposed to trauma, is a single early intervention more effective than multiple early interventions?</td>
<td>Population: Adults exposed to trauma, including the subgroup with ASD. Intervention: Single early psychological or pharmacological intervention. Comparator: Early combined psychological or combined pharmacological interventions or combined psychological and pharmacological interventions. Outcome: Primary outcomes: symptoms of ASD or PTSD. Secondary outcomes: symptoms of depression, anxiety and substance misuse, social and occupational function, quality of life, treatment refusal, dropout over 12 months, side-effects, posttraumatic growth. Study design: Systematic reviews of randomised controlled trials, randomised controlled trials, pseudo-randomised controlled trials, non-randomised controlled trials, cohort studies, before-and-after controlled studies, case-control studies. Language: English.</td>
</tr>
</tbody>
</table>

* A new search (1996–2005) was conducted on this question as it was not addressed in either the NICE or VA/DoD reviews.

Studies included in previous reviews

This question was not addressed in either of the previous reviews (NICE, 2005; VA/DoD, 2004). However, two studies that compared single and multiple psychological interventions for ASD were identified in response to the psychology intervention questions put by NICE (Bryant et al., 1995, 2005):

- one study compared prolonged exposure with prolonged exposure and anxiety management (Bryant et al., 1999).
- one study compared trauma-focused CBT with trauma-focused CBT and hypnotherapy (Bryant et al., 2005).

Studies included in the current review (2004–2005)

No studies, beyond those identified in the NICE review, were found to address whether a single or multiple early intervention is more effective in a population with ASD.

Treatment comparisons

PROLONGED EXPOSURE VERSUS PROLONGED EXPOSURE AND ANXIETY MANAGEMENT

Previous evidence: NICE Guidelines evidence statements

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between prolonged exposure and prolonged exposure and anxiety management on reducing the severity of PTSD symptoms (IES–self-report) (k = 1; n = 29; SMD = -0.31; 95% CI, -1.04 to 0.43).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between prolonged exposure and prolonged exposure and anxiety management on reducing the severity of PTSD symptoms (IES – self-report) at follow-up (6 months) (k = 1; n = 26; SMD = 0.03; 95% CI, -0.74 to 0.8).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between prolonged exposure and prolonged exposure and anxiety management on reducing the severity of PTSD symptoms (CAPS2–clinician) (k = 1; n = 29; SMD = -0.21; 95% CI, -0.94 to 0.52).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between prolonged exposure and prolonged exposure and anxiety management on reducing the severity of PTSD symptoms (CAPS2–clinician) at follow-up (6 months) (k = 1; n = 26; SMD = -0.17; 95% CI, -0.95 to 0.6).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between prolonged exposure and prolonged exposure and anxiety management on reducing depression symptoms (BDI – self-report) (k = 1; n = 29; SMD = -0.13; 95% CI, -0.86 to 0.6).
The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between prolonged exposure and prolonged exposure and anxiety management on reducing depression symptoms (BDI – self-report) at follow-up (6 months) (k = 1; n = 26; SMD = –0.11; 95% CI, –0.88 to 0.66).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between prolonged exposure and prolonged exposure and anxiety management on reducing anxiety symptoms (STAI self-report) at follow-up (6 months) (k = 1; n = 26; SMD = 0.11; 95% CI, –0.62 to 0.84).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between prolonged exposure and prolonged exposure and anxiety management on reducing anxiety symptoms (STAI – self-report) at follow-up (6 months) (k = 1; n = 26; SMD = 0.12; 95% CI, –0.65 to 0.89).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between prolonged exposure and prolonged exposure and anxiety management on reducing the likelihood of leaving treatment early (k = 1; n = 37; RR = 0.95; 95% CI, 0.28 to 3.23).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between prolonged exposure and prolonged exposure and anxiety management on reducing the likelihood of leaving treatment early at follow-up (6 months) (k = 1; n = 37; RR = 1.14; 95% CI, 0.42 to 3.08).

There is limited evidence favouring prolonged exposure over prolonged exposure and anxiety management on reducing the likelihood of having a PTSD diagnosis at follow-up (6 months) (k = 1; n = 38; RR = 0.64; 95% CI, 0.37 to 1.11).

Further evidence identified in the current review

No further studies that compared combination prolonged exposure and anxiety management with prolonged exposure alone, were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

Trauma-focussed CBT versus trauma-focussed CBT and hypnosis

Previous evidence: NICE Guidelines evidence statements

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and trauma-focussed CBT and hypnosis on reducing the severity of PTSD symptoms (IES – self-report) (k = 1; n = 47; SMD = 0.13; 95% CI, –0.45 to 0.70).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and trauma-focussed CBT and hypnosis on reducing the severity of PTSD symptoms (IES – self-report) at follow-up (6 months) (k = 1; n = 47; SMD = 0.07; 95% CI, –0.50 to 0.64).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and trauma-focussed CBT and hypnosis on reducing the severity of PTSD symptoms (CAPS2–clinician) (k = 1; n = 47; SMD = –0.01; 95% CI, –0.58 to 0.56).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and trauma-focussed CBT and hypnosis on reducing the severity of PTSD symptoms (CAPS2–clinician) at follow-up (6 months) (k = 1; n = 47; SMD = –0.02; 95% CI, –0.59 to 0.56).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and trauma-focussed CBT and hypnosis on reducing depression symptoms (BDI12 – self-report) (k = 1; n = 47; SMD = –0.2; 95% CI, –0.77 to 0.37).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and trauma-focussed CBT and hypnosis on reducing depression symptoms (BDI12 – self-report) at follow-up (6 months) (k = 1; n = 47; SMD = –0.26; 95% CI, –0.83 to 0.32).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and trauma-focussed CBT and hypnosis on reducing anxiety symptoms (BAI – self-report) (k = 1; n = 47; SMD = –0.04; 95% CI, –0.62 to 0.53).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and trauma-focussed CBT and hypnosis on reducing anxiety symptoms (BAI – self-report) at follow-up (6 months) (k = 1; n = 47; SMD = –0.15; 95% CI, –0.72 to 0.43).

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and trauma-focussed CBT and hypnosis on reducing the likelihood of leaving treatment early (k = 1; n = 63; RR = 1.17; 95% CI, 0.50 to 2.75).
The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and trauma-focussed CBT and hypnosis on reducing the likelihood of leaving treatment early at follow-up (6 months) (k = 1; n = 63; RR = 1.17; 95% CI, 0.5 to 2.75). 1

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and trauma-focussed CBT and hypnosis on reducing the likelihood of having a PTSD diagnosis (k = 1; n = 63; RR = 1.21; 95% CI, 0.60 to 2.46). 1

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and trauma-focussed CBT and hypnosis on reducing the likelihood of having a PTSD diagnosis at follow-up (6 months) (k = 1; n = 63; RR = 1.06; 95% CI, 0.59 to 1.92). 1

Further evidence identified in the current review

No further studies that compared combination trauma-focussed CBT and hypnosis with trauma-focussed CBT alone, were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

TRAUMA-FOCUSED CBT AND HYPNOSIS VERSUS SUPPORTIVE PSYCHOTHERAPY

Previous evidence: NICE guidelines evidence statements

There is limited evidence favouring trauma-focussed CBT and hypnosis over supportive psychotherapy on reducing the severity of PTSD symptoms (IES–self-report) (k = 1; n = 45; SMD = –1.07; 95% CI, –1.7 to –0.44). 1

There is limited evidence favouring trauma-focussed CBT and hypnosis over supportive psychotherapy on reducing the severity of PTSD symptoms (IES–self-report) at follow-up (6 months) (k = 1; n = 45; SMD = –0.73; 95% CI, –1.33 to –0.12). 1

There is limited evidence favouring trauma-focussed CBT and hypnosis over supportive psychotherapy on reducing the severity of PTSD symptoms (CAPS2 – clinician) (k = 1; n = 45; SMD = –0.92; 95% CI, –1.54 to –0.3). 1

There is limited evidence favouring trauma-focussed CBT and hypnosis over supportive psychotherapy on reducing the severity of PTSD symptoms (CAPS2 – clinician) at follow-up (6 months) (k = 1; n = 45; SMD = –0.59; 95% CI, –1.19 to 0). 1

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and hypnosis and supportive psychotherapy on reducing depression symptoms (BDI2 – self-report) (k = 1; n = 45; SMD = –0.45; 95% CI, –0.95 to 0.04). 1

The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between trauma-focussed CBT and hypnosis and supportive psychotherapy on reducing depression symptoms (BDI – self-report) at follow-up (6 months) (k = 1; n = 45; SMD = –0.27; 95% CI, –0.85 to 0.32). 1

There is limited evidence favouring trauma-focussed CBT and hypnosis over supportive psychotherapy on reducing anxiety symptoms (BAI – self-report) (k = 1; n = 45; SMD = –0.62; 95% CI, –1.22 to 0.02). 1

There is limited evidence favouring trauma-focussed CBT and hypnosis over supportive psychotherapy on reducing anxiety symptoms (BAI – self-report) at follow-up (6 months) (k = 1; n = 45; SMD = –0.62; 95% CI, –1.22 to 0.02). 1

There is limited evidence favouring supportive psychotherapy over trauma-focussed CBT and hypnosis on reducing the likelihood of leaving treatment early (k = 1; n = 54; RR = 2.8; 95% CI, 0.64 to 12.26). 1

There is limited evidence favouring supportive psychotherapy over trauma-focussed CBT and hypnosis on reducing the likelihood of leaving treatment early at follow-up (6 months) (k = 1; n = 54; RR = 2.8; 95% CI, 0.64 to 12.26). 1

There is evidence favouring trauma-focussed CBT and hypnosis over supportive psychotherapy on reducing the likelihood of having a PTSD diagnosis (k = 1; n = 54; RR = 0.6; 95% CI, 0.30 to 1.18). 1

There is evidence favouring trauma-focussed CBT and hypnosis over supportive psychotherapy on reducing the likelihood of having a PTSD diagnosis at follow-up (6 months) (k = 1; n = 54; RR = 0.69; 95% CI, 0.39 to 1.19). 1
Further evidence identified in the current review

No further studies that compared combination trauma-focussed CBT and hypnosis with supportive psychotherapy, were identified.

Current review evidence statements

As no new studies were identified, there are no current review evidence statements.

Updated evidence statements on the combined evidence from previous and current reviews

As there are no current review evidence statements, there are no updated evidence statements.

Summary of the evidence

There is a body of evidence supporting trauma-focussed CBT for the treatment of acute stress disorder and acute PTSD. There appears to be little advantage in the addition of anxiety management therapy or hypnosis, although methodological issues limit the inferences that can be made about this. As such, in the interests of simplicity, these guidelines support the NICE recommendations and those outlined in the previous section, that the practitioners consider the application of trauma-focussed CBT for the treatment of ASD and acute PTSD. Currently no studies have been identified that examine combination pharmacological interventions or combination pharmacological and psychological interventions for ASD.

RECOMMENDATIONS

5.17 Trauma-focussed CBT should be used for the treatment of ASD and acute PTSD.
A search of economic databases (ECONLIT, National Health Service Economic Evaluation database and Health Economic Evaluations Database (HEED) was undertaken to identify studies that reported an economic evaluation of treatments for ASD and PTSD. Key search terms included: economic, cost, resource, economic evaluation, cost-benefit, cost-utility, cost-effectiveness.

Twelve records were retrieved of which five were considered potentially useful (see Table 6d). The excluded studies and reason for exclusion are listed in Appendix H.

Issakidis et al (2004) conducted a cost-effectiveness study that aimed to identify the averted burden and economic efficiency of current and optimal treatment for the major mental disorders. Outcome was calculated as averted ‘years lived with disability’ (YLD), with direct health care costs were calculated in Australian dollars for the year 1997–98. The cost per YLD averted (efficiency) was calculated for those already in contact with the health system for a mental health problem (current care) and for a hypothetical optimal care package of evidence-based treatment for this same group. Current coverage was around 40 per cent for most disorders with the exception of social phobia at 21 per cent. Receipt of interventions consistent with evidence-based care ranged from 32 per cent of those in contact with services for social phobia to 64 per cent for PTSD. In terms of direct treatment costs, Issakidis found that PTSD treatment has higher per case per year costs than any of the other anxiety disorders ($1224 compared to $1188 for panic/agoraphobia, $1011 for social phobia and $795 for generalised anxiety disorder). According to this study, individuals with PTSD constitute one third of people treated for an anxiety disorder, but their treatment including mental health, general health and pharmaceutical services, accounts for 40 per cent of the total cost of treatment for all anxiety disorders. The cost of this care was estimated at $400 million, resulting in a cost per YLD averted ranging from $7761 for generalised anxiety disorder to $34 389 for panic/agoraphobia. Cost per YLD averted for PSTD was $23 656 and $15 728 for current and optimal treatment (cognitive behavioural therapy and/or medication), respectively. Overall, under optimal care, costs remained similar but health gains were increased substantially, reducing the cost per YLD to <320 000 for all disorders. The authors conclude that evidence-based care for anxiety disorders would produce greater population health gains at a similar cost to current care, resulting in a substantial increase in the cost-effectiveness of treatment.

Chan et al (2003) aimed to determine the impact of motor vehicle accident-related psychiatric disorders on health and economic costs in quantitative terms. Using data on victims of motor vehicle accidents through the State Insurance Commission, South Australia, the authors calculated that the total health and economic cost in Australian dollars for the 391 victims was over A$6.36 million. Approximately nine months after the accident, of the 391 subjects who replied to the questionnaires, 31 per cent were identified as depressed and 62 per cent as anxious, while 29 per cent met criteria for PTSD. Chan concluded that PTSD cases incurred significantly higher health care costs compared with non-PTSD cases (p <0.001), with untreated PTSD cases incurring significantly higher economic losses compared with treated PTSD and non-PTSD cases (p <0.05).

A United States study by Walker et al (2003) examined the health care costs of a large group of women who were members of a large metropolitan health maintenance organisation (HMO). Participants were classified into three groups on the basis of PTSD checklist (PCL) (Weathers et al., 1993) score: low (<30), moderate (30–44) and high (>45). The cost accounting system of the HMO was used to collect data on health care costs, controlling for chronic medical illness and other forms of psychological distress. The authors estimated that total unadjusted mean annual health care costs were US$3060 for the high PCL score group, US$1779 for the moderate PCL score group, and US$1646 for the low PCL score group. After adjusting for depression, chronic medical disease and demographic factors, women with high PCL scores had significantly greater odds of having non-zero health care costs compared with women with low PCL scores. Compared with women in the low PCL score group, those in the moderate PCL score group had, on average, a 38 per cent increase in adjusted total annual median costs, and those in the high PCL score group had a 104 per cent increase. The authors suggest that instituting health services interventions, to improve recognition and treatment of PTSD in primary and specialty care clinics, may be a cost-effective approach for lowering the prevalence of this disorder.
Zatzick et al (2000) investigated the association between psychiatric disorders, length of stay (LOS) and cost in a large cohort of trauma inpatients in the United States. The authors identified all trauma-registry recorded psychiatric diagnoses among people admitted to University of California Davis Medical Center between January 1993 and December 1996. Linear and logistic regressions were used to assess the unique effects of psychiatric diagnoses on inpatient LOS and cost. The authors estimated that 29 per cent of participants had one or more registry-recorded psychiatric diagnosis, with patients with stress disorders, delirium, and psychoses demonstrating a 46–103 per cent increase in LOS and cost (p < 0.01). Key conclusions from this research are that people with recognised psychiatric disorders uniquely impact inpatient trauma surgery LOS and cost. Further investigations of the processes and outcomes of care could lead to cost-effective performance improvement efforts that target the amelioration of comorbid psychiatric disorders among physically injured trauma survivors.

A United States study by Fontana and Rosenheck (1997) compared the outcomes and costs of three models of Department of Veterans Affairs (VA) inpatient treatment for PTSD: 1) long stay specialised inpatient PTSD units, 2) short-stay specialised evaluation and brief treatment PTSD units, and 3) non-specialised general psychiatric units. Data were drawn from 785 Vietnam veterans undergoing treatment at 10 programs across the country. The veterans were followed up at 4-month intervals for one year after discharge. Successful data collection averaged 66.1 per cent across the three follow-up intervals. All models demonstrated improvement at the time of discharge, but during follow-up symptoms and social functioning rebounded toward admission levels, especially among participants who had been treated in long-stay PTSD units. Veterans in the short-stay PTSD units and in the general psychiatric units showed significantly more improvement during follow-up than veterans in the long-stay PTSD units. Greatest satisfaction with their programs was reported by veterans in the short-stay PTSD units. Finally, the long-stay PTSD units proved to be 82.4 per cent and 53.5 per cent more expensive over one year than the short-stay PTSD units and general psychiatric units, respectively. The authors concluded that the paucity of evidence of sustained improvement from costly long-stay specialised inpatient PTSD programs, and the indication of high satisfaction and sustained improvement in the far less costly short-stay specialised evaluation and brief treatment PTSD programs, suggest that systematic restructuring of VA inpatient PTSD treatment could result in delivery of effective services to larger numbers of veterans.

Although one of these studies provided a cost-benefit analysis of current and optimal, evidenced-based treatment approaches for PTSD and three identified the high cost of PTSD when left untreated, no study was found that systematically outlined the economic burden of posttraumatic mental health problems, either in the early stages of development or once they become long-term or chronic. There is also no overall assessment of the cost and benefit of approaches currently used to treat ASD and PTSD that fully takes into account the type and timing of the intervention and the impact of comorbidity.

**COMMENTARY ON ECONOMIC BURDEN**

The reviewed literature clearly outlines the high cost associated with access to health care and long-term disability when people have PTSD symptoms. PTSD is a high burden disorder that impairs functioning in many, if not all, areas of life with consequences extending beyond the individual to impact on family members and society as a whole. To date there has been no comprehensive economic assessment of PTSD from a social perspective. Studies included in this review focus mainly on health service utilisation and there is a paucity of evidence that uses surrogate outcomes of burden including rates of hospitalisation, work impairment and a greater risk of motor vehicle accidents. Further, the lack of evidence pertaining to treatment costs makes it difficult to identify whether increased health care costs are a direct result of PTSD or are indirectly accounted for by the poor physical health commonly associated with PTSD. The importance of addressing these issues through the use of health economic techniques was comprehensively addressed by McCrone et al (2003). Health economics provides tools (including cost-effectiveness, cost–benefit, and cost–utility analyses) to ascertain the relative efficiency of different treatment options. McCrone concludes that the quality of life and resource consequences of PTSD require a better understanding of the economics of the disorder and the alternative ways to treat it. These sentiments are echoed by the authors of the costing articles identified in the preceding section. The economic burden associated with PTSD is significant. Treatments are available to alleviate this burden but treatments require the use of scarce resources. In this environment of increased fiscal restraint, there is a need to identify those health care interventions, whether they are psychosocial or pharmacological, that provide the greatest benefit for the limited health dollar.
CURRENT FUNDING OF ASD/PTSD TREATMENT

In the Australian health care system, a diverse range of practitioners provides treatment services for adults with PTSD, variously funded by the federal and state governments as well as third party insurers and the affected individuals themselves. As a result of these diverse funding arrangements, there are differences in availability of treatment between states. To date, there is no overall assessment of financing arrangements for the treatment of ASD and PTSD in Australia and the extent of unmet need for treatment is not known. In this context, it is difficult to make an assessment of the feasibility or cost and benefit of recommendations made in these guidelines. However, it is worth noting, for example, that the guideline recommendation for 90 minute sessions for trauma-focussed therapy has important costing implications. Currently, fee structures for GPs, psychiatrists and psychologists do not support consultation times of this length. The briefer consultation times supported by fee structures inevitably favour brief interactions rather than the recommended trauma-focussed interventions. Thus, under the current health care system, practitioners are not rewarded for providing evidence-based treatment.

POTENTIAL IMPLICATIONS

A number of implications follow from the above discussion. First, there is an urgent need for a comprehensive assessment of the economic burden associated with PTSD. Such research would provide the platform for identifying, measuring and valuing the private and social costs associated with PTSD. Second, rigorous research is required to ascertain the cost-effectiveness of different interventions identified by the systematic review and recommended as treatment options. Of particular interest would be a study that looks at each recommendation if delivered as first, second or third line treatment and is then able to identify the optimal package of cost-effective interventions. Given the impact of PTSD on morbidity and quality of life, it is particularly important that the economic evaluation uses a measure of disease burden as the outcome (i.e. DALY, QALY, YLD). Third, an assessment of current financing arrangements for treating ASD and PTSD should be conducted to ensure that adequate resources are provided. This strategy should complement the economic evaluation approach to ensure that the full spectrum of treatment options are evaluated and costed.

RECOMMENDATIONS

Given the scarcity of available data, the breadth of social, personal and health cost associated with ASD and PTSD, and the large number of interventions assessed for the purpose of developing these guidelines, it is not possible to conduct a full evaluation of the cost-effectiveness of recommended interventions. Instead, key economic considerations and recommendations for further research are outlined.

6.1 Conduct a comprehensive assessment of the economic burden associated with PTSD.
6.2 Implement economic evaluation studies alongside clinical evaluations of various treatment options.
6.3 Review financing arrangements from the treatment of PTSD in Australia.
Table 6.1 Summary of economic evaluation literature

<table>
<thead>
<tr>
<th>Framework</th>
<th>Intervention and comparator</th>
<th>Outcome measures</th>
<th>Result</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reference:</strong> Issakidis et al. (2004)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Costs: Govt/Health System perspective</td>
<td>Comparator: Null</td>
<td>Cost per YLD averted</td>
<td>Cost of evidence-based optimal care for PTSD: Current total $158.2M Optimal total $149.2M</td>
<td>Optimal care package for PTSD from: Davidson 2000; Foa et al 2000 No indirect costs included Only does CEA as a package, not for individual interventions. Cannot see if initial treatment with, for e.g. CBT vs pharmacotherapy is more CE.</td>
</tr>
<tr>
<td>1 year time horizon</td>
<td>Intervention: Optimal care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No discounting as only 1 year</td>
<td>MILD PTSD: 30% Psychiatrist CBT 30% Psychologist CBT 30% GP prescribed SSRI/TCA 10% GP referred self help</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year 1997–98</td>
<td>MOD/SEVERE PTSD: 36% psychologist CBT 13% GP SSRI/TCA 17% Psychiatrist SSRI/TCA 34% combined CBT+SSRI/TCA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study population: All those who meet criteria for the disorder and are currently in contact with health services. Study based in Australia.</td>
<td>Health State Preference Values measured using time trade off method in a population of GP's familiar with the disorder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Reference:</strong> Chan et al. (2003)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study population: Victims of motor vehicle accidents in South Australia November 1996–March 1999.</td>
<td>29% of study population were suffering PTSD</td>
<td>Costs: Accounting Records on health and economic costs</td>
<td>Mean total costs PTSD: Health Care: $7662 Economic: $23 254 Non-PTSD: Health care: $4377 Economic: $13 832</td>
<td>Statistically significant difference in both health care and economic costs between the two groups</td>
</tr>
<tr>
<td><strong>Reference:</strong> Walker et al. (2003)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1996–97. 1225 female members of metropolitan health maintenance organisation suffering PTSD. Classified into low, moderate and high. Using defined cut-offs, the low group is unlikely to be suffering PTSD, whereas the other two groups are potential patients. US study.</td>
<td>Costs assessed using HMOs automated cost-accounting system, including outpatient services, prescription drugs and ancillary services such as laboratory use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Reference:</strong> Zarick et al. (2000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Reference:</strong> Fontana &amp; Rosenheck (1997)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comparison of three models of inpatient care. Vietnam Veterans enrolled in study from November 1991 to Jan 1994. Across 10 sites in the US.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CBT = cognitive behavioural therapy; CE = cost effectiveness; CEA = cost effectiveness analysis; GP = general practitioner; HMO= health maintenance organisation; M = million; NSMHWB = Australian National Survey of Mental Health and Wellbeing (Australian Bureau of Statistics, 1997); SSRIs = selective serotonin reuptake inhibitors; TCA = tricyclic antidepressants; VA = Department of Veterans Affairs; YLD = years lived with disability
This section contains broad comment on issues to be considered when applying the guideline recommendations to particular populations who develop PTSD following trauma, and to particular types of trauma. It is beyond the scope of the section to include an exhaustive list of all traumatised populations and so it is limited to populations for whom specific contextual information may assist practitioners in the sensitive application of recommended treatments.

While there are significant differences between the trauma populations identified in this section, an experience common to many is exposure to sustained and/or repeated traumatic experiences, sometimes referred to as type II trauma (Terr, 1991). In many cases these sustained and/or repeated traumatic events are of human design, intended to leave the victim fearing, and feeling helpless to prevent, recurrence. Examples of type II trauma include childhood sexual or physical abuse, domestic violence, incarceration as a prisoner of war, torture and, arguably, prolonged combat. Repeated exposure to trauma on a community and familial level, such as may be the case in the Aboriginal and Torres Strait Islander community, is also consistent with this definition. It is also worth noting that, because of the sustained nature of some these traumatic experiences, people presenting for treatment may still be facing ongoing threat and be at risk of further exposure to trauma. Emergency and defense personnel, victims of domestic violence and victims of sexual assault perpetrated in the context of their current employment or intimate and family relationships, are some of the groups whose treatment may be affected by having to return to unsafe environments.

In the context of such ongoing risk, the focus of interventions should be on ensuring safety, stabilisation and symptom management, rather than commencing the trauma-focused components of treatment.

As outlined in the introduction, there is a body of literature suggesting that the symptom constellation that follows type II trauma is broader than PTSD, although not necessarily reflected merely in more extensive comorbidity with other psychological disorders (van der Kolk et al., 1996). This presentation, often referred to as complex PTSD or disorders of extreme stress, not otherwise specified (DESNOS), includes features such as impulsivity, problems with emotional regulation, identity disturbance, dissociative symptoms, self-destructive behaviour, abnormalities in sexual expression, and somatic symptoms (DSM-IV: APA, 1994). Issues of deliberate self harm and suicidality are more likely to be present in this group. All of these features need to be considered in both treatment planning (see recommendations in Chapter 2 — Factors influencing treatment outcome) and in delivering psychological interventions (see recommendations in Chapter 4).

This section differs from the clinical practice recommendations sections in that it is not based on systematic review of the empirical evidence. Rather, it is based on information provided by specialists in these areas. Within this section, emphasis has been placed on populations under-represented in the studies included in the systematic review. Consequently the first two sections, on Aboriginal and Torres Strait Islander peoples, and refugees and asylum seekers, are more comprehensive, with background information provided as a context for understanding the impact of specific traumatic experiences. This material should be used in conjunction with the information about particular types of traumatic events that follows.

The special populations covered in the section are:
- Aboriginal and Torres Strait Islander peoples
- refugees and asylum seekers.

The categories of traumatic event covered in the section are:
- military and emergency service
- motor vehicle accidents
- crime
- sexual assault
- natural disasters
- terrorism.
ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLES

As stated in the introduction to this special populations section, the information provided is derived from expert opinion as to the application of the guidelines for this population. There were no studies in the systematic review that included participants reported to be Aboriginal or Torres Strait Islander peoples.

Specialised training in cultural competency and safety has been developed for practitioners working with Aboriginal and Torres Strait Islander peoples and wherever possible, Aboriginal and Torres Strait Islander peoples should be treated by practitioners with this training. However, in circumstances where this is not possible, culturally informed care for Aboriginal and Torres Strait Islander peoples should be available within non-specialised primary and mental health care settings. The information presented here is intended to assist practitioners in these settings, in their work with Aboriginal and Torres Strait Islander peoples.

Background issues

Since white settlement in Australia, Aboriginal and Torres Strait Islander peoples have suffered separation from land, family and cultural identity. This has resulted in multiple experiences of trauma, grief and loss that have affected people at the level of the individual, family, and community. In this process, some aspects of traditional kinship and community systems have been destroyed and, in some cases, formerly protective influences within those systems that buffered individuals and families from further trauma, have been lost. Thus, the legacy of historical trauma is still apparent in the increased risk and incidence of traumatic exposure amongst Aboriginal and Torres Strait Islander peoples today. In effect, family and community functioning can continue to be compromised in each subsequent generation by social and psychological problems (such as substance use), leading to a vicious cycle of deteriorating conditions, pervasive social disadvantage, and for individuals, increased risk of further victimisation and traumatic exposure, coupled with reduced psychological resilience. Notwithstanding these comments, it needs to be acknowledged that Aboriginal and Torres Strait Islander peoples have shown remarkable resilience in surviving such historical and ongoing adversity and continue to display cultural strengths today.

Impact of traumatic experience on the individual

Given this context, the notion of trauma and PTSD in Aboriginal and Torres Strait Islander peoples is inevitably complex. It is multigenerational and across all communities. Most Aboriginal and Torres Strait Islander peoples presenting with mental health problems in both urban and rural/remote locations, have multiple, severe traumatic exposure within their family, community and personally, that may include domestic violence, sexual abuse, murder, and suicide. In seeking to understand the impact of traumatic experiences on the individual, the practitioner should consider not just the nature or number of specific experiences, but the contextual factors that predispose and/or amplify the experience of and response to trauma. Traumatic experiences that are recurrent and difficult to talk about are likely to have had the most profound impact. Therefore, even when the focus is on a specific recent event (for instance a violent death), it is critical for the practitioner to explore the person’s prior experience of traumatic events — particularly those that occurred in early life, such as physical and sexual abuse.

Due to the importance of extended kinship systems to Aboriginal and Torres Strait Islander peoples, a traumatic loss is likely to be felt broadly throughout the kinship group, rather than confined to the immediate nuclear family. That is, a person may have several mothers or be considered a mother to several nieces/nephews/grandchildren and if this is not recognised, the intensity of the loss may be underestimated. The impact on children of exposure to the event or the subsequent psychological illness in the parent should always be considered. In addition, given the frequency of traumatic events in Indigenous communities, a broader approach may be required than what can be offered to an individual.

Presentation

Aboriginal and Torres Strait Islander peoples are generally very tolerant and hence when they do present to services, it is likely to be very serious even if it may not appear so on the surface, or at first contact. It is not uncommon for the individual to be in crisis at first contact with presentations of acute distress, including interpersonal chaos, self harm and depression. Substance abuse/dependence is very often the presenting problem, with abused substances including alcohol, illicit drugs, and prescribed medications, such as analgesics. It is common to see high levels of dissociative symptoms and prominent auditory and visual phenomena that could be mistaken for psychosis. In many cases PTSD co-exists with prolonged grief/depression. While some people experience text-book PTSD symptoms, many more present with the range of additional symptoms associated with chronic and complex trauma (i.e. enduring patterns of social, psychological and behavioural difficulties, usually compounded by substance use). Further, culture-bound expressions of distress are often interpreted by non-indigenous people as anger. The complexity of these presentations can lead to a diagnosis of personality disorder, with PTSD being overlooked. Clinicians should be aware that many Aboriginal and Torres Strait Islander women and men in refuges and in prison suffer PTSD.
Assessment

Access, engagement, and trust in the therapeutic setting are complicated for Aboriginal and Torres Strait Islander peoples by a number of factors. These include the complexity of the trauma (particularly community level trauma), cultural factors and the historical legacy of mistrust of authorities. The potential for stigma and discrimination associated with mental health treatment to pose a barrier to engagement should be considered. Experiences of chronic loss mean that issues of abandonment and (the potential for) shaming may be heightened. As such, the recommendation noted in Chapter 2, regarding the need to allow more time and attention to the therapeutic relationship for people who have experienced prolonged and repeated trauma, would generally apply to this group.

Due to the complexity of the presenting problems for this population, PTSD is often overlooked. A culturally appropriate assessment is required for any diagnosis to be reliable. If no suitably trained practitioner is available, consultation with an Aboriginal and Torres Strait Islander mental health worker is highly recommended.

Issues of eldership, traditional law, and taboo need to be understood, at least to some extent, for reliable assessment. The following general practical advice is offered:

- Gain permission from the person (and others in attendance) for interview.
- With empathy, explain purpose of questions, the timeframe of the assessment, and potential outcomes.
- Identify relationships between the person and others present and be aware of their significance.
- Check with the person whether they prefer to be interviewed with/without significant others present.
- Observe cultural norms (eg eye contact, seating arrangements).
- Do not refer to a dead person by name.
- Do not refer to certain close relatives by name (a Torres Strait Islander male may not refer to his brother-in-law by name).
- Do not criticise an elder or other members of the extended family.
- Be aware of confiding certain personal information to a member of the opposite sex as men’s and women’s business are usually kept separate.
- Anxiety can be generated by interviewing someone in a confined space.
- Spiritual experiences are not necessarily hallucinations or delusions.
- Be aware of possible somatisation symptoms.
- Allow for reflection, periods of silence and any questions.
- Minimise the use of direct questions.
- Advise the person of confidentiality.

Source: Adapted from Tim Armstrong, Mental Health Project Officer for Northern Rivers Division of General Practitioners (http://www.medicineau.net.au/clinical/abhealth/abhealt1345.html)

As noted in Chapter 2 — Comprehensive assessment of PTSD, the assessment of PTSD should not be limited to a recent traumatic event, but should take into account previous traumatic experiences. Even if the person’s PTSD or presentation for treatment has been triggered by a recent event, it is often the case that a recent loss or trauma brings up unresolved past events. The potential impact of the traumatic experiences of previous generations on members of the current generation, either directly (e.g., family environments characterised by psychosocial problems, violence, impaired parenting), or indirectly (e.g., vicarious traumatisation), should be considered.

Further, given the high physical health morbidity even in young people, careful screening or review of general health status may be important, especially if pharmacological treatment is likely to be prescribed, or if there is a lack of progress in treatment. Diseases such as diabetes, renal failure, chronic infection, anaemia etc can complicate recovery from traumatic events and vice versa.
Treatment

In the review of evidence-based treatment for PTSD, no trials have investigated treatment for Aboriginal and Torres Strait Islander peoples. In the application of these treatment guidelines to Aboriginal and Torres Strait Islander peoples the practitioner is advised to consider the recommendations in combination with common sense and knowledge of traditional practices. Where available, appropriate partnerships with indigenous mental health workers should be developed. In cases where this is not possible, consultation with indigenous mental health workers or other practitioners with appropriate cultural training is recommended.

Within Aboriginal and Torres Strait Islander cultures, traditional therapies include the use of healers, rituals, and ceremonies. In working with an Aboriginal person or Torres Strait Islander with PTSD, practitioners should apply the guidelines in a culturally sensitive way, with consideration given to what combination of traditional, pharmacological, and psychological approaches to treatment will be most effective for the individual. Narrative exposure therapy has been identified as a culturally sensitive approach for Aboriginal and Torres Strait Islander peoples. The value of using cultural social processes has been demonstrated in indigenous Cambodians who escaped to the United States post Vietnam and in American indigenous veterans.

In establishing treatment goals, practitioners should give consideration to a number of factors in addition to those outlined in Chapter 2 — Factors influencing treatment outcome. First, the magnitude of trauma in Aboriginal peoples and Torres Strait Islander families may be overwhelming to practitioners and lead them to feel powerless and be inclined to give up. Good supervision is essential and collaboration with an Aboriginal peoples or Torres Strait Islander mental health professional is preferred. Second, as noted in Chapter 2 above, with people who have suffered prolonged or repeated traumatic experiences, more preparatory work is required before trauma-focussed work begins. As such, unless the practitioner has the capacity to make a commitment to being available in the longer term, it is often more appropriate to address current life and behavioural problems, focussing on issues of structure and problem solving, rather than delving into a potentially long history of trauma. Third, specific cultural factors should also be considered. Issues of age, seniority, and gender impact on who should provide treatment and how the treatment should be given. If the practitioner is ignorant of, or disregards these traditions, the Aboriginal or Torres Strait Islander person may be less likely to engage effectively in treatment.

In regards to early interventions following traumatic events affecting whole communities, local and traditional Aboriginal peoples and Torres Strait Islander approaches should be identified and supported in preference to de briefing or other psychological interventions.

There are significant challenges in the application of these guidelines to Aboriginal and Torres Strait Islander peoples. In addition to the historical and current socio-political factors outlined, the pervasive and enduring social disadvantage and the prevalence and complexity of traumatic experience, geographical isolation and limited availability of appropriately trained mental health practitioners all combine to create considerable barriers to effective care for posttraumatic mental health conditions.

Recommended reading


REFUGEES AND ASYLUM SEEKERS

As stated in the introduction to this special populations section, the information provided is derived from expert opinion as to the application of the guidelines for this population. Three studies in the systematic review included participants that were refugees and asylum seekers. The limited evidence-base in the field for both direct clinical trauma work and more general psychosocial interventions thus needs to be acknowledged.

In treating refugees and asylum seekers with PTSD, the practitioner is faced with a number of complex factors over and above the individuals’ traumatic experiences, including language, ethnocultural, socio-political and community issues, as well as the persons’ current clinical and psychosocial situation. It is not uncommon for practitioners to feel overwhelmed by these cultural and clinical complexities. In some cases this can lead the practitioner to being immobilised for fear of making mistakes, and in other cases it can lead to practitioners ignoring the complexities completely and proceeding as though they did not exist. Either response is unlikely to result in effective treatment. The middle ground, in which the practitioner is mindful of ethnocultural issues, but does not attempt to deal with them as the end in itself, is ideal. The practitioner’s genuine interest and respect are the most effective tools for building trust and the positive therapeutic relationship needed to help the individual recover from their traumatic experience.

Practitioners working with refugees and asylum seekers need to be culturally skilled including having awareness of biases, awareness of values, avoidance of stereotyping, the capacity to respond to potential conflicts between traditional values and values of the dominant culture and the ability to choose the appropriate approach. Practitioners should also recognise that cultural factors interact with what are commonly termed social factors — class, education, social status, rural or urban background.

In working with refugees and asylum seekers, interpreters are often involved. Practitioners should be mindful of the following issues when working with interpreters. First, in regard to perceptions of confidentiality, in small migrant communities, interpreters are frequently educated members the community, often community leaders. People may feel that their confidentiality is compromised when they have to disclose their experiences, through known members of their own community. Secondly, when interpreters are used for specific interventions such as imaginal exposure, it is important that the interpreter understands the procedure as well as the underlying rationale and potential client responses, so that the intervention is not unintentionally compromised. Finally, practitioners should be aware of the potential negative emotional impact on interpreters of re-telling the client’s traumatic experiences. In addition to the general point made in Chapter 2 regarding the potential for all practitioners in the field of posttraumatic mental health to be adversely affected by the work, the possibility that the interpreter has suffered similar traumatic experiences of their own, needs to be considered.

The following section outlines a range of general issues with which practitioners working with refugees and asylum seekers in Australia should be familiar. Further information about the specific background and experience of each person is of course still required.

Background issues

There is an inevitable political context in which the traumatic experiences and subsequent treatment of refugees and asylum seekers occur. Within Australia, as well as internationally, government policy, community attitudes, and media coverage of refugee and asylum seeker issues impact the mental health and well-being of this group. The impact can be direct, creating a welcoming or hostile environment, or indirect, potentially influencing public attitudes. For asylum seekers, these factors have a direct bearing on government policies relating to detention, visa options, and fundamental rights and entitlements such as access to medical care.

The traumatic experiences of refugees need to be understood in the context of socio-political factors in the country of origin. It is helpful for the practitioner to have an understanding of these factors at both the macro level — the nature and history of the conflict and its impact on the individual, their family, and community over time — as well as at the level of the individual's experience.

There are three defining characteristics of the refugee and asylum seeker experience, common to most:

- trauma (experienced or witnessed situations where their lives have been threatened or people have been killed)
- loss (of family friends and relatives, possessions, livelihood, country, status, etc)
- deprivation (of food, water, shelter, education and medical attention).
The frequency and nature of traumatic exposure inevitably varies, but the following experiences, designed to maximize psychic injury, are common:

- Extreme forms of violence that have been repeated and/or prolonged.
- Destruction of identity and the breakdown of families and communities, which may occur deliberately through the systematic disruption of core attachments to families, friends, and religious and cultural systems.
- Conditions of inescapability and unpredictability, that maximize the experience of helplessness.
- Loss under violent circumstances with consequences such as prolonged grief.
- Witnessing of atrocities such as mass killings, children targeted for violence and death, the violation of sacred values, betrayal, and the weakness of restorative justice.
- Deliberate erosion of personal integrity — physical boundaries invaded, the right to privacy violated, basic functions of eating, sleeping closely controlled, confronted with impossible choices, such as choosing who should die or who should be left behind.

The practitioner should also be aware that once in Australia there are several stressors that can continue to impact upon the mental health of refugees, including:

- concern about the safety of relatives and friends remaining in the country of origin when conflict is ongoing
- loss or separation from family and friends
- difficulties in tasks of settlement such as learning a new language, gaining employment, and inter-generational tensions
- discrimination in the host community
- minority status in the dominant Australian culture
- in the case of asylum seekers, environmental and policy factors such as mandatory detention and temporary protection (see additional issues specific to this group below).

Presentation

As noted above, refugees and asylum seekers have typically been exposed to prolonged and repeated traumatic experiences. In those with PTSD, common comorbid problems include:

- anxiety, depression, substance abuse, compulsive gambling and brief reactive psychoses
- interpersonal difficulties associated with mistrust, fear, anger and withdrawal
- high-risk and maladaptive behaviours
- grief responses such as numbing, anger, hopelessness and meaninglessness
- family conflict, family breakdown and domestic violence
- physical illness.

In seeking to understand refugees and asylum seekers with PTSD, the potential existential impact of this particular type of traumatic experience needs to be recognised. For example:

- Violence and uncertainty experienced during trauma may lead to anxiety, fear and helplessness.
- Forced impossible choices, and experiences of humiliation experienced, may lead to feelings of guilt and shame.
- Disruption of relationships, separation, and isolation may lead to grief, depression, and altered interpersonal relatedness (e.g., fear of relationships, dependency or extreme self-sufficiency).
- Shattered values of human existence resulting from trauma may lead to a loss of faith in humanity, distrust, sensitivity to injustice, and idealisation and devaluing of others.
- Anger and potentially aggressive behaviour can result from low frustration tolerance, protest about loss, reaction to injustice and betrayal, and as a defense against shame and guilt.

It is also important to recognise that individual strengths can emerge in the face of trauma.
**Assessment**

A framework for assessment that covers the multiple potential contributing factors to a refugee or asylum seeker’s PTSD and related problems, is critical. Table 7.1 summarises the information that should be collected for a comprehensive assessment.

<table>
<thead>
<tr>
<th>Assessment domain</th>
<th>Implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Country of origin and date of arrival</td>
<td>This information alone alerts the assessor to:</td>
</tr>
<tr>
<td></td>
<td>• region-specific physical health problems</td>
</tr>
<tr>
<td></td>
<td>• nature and duration of violence and hardship</td>
</tr>
<tr>
<td></td>
<td>• access to health care.</td>
</tr>
<tr>
<td>Visa status</td>
<td>Visa status is critical to understanding rights and entitlements and thereby the stresses of the client’s everyday environment.</td>
</tr>
<tr>
<td>Language</td>
<td>Check preferred language and country of origin of interpreter as some prefer that the interpreter does not come from their country</td>
</tr>
<tr>
<td>Cultural background</td>
<td>• Cultural notions of causal attributions, stigma, help-seeking behaviour, and concepts of healing are important to assess, as well as familiarity with systems in Australia.</td>
</tr>
<tr>
<td></td>
<td>• A cultural, ethnic or religious group is very diverse; generalizations need to be cautious.</td>
</tr>
<tr>
<td></td>
<td>• Some may wish to involve other family members in health care decision making.</td>
</tr>
<tr>
<td>Extent of exposure to violence and other traumatic events</td>
<td>A ‘thumbnail’ sketch is sufficient for the assessment process and provides an indication of likely physical and psychological health sequelae.</td>
</tr>
<tr>
<td>Family functioning</td>
<td>Children and adolescents have usually been directly affected through the experience and/or witnessing of violence, disrupted schooling and ongoing loss or separation from important caregivers. Ascertaining whether children and other family members require support involves proactive and sensitive exploration.</td>
</tr>
<tr>
<td>Economic circumstances including housing, employment</td>
<td>Potential sources of stress or strength</td>
</tr>
<tr>
<td>Legal-immigration situation re refugee determination or family sponsorship</td>
<td>Sponsorship issues and refugee determination processes are major sources of stress and mental health problems.</td>
</tr>
<tr>
<td>Physical health screening including dental care</td>
<td>Considerations include:</td>
</tr>
<tr>
<td></td>
<td>• physical injuries or pain which are the result of torture/physical trauma</td>
</tr>
<tr>
<td></td>
<td>• somatisation of a psychological problem.</td>
</tr>
</tbody>
</table>

As noted in recommendations for assessment in Chapter 2 above, a comprehensive assessment should go beyond the DSM-IV diagnosis of PTSD to include broader psychosocial factors. In refugees and asylum seekers, particular attention should be paid to: indicators of family breakdown, behavioural problems, quality of daily functioning, socially disruptive, aggressive or withdrawn behaviour, and physical symptoms. In undertaking the assessment and planning treatment, the recommendations outlined in Chapter 2 — Factors influencing outcome, for people with PTSD arising from prolonged and repeated trauma apply. The following additional considerations are recommended for refugees and asylum seekers with PTSD:

- Trust and rapport are very important. First appointments often need to be longer and/or several appointments may be needed for a comprehensive assessment.
- Refugees need to be seen in a safe place which does not trigger traumatic memories of overly-officious, authoritarian behaviour.
- Medical settings may act as reminders of torture.
- The gender of the therapist can be especially important for survivors of sexual assault.
- A person’s hostility may be a reaction to fear and uncertainty.
- Information should be provided and the person encouraged to ask questions to promote a sense of control.
- Explanations of the meaning of confidentiality are helpful.
- Intrusive investigative procedures may be frightening.
- Factors affecting ‘non-compliance’ are important to anticipate, such as cultural beliefs about damaging effects of investigations such as taking blood, attitudes to medication and misunderstanding of side-effects, and suddenly stopping medication.
Treatment

A small number of studies suggest that culturally-adapted CBT (including exposure) may be effective for refugees with trauma-related disorders. There is a need, however, to define more clearly who needs specific psychological (specifically CBT) interventions and/or pharmacological interventions over and above the general psychosocial assistance and counselling that is given in contemporary programs provided by torture and trauma services.

Consistent with the treatment guidelines for individuals with complex PTSD outlined in Chapter 2, it is essential that a therapeutic relationship and conditions of trust and safety are established in working with refugees and asylum seekers. In addition, the clinician should consider the following issues:

- The need for a holistic framework for treatment, which parallels the holistic framework for assessment.
- The value of different levels of intervention — individual, family, community, and important settings such as schools.
- Due regard for coping strategies that develop in response to situations of chronic violence and extensive losses — such as denial, withdrawal, and anger — and their protective value for the person.
- The critical role of guilt and shame in maintaining health problems.

In working with a refugee or asylum seeker, treatment goals need to extend beyond PTSD. Of uppermost importance for refugees and their families, is usually the rebuilding of their lives through a successful settlement process. The practitioner should facilitate opportunities for retraining, employment, recovery of status, and establishing connections. Attention also needs to be paid to physical health as the alleviation of physical health problems can be a pathway to mental health well-being.

Finally, it needs to be recognised that mental health problems in refugees are the result of systematic violation of their human rights. Restoration of faith in human beings, the right to health, the right to protection from human rights violations, and restoration of justice are part of the process of healing for refugee survivors of torture and trauma. Services which address the mental health needs of survivors must respect and reinforce the concept of human rights as expressed in various international charters and agreements (Aristotle, 1990).

Additional issues specific to asylum seekers subject to mandatory detention and temporary protection

Australia’s policies of mandatory detention and temporary refugee protection have been implicated as predictors of PTSD in refugees in Australia. Steel and colleagues (2004, 2006) report an extremely high incidence of PTSD in temporary visa holders and asylum seekers in detention.

The particular difficulties of working with this group of asylum seekers should be noted. Asylum seekers subject to mandatory detention or temporary protection often have difficulty engaging in therapy to address their trauma, as their traumatic experiences are, in many cases, ongoing. Most have a history of premigration trauma, followed by a dangerous and traumatic flight to safety and finally detention in penal-like institutions. The limitations of the temporary visas (reduced access to settlement services and welfare benefits) cause severe distress to many. Some visa conditions do not allow the visa holder to work, to access welfare support or to access a Medicare card, conditions which provoke extreme levels of anxiety.

During their time as temporary visa holders, asylum seekers face further distressing events — interviews to apply for permanent protection, the frequent rejections of their application, the appeals to the Refugee Review tribunal and other courts of appeal. Many report that their intense intrusive and disturbing thoughts and nightmares are about being arrested by detention guards and returned to detention or being deported — they experience ‘flash-forwards’. Mcinerney and Kaye (2006) argue that standard diagnostic categories and individual therapy in these conditions may be inadequate to address these complexities that have such a devastating impact on asylum seekers’ lives.

There are significant challenges in the application of these guidelines to refugees and asylum seekers. In addition to the complexity and severity of their traumatic experience, with its potential impact on fundamental beliefs about self and others, in many cases refugees and asylum seekers face ongoing stressors of re-settlement and in some cases, ongoing trauma of detention. Asylum seekers in detention are generally in geographically remote areas with limited or no access to appropriately trained mental health practitioners. Thus, there are considerable barriers to effective care for their posttraumatic mental health needs.
Recommended reading


MILITARY AND EMERGENCY SERVICE PERSONNEL

As stated in the introduction to this special populations section, the information provided is derived from expert opinion as to the application of the guidelines for this population. Twenty seven studies in the systematic review included participants that were military (25) or emergency service (2) personnel. This section addresses a number of the issues common to military and emergency service personnel. Additional issues specific to military veterans are outlined at the end of the section.

The nature of the exposures experienced in military and emergency service personnel is somewhat different to that in other trauma exposed populations. Their operational role entails an expectation of trauma exposure. While systems are in place within organisations to minimise the risks of injury, and personnel are specifically trained to deal with threat and danger, these strategies clearly have their limitations.

Increasingly, as the armed services are involved in humanitarian and peacekeeping duties, military personnel can be exposed to situations of considerable human suffering without any immediate threat to themselves. In this regard, over the last decade, the exposures of military personnel have an increasing commonality with that of emergency service workers. As such, the issues common to both groups will be outlined first, followed by specific issues for consideration in the military veteran population.

Organisational factors

The particular challenge with these groups of people is to implement treatment as early as possible. Using the principles of secondary prevention, this minimises the development of a series of secondary patterns of adaptation that in themselves can present a significant disadvantage. The systems of care that ensure early identification, such as screening and addressing stigmatisation in the workplace, are of particular importance.

Recognition of the value to an organisation of maintaining the skill base of highly trained officers is an important priority in encouraging a general attitudinal change within these organisations. Significant experience in dealing with these particular groups is also an important matter for clinicians because understanding the specific culture of these organisations can be central to the development of a positive therapeutic relationship with the ASD or PTSD sufferer.

Screening

Systematic screening potentially has an important role in identifying ASD or PTSD in groups of military and emergency services personnel who are either engaged in repeated high risk exposures or have had a recent deployment or major event which carries a significant risk of PTSD. However, it should be recognised that the emergence of symptoms might be delayed, pointing to the value of an annual health assessment above and beyond an initial screening process. The administration of screening questionnaires should only be seen as a guide to a more systematic diagnostic assessment by a trained clinician.

A range of psychometric instruments have been trialled in police, military and fire services for monitoring the emergence of symptoms. Given the issues about under reporting, there is some evidence that lower thresholds should be used in determining referral for a clinical assessment. Any screening process should also regularly interview a fixed proportion of people who are symptomatic to remove the stigma of referral for follow-up. Measures of an exposure and symptom questionnaire need to be flexibly applied in regards to the nature of the exposure. The PCL (described in recommendations in Chapter 2 — Self-report measures) has a military version which addresses this challenge because it does not simply focus on exposure to a sole traumatic event. This approach should be considered with other standard measures.
Symptom presentation

The presentation of symptoms for this group tends to be somewhat different to other traumatic stress victims. The association between the trauma exposures and the workplace means PTSD often has an indirect presentation in these cases. For example, the individual's difficulties may become manifest as increasing conflict with senior personnel over a variety of operational and disciplinary issues. Furthermore, the individual may have had a prolonged period of symptomatic distress which they have attempted to minimise and deny. The general sense of camaraderie and collegial support in these organisations often assists the individual in maintaining a façade of functioning. A failed promotion or a disciplinary charge often becomes the focal point around which an individual's distress is manifest, and may themselves be a consequence of the individual's increasingly disorganised behaviour. The indirect manifestation of the individual's distress can delay the appropriate assessment and diagnosis.

The clinical manifestation of an individual's distress in these situations can occur in a variety of ways:

- Comorbid alcohol abuse is not an uncommon presentation where the individual attempts to self medicate. The associated interpersonal and work-related difficulties may lead to individuals, other than the person suffering from PTSD, being aware of the difficulties prior to the sufferer.
- Interpersonal conflict with family and, in particular, violent outbursts, is another indirect manifestation that may first be brought to the attention of welfare services from a secondary victim, such as the spouse.
- The individual may initially present with a prolonged period of numbing and increasing interpersonal insensitivity. This can be manifest as inappropriate management of junior personnel or conflict with superiors.
- An intense pattern of distress may emerge in response to a recent traumatic event. The recent event may have some particular similarity to prior exposure which played an important role in the initial disruption of the individual's reactivity to stress. Hence, the longitudinal pattern of symptoms needs to be assessed, as well as the acute disorganisation in response to recent exposures.
- Individuals who leave an organisation may first present some time after their discharge. The loss of identity and support through the structure of the organisation, which has provided the raison d'être for the individual's functioning, can lead to the progressive emergence of PTSD symptoms, including increasing and distressing recollections and nightmares.

Assessment

Individuals with a work-related disability are often placed in a difficult conflict about seeking assistance because this can lead to significant discrimination and disadvantage in the workplace. This is a recognised difficulty when presenting to occupational health services. This requires a high index of suspicion from the assessing practitioner. It is important that supervisors who are familiar with the individual's normal disposition and capability have some awareness of the indirect manifestation of the effects of PTSD in the workplace, so that appropriate referrals can occur. The health professional needs to have access to personnel records to assist in a clinical assessment.

The clinical presentation of emergency service and military personnel infrequently occurs following the initial exposure to a single traumatic incident. The more typical scenario is where the individual breaks down after repeated experiences of a variety of traumatic incidents, which entail varying degrees of a sense of personal threat, often combined with the witnessing of harm or death to others. The extent to which a specific incident is personalised through some identification with the event or the victim, plays an important role in modifying the resilience and vulnerability of the individual. Major terrorist incidents, disasters with multiple losses of life, and exposure to gruesome or horrific accident scenes carry a particular risk for such individuals.

The available evidence suggests that prolonged exposure or repeated intense exposures over a period of time leads to an accumulated risk. As a consequence, the recommendation regarding assessment for people exposed to prolonged or repeated trauma in Section Chapter 2 — Comprehensive assessment of PTSD, applies; the history obtained from military and emergency service personnel should focus on the lifetime exposure, as well as the immediate antecedent event that may have prompted the presentation for treatment.

Treatment

In general, the standard evidence-based treatments apply to military and emergency service personnel. Specific consideration of the following points may be helpful:

- Treatment planning needs to take into consideration the multiplicity of traumatic exposures that military and emergency service personnel have had to deal with and the consequent multiple triggers or trauma reminders.
- Addressing the issues of emotional numbing can be of particular relevance to those individuals who have had a prolonged period of service where this method of adaptation may have become ingrained.
The existence of comorbid substance abuse is a frequent therapeutic challenge. Evidence suggests this should be dealt with alongside the initial control of an individual's symptomatic distress. This approach takes account of the fact that frequent alcohol usage has been a form of self medication which the individual has used to address their difficulties.

A particular challenge when working with currently serving emergency service or military personnel is the management of exposure to further stressors in the workplace during the immediate aftermath of treatment. In general, it is important to remove the external threat and triggers to the individual's distress. A model of sensitisation and kindling is a valuable theoretical construct to inform any cognitive behavioural management.

The challenge of determining recommendations for future duties should be based on an individual's residual pattern of arousability and general adaptation. If a significant degree of triggered distress remains, it is probable that further exposures will exacerbate the individual's symptoms. In these instances, it is best to minimise the probability of such exposures and recommend alternative duties.

**Additional issues specific to military and ex-military personnel**

There is some evidence to suggest that military recruits have increased rates of childhood physical abuse, sexual abuse and neglect, as well as high rates of family dysfunction compared with community averages. The practitioner needs to be aware of any such pre-military history, as it is likely to influence the establishment of a therapeutic relationship as well as treatment planning.

On joining the service, military personnel are then confronted with a range of experiences that may contribute to mental health problems. Perhaps of most importance, is the unique requirement for military personnel to be prepared to kill other human beings in the course of their duties. This capacity is fostered through their training to respond to a threat with aggression and to respond to orders with 'instinctive obedience'. For most, the preparedness to kill another person challenges their personal values and the act of doing so can have long-term effects on their fundamental beliefs.

During deployment, it is not uncommon for military personnel to experience multiple traumatic events. Military deployment almost invariably involves exposure to real or threatened death and serious physical injury that can lead to PTSD. Furthermore, the nature of traumatic events experienced on deployment can challenge fundamental beliefs about the self, the world, and humanity. For example, traumatic events may involve the death of civilians and destruction of communities on a scale that is often unimaginable and for which the veteran has had little preparation. Military personnel themselves may have committed acts of violence that, with the benefit of hindsight or emotional distance from the event, may be deemed to be atrocities — such experiences may shatter previously held beliefs about the self.

It was initially thought that peacekeepers suffered low rates of exposure to traumatic stressors, however a number of studies have indicated that peacekeeping missions may present a range of unique stressors that can have a significant psychological impact on deployed personnel. Peacekeepers are often exposed to war zone stress as well as experiencing frustrations associated with peacekeeping duties, such as restrictive rules of engagement (Litz et al., 1997). Experiences that were rated to be moderately to extremely negative, in a recent study of peacekeepers deployed to Kosovo, included: knowing that many of the war criminals were not arrested (73%), seeing children who were the victims of war (67%), seeing civilians in despair (58%), seeing the physical devastation (52%), and knowing that there was a lack of supplies for civilians (52%).

An understanding of the psychological underpinnings of the veteran's initial presentation and a preparedness to give sufficient time to the veteran to establish a trusting relationship will be immeasurably helpful. Given the war-related nature of traumatic events experienced by many veterans, they may anticipate negative evaluation on the part of the health practitioner. To work effectively with military personnel, the practitioner must demonstrate a willingness to listen and the capacity to tolerate the details of traumatic experiences whilst maintaining a positive regard for the individual throughout.

Most clinical treatment trials with veteran populations, both pharmacological and psychological, have shown treatment to be less effective than for non-veterans with PTSD. This may be due to characteristics of the veterans themselves (their gender, nature and duration of traumatic experiences, chronicity of PTSD, high rate of comorbidity), the less rigorous treatment interventions generally used with this population, or potentially complicating factors relating to veterans' compensation, pensions, and other entitlements. Although the practitioner may anticipate more modest outcomes, the general recommendations regarding treatment for PTSD still apply.
MOTOR VEHICLE ACCIDENT AND OTHER INJURY SURVIVORS

As stated in the introduction to this special populations section, the information provided is derived from expert opinion as to the application of the guidelines for this population. Thirty-two studies in the systematic review included participants that were injury survivors from motor vehicle accidents or other causes. With study participants recruited from hospital admissions, most of what we know about motor vehicle accident (MVA) and other injury survivors is based on people who have been severely injured and hospitalised, or at least admitted to a hospital emergency department. MVA survivors with less severe injuries, for example soft tissue injury, may of course also develop PTSD, and many of the issues discussed in this section are relevant to that group. This section addresses issues of PTSD in the context of physical injury and so does not include MVA survivors with PTSD who have sustained no physical injuries. The guideline recommendations can be applied to this group without need for special consideration.

Approximately 2 per cent of all Australians every year are injured severely enough to require a hospital admission. The frequency with which such severe injury occurs makes it one of the greatest causes of PTSD in Australia. MVAs are a major cause of severe injury and therefore contribute significantly to the PTSD rate in Australia. Consistent with common responses to traumatic experience noted in Chapter 2, many injury survivors will display PTSD symptoms (nightmares, intrusive memories) in the initial weeks after being injured, but for most these symptoms will resolve within three months. Approximately 10–15 per cent of injury survivors will go on to develop chronic PTSD.

The severity of the injury in terms of its relationship to mortality does not predict the development of PTSD. That is, those with a life threatening injury are no more likely to develop PTSD than those who suffer a serious injury that is not life threatening. The rate of PTSD in those with soft tissue injury has not been established, but if the rate of PTSD is unrelated to injury severity, it may also be in the 10–15 per cent range. The relationship between injury severity and PTSD is, however, different with traumatic brain injury (TBI). Those with severe TBI are less likely to develop PTSD, while those who suffer a mild TBI are just as likely to develop PTSD as those with no brain injury. This is probably associated with the high level of amnesia experienced by those with a severe TBI — those with no memory of the event are less likely to develop PTSD.

Common presenting problems in injury survivors include distressing memories and nightmares about the accident, insomnia, irritability, elevated startle response, and concentration problems. Individuals often avoid situations that are consistent with the event in which they were injured. For example, those injured in a MVA often experience fear of driving and avoidance of traffic. Individuals surviving assault are often avoidant of social situations, especially where there may be crowds or intoxicated people. In some cases individuals become avoidant of hospitals and fail to attend appointments, or do not have follow-up surgery. This may significantly impact their physical recovery. Practitioners should be aware that many injury survivors suffer mild TBI, and have no memory of some parts of the event in which they were injured. Interestingly, although these people may not be able to remember critical aspects of the event, they can still be fearful and avoidant of situations which trigger memories of the event. Depression is very commonly comorbid with PTSD in injury survivors. This is especially the case with those who experience orthopaedic injuries which require long term rehabilitation. The loss of important roles, financial difficulties and uncertainty about the future often contributes to depression. Many injury survivors also suffer chronic pain and this pain can serve to trigger memories of the accident. This can result in individuals avoiding situations which may cause pain to escalate, such as exercise or physiotherapy.

Assessment

There are three main issues pertaining to injury survivors with PTSD that need to be considered during assessment.

First, be aware of the timing of the assessment. There is strong evidence that many PTSD-type reactions that occur in the initial two months will subside in the following period. Intense reactions in this period are less likely to subside without intervention and may need immediate attention. Less severe reactions, however, which are common in this period, are more likely to be transient and resolve without treatment.

Second, injury survivors are characterised by comorbid presentations that have implications for treatment planning. As discussed, depression, mild TBI, and chronic pain are the major problems that co-exist with PTSD after severe injury. It is important to ask specifically about each of these problems to determine the primary presenting problem. Often patients will focus on pain because of its highly intrusive and aversive nature. The practitioner needs to focus interview questions specifically on PTSD or depression in order to avoid missing important information. In the case of mild TBI, it should be noted that people can meet the re-experiencing criteria for PTSD if they are distressed by reminders of the injury causing event (e.g., returning to driving) even if they cannot recall some critical aspects of the accident.

Third, many injury survivors are involved in litigation for criminal or civil purposes. This issue can complicate treatment planning because it can confound the motivational stance of the patient, especially if legal advice is suggesting a particular view about PTSD and its treatment. Assessment should explicitly enquire about litigation status.
**Treatment**

Injury survivors are often entitled to treatment for mental health conditions arising from their accident through individual state-based authorities. This is especially the case for MVAs and work place accidents. Practitioners should be familiar with entitlements and procedures in the state in which they work.

Treating injury survivors should follow standard guidelines, with particular attention to several possible modifications that are dependent on comorbid presentations.

Chronic pain is a major obstacle to treating PTSD because it can actively interfere with attention on therapy tasks. Also, pain can act as a reminder of the trauma and complicate treatment for pain and PTSD. Depending on the severity of the pain, it may be preferable to achieve adequate pain management prior to the commencement of PTSD treatment.

Depression that is comorbid with PTSD typically leads to a more severe clinical presentation. As outlined in the guideline recommendations, suicidal ideation requires careful assessment and management prior to commencement of exposure therapy.

Patients with brain injury who are amnesic of the accident (or part of it) may benefit more from in vivo exposure to situations that elicit anxiety than imaginal exposure. This approach can be beneficial because imaginal exposure can be limited when there are few memories of the trauma, and when attentional deficits interfere with focus on trauma memories for prolonged periods.

Although exposure therapy is the treatment of choice for people who develop PTSD following injury, practitioners should be aware that any therapy that actively addresses trauma memories has the potential to alter memory and, therefore, may be subjected to scrutiny in court. Some courts are particularly concerned about the use of hypnosis and EMDR as techniques that have the potential to modify trauma-related memories. Thus the use of these treatments may lead to a client’s evidence being inadmissible in court. It is advisable to avoid these treatments in cases that are subject to litigation. If such approaches are adopted, the practitioner would be advised to videotape all sessions.

**VICTIMS OF CRIME**

As stated in the introduction to this special populations section, the information provided is derived from expert opinion as to the application of the guidelines for this population. Twenty seven studies in the systematic review included participants that were victims of crime.

**Background**

There is debate in the literature about what constitutes a victim of crime, but the following United Nations. (1985) definition is widely accepted:

…persons who, individually or collectively, have suffered harm, including physical or mental injury, emotional suffering, economic loss or substantial impairment of their fundamental rights, through acts or omissions that are in violation of criminal laws operative within Member States, including those laws proscribing criminal abuse of power.

Around 30 per cent of the Australian population report being a victim of crime (including robbery, burglary, attempted burglary, car theft, car vandalism, bicycle theft, sexual assault, theft from car, theft of personal property, assault and threats) in a given year. However, PTSD is not a potential outcome for all victims of crime. The diagnosis is applicable only in cases where the crime constituted a potentially traumatic event as defined by DSM-IV. In general terms these are crimes of an interpersonal and violent nature. A much lower, though still significant figure of 4 per cent of the Australian population, report being a victim of personal crimes, such as robbery, sexual assault and assault with force, that are more likely to be associated with subsequent PTSD. When looking at recorded (by the police) crimes, males are more likely than females to be victims of all personal crimes, except sexual assault and abduction. For example, in 2003, just under 1 per cent of males reported to police that they were a victim of assault and 0.15 per cent of females reported being a victim of sexual assault or kidnapping (ABS, 2005). However, because there is a suspected low incidence of reporting, the true figure of victimisation, particularly for sexual crimes, is unknown.

The prevalence of PTSD in victims of crime is dependent upon the type of crime, the method of measurement and the definitions used. The lifetime PTSD prevalence rate for victims of crime is estimated to be about 25–28 per cent, with higher rates following interpersonal crimes such as rape (e.g., 45–60% following rape in women). In an Australian representative sample, it was found that 5.4 per cent of women reported experiencing a rape and 10.2 per cent reported molestation. Of those who reported that the most traumatic event they had experienced was rape, 9.2 per cent met criteria for PTSD in the past 12 months. Males who are raped appear to report a higher prevalence rate of PTSD.
Anecdotal reports suggest that PTSD in victims of crime is frequently erroneously diagnosed. It has been noted that the diagnosis is sometimes given based upon the type of incident leading to therapy, rather than the actual presentation, and the symptoms cited to support the diagnosis were frequently not PTSD criteria. With this in mind, it has been found that victims of crime are more likely to suffer from depression rather than PTSD, with up to 13 per cent of rape victims attempting suicide.

**Assessment**

In addition to the recommendations regarding assessment in Chapter 2 — Comprehensive assessment of PTSD, issues of particular relevance to victims of crime during assessment include the following:

- The practitioner should clarify with the person whether the interview is a forensic assessment or a therapeutic assessment.
- A full assessment of the person’s functioning and impairment before the crime in question and an assessment of current functioning needs to be conducted.
- An assessment of the full breadth of areas affected by the crime—including reactions to both personal victimisation and property damage, subsequent family, vocational and social relationships, as well as the affective and psychological reaction of the victim.
- General interview-based questions should be used to initiate the assessment procedure rather than specific questions or structured questionnaires, which may prime the person to answer in certain ways.
- Unless conducting a forensic assessment, conclusions should be fed back to the person and explained appropriately so as to minimise later confusion should these results be called into court.
- It is essential that complete and full notes be taken during the assessment interviews and subsequent treatment sessions. Failure to do so may later prejudice the victims’ rights should any court case ensue.

**Treatment**

An awareness of the legal system is important when treating victims of crime with PTSD. In Australia, the rights and laws pertaining to victims of crime are predominantly state based rather than national and hence vary between states. However, all the states have some mechanism whereby victims of crime can claim either compensation and/or access to mental health treatment for conditions related to their victimisation. Mental health practitioners need to have knowledge of these laws and services specific to where they practice.

In addition to the recommendations regarding treatment outlined in Chapter 4, issues of particular relevance to victims of crime include the following:

- Due to the nature of criminal compensation some people may perceive a vested interest in maintaining symptomatology until all proceedings have completed. It is advised that the therapist address this issue with the person before initiating treatment.
- Prolonged imaginal exposure to the event, when managed by a well trained therapist, has demonstrated efficacy with victims of crime and should be administered, sensitively, as a matter of course.
- It can be difficult for new therapists to avoid being compromised in their role as an agent of change to become, instead, an advocate. Therapeutic outcomes are best served through objective analysis of the presenting problems and the impartial application of evidence-based practice.
- Treatment sessions should be recorded, where possible, so that any accusations of tainted evidence arising during later litigation can be evaluated. Of course the rationale for recording sessions should be carefully explained to the person and their consent obtained before recording begins.

Beyond these general considerations, an individual’s needs will vary depending on the nature of the crime. For example, there is domain specific knowledge related to rape victims that may be less relevant to victims of assault; practitioners should acquaint themselves with these areas before providing treatment. Secondary consultation with a counsellor from a specialist sexual assault centre in your state would be recommended. The practitioner may also consider referring the person to a specialist sexual assault centre for advocacy or assistance with court proceedings if the practitioner is not going to offer this service themselves.
**SEXUAL ASSAULT**

As stated in the introduction to this special populations section, the information provided is derived from expert opinion as to the application of the guidelines for this population. Twenty four studies in the systematic review included participants that were survivors of sexual assault.

This section applies to adults with PTSD arising from sexual assault, whether that assault occurred during childhood or adulthood. As such, the nature of the traumatic event is highly variable (from repeated childhood sexual abuse to a discrete adult rape) and the posttraumatic mental health sequelae are consequently also highly variable. The guidelines are applicable to survivors of sexual assault with PTSD, with or without comorbid disorders. Of course not all survivors of sexual assault will have PTSD and therefore PTSD treatment guidelines will not be applicable to all.

**Background**

The mental health practitioner treating survivors of sexual assault should be aware of a number of important background issues. Sexual assault is a unique crime in that it is most often carried out in private, is shrouded in secrecy and involves a victim who often blames himself or herself. In children the majority of sexual abuse is perpetrated by a family member or person known to the child. (The media push for awareness via the concept of ‘stranger-danger’ only addressed a minority of perpetrators and victims). As a consequence, many adult survivors of child sexual abuse may still have contact with their abuser.

Sexual assault was rarely discussed in Australia until the 1970s and childhood sexual assault was almost never disclosed. Unfortunately, when childhood sexual abuse was disclosed, the victim risked being accused of fantasising, lying, seeking attention or seeking revenge. In the past 30 years survivors of sexual assault have increasingly reported the assault, but there is still considerable societal, familial and individual pressure to remain silent. People alleging sexual assault are the least likely of all crime victims to report the offence to the police. Further, of those reported, only a small proportion are prosecuted — one in six rapes and less than one in seven reports of incest sexual penetration of a child. These conviction rates are substantially lower than rates for other offences, and unfortunately there is no trend towards successful convictions over time. Convictions for rape have actually fallen since the late 1980s.

Negative stereotypes of sexual assault survivors as unworthy or undeserving continue to prevail in both the legal system and broader society. These stereotypes inevitably impact on the individual, creating additional distress beyond the traumatic experience itself.

Given the ‘hidden’ nature of sexual assault and low reporting and conviction rates, it is perhaps not surprising that there is little reliable information on the prevalence of sexual assault or childhood sexual assault in the Australian population. Existing data is based on the Australian Institute of Criminology’s studies on sexual assault and the criminal justice system, and the Australian Bureau of Statistics Women’s Safety Survey. To-date there has been no large-scale national population survey that includes childhood violence against boys. As a result, current knowledge about childhood sexual assault on boys is dependent on reports made to statutory child protection agencies. It is estimated that the prevalence of sexual assault before the age of 18 years in the Australian community ranges between 15 and 30 per cent for females, and between 3 and 15 per cent for males. As adults, those at greater risk of sexual assault are female, young and single, have a prior history of sexual assault, and have existing relationships with offenders.

It is important to acknowledge the intergenerational transmission of abuse. Women abused as children may repeatedly form relationships with abusive, violent partners who may, in turn, sexually and/or physically abuse her children. Additionally, if, for example, female caregivers are depressed, children may be receiving little protection and/or no positive parenting guidance or strategies.

**Adult versus childhood sexual assault**

For adults with PTSD following sexual assault, the trauma may range from a discrete adult trauma of rape to repeated sexual abuse during childhood, or a combination of both. The nature of childhood sexual abuse itself is highly variable. Sexual abuse involving penetration (digital or otherwise), as opposed to touching or fondling, has been found to be the most harmful abuse experienced. This is also true of sexual abuse involving degradation and violence. Not surprisingly, typical presenting problems differ according to the type and number of sexual assaults experienced. The practitioner should be aware of these typical presentations (outlined below) and ensure a comprehensive assessment of sexual assault, especially if a prior history of assault or sexual abuse is suspected. In some cases, the individual who has been sexually abused as a child will present for treatment of PTSD for the first time as an adult.
A. COMMON PRESENTING PROBLEMS IN SURVIVORS OF ADULT SEXUAL ASSAULT

- recurrent daytime memories/flashbacks and distressing dreams
- intrusive physical symptoms such as palpitations, sweating, breathing difficulties
- hypervigilance (e.g. fear of going out)
- sleep problems
- eating difficulties
- mistrust of males/females affecting the formation of relationships
- loss of interest in usual activities.

B. COMMON PRESENTING PROBLEMS IN ADULT SURVIVORS OF CHILDHOOD SEXUAL ASSAULT

- PTSD with prominent avoidance/numbing symptoms
- depression/anxiety
- personality disorders (e.g. borderline personality disorder)
- attachment disorders
- self harming
- recurrent thoughts of death, suicidal behaviour
- drug and/or alcohol abuse
- substance abuse
- eating disorders
- relationship problems
- sexual difficulties
- promiscuity or acting out sexually
- parenting problems
- regular dissociative episodes.

Assessment

As noted above, many survivors of sexual assault have experienced prior assault in adulthood or as children. It can be difficult in some cases to assess whether the most recent assault is the cause of PTSD or whether it is the result of previous or repeat assault(s). Consistent with the assessment recommendation in Chapter 2 above, a comprehensive assessment should include a detailed lifetime history of sexual assault and psychological sequelae of any previous trauma. In addition, with survivors of childhood sexual assault it is important to gain an understanding of their family background. It is unclear whether there is a direct causal link between childhood sexual assault and adverse psychological and social outcomes. It has been suggested that the fundamental damage is to the child’s developing capacities for trust, intimacy, agency and sexuality, and that many of the mental health problems of adult life associated with histories of abuse are second-order effects.

Given the societal context of sexual assault, it is essential that the practitioner accepts the person’s account of their traumatic experience without seeking to investigate the authenticity of their claims. Victims/survivors have often had negative responses to their disclosures from friends, family or the criminal justice system and may anticipate disbelief and denial from the clinician.

The gender of the practitioner needs to be given due consideration in working with survivors of sexual assault. It cannot be assumed that a female or male will prefer to work with a practitioner of either the same or the opposite gender. This matter needs to be discussed and if possible, the person given the choice of therapist gender.
Treatment

Recommended treatments for PTSD outlined in Chapter 4 above, apply to survivors of sexual assault. The recommendation to allow more time for establishing a therapeutic relationship, and teaching emotional regulation skills in those with prolonged and/or repeated traumatic experiences, is generally relevant to survivors of childhood sexual assault. In addition, the following specific considerations apply to sexual assault survivors with PTSD.

Given the broader legal context, practitioners working with survivors of sexual assault should have knowledge of relevant reporting, compensation and restorative justice approaches, in order to provide the person with appropriate support and advice.

If the person has ongoing involvement with the criminal justice system there is a high risk of additional distress from a variety of sources, including contact with the alleged offender, cross examination and the general experience of the court system. This will inevitably impact on treatment and should be taken into consideration in treatment planning. In general terms, it would not be reasonable to postpone treatment until the end of (often lengthy) legal proceedings, but the practitioner and PTSD sufferer should give careful consideration to the appropriate timing of trauma-focussed work in this context. In circumstances when the decision is made to defer treatment, the practitioner should consider referring the person to a specialist sexual assault centre for support during legal proceedings.

NATURAL DISASTERS

As stated in the introduction to this special populations section, the information provided is derived from expert opinion as to the application of the guidelines for this population. Four studies in the systematic review included participants that were survivors of natural disaster.

Please note that this section does not provide guidelines for disaster response more broadly. The National Mental Health Disaster Response Committee has been established to inform planning, preparation, rescue and response as well as the recovery period, in terms of mental health.

Disasters, by their nature, are large-scale events that impact upon significant groups within the community. There are a variety of natural and other types of disasters. Some, such as earthquakes and bushfires affect a local community and impact on a relatively well defined geographical region. Others, such as aeroplane crashes, involve individuals from many geographic regions as well as a local community where the actual accident occurred. Furthermore, these events may be brief and dramatic, such as a bushfire, or may have evolved over a much longer timeframe, such as a flood or drought. The nature of exposure to trauma in disasters varies considerably according to the type of disaster and the proximity of the individual to the causal agent. Equally, the various roles that people can play in disasters means there will be a significant difference in the impact upon the primary victims, compared with the impact on secondary victims, (i.e., emergency service personnel who are required to become engaged in the search and rescue). This section includes issues for consideration by both service planners and service providers.

Issues for service planners

For natural disasters, there is some support for using generic, community-based low-level services as preferred sources of support. These underpin the identification of needs and uptake of more specialist mental health interventions. The size of the population affected by a natural disaster is critical in determining the structure of the treatment services required to deal with the aftermath. Optimally, any treatment services should be linked to the existing health services in which disaster victims have confidence prior to the event. A frequent mistake is that planners presume there will be an early need for services, when in fact there tends to be low rates of uptake of services in the immediate aftermath of the disaster, with a progressive increase in need over a period of approximately two years after the event. In the aftermath of the disaster, particularly in light of the evidence about debriefing, those responsible for disaster management should attempt to limit the many volunteers who have emerged to provide ‘post disaster counselling’ in the aftermath of such an event. These individuals and their desire to assist can at times become a major issue in terms of the logistics and management of the large number of people converging on the disaster zone. It is important that the evidence about debriefing and acute treatments are provided to those involved in policymaking to ensure that the structure and nature of the services provide evidence-based interventions.

In the acute aftermath, psychological first aid is optimally provided in conjunction with the acute welfare needs of the population. Also, a decision should be made in the early recovery phase as to whether a systematic outreach, with an emphasis on screening, is to be instigated. If such a program is to be implemented, the high-risk groups should be identified and targeted. At-risk groups will be those who have lost family or suffered major property destruction or sustained injury.
Disasters are an opportunity to address many longstanding deficiencies in the provision of mental health care in the affected populations. Therefore, these events are of considerable importance in ensuring that high quality evidence-based care programs are put in place. They provide an opportunity for upgrading and improving the quality of clinical care for the broader population. Individuals who have been previously traumatised may first present for treatment in the aftermath of a disaster. Therefore, the skill base of the clinicians intervening with a disaster affected population should be capable of dealing with the broad range of traumatic events.

In disasters involving the loss of a large number of lives, specific consideration needs to be given to the issue of traumatic bereavement. In such instances, the sole treatment of PTSD will not address the full extent of the person’s predicament. The interaction between an individual’s traumatic memories and the grief process needs to be addressed. Also, in large mass casualty situations, providing basic skills and training to the surgeons, doctors and nurses involved in care can be a method of disseminating information and basic principles to a large number of people.

Media coverage of disasters provides an opportunity to use this coverage to provide information to a large number of people. Equally, it is important to have a series of information resources that can be made available to various organisations that have ongoing contact with those affected by the disaster. Such information sheets can assist in facilitating the linking of those in need with appropriate treatment services.

**Issues for service providers**

The immediate aftermath of a disaster involves a dramatic period where there is an attempt to mitigate the immediate physical threats and take steps to ensure the physical safety and wellbeing of the affected population. This involves the provision of emergency food and shelter and securing people’s possessions if their homes have been destroyed. There is also the need to document and take stock of the losses incurred. In the immediate aftermath of these events, there is a small group of people who become acutely distressed and may develop an acute distress disorder. However, the majority of people rise to the practical demands of the situation and their psychological distress is not an immediate issue.

There is often a long window of presentation to health services following such events. There is an expectation within communities that people who have sustained significant losses will experience a degree of enduring distress. However, once there is a relative degree of normality returning within a community, the experience of distress for some individuals will remain and may even intensify. It is at such times that presentations for care often increase in frequency. In other words, once the external demands begin to decrease and the obvious causes of distress lessen, individuals begin to acknowledge the possibility that their distress is out of keeping with the reality of their circumstances and may seek care.

Psychological distress in the aftermath of disasters can emerge in the form of family dysfunction, substance abuse, and conflict within the affected community. Disasters not only trigger PTSD but a range of other possible presentations, such as adjustment disorders, somatic distress, major depressive disorder, and substance abuse.

One of the more characteristic presentations of PTSD in this setting is the considerable anxiety that the individuals will demonstrate if the threat of a similar event begins to emerge. Their triggered pattern of distress is a matter that is readily observed.

**Assessment**

Unless the entire infrastructure of a community is destroyed, most disaster victims prefer to utilise the care networks that they are familiar with, focusing primarily on the local general practitioners. Given the delay in help-seeking, an opportunity exists for training general practitioners in the diagnosis and assessment of PTSD and other psychiatric conditions which are likely to emerge.

Given the predictability of disorder, if the affected population can be well circumscribed, an outreach program involving screening should be considered for high-risk individuals. Such an approach should only be contemplated if the appropriate clinical services are in place to provide care to those who are identified. Standard diagnostic tools such as the PCL and the CAPS, described in Chapter 2, are appropriate for use in this setting.

The assessments conducted in these populations should consider the fact that there will be a background pool of psychiatric morbidity within the affected community. The challenge is to define those individuals who have had an exacerbation or modification of existing symptom patterns, as opposed to the emergence of a new condition. This is relevant to the provision of treatment.
Treatment
As noted above, various forms of psychological distress are seen in survivors of natural disasters and there is likely to be a wide range of clinical needs. For those who develop ASD and/or PTSD, the recommended treatments generally apply. There are however, a number of specific challenges:

- Large numbers of people will potentially require access to treatment over a prolonged period of time. It is important that evidence-based treatments for PTSD are available to these affected communities. This is a particular challenge in rural and remote communities where there is often a paucity of appropriately trained practitioners.

- Multiple members of the same family may be suffering simultaneously, possibly impacting upon the pattern of symptomatic distress; for example, if both a husband and wife are suffering. Treatment may need to address these relationship dimensions because they can serve to influence the patterns of withdrawal and avoidance.

- In cases where the individual with PTSD has suffered economic and social disadvantage as a result of the disaster, the circumstances in which they find themselves can serve as a constant reminder of their traumatic experience and thus complicate the treatment.

Recommended reading

TERRORISM
As stated in the introduction to this special populations section, the information provided is derived from expert opinion as to the application of the guidelines for this population. No studies in the systematic review included participants that were reported to be survivors of acts of terrorism.

Please note that this section does not provide guidelines for disaster response more broadly. The National Mental Health Disaster Response Committee has been established to inform planning, preparation, rescue and response as well as the recovery period, in terms of mental health.

There have been several attempts to develop precise working definitions of terrorism. The United Nations has proposed a short legal definition: ‘[an act of terrorism is] the peacetime equivalent of a war crime’. More precise definitions of terrorism tend to be relative, because judgments about acts of political violence are often subjective. For example, the United States Department of Defense defines terrorism as:

…the calculated use of unlawful violence or threat of unlawful violence to inculcate fear; intended to coerce or to intimidate governments or societies in the pursuit of goals that are generally political, religious, or ideological.

Although more comprehensive, this definition is problematic because it relies on vague terms which are left open to interpretation (such as ‘unlawful violence’, ‘intended to coerce or intimidate’, ‘the pursuit of goals...’).

Terrorist acts usually involve high levels of destruction to property and, more importantly, to people. There is likely to be widespread threat to life and actual loss of life. There may well be exposure to grotesque sights for those involved, including the death and suffering of others; this may include close family members and friends. Difficulty (or inability) in helping others in the aftermath of the attack may precipitate feelings of helplessness and guilt.

The fear generated by terrorist attacks is unsurprising; they are characterised by many features typical of high severity traumatic events. Terrorist acts are generally unpredictable in terms of place, timing, and potential victims; as such, they are completely uncontrollable (at least for the general population), increasing the risk of perpetual hypervigilance. Bioterrorism carries added threat since it is so poorly understood and is, effectively, ‘invisible’. It is hard to be definite about whether an individual or group has been ‘contaminated’ and, even if individuals have clearly been exposed to pathogens, the likely health effects are rarely clear.

It is important to remember that the main goal of terrorism is exactly that — to generate feelings of terror in the community. Acts of terrorism are extremely rare (particularly in Australia) and the effects of fear and hypervigilance are often well in excess of the actual damage posed by, or caused by, the terrorist act.
In short, terrorist acts are generally high magnitude traumatic events, of very rare occurrence, capable of generating widespread fear and hypervigilance.

Importantly for these guidelines, there has recently been an increase in the (perceived) threat of imminent terrorist activity. For mental health professionals, this raises questions as to the best way to prepare for such attacks and the best way to manage the mental health consequences.

Preparing for the threat of terrorism
Reactions to terrorism can be made worse by sensational media reports and by poor communication by public officials. Thus, a key role for mental health professionals is often that of working with the media and public officials to ensure that appropriate messages are disseminated. Communications to the general population should be informed by the following recommendations (adapted from Foa et al., 2005):

• Provide realistic information on the likelihood of a terrorist attack and possible impact.
• Communicate that the individual risk is quite low.
• Explain that negative health behaviours which may increase during times of stress (e.g., smoking, unhealthy eating, substance use) constitute a greater health hazard than the hazards likely to stem from terrorism.
• Emphasise that the only action required on the individual level is increased vigilance of suspicious actions, which should be reported to authorities.
• Clearly communicate the meaning of different levels of warning systems.
• When issuing a warning, specify the type of threat, the type of place threatened, and indicate specific actions to be taken.
• Make the public aware of steps being taken to prevent terrorism without inundating people with unnecessary information.
• Provide the public with follow-up information after periods of heightened alert.

Communications by the media and public officials should also include simple information about resilience and about expectations of recovery. Many simple fact sheets on resilience in the face of terrorism are available on the internet (see, for example, http://www.acpmh.unimelb.edu.au, http://www.ncptsd.org http://www.usuhs.mil/csts, http://www.apa.org/topics/topictrauma.html).

Responding to an attack

A. IMMEDIATE
An attack of small to moderate impact is likely to generate moderate to major psychological and behavioural reactions in the short term, and the greater the harmful impact of the attack, the greater the likely reaction. Proximity to the attack and number of attacks will influence the severity of individual reactions. There is no reason to assume that the nature of clinical reactions, when they occur, would be significantly different to those seen following other types of traumatic events.

Immediate reactions are likely to include heightened anxiety, panic attacks, sleep and substance use problems, absenteeism from work, and retaliatory reactions against minorities identified with the terrorists. Reactions are likely to subside over the medium term (days to weeks), although repeated attacks and/or widespread loss of life and/or significant damage to infrastructures may result in increased psychological and behavioural reactions.

It is important to remember that most people will recover without any mental health assistance; thus, interventions at this stage should be based around providing information and activating community support:

• support the work of the emergency services
• activate and facilitate community support networks
• provide accurate information about the event and its consequences
• facilitate accurate and balanced communication by the media, schools, workplaces, etc
• establish information and drop-in centres to provide information, support, contacts, etc.
Although debate exists in this area, it seems reasonable to implement some kind of low key screening to facilitate identification of those individuals who are not showing the normal recovery trajectory and who are developing identifiable mental health problems. This might be done as part of a public health approach (‘... if you are experiencing several of these symptoms, we suggest you visit your local GP’) or in a more restricted manner (such as through advertising telephone numbers for trained personnel to conduct screening). The key point is that secondary prevention — early intervention for individuals with mental health problems following trauma — is demonstrably effective if they can be identified. This approach requires that educational material is made available to general practitioners to ensure that appropriate assessment, education and advice is forthcoming.

B. LONGER TERM

Significant longer term mental health reactions are likely to be limited to a relatively small proportion of the population. These reactions may include traumatic stress symptoms, other anxiety disorders, depression and substance use, all of which may be associated with impaired functioning and increased distress. The ongoing fear of another attack is likely to pervade all reactions to a greater or lesser extent.

With regard to interventions, there is little empirical knowledge about optimum interventions following terrorism and no available empirical knowledge about interventions following bio-terrorism. However, there is no reason to assume that interventions for those developing PTSD and related conditions following terrorism should be any different to those recommended for other trauma survivors. Thus, decisions regarding interventions with populations who have undergone a terrorist attack should be driven by the recommendations in the remainder of these guidelines.

Notes:
1. Parts of the first paragraph were adapted from http://en.wikipedia.org/wiki/Terrorism
2. The remainder of this section relied heavily on information taken from Ursano (2003).

Recommended Reading:

ADDENDUM TO THE SPECIAL POPULATIONS SECTION: NICE GUIDELINE RECOMMENDATIONS FOR THE RECOGNITION AND MANAGEMENT OF PTSD IN CHILDREN AND YOUNG PEOPLE

As noted in Chapter 1, the current guidelines did not include a systematic review of the literature on children. As a guide to assist practitioners, however, we include the following recommendations made by the United Kingdom National Institute for Clinical Excellence (NICE) in their Clinical Practice Guidelines for PTSD. The full NICE Guidelines are available from their website (http://www.nice.org.uk).

Recognition in primary care
For children, particularly younger children, consideration should be given to asking the child and/or the parents about sleep disturbance or significant changes in sleeping patterns.

Specific recognition issues for children
Children, particularly those aged under 8 years, may not complain directly of PTSD symptoms, such as re-experiencing or avoidance. Instead children may complain of sleeping problems. It is therefore vital that all opportunities for identifying PTSD in children should be taken. Questioning the children as well as parents or guardians will also improve the recognition of PTSD. PTSD is common (up to 30%) in children following attendance at emergency departments for a traumatic injury. Emergency department staff should inform parents or guardians of the risk of their child developing PTSD following emergency attendance for a traumatic injury and advise them on what action to take if symptoms develop.

- When assessing a child or young person for PTSD, health care professionals should ensure that they separately and directly question the child or young person about the presence of PTSD symptoms. They should not rely solely on information from the parent or guardian in any assessment.
- When a child who has been involved in a traumatic event is treated in an emergency department, emergency staff should inform the parents or guardians of the possibility of the development of PTSD, briefly describe the possible symptoms (sleep disturbance, nightmares, difficulty concentrating and irritability) and suggest that they contact their GP if the symptoms persist beyond one month.

Early intervention
The treatments for children with PTSD are less developed, but emerging evidence provides an indication for effective interventions.

- Trauma-focussed CBT should be offered to older children with severe posttraumatic symptoms or with severe PTSD in the first month after the traumatic event.

PTSD where symptoms have been present for more than three months after a trauma
- Children and young people with PTSD, including those who have been sexually abused, should be offered a course of trauma-focussed cognitive behavioural therapy adapted appropriately to suit their age, circumstances and level of development.
- The duration of trauma-focussed psychological treatment for children and young people with chronic PTSD should normally be 8–12 sessions when the PTSD results from a single event. When the trauma is discussed in the treatment session, longer sessions than usual are usually necessary (e.g., 90 minutes). Treatment should be regular and continuous (usually at least once a week) and should be delivered by the same person.
- Drug treatments should not be routinely prescribed for children and young people with PTSD.
- Where appropriate, families should be involved in the treatment of PTSD in children and young people. However, treatment programs for PTSD in children and young people that consist of parental involvement alone are unlikely to be of any benefit for PTSD symptoms.
- When considering treatments for PTSD, parents and, where appropriate, children and young people should be informed that, apart from trauma-focussed psychological interventions, there is at present no good evidence for the efficacy of widely-used forms of treatment of PTSD such as play therapy, art therapy or family therapy.
GLOSSARY OF TERMS

**Carer** – A person not employed as a health practitioner who provides care for another individual with a long-term medical condition.

**Case-control study** – A study conducted in a naturalistic setting, which compares people who show improvement on the outcome(s) of interest with those who do not.

**Clinician/health professional or provider** – A professional such as a doctor, nurse, psychologist or psychiatrist employed in clinical practice.

**Cohort study** – A study in which subjects who have a certain condition and/or receive a particular treatment are followed over time and have measures taken at two or more points in time.

**Comorbidity** – The occurrence of more than one mental health disorder at the same time.

**Comparator** – The comparison treatment or condition (e.g. waitlist) used to measure the effectiveness of the treatment under investigation.

**Completer data** – Outcome data that is based only on those who completed treatment, rather than also including those who dropped out of treatment.

**Confidence interval** – The probability that a population parameter will lie within an estimated range of values.

**Consumer** – A person who has experienced mental health problems following a traumatic event and has used or required health services.

**Cost-effectiveness** – The relative costs and benefits of a range of intervention options.

**Differential diagnosis** – An alternative diagnosis that could be made on the basis of observed signs and reported symptoms.

**Early intervention** – Interventions within the first month of the traumatic event, including those that target all adults exposed to the event, and those that target only those with symptoms of ASD or early PTSD.

**Effectiveness** – The degree to which a particular intervention produces beneficial outcomes in everyday settings.

**Efficacy** – The degree to which a particular intervention produces beneficial outcomes under ideal research conditions.

**Epidemiological study** – A study that investigates the incidence and prevalence of a particular disorder across the population.

**Expert consensus** – The agreed position of experts in the field — relied upon only in the absence of research evidence on the issue.

**Fixed-effects model** – A fixed-effects model of meta-analysis is based on a mathematical assumption that every study is evaluating a common treatment effect. That means the effect of treatment, allowing for chance, was the same in all studies. Another way of explaining this is to imagine that if all the studies were infinitely large they would give identical results.

**Functional improvement** – Outcomes that indicate a higher degree of social, occupational and/or psychological functioning.

**Grading scheme** – A set of criteria used to rate the strength of research evidence.

**Heterogeneity in studies** – Different outcomes for the same interventions across studies.

**Historically controlled study** – A study in which a group receiving an intervention is compared to another group who has received the same intervention in the past.

**Intent-to-treat** – Outcome data includes all subjects randomised to receive a treatment in a randomised controlled trial, regardless of whether they complete treatment.

**Internal validity** – The extent to which the outcomes of the study are due to the effects of the variable under investigation and not other, extraneous variables.

**Interpersonal trauma** – Traumatic experience that involves intentional threat or injury caused by another person such as physical or sexual assault.
Interrupted time series – A study in which participants are assessed before and after an intervention on multiple occasions. The trend found in multiple pre-tests are then compared to trends in multiple post-tests. The study may or may not contain a control group.

Meta-analysis – A statistical analysis that combines the results of a number of studies that have investigated the same research question.

Observational study – Study in which investigators observe patients in natural settings.

Outcomes of interest – The specific aspects of functioning, including psychological, social and occupational changes, which are used to evaluate the effects of an intervention.

Peer review – A process by which research is reviewed by experts in the same field to determine whether it meets specific criteria for approval.

Posttraumatic growth – Positive psychological change experienced as a result of the struggle with traumatic experiences.

Pseudorandomised controlled trial – A study that includes both an intervention and control condition to which participants are allocated on the basis of pre-existing characteristics.

Publication bias – The greater likelihood for studies with positive findings to be submitted and/or published compared to those with negative or null findings.

Qualitative synthesis – A summary of research evidence that is based on a subjective analysis of the data rather than statistical analysis.

Quality of life (health-related quality of life) – A multidimensional concept that encompasses the social, occupational, psychological and physical aspects of a person’s functioning and enjoyment of life.

Random effects model – A random effects model of meta-analysis assumes that the true treatment effects in the individual studies may be different from each other. That means there is no single number to estimate in the meta-analysis, but a distribution of numbers. The most common random effects model also assumes that these different true effects are normally distributed. The meta-analysis therefore estimates the mean and standard deviation of the different effects.

Randomised control trial – A clinical trial in which participants have the same likelihood of being allocated to a treatment or control condition. Both control and intervention groups are reassessed posttreatment to investigate differences in outcomes.

Recovery – Includes reduction in PTSD symptoms and achieving optimal psychosocial functioning across social, occupational and/or personal settings. Recovery can be an outcome of treatment or occur as a result of a person’s existing internal and external resources.

Relative risk – The probability of an event occurring (or disorder developing) in one group (exposed) compared to another (non-exposed) group.

Research question – Specific and clearly defined questions concerning key areas of interest which are addressed in the systematic review of the literature.

Screening – Assessment process that aims to identify individuals who are experiencing mental health problems and/or are not showing the normal recovery trajectory following the experience of a traumatic event.

Secondary prevention – early intervention for individuals who have developed mental health problems following trauma, designed to prevent more severe or protracted mental health problems.

Single arm study – A study designed to investigate participants receiving one type of treatment at a particular time, often in order to compare outcomes with those of another treatment at a later date.

Stakeholders – Parties with a specific interest in the area under investigation.

Standardised mean difference – A statistical method used to combine the outcomes of studies, including those utilising different measures, in order to examine the effect of an intervention.

Systematic review – A process by which specific, well-defined research questions are investigated according to a predetermined protocol that outlines explicit methods for searching literature, evaluating studies and collating findings.

Therapeutic alliance – A working relationship between a health practitioner and a person receiving treatment.
REFERENCES


NHMRC (National Health and Medical Research Council) (2000a). *How to review the evidence: Systematic identification and review of the scientific literature*. Canberra: NHMRC.

NHMRC (National Health and Medical Research Council) (2000b). *How to use the evidence: Assessment and application of scientific evidence*. Canberra: NHMRC.

NHMRC (National Health and Medical Research Council) (2001). *How to compare the costs and benefits: Evaluation of the economic evidence*. Canberra: NHMRC.


